IL323621A - 5-amino-6, 8-dihydro-1h-furo [3, 4-d] pyrrolo [3, 2-b] pyridine-2-carboxamide derivatives as mta-cooperative inhibitors of prmt5 - Google Patents
5-amino-6, 8-dihydro-1h-furo [3, 4-d] pyrrolo [3, 2-b] pyridine-2-carboxamide derivatives as mta-cooperative inhibitors of prmt5Info
- Publication number
- IL323621A IL323621A IL323621A IL32362125A IL323621A IL 323621 A IL323621 A IL 323621A IL 323621 A IL323621 A IL 323621A IL 32362125 A IL32362125 A IL 32362125A IL 323621 A IL323621 A IL 323621A
- Authority
- IL
- Israel
- Prior art keywords
- methyl
- butyl
- propyl
- compound
- ethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
WO 2024/199255 PCT/CN2024/083980 5-AMINO-6,8-DIHYDRO-lH-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2- CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 CROSS-REFERENCE TO RELATED APPLICATIONS [0001]This application claims the benefit of priority of International Application No. PCT/CN2023/085078, filed March 30, 2023, International Application No.PCT/CN2023/110807, filed August 2, 2023, and International Application No. PCT/CN2024/080582, filed March 7, 2024, the contents of which are hereby incorporated by reference in their entireties. FIELD OF THE INVENTION [0002]This disclosure provides 5-AMINO-6,8-DIHYDRO-lH-FURO[3,4-d]PYRROLO[3,2- b]PYRIDINE-2-CARBOXAMIDE derivatives, the use thereof, e.g., for selectively inhibiting the activity of PRMT5 in cooperation with methylthioadenosine (MTA) in tumors bearing MTAPDEL mutations, and pharmaceutical compositions comprising the compounds. BACKGROUND OF THE INVENTION [0003]Epigenetic modification is a process that can modify genetic output changing the primary DNA sequence. Epigenetic modification plays an important role in gene expression and regulation, protein production and cell differentiation in multiple dimensions. Typically, this process is reversible and selective, on DNA, its regulatory proteins such as histones and other proteins such as transcription factors [Bradbury, E. M., BioEssays, 1992,14 (1): pp. 9-16], PMTs (protein methyltransferases) are central players on epigenetic modifications, consisting of two sub-families named PKMTs (protein lysine methyltransferases) and PRMTs (protein arginine methyltransferases) [Copeland, R.A., et al., Oncogene, 2012.32 (8): pp. 939-46]. PMTs are associated with various human diseases and considered as potential therapeutic targets VCopeland, R. A., et al., Oncogene, 2012,32 (8): pp. 939-46], [0004]As the name implies, PRMTs catalyze the methylation of the arginine residues of proteins. Besides their primary functions of methylating the histone tails, PRMTs also target other cellular proteins such as NAB2p, FOXOl, PABP1, Sm Di, etc. [Bedford, M. T., et al., Molecular Cell, 2005,18 (3): pp. 263-72]. Divided by the products, the 9 mammalian PRMTs can be classified into 3 subtypes: type 1 (PRMTI, PRMT2, PRMT3, PRMT4, PRMT6 and PRMTS) catalyzes aDMA (asymmetrical dimethylated arginine) formation; type II (PRMT5, PRMT9) catalyzes sDMA (symmetrical dimethylated arginine); and type III (PRMT7) catalyzes MMA (monomethylated arginine) formation [Yang, Y., et al., Nature Reviews Cancer, 2012,(1): pp. 37-50]. In addition, type I/II PRMTs can also catalyze MMA formation as an intermediate to aDMA and sDMA. The PRMTs comprise a pocket to interact with its cofactor WO 2024/199255 PCT/CN2024/083980 SAM (S-adenosyl methionine), and an adjacent pocket to interact with the arginine residue on a protein, namely SAM-pocket and substrate-pocket. The methylation process involves an SN2-like mechanism of transferring an activated methyl group from cofactor SAM to the guanidino group on the arginine residue. [Bedford, M. T.,et al., Molecular Cell, 2005,18 (3): pp. 263-72], The side product of the process is SAH (S-adenosyl-L-homocysteine). [0005]The overall arginine level in cells is roughly 1500:3:2:1 for Arg:aDMA:MMA:sDMA, and PRMT5 accounts for the vast majority of sDMA formation [Dhar, S., et al., Scientific Reports, 2013,3: 1311], In contrast with PRMTI, the major type I PRMT which functions on its own in cells, PRMT5 binds to MEP50 (methylosome protein 50) to form a heterocomplex that is often elevated in cancer cells and correlates to poor patient survival [Gao, G., et al., Nucleic Acids Research, 2019,47 (10):pp. 5038-48], PRMT5 promotes tumorigenesis by varied mechanisms. PRMT5 is a strong repressor of numerous genes; when PRMT5 methylates histones H2a and H4 on Arg3 and histone H3 on Arg8, it represses gene transcripts involved in differentiation, transformation, cell-cycle progression and tumor suppression [Karkhanis, V., et al., Trends in Biochemical Sciences, 2011,36 (12): pp. 633-41], Besides its epigenetic roles, PRMT5 may also regulate RNA-binding proteins such as splicing factors. For instance, a reproducible event was observed in PRMT5 knockout mice, in which exon 6 skipping of MDM(murine double minute 4) occurred and p53 was released to upregulate p53 pathway [Gerhart, S. K, et al., Scientific Reports, 2018,8: 9711], In addition, PRMT5 could directly influence key proliferation pathways by direct methylation of p53 [Jansson, M., et al., Nature Cell Biology, 2008,10 (12): pp. 1431-9], EGER [Hsu, J.-M., et al., Nature Cell Biology, 2011,13 (2): pp. 174- 57], PI3K [PYei, T.-Y.W., et al., Cellular Signaling, 2014,26 (12): pp. 2940-50], etc.. Thus, PRMT5 has a good potential to become a clinically relevant target. [0006]On the other hand, PRMT5 is an essential gene in normal tissues, and the systemic inhibition of PRMT5 may result in significant liabilities, especially hematologic toxicity [Ahnert, J. R.,et al., Journal of Clinical Oncology, 2021,39 (15-suppl): p. 3019]. Therefore, strategies to selectively block the PRMT5 activities in tumor cells are required for a safer therapy. [0007]Homozygous deletion of tumor depressor CDKN2A (cyclin dependent kinase inhibitor 2A) occurs in about 15% of all tumor types. Interestingly, the mutation frequently involves the co-deletion of proximate genes existing in 9p21, including the gene that encodes MTAP (methylthioadenosine phosphorylase) [Firestone, R. S., et al., Journal of American Chemical Society, 2017,139 (39): p. 13754-60]. As a result of MTAP deletion, MTA (methylthioadenosine), the substrate of MTAP, accumulates. MTA is structurally related to SAM, and is a weak ligand/inhibitor of PRMT5 that occupies the same pocket with SAM. The formation of MTA-PRMT5 complex provides chances for further PRMT5 inhibition by WO 2024/199255 PCT/CN2024/083980 formation of a tertiary complex. In such way, a correlation of MTAP null status and dependency of PRMT5 is established through MTA concentration level, to provide a precise oncological therapy. [0008]Currently, most of the clinical-stage PRMT5 inhibitors are unable to differentiate normal cells and cancer cells, based on a SAM/MTA competitive mechanism (JNJ64619178, PF06939999, PRT543, and PRT811) or a non-MTA cooperative mechanism (GSK3326595). There thus remain unmet and continuous medical needs for potent and selective MTA- cooperative PRMT5 inhibitors. SUMMARY OF THE INVENTION [0009]One objective of the present invention is to provide PRMT5 inhibitory compounds, and methods of preparation and uses thereof. [0010] Aspect 1.A compound of Formula (1): or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof, wherein:L is a single bond or -C(R8R9)-;R1 andR 2 are each independently selected from hydrogen, -C1-8alkyl, -C3-C8cycloalkyl, - C3-C12cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12-membered heteroaryl, wherein each of said -Ci-galkyl, -C3-C8cycloalkyl, 3- to 12-membered heterocyclyl, - C6-C12aryl and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent Rla ; orR1 and R2 together with the nitrogen atom to which they are attached, form a 3- to 8- membered unsaturated or saturated ring, said ring comprising 0-3 additional heteroatoms independently selected from nitrogen, oxygen or sulfur and said ring is optionally substituted with at least one substituent Rla ;Rla is independently hydrogen, halogen, deuterium, -C-galkyl, -C3-C8cycloalkyl, -C3- C12cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C!2aryl, 5- to 12-membered heteroaryl, - ORlb , -SO2Rlb , -SO2NRlbRlc , -CORlb , -CO2Rlb , -CONRlbRlc , -NRlbRlc , -NRlb CORlc , - NRlb CO2Rlc , -NRlb SO2Rlc , oxo, or -CN, wherein each of said -C-salkyl, -C3-C8cycloalkyl, -C3- C!2cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C!2a1yl and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent Rld; or WO 2024/199255 PCT/CN2024/083980 two Rla together with the atom(s) to which they are attached, form a 3- to 8-membered unsaturated or saturated ring, said ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur and said ring is optionally substituted with at least one substituent Rld;Rlb andR lc are each independently selected from hydrogen, -C1-8alkyl, -C3-C8cycloalkyl, 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12-membered heteroaryl, wherein each of said -C1-8alkyl, -C3-C8cycloalkyl, 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12- membered heteroaryl is optionally substituted with at least one substituent Rlc ;Rld and Rle are each independently hydrogen, halogen, -C1-8alkyl, -C3-C8cycloalkyl, -C3- C12cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C12aryl, 5- to 12-membered heteroaryl, - ORlf , -SO2Rlf , -SO2NRlf Rlg, -CORlf , -CO2Rlf , -CONRlf Rlg, -NRlf Rlg, -NRlf CORlg, - NRlf CO2Rlg, -NRn SO2Rlg, oxo, or -CN, wherein each of said -C1-8alkyl, -C3-C8cycloalkyl, -C3- C12cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent Rlh ;Rlf and Rlg are each independently selected from hydrogen, -C1-8alkyl, -C3-C8cycloalkyl, 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12-membered heteroaryl, wherein each of said -C1-8alkyl, -C3-C8cycloalkyl, 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12- membered heteroaryl is optionally substituted with at least one substituent R1;Rlh and R״ are each independently hydrogen, halogen, -C1-8alkyl, -C3-C8cycloalkyl, -C3- C12cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C!2aryl, 5- to 12-membered heteroaryl, - ORlj , -SO2Rlj , -SO2NRljRlk, -COR1J, -CO2R1j, -C0NRljRlk, -NRljRlk, -NRljCORlk, - NR1JCO2Rlk, -NR1-؛SO2Rlk, oxo, or -CN, wherein each of said -C!-8alkyl, -C3-C8cycloalkyl, -C3- C12cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent selected from the group consisting of halogen, -C!-8alkyl, -C!-8alkoxy, -C2-8alkenyl, -C2-8alkynyl, -C3-C8cycloalkyl, 3- to 8-membered heterocyclyl, -C6-C!2aryl, 5- to 12-membered heteroaryl, -CN, -OH, -NH2 or oxo;R '؛ and Rlk are each independently selected from hydrogen, -C1-8alkyl, -C3-C8cycloalkyl, 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12-membered heteroaryl, wherein each of said -C!-8alkyl, -C3-C8cycloalkyl, 3- to 12-membered heterocyclyl, -C6-C!2aryl and 5- to 12- membered heteroaryl is optionally substituted with at least one substituent selected from the group consisting of halogen, -C1-8alkyl, -C1-8alkoxy, -C2-8alkenyl, -C2-8alkynyl, -C3-C8cycloalkyl, 3- to 8-membered heterocyclyl, -C6-C12aryl, 5- to 12-membered heteroaryl, -CN, -OH, -NH2 or oxo;R3 is selected from hydrogen, halogen, -C!-8alkyl, -C3-C8cycloalkyl, -CN, -OH, or -NH2, wherein each of said -C1-8alkyl and -C3-C8cycloalkyl is optionally substituted with at least one substituent selected from the group consisting of halogen, -C1-8alkoxy, -C1-8alkyl, -C3- WO 2024/199255 PCT/CN2024/083980 Cscycloalkyl, and 3- to 8-membered heterocyclyl;R4, R5, R6, R7, R8 and R9 are each independently selected from hydrogen, halogen, -C1- 8alkyl or -C3-C8cycloalkyl, wherein each of said -C1-8alkyl and -C3-C8cycloalkyl is optionally substituted with at least one substituent selected from the group consisting of halogen, -Cu salkoxy, -C1-8alkyl, -C3-C8cycloalkyl, 3- to 8-membered heterocyclyl, C6-C12aryl, 5- to 12- membered heteroaryl, oxo, -CN, -0R4a , -SO2R4a , -SO2NR4a R4b , -COR4a , -CO2R4a , -CONR4a R4b , - NR4a R4b , -NR4a COR4b , -NR4a CO2R4b , or -NR4a SO2R4b ;R4a and R4b are each independently hydrogen, -C1-8alkyl, C3-C8cycloalkyl, 3- to 8- membered heterocyclyl, -C6-C12aryl, or 5- to 12-membered heteroaryl; each of said -C-galkyl, C3-C8cycloalkyl, 3- to 8-membered heterocyclyl, -C6-C12aryl, or 5- to 12-membered heteroaryl is optionally substituted with at least one halogen, -OH, -C1-8alkyl, -C1-8alkoxy, C1-8alkoxy-C1- salkyl-, -C2-8alkenyl, -C2-8alkynyl, -C3-C8cycloalkyl, 3- to 8-membered heterocyclyl, -C6-C12aryl, or 5- to 12-membered heteroaryl. [0011] In one embodiment,R1 and R2 are each independently selected from -C1-8alkyl, -C3- Cscycloalkyl, -C3-C12cycloalkenyl and 3- to 12-membered heterocyclyl, wherein each of said - Cusalkyl, -C3-C8cycloalkyl, -C3-C12cycloalkenyl and 3- to 12-membered heterocyclyl is optionally substituted with at least one substituent Rla . Rla is defined as previously. [0012] In one embodiment,R1 and R2 are each independently selected from -C1-8alkyl, wherein said -Ci-galkyl is optionally substituted with at least one substituent Rla . Rla is defined as previously. Preferably, R1 and R2 are each independently selected from -C!-4alkyl, wherein said -C1-8alkyl is optionally substituted with at least one substituent Rla . Rla is defined as previously. More preferably, R1 and R2 are each independently selected from methyl, ethyl and propyl (iso-propyl or n-propyl), wherein each of said methyl, ethyl and propyl (iso-propyl or n- propyl) is optionally substituted with at least one substituent Rla . Rla is defined as previously. In one embodiment,R1 is methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), each of said methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl) is optionally substituted with at least one substituent Rla , Rla is defined as previously. In one embodiment,Rla is phenyl, pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, triazolyl (preferably, lH-l,2,4-triazolyl, 4H-l,2,4-triazolyl), pyridinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl; each of said phenyl, pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, triazolyl (preferably, lH-l,2,4-triazolyl, 4H-l,2,4-triazolyl), pyridinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rld, Rld is defined as previously. In one WO 2024/199255 PCT/CN2024/083980 R1a > embodiment,R1 is ؛R ^n4 , Y is N or CH; n4 is 0, 1, 2, 3 or 4; preferably, n4 is 1, 2 or 3. In id="p-13" id="p-13" id="p-13"
id="p-13"
[0013] In one embodiment,R1 is (R ؛n4 , Y is N or CH; preferably, zero, one, or two occurrences of Y are N and the rest are CH; more preferably, zero or one occurrence of Y is N and the rest are CH; Rla is hydrogen or C1-8alkyl; preferably, Rla is hydrogen, methyl, ethyl, propyl (iso-propyl or n-propyl), or butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl); more preferably, Rla is hydrogen, methyl, ethyl, or propyl (iso-propyl or n-propyl); Rld is independently selected from halo, methyl substituted with one or more halo, C3-5cycloalkyl optionally substituted with fluoro, or -CN; preferably, Rld is independently selected from -F, -Br, -1, -CF3, cyclopropyl, fluorocyclopropyl, cyclobutyl or -CN; n4 is 0, 1, 2, 3 or 4; preferably, n4 is id="p-14" id="p-14" id="p-14"
id="p-14"
[0014] In one embodiment,R1 and R2 are each independently selected from methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, chromanyl, isochromanyl, dihydropyranopyridinyl6 WO 2024/199255 PCT/CN2024/083980 (preferably, 5,8-dihydro-6H-pyrano[3,4-b]pyridinyl, 3,4-dihydro-2H-pyrano[3,2-b]pyridine or 7,8-dihydro-5H-pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3-b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4-tetrahydronaphthalenyl), benzo[d]thiazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso- butyl or tert-butyl), cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro-6H-pyrano[3,4-b]pyridinyl, 3,4-dihydro-2H- pyrano[3,2-b]pyridine or 7,8-dihydro-5H-pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H- pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3- b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4-tetrahydronaphthalenyl), benzo[d]thiazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rla . Rla is defined as previously. [0015] In one embodiment,R1 is 3- to 12-membered heterocyclyl, said 3- to 12-membered heterocyclyl is optionally substituted with at least one substituent Rla , Rla is defined as previously. Preferably, R1 is 6- to 10-membered heterocyclyl, said 6- to 10-membered heterocyclyl is optionally substituted with at least one substituent Rla , Rla is defined as previously. In one embodiment,R1 is 3- to 12-membered heterocyclyl, said 3- to 12-membered heterocyclyl is optionally substituted with at least one substituent Rla ; and R2 is -Ci-galkyl which is further substituted with 3- to 12-membered heterocyclyl, -C6-C12aryl, 5- to 12-membered heteroaryl, and each of said 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent Rld. Preferably, R2 is -C1-4alkyl which is further substituted with 5- to 10-membered heterocyclyl, phenyl or 5- to 6-membered heteroaryl, and each of said 5- to 10-membered heterocyclyl, phenyl and 5- to 6-membered heteroaryl is optionally substituted with at least one substituent Rld. [0016] In one embodiment,R1 is 3- to 12-membered heterocyclyl, said 3- to 12-membered heterocyclyl is optionally substituted with at least one substituent Rla , Rla is defined as previously. In one embodiment,R1 is tetrahydropyranyl, said tetrahydropyranyl is optionally substituted with at least one substituent Rla , Rla is defined as previously. Preferably, Rla is -C!.
WO 2024/199255 PCT/CN2024/083980 O galkoxy, more preferably, Rla is methoxy or ethoxy. In one embodiment,R1 is ° , Rlb is -C1-8alkyl, preferably, Rlb is methyl or ethyl. [0017] In one embodiment,R1 is 3- to 12-membered heterocyclyl; preferably, R1 is tetrahydroquinolinyl, said tetrahydroquinolinyl is optionally substituted with at least one substituent Rla , Rla is defined as previously. In one embodiment,Rla is H. In one embodiment, R1 is '—/ or ׳ [0018] In one embodiment,R1 is 3- to 12-membered heterocyclyl; preferably, R1 is chromanyl or isochromanyl, each of said chromanyl or isochromanyl is optionally substituted with at least one substituent Rla , Rla is defined as previously. In one embodiment,Rla is H. In one embodiment,Rla is -F, -CH3, or -CF3. In one embodiment,R1 is n5( Rla ) independently selected from methyl, ethyl, propyl, halo, methyl substituted with one or more halo, C3-5cycloalkyl, or -CN, or two Rla attached to the same atom form C3-5cycloalkyl;preferably, Rla is hydrogen, methyl, ethyl, -F, -Cl, -Br, -1, -CF3, cyclopropyl, or -CN, or two Rla attached to the same atom form cyclopropyl; n5 is 0, 1, 2, 3, 4 or 5; preferably, n5 is 1, 2, 3, 4, or 5; more preferably, n5 is 1, 2, 3, or 4; yet more preferably, n5 is 1, 2, or 3. id="p-19" id="p-19" id="p-19"
id="p-19"
[0019]Rla can be the substituent group(s) on the moiety of or on the WO 2024/199255 PCT/CN2024/083980 [0020] In one embodiment,R1 is benzyl, pyridylmethyl, pyridazinylmethyl, pyrimidinylmethyl, pyrazinylmethyl, 1-pyridylethyl, 1-pyridazinylethyl, 1-pyrimidinylethyl or 1- pyrazinylethyl, each of said benzyl, pyridylmethyl, pyridazinylmethyl, pyrimidinylmethyl, pyrazinylmethyl, 1-pyridylethyl, 1-pyridazinylethyl, 1-pyrimidinylethyl or 1-pyrazinylethyl is optionally substituted with at least one substituent Rld, Rld is defined as previously. In one embodiment,Rld is each independently hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl (iso- propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), phenyl, pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, triazolyl (preferably, lH-l,2,4-triazolyl, 4H-1,2,4- triazolyl), pyridinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl, tetrahydrofuropyridinyl, -OR11, -SO2R11 or -CN, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso- butyl or tert-butyl), phenyl, pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, triazolyl (preferably, lH-l,2,4-triazolyl, 4H-1,2,4-triazolyl), pyridinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rlh ; R11 is each independently selected from hydrogen, methyl, ethyl, propyl (iso-propyl or n-propyl), cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or phenyl, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or phenyl is optionally substituted with at least one substituent R11; Rlh and R11 are each independently hydrogen, -F, -Cl, -Br, -1, methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -OH, or - CN. [0021] In one embodiment,R2 is C1-8alkyl. In one embodiment,R2 is methyl, ethyl, propyl (iso-propyl or n-propyl), or butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl). In one embodiment,R2 is methyl, ethyl, or propyl (iso-propyl or n-propyl). In one embodiment,R2 is methyl. [0022] Aspect 2.The compound of aspect 1, wherein the compound is of formula (11a) or (lib): (Ha) (11b)preferably, the compound is of formula (lie) or (lid): WO 2024/199255 PCT/CN2024/083980 (He)or preferably, the compound is of formula (He), (Ilf), (11g) or (IIh): (Hg) (Uh)wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in aspect 1. [0023] Aspect 3. The compound of aspect 1, wherein the compound is of formula (Illa): (Ilia);preferably, the compound is of formula (111b): more preferably, the compound is of formula (Ilic): (Ilic);even more preferably, the compound is of formula (Hid), (Ilie), (Illf) or (Illg): WO 2024/199255 PCT/CN2024/083980 (Ilie), (111g);even more preferably, the compound is of formula (Illh), (Illi), (Illj) or (Illk): R5 (Illh), (Ulj), (IUk); wherein, nl is 0, 1, 2 or 3; preferably, nl is 1 or 2; more preferably, nl is 1;Rla , Rlb , R2, R3, R4, R5, R6, R7 and L are as defined in aspect 1. [0024] Aspect 4.The compound of aspect 1, wherein the compound is of formula (IVa), (IVb), (IVc), (IVd), (IVe), (IVf), (IVg) or (IVh): WO 2024/199255 PCT/CN2024/083980 preferably, the compound is of formula (IVi), (IVj), (IVk), (IV1), (IVm), (IVn), (IVo), (IVp), (IVq), (IVr), (IVs), (IVt), (IVu) or (IVv): El ( JA1 ؛) •(bAl) 086£80/tOZN3/13d SSZ661/+707 OM WO 2024/199255 PCT/CN2024/083980 (IVu); (IVv);wherein, n2 is 0, 1, 2 or 3; preferably, n2 is 0, 1 or 2;Rla , R2, R3, R4, R5, R6, R7 and L are as defined in aspect 1.
Rla can be substituted on any position of that can fulfill the valencytheory. [0025] Aspect 5.The compound of aspect 1, wherein the compound is of formula (Va):R3 (R1d)n3 (Va), wherein, n3 is 0, 1, 2, 3 or 4; preferably, n3 is 1, 2 or 3;each occurrence of X is independently N or CH; preferably, zero, one or two occurrences of X are N, and the rest are CH;Rla , Rld, R2, R3, R4, R5, R6, R7 and L are as defined in aspect 1;14 WO 2024/199255 PCT/CN2024/083980 preferably, the compound is of formula (Vb), (Vc), (Vd), (Ve) or (Vf): (Vb), (Vc), (Vd), (Ve),R3 (Vf); wherein, n3 is 0, 1, 2 or 3; preferably, n3 is 1 or 2; more preferably, n3 is 1;Rla , Rld, R2, R3, R4, R5, R6, R7 and L are as defined in aspect 1;more preferably, the compound is of formula (Vg), (Vh), (Vi), (Vj), (Vk), (VI), (Vm), (Vn) or (Vo): WO 2024/199255 PCT/CN2024/083980 (Vi), (vj), (Vn), (Vo);even more preferably, the compound is of formula (Vp), (Vq), (Vr), (Vs), (Vt), (Vu), (Vv),(Vw), (Vx), (Vy) or (Vz): (Vp), (Vr), (Vs), WO 2024/199255 PCT/CN2024/083980 (Vz),wherein, Rla , Rld, R2, R3, R4, R5, R6, R7 and L are as defined in aspect 1. [0026] Aspect 6.A compound of Formula (VI): or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof, wherein:R1 and R2 are each independently selected from hydrogen, -C1-8alkyl, -C3-C8cycloalkyl, - C3-C!2cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C12a1yl and 5- to 12-membered heteroaryl, wherein each of said -C1-8alkyl, -C3-C8cycloalkyl, 3- to 12-membered heterocyclyl, - C6-C12aryl and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent Rla ; or17 WO 2024/199255 PCT/CN2024/083980 R1 and R2 together with the nitrogen atom to which they are attached, form a 3- to 8- membered unsaturated or saturated ring, said ring comprising 0-3 additional heteroatoms independently selected from nitrogen, oxygen or sulfur and said ring is optionally substituted with at least one substituent Rla ;Rla is independently hydrogen, halogen, deuterium, -C1-8alkyl, -C3-C8cycloalkyl, -C3- C12cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C12aryl, 5- to 12-membered heteroaryl, - ORlb , -SO2Rlb , -SO2NRlbRlc , -CORlb , -CO2Rlb , -CONRlbRlc , -NRlbRlc , -NRlb CORlc , - NRlb CO2Rlc , -NRlb SO2Rlc , oxo, or -CN, wherein each of said -C1-8alkyl, -C3-C8cycloalkyl, -C3- C12cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent Rld; ortwo Rla together with the atom(s) to which they are attached, form a 3- to 8-membered unsaturated or saturated ring, said ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur and said ring is optionally substituted with at least one substituent R,d;Rlb and Rlc are each independently selected from hydrogen, -C1-8alkyl, -C3-C8cycloalkyl, 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12-membered heteroaryl, wherein each of said -C1-8alkyl, -C3-C8cycloalkyl, 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12- membered heteroaryl is optionally substituted with at least one substituent R,e;Rld and Rle are each independently hydrogen, halogen, -C1-8alkyl, -C3-C8cycloalkyl, -C3- C12cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C!2aryl, 5- to 12-membered heteroaryl, - ORlf , -SO2Rlf , -SO2NRlf Rlg, -CORlf , -CO2Rlf , -CONRlf Rlg, -NRlf Rlg, -NRlf CORlg, - NRlf CO2Rlg, NRlf SO2Rlg, oxo, or -CN, wherein each of said -C!-8alkyl, -C3-C8cycloalkyl, -C3- C12cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent Rlh ;Rlf and Rlg are each independently selected from hydrogen, -C!-8alkyl, -C3-C8cycloalkyl, 3- to 12-membered heterocyclyl, -C6-C!2aryl and 5- to 12-membered heteroaryl, wherein each of said -C1-8alkyl, -C3-C8cycloalkyl, 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12- membered heteroaryl is optionally substituted with at least one substituent R11;Rlh and R״ are each independently hydrogen, halogen, -C!-8alkyl, -C3-C8cycloalkyl, -C3- C!2cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C!2a1yl, 5- to 12-membered heteroaryl, - OR1J, -SO2R1j, -SO2NRljRlk, -C0Rlj , -C02R1j, -C0NRljRlk, -NRljRlk, -NRljC0Rlk, - NRljC02Rlk, -NRljSO2Rlk, oxo, or -CN, wherein each of said -C1-8alkyl, -C3-C8cycloalkyl, -C3- C!2cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C!2a1yl and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent selected from the group consisting of halogen, -C1-8alkyl, -C!-8alkoxy, -C2-8alkenyl, -C2-8alkynyl, -C3-C8cycloalkyl, 3- to 8-membered heterocyclyl, -C6-C12aryl, 5- to 12-membered heteroaryl, -CN, -OH, -NH2 or oxo; WO 2024/199255 PCT/CN2024/083980 R,j andR lk are each independently selected from hydrogen, -C1-8alkyl, -C3-C8cycloalkyl, 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12-membered heteroaryl, wherein each of said -C1-8alkyl, -C3-C8cycloalkyl, 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12- membered heteroaryl is optionally substituted with at least one substituent selected from the group consisting of halogen, -C1-8alkyl, -C1-8alkoxy, -C2-8alkenyl, -C2-8alkynyl, -C3-C8cycloalkyl, 3- to 8-membered heterocyclyl, -C6-C12aryl, 5- to 12-membered heteroaryl, -CN, -OH, -NH2 or oxo;R6andR 7 are each independently selected from hydrogen or methyl. [0027] Aspect 7.The compound of aspect 6, wherein the compound is formula (Vila): y -|y(R1d)n4(Vila),wherein, n4 is 0, 1, 2, 3 or 4; preferably, n4 is 1, 2 or 3;each occurrence of Y is independently N or CH; preferably, zero, one or two occurrences of Y are N, and the rest are CH;Rla , Rld, R2, R6 and R7 are as defined in aspect 6;preferably, the compound is formula (VIIb), (VIIc), (Vlld), (Vile) or (VIIf): (VHd), (VIIc), WO 2024/199255 PCT/CN2024/083980 (Vllf); wherein, n4 is 0, 1, 2 or 3; preferably, n4 is 1 or 2; more preferably, n4 is 1;Rla , Rld, R2, R6 and R7 are as defined in aspect 6;even more preferably, the compound is formula (Vllg), (Vllh), (Vlli), (Vllj), (Vllk), (VIII),(Vllm), (Vlln), (VIIo), (VIIp) or (Vllq): R1d (Vllm), (Vlln), R1d WO 2024/199255 PCT/CN2024/083980 (Vllq), (VHp), wherein, Rla , Rld, R2, R6 and R7 are as defined in aspect 6. [0028] Aspect 8.The compound of aspect 6, wherein the compound is formula (Villa): (Villa),wherein, n5 is 0, 1, 2, 3 or 4; preferably, n5 is 1, 2 or 3;Z1 and Z2 are each independently selected from O or CH2;Z3 and Z4 are each independently selected from N or CH;Rla , R6 and R7 are as defined in aspect 6;preferably, the compound is formula (Vlllb), (VIIIc), (Vllld), (Ville), (VIIIf), (Vlllg),(VIHh), (Villi), (Vlllj), (VIHk), (VIII1), (Vlllm), (VIHn) or (VIIIo): WO 2024/199255 PCT/CN2024/083980 (Vlllf) (VIIII) (VTITi) (Vllln) (VIIIo) wherein, n5 is 0, 1,2 or 3; preferably, n5 is 1 or 2;Rla , Rld, R2, R6 and R7 are as defined in aspect 6; WO 2024/199255 PCT/CN2024/083980 Rla can be substituted on any position of that canfulfill the valency theory. [0029] Aspect 9.The compound of any one of the preceding aspects, wherein R1 and R2 are each independently selected from hydrogen, methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C3-C12cycloalkenyl, 3- to 12-membered heterocyclyl, phenyl and 5- to 12-membered heteroaryl, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 12- membered heterocyclyl, phenyl and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent Rla ; orR1 and R2 together with the nitrogen atom to which they are attached, form a 3-, 4-, 5-, 6-, 7- or 8-membered unsaturated or saturated ring, said ring comprising 0, 1, 2 or 3 additional heteroatoms independently selected from nitrogen, oxygen or sulfur and said ring is optionally substituted with at least one substituent Rla ;Rla is independently hydrogen, -F, -Cl, -Br, -1, methyl, ethyl, propyl (iso-propyl or n- propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C3-C12cycloalkenyl, 3- to 12-membered heterocyclyl, phenyl, 5- to 12-membered heteroaryl, -ORlb , -SO2Rlb , - SO2NRlb Rlc , -CORlb , -CO2Rlb , -CONRlb Rlc , -NRlbRlc , -NRlb CORlc , -NRlb CO2Rlc , - NRlb SO2Rlc , oxo, or -CN, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C3-C12cycloalkenyl, 3- to 12- membered heterocyclyl, phenyl or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent Rld; ortwo Rla together with the atom(s) to which they are attached, form a 3-, 4-, 5-, 6-, 7- or 8- membered unsaturated or saturated ring, said ring comprising 0, 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur and said ring is optionally substituted 23 WO 2024/199255 PCT/CN2024/083980 with at least one substituent Rld;Rlb and Rlc are each independently selected from hydrogen, methyl, ethyl, propyl (iso- propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 12-membered heterocyclyl, phenyl or 5- to 12-membered heteroaryl, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 12- membered heterocyclyl, phenyl or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent Rle;Rld and Rlc are each independently hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl (iso- propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C3-C12cycloalkenyl, 3- to 12-membered heterocyclyl, phenyl, 5- to 12-membered heteroaryl, -OR,f , -SO2R1f , - SO2NRlf Rlg, -CORlf , -CO2Rlf , -CONRlf Rlg, -NRlf Rlg, -NRlf CORlg, -NRlf CO2Rlg, - NRlf SO2Rlg, oxo, or -CN, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C3-C12cycloalkenyl, 3- to 12- membered heterocyclyl, phenyl, and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent Rlh ;Rlf and Rlg are each independently selected from hydrogen, methyl, ethyl, propyl (iso- propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 12-membered heterocyclyl, phenyl or 5- to 12-membered heteroaryl, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclo butyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 12- membered heterocyclyl, phenyl or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent R11;Rlh and R״ are each independently hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl (iso- propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C3-C12cycloalkenyl, 3- to 12-membered heterocyclyl, phenyl, 5- to 12-membered heteroaryl, -0Rlj , -S02R1h - SO2NRljRlk, -C0Rlj , -CO2Rlj , -C0NRljRlk, -NRljRlk, -NRljCORlk, -NRljCO2Rlk, -NRljS02Rlk, oxo, or -CN, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C3-C12cycloalkenyl, 3- to 12-membered WO 2024/199255 PCT/CN2024/083980 heterocyclyl, phenyl and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent -F, -Cl, -Br, -1, methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec- butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, hepthoxy, octoxy, -C2-8alkenyl, -C2-8alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, 5- to 12-membered heteroaryl, -CN, -OH, -NH2 or oxo;Rlj and Rlk are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 12-membered heterocyclyl, phenyl and 5- to 12-membered heteroaryl, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 12-membered heterocyclyl, phenyl and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent - F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, hepthoxy, octoxy, -C2-8alkenyl, -C2-8alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, 5- to 12-membered heteroaryl, -CN, -OH, -NH2 or oxo. [0030] Aspect 10.The compound of any one of the preceding aspects, wherein R1 and R2 are each independently selected from hydrogen, methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro-6H- pyrano[3,4-b]pyridinyl, 3,4-dihydro-2H-pyrano[3,2-b]pyridine or 7,8-dihydro-5H-pyrano[4,3- b]pyridinyl), pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3-b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4- tetrahydronaphthaleny1), benzo [d]thiazolyl, triazolyl (preferably, lH-l,2,4-triazolyl, 4H-1,2,4- triazolyl), pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro- 6H-pyrano[3,4-b]pyridinyl, 3,4-dihydro-2H-pyrano[3,2-b]pyridine or 7,8-dihydro-5H- pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3-b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4-tetrahydronaphthalenyl), benzo[d]thiazolyl, triazolyl (preferably, 1H-1,2,4- triazolyl, 4H-l,2,4-triazolyl), pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, WO 2024/199255 PCT/CN2024/083980 thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rla ; orR1 and R2 together with the nitrogen atom to which they are attached, form a 3-, 4-, 5-, 6-, 7- or 8-membered unsaturated or saturated ring, said ring comprising 0, 1, 2 or 3 additional heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent Rla ;Rla is independently hydrogen, -F, -Cl, -Br, -1, methyl, ethyl, propyl (iso-propyl or n- propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro-6H-pyrano[3,4-b]pyridinyl, 3,4-dihydro-2H-pyrano[3,2-b]pyridine or 7,8-dihydro- 5H-pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3-b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4-tetrahydronaphthalenyl), benzo[d]thiazolyl, triazolyl (preferably, 1H-1,2,4- triazolyl, 4H-l,2,4-triazolyl), pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, tetrahydrofuropyridinyl - OR,b , -SO2R,b , -SO2NR,bR1c , -COR1b , -CO2R,b , -CONR,bR,c , -NR,bR,c , -NR,b COR,c , - NR,b CO2R1c , NR,b SO2R1c , oxo, or -CN, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro-6H-pyrano[3,4-b]pyridinyl, 3,4-dihydro-2H-pyrano[3,2-b]pyridine or 7,8-dihydro-5H-pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3-b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4-tetrahydronaphthalenyl), benzo[d]thiazolyl, triazolyl (preferably, lH-l,2,4-triazolyl, 4H-l,2,4-triazolyl), pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rld; ortwo Rla together with the atom(s) to which they are attached, form a 3-, 4-, 5- or 6- membered unsaturated or saturated ring, said ring comprising 0, 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent Rld;Rlb and Rlc are each independently selected from hydrogen, methyl, ethyl, propyl (iso- propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro-6H-pyrano[3,4-b]pyridinyl, 3,4- WO 2024/199255 PCT/CN2024/083980 dihydro-2H-pyrano[3,2-b]pyridine or 7,8-dihydro-5H-pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3- dihydrofuro[2,3-b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4- tetrahydronaphthalenyl), benzo[d]thiazolyl, triazolyl (preferably, lH-l,2,4-triazolyl, 4H-1,2,4- triazolyl), pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro-6H-pyrano[3,4-b]pyridinyl, 3,4-dihydro-2H- pyrano[3,2-b]pyridine or 7,8-dihydro-5H-pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H- pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3- b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4-tetrahydronaphthalenyl), benzo[d]thiazolyl, triazolyl (preferably, lH-l,2,4-triazolyl, 4H-l,2,4-triazolyl), pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rle;Rld and Rle are each independently hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl (iso- propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro-6H-pyrano[3,4-b]pyridinyl, 3,4-dihydro-2H-pyrano[3,2-b]pyridine or 7,8-dihydro-5H-pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3-b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4-tetrahydronaphthalenyl), benzo[d]thiazolyl, triazolyl (preferably, lH-l,2,4-triazolyl, 4H-l,2,4-triazolyl), pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl, tetrahydrofuropyridinyl, -OR״, -SO2R״, -COR", -CO2R״, -CONRlf Rlg, - NRlf Rlg, -NRlf CORlg, -NRlf CO2Rlg, oxo, or -CN, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro-6H-pyrano[3,4-b]pyridinyl, 3,4-dihydro-2H- pyrano[3,2-b]pyridine or 7,8-dihydro-5H-pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H- pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3- b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4-tetrahydronaphthalenyl), benzo[d]thiazolyl, triazolyl (preferably, lH-l,2,4-triazolyl, 4H-l,2,4-triazolyl), pyridinyl, WO 2024/199255 PCT/CN2024/083980 quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rlh ;Rlf and Rlg are each independently selected from hydrogen, methyl, ethyl, propyl (iso- propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro-6H-pyrano[3,4-b]pyridinyl, 3,4- dihydro-2H-pyrano[3,2-b]pyridine or 7,8-dihydro-5H-pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3- dihydrofuro[2,3-b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4- tetrahydronaphthalenyl), benzo[d]thiazolyl, triazolyl (preferably, IH-l,2,4-triazolyl, 4H-1,2,4- triazolyl), pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro-6H-pyrano[3,4-b]pyridinyl, 3,4-dihydro-2H- pyrano[3,2-b]pyridine or 7,8-dihydro-5H-pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H- pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3- b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4-tetrahydronaphthalenyl), benzo[d]thiazolyl, triazolyl (preferably, IH-l,2,4-triazolyl, 4H-1,2,4-triazolyl), pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent R11;Rlh and R״ are each independently hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl (iso- propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro-6H-pyrano[3,4-b]pyridinyl, 3,4- dihydro-2H-py1 ־ano[3,2-b]pyridine or 7,8-dihydro-5H-pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3- dihydrofuro[2,3-b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4- tetrahydronaphthalenyl), benzo[d]thiazolyl, triazolyl (preferably, 1H-1,2,4-triazolyl, 4H-1,2,4- triazolyl), pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl, tetrahydrofuropyridinyl, -OR1J, -CORlj , -CO2R1j, -CONRljRlk, -NRljRlk, -NRljCORlk, - WO 2024/199255 PCT/CN2024/083980 NRljCO2Rlk, oxo, or -CN, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro-6H-pyrano[3,4-b]pyridinyl, 3,4-dihydro-2H- pyrano[3,2-b]pyridine or 7,8-dihydro-5H-pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H- pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3- b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4-tetrahydronaphthalenyl), benzo[d]thiazolyl, triazolyl (preferably, lH-l,2,4-triazolyl, 4H-l,2,4-triazolyl), pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent -F, -Cl, -Br, -I, methyl, ethyl, propyl (iso- propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, hepthoxy, octoxy, -C2-8alkenyl, -C2- salkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl, tetrahydrofuropyridinyl, -CN, - OH, -NH2 or oxo;Rlj and Rlk are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro- 6H-pyrano[3,4-b]pyridinyl, 3,4-dihydro-2H-pyrano[3,2-b]pyridine or 7,8-dihydro-5H- pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3-b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4-tetrahydronaphthalenyl), benzo[d]thiazolyl, triazolyl (preferably, 1H-1,2,4- triazolyl, 4H-l,2,4-triazolyl), pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro-6H-pyrano[3,4- b]pyridinyl, 3,4-dihydro-2H-pyrano[3,2-b]pyridine or 7,8-dihydro-5H-pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3-b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4- tetrahydronaphthalenyl), benzo [d]thiazo lyl, triazolyl (preferably, lH-l,2,4-triazolyl, 4H-1,2,4- triazolyl), pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or WO 2024/199255 PCT/CN2024/083980 tetrahydrofuropyridinyl is optionally substituted with at least one substituent -F, -Cl, -Br, -1, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, hepthoxy, octoxy, -C2-8alkenyl, -C2-8alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl, tetrahydrofuropyridinyl, -CN, -OH, -NH2 or oxo;preferably, R1 and R2 are each independently selected from hydrogen, methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro-6H-pyrano[3,4-b]pyridinyl, 3,4-dihydro-2H-pyrano[3,2-b]pyridine or 7,8-dihydro-5H-pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3-b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4-tetrahydronaphthalenyl), benzo[d]thiazolyl, triazolyl (preferably, lH-l,2,4-triazolyl, 4H-l,2,4-triazolyl), pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl, wherein each of said methyl, ethyl, propyl (iso- propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro-6H-pyrano[3,4-b]pyridinyl, 3,4-dihydro-2H-pyrano[3,2-b]pyridine or 7,8-dihydro- 5H-pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3-b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4-tetrahydronaphthalenyl), benzo[d]thiazolyl, triazolyl (preferably, 1H-1,2,4- triazolyl, 4H-l,2,4-triazolyl), pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rla ; orR1 and R2 together with the nitrogen atom to which they are attached, form a 3-, 4-, 5-, 6-, 7- or 8-membered unsaturated or saturated ring, said ring comprising 0, 1, 2 or 3 additional heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent Rla ;Rla is independently hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl (iso-propyl or n- propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro-6H-pyrano[3,4-b]pyridinyl, 3,4-dihydro-2H-pyrano[3,2-b]pyridine or 7,8-dihydro- 5H-pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3-b]pyridinyl), tetrahydronaphthalenyl WO 2024/199255 PCT/CN2024/083980 (preferably, 1,2,3,4-tetrahydronaphthalenyl), benzo[d]thiazolyl, triazolyl (preferably, 1H-1,2,4- triazolyl, 4H-l,2,4-triazolyl), pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3-b]pyridinyl), tetrahydrofuropyridinyl, -ORlb or -CN, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro-6H-pyrano[3,4-b]pyridinyl, 3,4- dihydro-2H-pyrano[3,2-b]pyridine or 7,8-dihydro-5H-pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3- dihydrofuro[2,3-b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4- tetrahydronaphthalenyl), benzo[d]thiazolyl, triazolyl (preferably, lH-l,2,4-triazolyl, 4H-1,2,4- triazolyl), pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rld; ortwo Rla together with the atom(s) to which they are attached, form a 3-, 4-, 5- or 6- membered unsaturated or saturated ring, said ring comprising 0, 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent Rld;Rlb is each independently hydrogen, methyl, ethyl, propyl (iso-propyl or n-propyl), cyclopropyl or cyclobutyl;Rld is each independently hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl (iso-propyl or n- propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro-6H-pyrano[3,4-b]pyridinyl, 3,4-dihydro-2H-pyrano[3,2-b]pyridine or 7,8-dihydro- 5H-pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3-b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4-tetrahydronaphthalenyl), benzo[d]thiazolyl, triazolyl (preferably, 1H-1,2,4- triazolyl, 4H-l,2,4-triazolyl), pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl, tetrahydrofuropyridinyl, -ORlf , -NRlf Rlg, -NRlf CORlg, oxo, -SO2Rlf or -CN, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert- butyl), pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro-6H-pyrano[3,4-b]pyridinyl, 3,4- dihydro-2H-pyrano[3,2-b]pyridine or 7,8-dihydro-5H-pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3- WO 2024/199255 PCT/CN2024/083980 dihydrofuro[2,3-b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4- tetrahydronaphthalenyl), benzo[d]thiazolyl, triazolyl (preferably, IH-l,2,4-triazolyl, 4H-1,2,4- triazolyl), pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rlh ;Rlf and Rlg are each independently selected from hydrogen, methyl, ethyl, propyl (iso- propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro-6H-pyrano[3,4-b]pyridinyl, 3,4-dihydro-2H-pyrano[3,2-b]pyridine or 7,8-dihydro-5H-pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3-b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4-tetrahydronaphthalenyl), benzo[d]thiazolyl, triazolyl (preferably, IH-l,2,4-triazolyl, 4H-1,2,4-triazolyl), pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl, wherein each of said methyl, ethyl, propyl (iso- propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro-6H-pyrano[3,4-b]pyridinyl, 3,4-dihydro-2H-pyrano[3,2-b]pyridine or 7,8-dihydro-5H-pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3-b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4-tetrahydronaphthalenyl), benzo[d]thiazolyl, triazolyl (preferably, 1H-1,2,4-triazolyl, 4H-1,2,4-triazolyl), pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent R11;Rlh and R״ are each independently hydrogen, -F, -Cl, -Br, -1, methyl, ethyl, propyl (iso- propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro-6H-pyrano[3,4-b]pyridinyl, 3,4-dihydro-2H-pyrano[3,2-b]py1 ־idine or 7,8-dihydro-5H-pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3-b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4-tetrahydronaphthalenyl), benzo[d]thiazolyl, triazolyl (preferably, IH-l,2,4-triazolyl, 4H-1,2,4-triazolyl), pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl, tetrahydrofuropyridinyl, -OH, or -CN; WO 2024/199255 PCT/CN2024/083980 more preferably, R1 and R2 are each independently selected from hydrogen, methyl, ethyl, propyl (iso-propyl or n-propyl), cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8-dihydro-6H-pyrano[3,4- b]pyridinyl, 3,4-dihydro-2H-pyrano[3,2-b]pyridine or 7,8-dihydro-5H-pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3-b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4- tetrahydronaphthalenyl), benzo [d]thiazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl, wherein each of said methyl, ethyl, propyl (iso- propyl or n-propyl), phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl (preferably, 5,8- dihydro-6H-pyrano[3,4-b]pyridinyl, 3,4-dihydro-2H-pyrano[3,2-b]pyridine or 7,8-dihydro-5H- pyrano[4,3-b]pyridinyl), pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3-b]pyridinyl), tetrahydronaphthalenyl (preferably, 1,2,3,4-tetrahydronaphthalenyl), benzo[d]thiazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent R,a ; orR1 and R2 together with the nitrogen atom to which they are attached, form a 6-membered unsaturated or saturated ring, said ring is optionally substituted with at least one substituent Rla ;Rla is independently hydrogen, -F, -Cl, -Br, -1, methyl, ethyl, propyl (iso-propyl or n- propyl), cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyrimidinyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3-b]pyridinyl), benzo[d]thiazolyl, pyridinyl, quinolinyl, isoquinolinyl, thiazolyl, -ORlb or -CN wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), phenyl, pyrimidinyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3-b]pyridinyl), benzo[d]thiazolyl, pyridinyl, quinolinyl, isoquinolinyl or thiazolyl is optionally substituted with at least one substituent Rld;Rlb is each independently hydrogen, methyl, ethyl, propyl (iso-propyl or n-propyl), cyclopropyl or cyclobutyl;Rld is each independently hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl (iso-propyl or n- propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), phenyl, pyrimidinyl, tetrahydro-2H- pyranyl, pyridazinyl, pyrazinyl, triazolyl (preferably, lH-l,2,4-triazolyl, 4H-l,2,4-triazolyl), pyridinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl, tetrahydrofuropyridinyl, -ORlf , -SO2Rlf or -CN, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso- butyl or tert-butyl), phenyl, pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, triazolyl WO 2024/199255 PCT/CN2024/083980 (preferably, lH-l,2,4-triazolyl, 4H-l,2,4-triazolyl), pyridinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rlh ;Rlf is each independently selected from hydrogen, methyl, ethyl, propyl (iso-propyl or n- propyl), cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or phenyl, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or phenyl is optionally substituted with at least one substituent R11;Rlh andR 1' are each independently hydrogen, -F, -Cl, -Br, -1, methyl, ethyl, propyl (iso- propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -OH, or -CN. [0031] Aspect 11.The compound of any one of preceding aspects, wherein R1 and R2 are each independently selected from -C1-8alkyl, -C3-C8cycloalkyl, -C3-C12cycloalkenyl and 3- to 12- membered heterocyclyl, wherein each of said -C!-8alkyl, -C3-C8cycloalkyl, -C3-C12cycloalkenyl and 3- to 12-membered heterocyclyl is optionally substituted with at least one substituent Rla ; orR1 and R2 together with the nitrogen atom to which they are attached, form a 3- to 8- membered unsaturated or saturated ring, said ring comprising 0-3 additional heteroatoms independently selected from nitrogen, oxygen or sulfur and said ring is optionally substituted with at least one substituent Rla ;Rla is independently hydrogen, halogen, deuterium, -C1-galkyl, -C3-C8cycloalkyl, -C6- C!2aryl, 5- to 12-membered heteroaryl, -ORlb or -CN, wherein each of said -C!-8alkyl, -C3- Cgcycloalkyl, -C6-C!2aryl and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent Rld; ortwo Rla together with the atom(s) to which they are attached, form a 3- to 8-membered unsaturated or saturated ring, said ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur and said ring is optionally substituted with at least one substituent Rld;Rlb is each independently selected from hydrogen, -C1-8alkyl, wherein said -C1-8alkyl is optionally substituted with at least one substituent Rle;Rld and Rle are each independently hydrogen, halogen, -C!-8alkyl, -C3-C8cycloalkyl, -C6- C!2aryl, 5- to 12-membered heteroaryl, -ORlf , -SO2Rlf or -CN, wherein each of said -C!-8alkyl, - C6-C12aryl and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent Rlh ;Rlf is each independently selected from hydrogen, -C-galkyl and -C3-C8cycloalkyl, wherein each of said -C!-8alkyl and -C3-C8cycloalkyl is optionally substituted with at least one substituent Rn ;Rlh andR ״are each independently hydrogen, halogen, -C1-8alkyl or -CN; WO 2024/199255 PCT/CN2024/083980 preferably, R1 and R2 are each independently selected from methyl, ethyl, propyl (iso- propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, chromanyl, isochromanyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl, wherein each of said methyl, ethyl, propyl (iso- propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, chromanyl, isochromanyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rla ; orR1 and R2 together with the nitrogen atom to which they are attached, form a 3-, 4-, 5-, 6-, 7- or 8-membered unsaturated or saturated ring, said ring comprising 0, 1, 2 or 3 additional heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent Rla ;Rla is independently hydrogen, -F, -Cl, -Br, -1, methyl, ethyl, propyl (iso-propyl or n- propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl (preferably, 2,3-dihydrofuro[2,3-b]pyridinyl), tetrahydrofuropyridinyl - ORlb or -CN, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rld; ortwo Rla together with the atom(s) to which they are attached, form a 3-, 4-, 5- or 6- membered unsaturated or saturated ring, said ring comprising 0, 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent Rld;Rlb is each independently selected from hydrogen, methyl, ethyl, propyl (iso-propyl or n- propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl and octyl, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl and octyl is optionally substituted with at least one substituent Rle;Rld and Rle are each independently hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl (iso- propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, cyclopropyl, WO 2024/199255 PCT/CN2024/083980 cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl, tetrahydrofuropyridinyl, -OR11, -SO2R11 or -CN, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, phenyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rlh ;Rlf is each independently selected from hydrogen, methyl, ethyl, propyl (iso-propyl or n- propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl is optionally substituted with at least one substituent R11;Rlh and R11 are each independently hydrogen, -F, -Cl, -Br, -1, methyl, ethyl, propyl (iso- propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl or -CN. [0032] Aspect 12.The compound of any one of preceding aspects, wherein R1 and R2 are WO 2024/199255 PCT/CN2024/083980 WO 2024/199255 PCT/CN2024/083980 WO 2024/199255 PCT/CN2024/083980 1 5׳ J J < cb $: N=Z N=< N=< N=، N= N= N= N=/O O O O C^f o WO 2024/199255 PCT/CN2024/083980 y v ^° or o or ■A A A "0ג d1 d1 d1 "dF F3C ( F3C or F3C F3C (F3C or F3C 0^ k 'WA׳ t* f*?‘ f* Af׳ ؟־ d cd ؟ ■ H- vi■ ■f cf 1 , f , A , A , A , A (A or A ), A (A or or WO 2024/199255 PCT/CN2024/083980 ) or R1 and R2 together with the nitrogen atom to which they are attached, form F,C The compound of any one of the preceding aspects, wherein L is a single Aspect 13. [0033] bond. [0034] Aspect 13*. The compound of any one of the preceding aspects, wherein Rla isindependently selected from hydrogen, methyl, ethyl, propyl, halo, methyl substituted with one or more halo, C3-5cycloalkyl, or -CN, or two Rla attached to the same atom form C3-5cycloalkyl; preferably, Rla is independently selected from hydrogen, methyl, ethyl, -F, -Cl, -Br, -I, -CF3, cyclopropyl, or -CN, or two Rla attached to the same atom form cyclopropyl. [0035] Aspect 13".The compound of any one of the preceding aspects, wherein Rld is independently selected from hydrogen, halo, C!-4alkyl, C!-4alkyl substituted with one or more halo, C1-4alkyl substituted with -OH, -O-C1-4alkyl, -O-C1-4alkyl substituted with one or more 41 WO 2024/199255 PCT/CN2024/083980 halo, C3-5cycloalkyl optionally substituted with fluoro, -SO2-C1-4alkyl, or -CN; preferably, Rld is selected from hydrogen, -F, -Br, -Cl, -1, methyl, ethyl, propyl, butyl, -CF3, hydroxypropyl, methoxy, trifluoromethoxy, cyclopropyl, fluorocyclopropyl, cyclobutyl, -SO2CH3, or -CN. [0036] Aspect 13'" .The compound of any one of the preceding aspects, wherein R2 is C!. 8alkyl; preferably, R2 is methyl, ethyl, propyl (iso-propyl or n-propyl), or butyl (n-butyl, sec- butyl, iso-butyl or tert-butyl); more preferably, R2 is methyl, ethyl, or propyl (iso-propyl or n- propyl); yet more preferably, R2 is methyl. [0037] Aspect 14.The compound of any one of the preceding aspects, wherein R3 is selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec- butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -CN, -OH or -NH2, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl is optionally substituted with at least one substituent selected from -F, -Cl, -Br, -1, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, hepthoxy, octoxy, methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or 3- to 8-membered heterocyclyl;preferably, R3 is selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -CN, -OH or -NH2;more preferably, R3 is selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl (iso- propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -CN, -OH;even more preferably, R3 is selected from hydrogen, -F, -Cl, methyl, ethyl, propyl (iso- propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl);even more preferably, R3 is selected from hydrogen. [0038] Aspect 15.The compound of any one of preceding aspects, wherein R4, R5, R6, R7, Rand R9 are each independently selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, wherein each of said methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert- butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl is optionally substituted with at least one substituent selected from -F, -Cl, -Br, -I, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, hepthoxy, octoxy, methyl, ethyl, propyl WO 2024/199255 PCT/CN2024/083980 (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8- membered heterocyclyl, phenyl, 5- to 12-membered heteroaryl, oxo, -CN, -OR4a , -SO2R4a , - SO2NR4a R4b , -C0R4a , -CO2R4a , -CONR4a R4b , -NR4a R4b , -NR4a COR4b , -NR4a CO2R4b , or- NR4a SO2R4b ;R4a and R4b are each independently hydrogen, methyl, ethyl, propyl (iso-propyl or n- propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; each of said methyl, ethyl, propyl (iso- propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl is optionally substituted with at least one - F, -Cl, -Br, -I, -OH, methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso- butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, hepthoxy, octoxy, C1-8alkoxy-C1-8alkyl-, -C2-8alkenyl, -C2-8alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl;preferably, R4, R5, R6, R7, R8 and R9 are each independently selected from hydrogen, -F, - Cl, -Br, -1, methyl, ethyl, propyl (iso-propyl or n-propyl), butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl), pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl;more preferably, R4, R5, R6, R7, R8 and R9 are each independently selected from hydrogen, - F, -Cl, -Br, -1, methyl, ethyl, propyl (iso-propyl or n-propyl), cyclopropyl, cyclobutyl;even more preferably, R4, R5, R6, R7, R8 and R9 are each independently selected from hydrogen, -F, -Cl, -Br, -I, methyl. [0039] Aspect 15’.A compound of formula (VIIIp): or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereofor an N-oxide thereof, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a tautomer thereof, or a deuterated analog thereof, wherein: (VIIIp), WO 2024/199255 PCT/CN2024/083980 Rla ’ is independently selected from hydrogen, methyl or ethyl; Rla " is hydrogen; or Rla and Rla " together with the atom to which they are attached, form a C3-5cycloalkyl;n5 ’ is 0, 1 or 2; andRla , R2, R6, and R7 are as defined in any one of the preceding aspects. [0040] In one embodiment: Rla is independently selected from halo, methyl substituted with one or more halo, C3- scycloalkyl or -CN; preferably, -F, -Cl, -Br, -1, -CF3, cyclopropyl or -CN;R2 is Ci-galkyl; preferably, methyl;R6 is hydrogen or methyl; preferably, hydrogen; andR7 is hydrogen. [0041] Aspect 15".A compound of formula (Vllr): or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a tautomer thereof, or a deuterated analog thereof, wherein Y’ is N or C(Rld), and Rla , R,d, R2, R6, and R7 are as defined in any one of the preceding aspects. [0042] In one embodiment: Rla is hydrogen or methyl;Rld is independently selected from hydrogen, halo, methyl substituted with one or more halo, C3-5cycloalkyl optionally substituted with fluoro, or -CN; preferably, hydrogen, -F, -Br, -I, -CF3, cyclopropyl, fluorocyclopropyl, cyclobutyl or -CN;R2 is C1-8alkyl; preferably, methyl, ethyl, or propyl;R6 is hydrogen or methyl; andR7 is hydrogen. [0043] In one embodiment, Y’is N. In one embodiment, Y’is C(Rld). [0044] Aspect 16.The compound of any one of the preceding aspects, wherein the compound is selected from: WO 2024/199255 PCT/CN2024/083980 Example 1 Example 2 Example 3) 0 NH2W J J( > ״NH Lo>NF XX 8^ F^/L/F XX — Example 4 Example 5 Example 6P cp" y XO NH2 Hn nIA/ H /o XO O _,N NH2( Hl T )—N N ^P־XoV ן h X>O’ Example 7 Example 8 Example 9Bn -'Byy KCN O XxrX^ 2OZ p—N N<__ ) R- ox >؛ XX Example 10 Example 11 Example 12PVFO /^/N^NH2؛ or >OO/ — N N ^F J " XX XO 0 /^N NH2H WJ J ( > "N0^ 2 H L / u __/ L01/ F v^F XO 0 _,N NH2h HI I < >"N N^p^0^ > H L /u __/ 0 ،Xf Example 13 Example 14 Example 15) O NH2( h1 I )—N N ~-XOV 2 H 2 ץu __ / 1—oo XX 4, NO / .../Nx^ n4 ]1 T/ N H^/O — ؛ / __ XX B N 0 _,N NH2 יוF X7 XXExample 16 Example 17 Example 18 WO 2024/199255 PCT/CN2024/083980 Sha <0 V0 H HX Y ° N__ / O Bh ׳tx ־' Fx^F CN Example 19 Example 20 Example 21 XMT XO O _,N NH2Hl ( > ״N XO 0 _,N NH2W j 1( > ״N N^A ״,,F O H ^FNC ל 7 — 0u __/ oNF VA F 0—7 5 h A / 0^FExample 22 Example 23 Example 24 0? px ״’ ) 0 NH2 H W J T < ״n n^a Vj H T> ^j N XXXX״ N=L N-~N'f3cWExample 25 Example 26 Example 27Xo O _^N NH2)I 1< ) ״N N AXOV H L /u _ / —0o Ap;x N >؛^ >X {1^* F N^ Example 28 Example 29 Example 30 U Hl J/CI H /_/ ،-o o F OAX' -d" ־ NC y^ NH، Example 31 Example 32 Example 33 WO 2024/199255 PCT/CN2024/083980 f 3c Z NOnA J TAn N^Ax f 3c XO 0 z^^N NH2H hT r < )1״N N^x/0^ 5 H L /؛- / __ u)( Example 34 Example 35 Example 36 yo f 3c A 0 _,N NH2xA Wif J / N N^AA،■ O A f 3c 0 N N h2—N N^AA H / f 3cExample 37 Example 38 Example 39Z/N/NH2N 0 ,^,N NH2 >׳ r !׳ — na'؟ NO z'~^ N ،nA Hfl TN N PH / f 3c An nAA pL Br ^N N^^ f 3c Example 40 Example 41 Example 42NO z-~./ Nz / ،M Hi JF N N ^/ ג f ■> h / 1 — o __ r y^F NC p o nh 2 w 1׳?, ° ؛ NA / 1 / F f 3c p ’ Example 43 Example 44 Example 45 NC^ ، NO z~~-/N<../NH2M Hfj JF 5 H L / y^F F ، NO NH2nA H/1 TAn'__/ A o Example 46 Example 47 Example 48 p O NH2/PA nV 0 1 / FBr Rr .d " Example 49 Example 50 Example 51 WO 2024/199255 PCT/CN2024/083980 ، N 0 NH2nX — UUnJ ° /־ 0 /^/Nx/NH2 HI T/ ،0Cv ° f 3c Example 52 Example 53 Example 54/^/N^/NHz Hl J 0 — ؛ / f 3c p 0 nh ל xx pH °( / F 0 /F^vn x/NHMJ T—M h^H)/ '—0 f 3c Example 55 Example 56 Example 57 0 /xA/X Hi J—N [j H/ '—0Ox f 3c 0 n H2W J I—n/ 0 f 3c 0 /^/NX/-NH2MJ J—N ^MJ/ '-0 cS ־^f 3c Example 58 Example 59 Example 60J J O NH2M HI J)־N Br NN 0 /^x.N^NH2n mH TXn Br O N N h2 —n / x o Br Example 61 Example 62 Example 63O ^,n^nh;—N N^X__ _ H // O cS ־^°Br O /N. ,nh 2n HIT )-NA/ N / H yn f xrU NH2 N= yUF Example 64 Example 65 Example 66 WO 2024/199255 PCT/CN2024/083980 /^/N/NH2—A 'HOTT>׳"N N/ H /nJ 0 NH2Hi I—n/ '-0 f 3c 0 /~-_/N^/NH2 n=2 " L° Example 67 Example 68 Example 69 N= nh 2 ؟ n ^؟ 0—N fl JJ/ H Br n^nh 2 ^؟ 0؛ N —/ 0 Cj^°Br Example 70 Example 71 Example 72__ /N NH2 HJ I/ '—o Cl 0 __ /N NH2 Hl I— ؛ /ryCl NH2 ؟ 0 ^^/ N yI TN AFvJ^H Jo J^0FExample 73 Example 74 Example 75NH2 Hl TJH U F 0 NH2 Mil F3C N V N H2—N N^A___ _ H /O — י /cSaBrExample 76 Example 77 Example 78O nh 2hI T—N/ H (־jhBr 0 /-^N^NH2wj T—N/ 0 Cj^ABr 0 /-^N^NH2Wj l—N/ 0 Cj^0Br Example 79 Example 80 Example 81 Hi T JH Jo Jjy0 f 3c 0 __ /N NH2wj T، - A ^ץ N N — F3C 0 ___/N NH2wj T—N N^ץA I Example 82 Example 83 Example 84 WO 2024/199255 PCT/CN2024/083980 n^nh 2 ^؟ ^ 0—N nAAHI / N f 3c n^nh 2 ^؟ 0—N nHAx / Nf 3c O /-^N^NH2HI 1—N— ؛ /VH°/ N Example 85 Example 86 Example 87O z^/N/NH2HI I—N N^Y ^3° / N o _Y HI I•—N N^Y ^Y f 3c NH2 ؟ 0 ^^/ NHI T—N h '"I— ؛ /Ihn >؛f 3c qH Example 88 Example 89 Example 90,^,N NH2— I— ؛ / f 3c NCV^N NHHi T—N f)/ —o cS^ 0f 3c n n h2—N N^HH f 3c / Example 91 Example 92 Example 93/^N^NH2—1// 0f 3c / T—N N^Yx HH h 0 ny N H2 FvYn X° V7Br Example 94 Example 95 Example 96NH2—N N^YxY X°V7NC 0 ^^NyNH,—Nj -'Ho f 3c 0^ yy nY N H2—N N^YxY'H״ fY^f 3c Example 97 Example 98 Example 99,^,N NH2—N nAA, H ״ /M" f 3c 0^ nn H2—N N^HHO //N/NH2HI T—N N^YH r> / o H • Example 100 Example 101 Example 102 WO 2024/199255 PCT/CN2024/083980 Hi T—NK.k CV rF3C 0Hi J—N N ץ)M v) NH2 ؟ O /^^N-a wM T/ N h l"'// ،—oF-/=< yMF Example 103 Example 104 Example 105 0x/^E N Y N H2Mn/ 3 H // °N= 0 NH2 ' L° n^nh 2 ^؟Yuno — ؛ /N= Example 106 Example 107 Example 108/--kkk s N= 0 NH2 Wj T N 'Hx F3c O /-^N^NH2 MMf T n=^H L° f 3c Example 109 Example 110 Example 111 Ml TN 'k... h 3 ?/ 0N wjf To ^־־ /N O NNH mCCT /" oN= F3C Example 112 Example 113 Example 114NH2 w j TN N-kxJ. H MN F3C O /-^N^NH2—A XIIkNe r F3c -a w j T kN Example 115 Example 116 Example 117 Mi T—N N^kkAL°Ml I—NJ. H uN= Ml I J. H uN=y^F Example 118 Example 119 Example 120 WO 2024/199255 PCT/CN2024/083980 Wj T n4،h l° 3^ f 0 Nv N H2—N N^XXF WH L /r L 0yv FBr 0 .fyNyNH;—N nHVf3... H ^0־yv FBr Example 121 Example 122 Example 123nh 2 ؟. n ^؟ J. ' M (37 f Br nh 2 ؟ n ^؟ 0anz^33*/־־■(37 f Br Q y^/Ny/NH2 J. H n 3(7 F F3C Example 124 Example 125 Example 126O /V/NH2'X—N A'A- , H // ^03^7 F f 3c nh 2 ؟ n ^؟ 0N^XX،،،J.... H WN= ^^F Br O /-^N^NH2 N=^H L°Vv F Br Example 127 Example 128 Example 129o nh 2'X—N nAA،،، f 3c O /^/Nxy/NH2nn=^h l° fF3C 0 NH2— N N-^XX 0^ Example 130 Example 131 Example 132nh 2 ؟. n ^؟X—N nAxJ..H M (37 F Br n^nh 2 ^؟ O 0 /־־■3v F Br NH2 ؟. N ^؟ 0 y J..H u 3(7 F f 3c Example 133 Example 134 Example 135NH2 HI J n A) ,/ A 3> f 3c NH2 ؟ 0 ^-/ NHi TV 6 Br 0 __ /N NH2Hj J—m A'y')— ؛ ״ y3>f Br Example 136 Example 137 Example 138 WO 2024/199255 PCT/CN2024/083980 w j T—N 0 ■Br 0 NH2Aaj T0y ؛ n yx —/ " H3j ^f Br f 3c yN nAA/ h ? / o Example 139 Example 140 Example 141 Ml T—N.... H V /° =؟ N n^nh 2 ^؟ OHn n^AAxJ... H uM^^F Br n^nh 2 ^؟ 0hn n=^h l° Vy FBr Example 142 Example 143 Example 144//N/NH2—N wAy J.... H u ^37 ff 3c ؛ O Nxx N H—NH /־־" ^3/ Ff 3c N h2—n y' ; y— ؛ H1Ff 3c Example 145 Example 146 Example 147/^^Nx/NH2HJ T—N h yy__ / ^0 f 3c o nh 2—N nAAf y-H L /y^ F f 3c 0^ N h2—n n Ay- O... H u yy Ff 3c Example 148 Example 149 Example 150N NH2—N N^AAx ...... H y ؛ 0 zH / N Y N H—Nf y-H L /r — 0 NH2 ؟ 0 ^^/ NAAj T< yN N״y v ...h y?nA 0Vy F Example 151 Example 152 Example 153NH2/x W1 T^־N N^X0 L° 0 //N/NH2z HJ I < yN N^y.... H A ?N= 0yj^F f 3c 0AyM n^AAx n=^h l°^y Ff 3c Example 154 Example 155 Example 156 WO 2024/199255 PCT/CN2024/083980 0 NH2JJ. H uN=0^Ff 3c O NH20^ Hl TL° f 3c Example 157 Example 158 Example 159 /x Hi T HNO ^־ /יNW HJ To ؛~ /XX f 3c NH2 ؟ 0 ^^/ NHJ T< x 'ץ ؛^ N —/ 0 f 3c Example 160 Example 161 Example 162 Hi J—N/ HN—( O// X__ /f 3c hj T—n— ؛ /N^< 0// X_/f 3c Hi T—N/ H(vXf 3cExample 163 Example 164 Example 165O W J J/ O cS ־kf 3c W j T HH f 3c NH2 ؟ 0 ^-/ NhI l HH X> vvXf 3cExample 166 Example 167 Example 168NNH,y—A(X—N N ^Xx^ f 3c 0 /N. ^NH2y—A(X HH X h vvXf 3c O /-^N^NHW j T—NH /dl Example 169 Example 170 Example 171O NH2Hi T—n y^Xx/ H 0 /-^N^NH2mI T....״ n n^nh 2 ^؟ 0—N N^lxF H L /r —0 Example 172 Example 173 Example 174 WO 2024/199255 PCT/CN2024/083980 HI T. H L6 0 Hl Tf y- H L /o — ؛ r 0 HI T. H Example 175 Example 176 Example 177^N^NHo HUTf y- H L /— ؛ r 0 /^/Nxy/NH2—N N '1' H /— ؛ / Br O //N/NH2—N/ 0 Br Example 178 Example 179 Example 180 mI I—N ^^1— ؛ / f 3cExample 181، NOM W J T< > ״Nb 3 N=N^/N- f 3cy ? pyf 3c ....
Br'15 W/ O /-^ y.^HH __) ،— o، NIv' v^F HHI" fVV,N Vy F XO 0 /-^n^nh 2yl HI J /N_ / H<^HN v^F <، XN O /~->/N^/NH2N1 — J Tri X f 3c WO 2024/199255 PCT/CN2024/083980 O NH27— w ( NO //N NH2M y-d Y^N nAA d ■°NO /-../N /NN^? J T^N' __/ '—O، NFVVNCQ^fN^، N 0T ؟ — 7<، N 0 NH2J| TN^NH2 ׳ NO /x ،N^ W'j T^n ^'ץ— ؛ / 'o / N h^/ ^0^N N^X^.;y VCN ، NO z^^n^/n H2N— j T'ז^ ، NO /^^n^nh 2TN^^ H / 1 11 4 N Ox _,N NH2 רN=L HJy scf 3Br Q oh1T Q °h1nTnh' Q °r-a NTNH2 /j h T>/) b t S Ooo £N^،^F /o7=O^oN /> O _,N NH2y //0 _,N NH2yxz 1n^nh 2 ^؟ ץ ס כ 7( >"N N ^H uN <׳״ )H Y>dj sdy f Cnf Cn NFvvV^Fv^FV^F WO 2024/199255 PCT/CN2024/083980 KHg X0 0 _,N NH2Hx W1 J yv x H x o >An d^"־ 0pMeOX f 300، N--N 03W N—7pPf y 0 nh 2nd W J T،، N N^W (■״ >y^j h xx FX NC n^nh 2 /-؟ 0 PX cy F°w^f NTNH2yy y—I 1p BpS־ יס NC fXn PF F ) H w L N~-N'OHO /^^N^/NH2__/ י_ ן //! TOHO /^^N^/NH2ן ן! // __ y / __ ,OHO NH2ץ ךז // __ y /J! A ؟ — / — /( ) ״N N 'VVXOP ) H L // / 1- א! /I< )IN N/pX y^y H L>/ / א J! /I< y״N n ־^x y^ H x> ، NFvvFH Npp VXFyyVP F p =A* R HP*P7 OA W J J N xVF > H X /__ / '—O Cp^f ypp T//N^NH2A n_ y h 1 0hHTO^n H^y?__/ XqA / JL /A f 5 H L /יל " X fh PF VP Ffh XF n AyAT N N^A — ؛ — 1p H A / r _ / 0—י ay F B? px* d" " F3C Shy ,d- ) 0 _,N NH2wj 1O' yay ny NH2Vj H nH־ 3 ,^p 3 ־ 6 nHAd nA^ oSAyyyy A5NH1 Shx' A;nAaaA YNH2 ^؟ O/ yQF°yXX NYNH2 YA' ° /-- / YY YA J YF ^N N^HYxA x ° yAf 3c Y hA y^ N f 3c A hX ° yANC aOi NTNH2Awy h2Q/ °yay ny NH2Yj B A aacn F VN AO)X • NC x ؛< Fp) BY ci-Ynf 3c,f/F /?—3 ,F°yya ny NH2Q °yXX NTNH2A Hnr Nx NH־Am nAAF Yn N YAj L° ciA^nNC X צA H x ° vY c1 S V O z-^ /A YA A YA-mYx"2d y Q /-^/N NHyy Yh Y YF N 'A'3F An Z nAA X ؛ F N N^Hp H / H /F_/ YJ A2_/ 1—oA/ NCG^c1 WO 2024/199255 PCT/CN2024/083980 to ' ״ ׳ x ؛ top NC ti> PX' ^־ClNCOtoCTVa[nt NH2F VN AC)A NC A VNC AA d NC Qf °kt nt n"־XO 0 _,N NH2A 1NH2 ؟ XO O /-^NA AJ J/v N 1O N= ( >״N N^^R y^NNC ^؟ N N ״ < )hci^3n f 3cXo 0 _,N NH2Hi JXO O _,N NH2Wj JXO 0 NH2A Al J( > ■״N N^toto=<> H u Br ؛ N N^V " < )0^ > H X> R f 3c א o^> H L> f 3c/ ■R' ״ r ׳ NC RHiX"■ B f 3c to fC" d" ־ f 3c N 0 ,^,N NH2 >؛A wl TO ft :Ax NH1 F ،N h__ / 0d Nf OoxN^ O״• f 3c Or hO! Af 3c tod N=< °tof 3c B8 M=Z °AX to to' N=/ ° ito ־—N WO 2024/199255 PCT/CN2024/083980 Xo 0 .N<_NHxxx xA 1XO 0 /^AAHd־־( xXX X O״N spnAX XO O /^NX^NH2/-( )—C<- ) "N N ' A'xvJ HpX d/ F ArF0 /^^N^NH2XA Xa X XI N N^A 0 ־ 0 ■ n^nh 2 ^؟Yun n^AA / H /nA nh 2 ؟ n ^؟ O) "N N^AfAxo — ؛ / 0 N A N H2) "N I'A-AO — ؛ / ___F uvNx/NHs ,״ 0 XII)1״N N^Ax/ H // 0f 7־=yx F NH2 ؟ O /-^N mPT)"N2J H x>^^F f 3c 0 /A's/A YCI X )1״N N A"A,H ud f 3c O NH2y 6 f 3c o NH2 YCII).llN N Ax, / H /o — ؛ / Ff 3c O /^^N^NH2 XX J )1״N N^Ax f 3c NH2 ؟ O /-^N YCII)"N) H M Br NH2 ؟ o /-^N mPT )u,n 2J H M y 0 /^,N NH2 Y—CII )1״N AA' > ■ -O /-^N^NH2—)u,No — ؛ / ___ FBr 0 /-^n^nh 2 ^Of x )u,N N^'-Ad X Br^,N NH2 YCI )1״N N ״A כ h u XF 0 /"uVNx/NH2—a Xu H^y p 0 /^/Nx_/NH2־a XXX X>״׳N N^Ax y? 6 WO 2024/199255 PCT/CN2024/083980 //N/NH2—a HOt JT>״N N^AA./ H /__ 7 ^0(37 f 0 /^N^NH h V1׳ 0 aA״a HI TAn n^AnJ " L°Ia F 0 N Y N H2!ן( ZxnA o /^,N NH2 XII AC)o — ؛ 0 aA״a HI TAn n^A__ / 0 (37 F o __ N NH2Hn nJa $>f 3c ־a Hi lAno " F3C Hn 4 f 3c//N/NH2Vn nAA__ 7 H / ___7 ^^37 f f 3c ־a Hi JXn f 3c 0 /A^^"A Hf J IAn n^AH u nA Br 0 //N/NH2An nAaA2 h A nA I^FBr ^^,N^NHs-N nAaI? - Br 0 /^/N^/NH2hOlXH J)_ /(37 FBrO /^/N NHhOlX n Br Hn nX3 H UM= NH2 ؟ 0 ^/ xNAn nHa H? H p 0 /^,N NH2 Y—CII An n^A nh 2 ؟ n ^؟ ^ 0AN N ׳-■A H /o — ؛ / (37 f o __/Nx/NHzAn nHA i / WO 2024/199255 o x AN.NH2 W N=d 0 z^N NH2 vgid O /^^N^NH2/—N/ H /N= > / Pd* N 0 f 3c A d " f 3c gw f 3c Ox AN.NH2؛ a ■ f 3c> X־^ N=d Br ^1d' Br g״w Br Br ,^1d" Br Ox NH2zW N= d ° Ox NH2 I ,gWO /~^N^NHf 3c Jf TN '^w ׳c M=d y^F WO 2024/199255 PCT/CN2024/083980 id="p-45" id="p-45" id="p-45"
id="p-45"
[0045] Aspect 17.A pharmaceutical composition comprising a compound of any one of aspects 1-16 or or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof, and a pharmaceutically acceptable excipient.
WO 2024/199255 PCT/CN2024/083980 [0046] In one embodiment,the pharmaceutical composition is for use as described herein, e.g., in any one of Aspects 18-22. [0047] Aspect 18.A method of decreasing or inhibiting PRMT5 activity, comprising administering to a subject in need thereof an effective amount of the compound according to any one of aspects 1-16, or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof, including the compound of formula (1) or any specific compound exemplified herein. [0048] Aspect 19.A method of treating a disease modulated by PRMT5, comprising administering to a subject in need thereof an effective amount of the compound according to any one of aspects 1-16, or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof, including the compound of formula (1) or any specific compound exemplified herein. [0049] Aspect 20.Use of a compound of any one of aspects 1 -16 or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof in the preparation of a medicament for treating a disease modulated by PRMT5. [0050] Aspect 21.The method of aspect 19 or the use of aspect 20, wherein the disease is cancer. [0051] Aspect 22.The method of aspect 19 or the use of aspect 20, wherein the disease is MTAP-null solid tumor, including lung cancer, bladder cancer, melanoma, pancreatic cancer, esophageal cancer, gastric adenocarcinoma, breast cancer, and glioblastoma. DETAILED DESCRIPTION OF THE INVENTION [0052]The following terms have the indicated meanings throughout the specification: [0053]Unless specifically defined elsewhere in this document, all other technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this invention belongs. [0054]The following terms have the indicated meanings throughout the specification: [0055]As used herein, including the appended claims, the singular forms of words such as "a", "an", and "the", include their corresponding plural references unless the context clearly indicates otherwise. [0056]The term "or" is used to mean, and is used interchangeably with, the term "and/or " unless the context clearly dictates otherwise. [0057]The term "alkyl" includes a hydrocarbon group selected from linear and branched, saturated hydrocarbon groups comprising from 1 to 18, such as from 1 to 12, further such as from 1 to 10, more further such as from 1 to 8, or from 1 to 6, or from 1 to 4, carbon atoms. Examples of alkyl groups comprising from 1 to 6 carbon atoms (i.e., C1-6 alkyl) include, but not WO 2024/199255 PCT/CN2024/083980 limited to, methyl, ethyl, 1-propyl or n-propyl ("n-Pr"), 2-propyl or isopropyl ("i-Pr"), 1-butyl or n-butyl ("n-Bu"), 2-methyl-l -propyl or isobutyl ("i-Bu"), 1-methylpropyl or s-butyl ("s-Bu"), 1,1-dimethylethyl or t-butyl ("t-Bu"), 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2- butyl, 3-methyl-l-butyl, 2-methyl-l-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3- methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl and 3,3-dimethyl-2-butyl groups. If there is no opposite definition, "Cnsalkyl" includes a hydrocarbon group selected from linear and branched, saturated hydrocarbon groups comprising from 1 to 8 carbon atoms, "C1-8alkyl" also includes a hydrocarbon group selected from linear and branched, saturated hydrocarbon groups comprising from 1 to 6 carbon atoms (C1-6alkyl) or 1 to carbon atoms (C1-4alkyl). [0058]The term "propyl " includes 1-propyl or n-propyl ("n-Pr"), 2-propyl or isopropyl ("i-Pr"). [0059]The term "butyl " includes 1 -butyl or n-butyl ("n-Bu"), 2-methyl-1 -propyl or isobutyl ("i-Bu"), 1-methylpropyl or s-butyl ("s-Bu"), 1,1-dimethylethyl or t-butyl ("t-Bu"). [0060]The term "pentyl " includes 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2- butyl, 3-methyl-l-butyl, 2-methyl-l-butyl. The term "pentyl " further comprises , id="p-61" id="p-61" id="p-61"
id="p-61"
[0061]The term "hexyl " includes 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2- pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl and 3,3- dimethyl-2-butyl. [0062]The term "alkylene " refers to a divalent alkyl group by removing two hydrogen from alkane. Alkylene includes but not limited to methylene, ethylene, propylene, and so on. [0063]The term "halogen " includes fluoro (F), chloro (Cl), bromo (Br) and iodo (1). [0064]The term "H" or "hydrogen" disclosed herein includes Hydrogen and the non- radioisotope deuterium. [0065]The term "alkenyl" includes a hydrocarbon group selected from linear and branched hydrocarbon groups comprising at least one C=C double bond and from 2 to 18, such as from to 8, further such as from 2 to 6, carbon atoms. Examples of the alkenyl group, e.g., C2-6 alkenyl, include, but not limited to ethenyl or vinyl, prop-l-enyl, prop-2-enyl, 2-methylprop-l-enyl, but- 1-enyl, but-2-enyl, but-3-enyl, buta-1,3-dienyl, 2-methylbuta- 1,3-dienyl, hex-l-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl, and hexa-1,3-dienyl groups.
WO 2024/199255 PCT/CN2024/083980 [0066]The term "alkenylene " refers to a divalent alkenyl group by removing two hydrogen from alkene. Alkenylene includes but not limited to, vinylidene, butenylene, and so on. [0067]The term "alkynyl" includes a hydrocarbon group selected from linear and branched hydrocarbon group, comprising at least one C=C triple bond and from 2 to 18, such as 2 to 8, further such as from 2 to 6, carbon atoms. Examples of the alkynyl group, e.g., C2-6 alkynyl, include, but not limited to ethynyl, 1-propynyl, 2-propynyl (propargyl), 1-butynyl, 2-butynyl, and 3-butynyl groups. [0068]The term "alkynylene" refers to a divalent alkynyl group by removing two hydrogen from alkyne. Alkenylene includes but not limited to ethynylene and so on. [0069]The term "cycloalkyl" includes a hydrocarbon group selected from saturated cyclic hydrocarbon groups, comprising monocyclic and polycyclic (e.g., bicyclic and tricyclic) groups including fused, bridged or spiro cycloalkyl. [0070]For example, the cycloalkyl group may comprise from 3 to 12, such as from 3 to 10, further such as 3 to 8, further such as 3 to 6, 3 to 5, or 3 to 4 carbon atoms. Even further for example, the cycloalkyl group may be selected from monocyclic group comprising from 3 to 12, such as from 3 to 10, further such as 3 to 8, 3 to 6 carbon atoms. Examples of the monocyclic cycloalkyl group include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, and cyclododecyl groups. In particular, examples of the saturated monocyclic cycloalkyl group, e.g., C3-8cycloalkyl, include, but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups. In a preferred embodiment, the cycloalkyl is a monocyclic ring comprising 3 to 6 carbon atoms (abbreviated as C3-6 cycloalkyl), including but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Examples of the bicyclic cycloalkyl groups include those having from 7 to 12 ring atoms arranged as a fused bicyclic ring selected from [4,4], [4,5], [5,5], [5,6] and [6,6] ring systems, or as a bridged bicyclic ring selected from bicyclo[2.2.1 ]heptane, bicyclo[2.2.2]octane, and bicyclo[3.2.2]nonane. Further Examples of the bicyclic cycloalkyl groups include those arranged as a bicyclic ring selected from [5,6] and [6,6] ring systems. [0071]The term "spiro cycloalkyl" includes a cyclic structure which contains carbon atoms and is formed by at least two rings sharing one atom. [0072]The term "fused cycloalkyl" includes a bicyclic cycloalkyl group as defined herein which is saturated and is formed by two or more rings sharing two adjacent atoms. [0073]The term "bridged cycloalkyl" includes a cyclic structure which contains carbon atoms and is formed by two rings sharing two atoms which are not adjacent to each other. The term "to 10 membered bridged cycloalkyl" includes a cyclic structure which contains 7 to 12 carbon atoms and is formed by two rings sharing two atoms which are not adjacent to each other.
WO 2024/199255 PCT/CN2024/083980 [0074]Examples of fused cycloalkyl, fused cycloalkenyl, or fused cycloalkynyl include but are not limited to bicyclo[ 1.1.0]butyl, bicyclo[2.1.0]pentyl, bicyclo[3.1.0]hexyl, bicyclo[4.1.0]heptyl, bicyclo[3.3.0]octyl, bicyclo[4.2.0]octyl, decalin, as well as benzo 3 to membered cycloalkyl, benzo C4-6 cycloalkenyl, 2,3-dihydro-IH-indenyl, IH-indenyl, 1, 2, 3,4- tetralyl, 1,4-dihydronaphthyl, etc. Preferred embodiments are 8 to 9 membered fused rings, which refer to cyclic structures containing 8 to 9 ring atoms within the above examples. [0075]The term "aryl" used alone or in combination with other terms includes a group selected from:5- and 6-membered carbocyclic aromatic rings, e.g., phenyl;bicyclic ring systems such as 7 to 12 membered bicyclic ring systems, wherein at least one ring is carbocyclic and aromatic, e.g., naphthyl and indanyl; and,tricyclic ring systems such as 10 to 15 membered tricyclic ring systems wherein at least one ring is carbocyclic and aromatic, e.g., fluorenyl. [0076]The terms "aromatic hydrocarbon ring" and "aryl" are used interchangeably throughout the disclosure herein. In some embodiments, a monocyclic or bicyclic aromatic hydrocarbon ring has 5 to 10 ring-forming carbon atoms (i.e., C5-10 aryl). Examples of a monocyclic or bicyclic aromatic hydrocarbon ring includes, but not limited to, phenyl, naphth-1 -yl, naphth-2-yl, anthracenyl, phenanthrenyl, and the like. In some embodiments, the aromatic hydrocarbon ring is a naphthalene ring (naphth-1-yl or naphth-2-yl) or phenyl ring. In some embodiments, the aromatic hydrocarbon ring is a phenyl ring. [0077]Specifically, the term "bicyclic fused aryl" includes a bicyclic aryl ring as defined herein. The typical bicyclic fused aryl is naphthalene. [0078]The term "heteroaryl" includes a group selected from:5- , 6- or 7-membered aromatic, monocyclic rings comprising at least one heteroatom, for example, from 1 to 4, or, in some embodiments, from 1 to 3, in some embodiments, from 1 to 2, heteroatoms, selected from nitrogen (N), sulfur (S) and oxygen (O), with the remaining ring atoms being carbon;7- to 12-membered bicyclic rings comprising at least one heteroatom, for example, from to 4, or, in some embodiments, from 1 to 3, or, in other embodiments, 1 or 2, heteroatoms, selected from N, O, and S, with the remaining ring atoms being carbon and wherein at least one ring is aromatic and at least one heteroatom is present in the aromatic ring; and11- to 14-membered tricyclic rings comprising at least one heteroatom, for example, from to 4, or in some embodiments, from 1 to 3, or, in other embodiments, 1 or 2, heteroatoms, selected from N, O, and S, with the remaining ring atoms being carbon and wherein at least one ring is aromatic and at least one heteroatom is present in an aromatic ring.
WO 2024/199255 PCT/CN2024/083980 [0079]When the total number of S and O atoms in the heteroaryl group exceeds 1, those heteroatoms are not adjacent to one another. In some embodiments, the total number of S and O atoms in the heteroaryl group is not more than 2. In some embodiments, the total number of S and O atoms in the aromatic heterocycle is not more than 1. When the heteroaryl group contains more than one heteroatom ring member, the heteroatoms may be the same or different. The nitrogen atoms in the ring(s) of the heteroaryl group can be oxidized to form N-oxides. [0080]Specifically, the term "bicyclic fused heteroaryl" includes a 7- to 12-membered, preferably 7- to 10-membered, more preferably 9- or 10-membered fused bicyclic heteroaryl ring as defined herein. Typically, a bicyclic fused heteroaryl is 5-membered/5-membered, 5- membered/6-membered, 6-membered/6-membered, or 6-membered/7-membered bicyclic. The group can be attached to the remainder of the molecule through either ring. [0081]"Heterocyclyl", "heterocycle" or "heterocyclic" are interchangeable and include a non- aromatic heterocyclyl group comprising one or more heteroatoms selected from nitrogen, oxygen or optionally oxidized sulfur as ring members, with the remaining ring members being carbon, including monocyclic, fused, bridged, and spiro ring, i.e., containing monocyclic heterocyclyl, bridged heterocyclyl, spiro heterocyclyl, and fused heterocyclic groups. [0082]The term "at least one substituent" disclosed herein includes, for example, from 1 to 4, such as from 1 to 3, further as 1 or 2, substituents, provided that the theory of valence is met. For example, "at least one substituent F" disclosed herein includes from 1 to 4, such as from 1 to 3, further as 1 or 2, substituents F. [0083]The term "divalent " refers to a linking group capable of forming covalent bonds with two other moieties. For example, "a divalent cycloalkyl group " refers to a cycloalkyl group obtained by removing two hydrogen from the corresponding cycloalkane to form a linking group, the term "divalent aryl group ", "divalent heterocyclyl group " or "divalent heteroaryl group " should be understood in a similar manner. [0084]Compounds disclosed herein may contain an asymmetric center and may thus exist as enantiomers. "Enantiomers " refer to two stereoisomers of a compound which are non- superimposable mirror images of one another. Where the compounds disclosed herein possess two or more asymmetric centers, they may additionally exist as diastereomers. Enantiomers and diastereomers fall within the broader class of stereoisomers. All such possible stereoisomers as substantially pure resolved enantiomers, racemic mixtures thereof, as well as mixtures of diastereomers are intended to be included. All stereoisomers of the compounds disclosed herein and/or pharmaceutically acceptable salts thereof are intended to be included. Unless specifically mentioned otherwise, reference to one isomer applies to any of the possible isomers. Whenever the isomeric composition is unspecified, all possible isomers are included.
WO 2024/199255 PCT/CN2024/083980 [0085]When compounds disclosed herein contain olefinic double bonds, unless specified otherwise, such double bonds are meant to include both E and Z geometric isomers. [0086]When compounds disclosed herein contain a di-substituted cyclic ring system, substituents found on such ring system may adopt cis and trans formations. Cis formation means that both substituents are found on the upper side of the 2 substituent placements on the carbon, while trans would mean that they were on opposing sides. For example, the di-substituted cyclic ring system may be cyclohexyl or cyclobutyl ring. [0087]It may be advantageous to separate reaction products from one another and/or from starting materials. The desired products of each step or series of steps is separated and/or purified (hereinafter separated) to the desired degree of homogeneity by the techniques common in the art. Typically such separations involve multiphase extraction, crystallization from a solvent or solvent mixture, distillation, sublimation, or chromatography. Chromatography can involve any number of methods including, for example: reverse-phase and normal phase; size exclusion; ion exchange; high, medium and low pressure liquid chromatography methods and apparatus; small scale analytical; simulated moving bed ("SMB") and preparative thin or thick layer chromatography, as well as techniques of small scale thin layer and flash chromatography. One skilled in the art could select and apply the techniques most likely to achieve the desired separation. [0088]"Diastereomers " refer to stereoisomers of a compound with two or more chiral centers but which are not mirror images of one another. Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher ’s acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereoisomers to the corresponding pure enantiomers. Enantiomers can also be separated by use of a chiral HPLC column. [0089]A single stereoisomer, e.g., a substantially pure enantiomer, may be obtained by resolution of the racemic mixture using a method such as formation of diastereomers using optically active resolving agents (Eliel, E. and Wilen, S. Stereochemistry of Organic Compounds. New York: John Wiley & Sons, Inc., 1994; Lochmuller, C. H., et al. "Chromatographic resolution of enantiomers: Selective review." J. Chromatogr., 113(3) (1975): pp. 283-302). Racemic mixtures of chiral compounds of the invention can be separated and isolated by any suitable method, including: (1) formation of ionic, diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods, (2) formation of diastereomeric WO 2024/199255 PCT/CN2024/083980 compounds with chiral derivatizing reagents, separation of the diastereomers, and conversion to the pure stereoisomers, and (3) separation of the substantially pure or enriched stereoisomers directly under chiral conditions. See: Wainer, Irving W., Ed. Drug Stereochemistry: Analytical Methods and Pharmacology. New York: Marcel Dekker, Inc., 1993. [0090]Some of the compounds disclosed herein may exist with different points of attachment of hydrogen, referred to as tautomers. For example, compounds including carbonyl -CH2C(O)- groups (keto forms) may undergo tautomerism to form hydroxyl -CH=C(OH)- groups (enol forms). Both keto and enol forms, individually as well as mixtures thereof, are also intended to be included where applicable. [0091]"Prodrug " refers to a derivative of an active agent that requires a transformation within the body to release the active agent. In some embodiments, the transformation is an enzymatic transformation. Prodrugs are frequently, although not necessarily, pharmacologically inactive until converted to the active agent. [0092]"Pharmaceutically acceptable salts" refer to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. A pharmaceutically acceptable salt may be prepared in situ during the final isolation and purification of the compounds disclosed herein, or separately by reacting the free base function with a suitable organic acid or by reacting the acidic group with a suitable base. The term also includes salts of the stereoisomers (such as enantiomers and/or diastereomers), tautomers and prodrugs of the compound of the invention. [0093]In addition, if a compound disclosed herein is obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, such as a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize various synthetic methodologies that may be used without undue experimentation to prepare non-toxic pharmaceutically acceptable addition salts. [0094]The terms "administration ", "administering ", "treating " and "treatment " herein, when applied to an animal, human, experimental subject, cell, tissue, organ, or biological fluid, mean contact of an exogenous pharmaceutical, therapeutic, diagnostic agent, or composition to the animal, human, subject, cell, tissue, organ, or biological fluid. Treatment of a cell encompasses contact of a reagent to the cell, as well as contact of a reagent to a fluid, where the fluid is in contact with the cell. The term "administration " and "treatment " also means in vitro and ex vivo treatments, e.g., of a cell, by a reagent, diagnostic, binding compound, or by another cell. The WO 2024/199255 PCT/CN2024/083980 term "subject " herein includes any organism, preferably an animal, more preferably a mammal (e.g., rat, mouse, dog, cat, and rabbit) and most preferably a human. [0095]The term "effective amount" or "therapeutically effective amount " refers to an amount of the active ingredient, such as compound that, when administered to a subject for treating a disease, or at least one of the clinical symptoms of a disease or disorder, is sufficient to affect such treatment for the disease, disorder, or symptom. The term "therapeutically effective amount " can vary with the compound, the disease, disorder, and/or symptoms of the disease or disorder, severity of the disease, disorder, and/or symptoms of the disease or disorder, the age of the subject to be treated, and/or the weight of the subject to be treated. An appropriate amount in any given instance can be apparent to those skilled in the art or can be determined by routine experiments. In some embodiments, "therapeutically effective amount " is an amount of at least one compound and/or at least one stereoisomer, tautomer or prodrug thereof, and/or at least one pharmaceutically acceptable salt thereof disclosed herein effective to "treat " as defined herein, a disease or disorder in a subject. In the case of combination therapy, the term "therapeutically effective amount " refers to the total amount of the combination objects for the effective treatment of a disease, a disorder or a condition. [0096]The term "disease " refers to any disease, discomfort, illness, symptoms or indications, and can be interchangeable with the term "disorder " or "condition ". [0097]Throughout this specification and the claims which follow, unless the context requires otherwise, the term "comprise", and variations such as "comprises" and "comprising" are intended to specify the presence of the features thereafter, but do not exclude the presence or addition of one or more other features. When used herein the term "comprising" can be substituted with the term "containing", "including" or sometimes "having". [0098]Throughout this specification and the claims which follow, the term "Cn -m" indicates a range which includes the endpoints, wherein n and m are integers and indicate the number of carbons. Examples include Cr-8, Cr-6, and the like. [0099]Illustrations herein showing a substituent(s) bonded to a cyclic group (e.g., aryl, heteroaryl, cycloalkyl, fused cyclic group, spiro cyclic group) through a bond between ring atoms are meant to indicate, unless specified otherwise, that the substituent(s) may be bonded to the cyclic group at any ring position of any ring in the cyclic group (e.g., any ring in a fused cyclic group), so long as such substitution results in a stable compound. [0100]Unless specifically defined elsewhere in this document, all other technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this invention belongs. EXAMPLES WO 2024/199255 PCT/CN2024/083980 General Synthesis [0101]Compounds disclosed herein, including salts thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes. [0102]The reaction for preparing compounds disclosed herein can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially non-reactive with the starting materials, the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent ’s boiling temperature. A given reaction can be carried out in one solvent or mixture of solvents. [0103]The selection of appropriate protecting group, can be readily determined by one skilled in the art. In the synthesis schemes, some protection/deprotection steps are not shown and can be incorporated before, after or in between any steps. The protecting group shown in the synthesis schemes may or may not be used based on reaction conditions. The sequences of reactions may vary and provide similar results. [0104]Reactions can be monitored according to any suitable method known in the art, such as NMR, UV, HPLC, LC-MS and TLC. Compounds can be purified by a variety of methods, including prep-HPLC and silica gel chromatography. Unless specified, prep-HPLC uses a buffered acetonitrile/water systems and silica gel chromatography (including column chromatography and prep-TLC) uses PE/EtOAc or DCM/MeOH systems as mobile phases. NMR spectra are recorded using a Bruker or Varian instrument with preset pulse sequences.
Scheme I WO 2024/199255 PCT/CN2024/083980 Deprotection R1-NH (vii) R2Amide Coupling (viii) M = hydrogen, boronic acid, boronic ester or metalsX = halogens or pseudohalogens Y = alkyl or substituted alkyl Pg = optional protective groups [0105]For example, compounds of Formula (I) can be formed as shown in Scheme I. Compound (i) and compound (ii) can be coupled together by transition metal catalyzed coupling to give compound (iii). Compound (iii) can be deprotected to give compound (iv). Compound (iv) can intramolecularly cyclize to give compound (v). Compound (v) can be saponified to give compound (vi). Compound (vi) can be coupled with compound (vii) to give compound (viii) [i.e., Formula (I)].
WO 2024/199255 Scheme II PCT/CN2024/083980 id="p-106" id="p-106" id="p-106"
id="p-106"
[0106]For example, compounds of Formula (I) can be formed as shown in Scheme II. Compound (i) can go through a dehydrative cyclization to give compound (ii). Compound (ii) can be saponified to give compound (iii). Compound (iii) can be coupled with compound (iv) to give compound (v) [i.e., Formula (I)]. Scheme III b) (vi) (viii)X1, X2 = halogens or pseudohalogens Y = alkyl or substituted alkyl [0107]For example, compounds of Formula (I) can be formed as shown in Scheme III.Compound (i) can be halogenated to give compound (ii). Compound (ii) can react with compound (iii) through an enamine-Heck reaction to give compound (iv). Compound (iv) can be aminated to give compound (v). Compound (v) can be saponified to give compound (vi).Compound (vi) can be coupled with compound (vii) to give compound (viii) [i.e., Formula (I)].
WO 2024/199255 Scheme IV PCT/CN2024/083980 OY (i) Amination Pg2N OYHalogenation Pg2N(iii) (vii) (viii) Amide Coupling Deprotection R1-NH (ix) R2 (x) M = hydrogen, boronic acid, boronic ester or metals X1, X2 = halogens or pseudohalogens Y = alkyl or substituted alkyl Pg = optional protective groups [0108]For example, compounds of Formula (I) can be formed as shown in Scheme IV. Compound (i) can be aminated, for example, via metal-catalyzed coupling reactions, to give compound (ii). Compound (ii) can be halogenated to give compound (iii). Compound (iii) and compound (iv) can be couple together by transition metal catalyzed coupling to give compound (v). Compound (v) can be deprotected to give compound (vi). Compound (vi) can intramolecularly cyclize to give compound (vii). Compound (vii) can be saponified to give compound (viii). Compound (viii) can be coupled with compound (ix) followed by optional deprotection to give compound (x) [i.e., Formula (I)].
WO 2024/199255 Scheme V PCT/CN2024/083980 CN Amination (vi) Amide Coupling Deprotection (vii) R1-NH (viii) R2 (ix) X = halogens or pseudohalogensY = alkyl or substituted alkyl Pg = optional protective groups [0109]For example, compounds of Formula (I) can be formed as shown in Scheme V.Compound (i) can be condensed with compound (ii) to give compound (iii). Compound (iii) can be aminated, for example, via metal-catalyzed coupling reactions, to give compound (iv).Compound (iv) can be deprotected to give compound (v). Compound (v) can intramolecularly cyclize to give compound (vi). Compound (vi) can be saponified to give compound (vii).Compound (vii) can be coupled with compound (viii) followed by optional deprotection to give compound (ix) [i.e., Formula (I)].
WO 2024/199255 Scheme VI PCT/CN2024/083980 Deprotection R1-NH (vii) R2Amide Coupling Deprotection(viii) Y = alkyl or substituted alkyl Pg = optional protective groups [0110]For example, compounds of Formula (I) can be formed as shown in Scheme VI. Compound (i) can be condensed with compound (ii) to give compound (iii). Compound (iii) can be deprotected to give compound (iv). Compound (iv) can intramolecularly cyclize to give compound (v). Compound (v) can be saponified to give compound (vi). Compound (vi) can be coupled with compound (vii) followed by optional deprotection to give compound (viii) [i.e., Formula (I)]. ABBREVIATIONS NMR nuclear magnetic resonanceUV ultravioletHPLC high performance liquid chromatographyprep preparation/preparativeLC-MS liquid chromatograph mass spectrometerTLC thin layer chromatographyPE petroleum etherEt ethylAc acetyldppf 1,1 '-bis(diphenylphosphino)ferrocene WO 2024/199255 PCT/CN2024/083980 Me methylDCM dichloromethaneBoc te/7-butyloxycarbonylNBS A-bromosuccinimideBu butylTf trifluoromethanesulfonyldba dibenzylideneacetoneBPD bis(pinacolato)diboronDMSO dimethyl sulfoxideXPhos 2-(dicyclohexylphosphino)-2',4',6'-triisopropylbiphenylTHF tetrahydrofuranPh phenylDMF A; A-di methyl formamideDIPEA diisopropylethylamineHATU l-[bis (dimethylamino)methylene]-lH-l,2,3-triazolo [4,5-b]pyridinium 3-oxid hexafluorophosphateBOPCI bis(2-oxo-3 -oxazolidinyl)phosphinic chlorideDMAP 4-dimethylaminopyridineMTBE methyl tert-butyl etherDIBAL-H diisobutyl aluminium hydrideSEM 2-(trimethylsilyl)ethoxymethylDMAC dimethylacetamidetR retention timeAIBN 2,2'-azobis(isobutyronitrile)SFC supercritical fluid chromatographyDPPA diphenyl phosphoryl azideDBU l,8-diazabicyclo[5.4.0]undec-7-eneBINAP 2,2׳-bis(diphenylphosphino)- 1,1 '-binaphthaleneDIAD diisopropyl azodicarboxylateTFA trifluoroacetic acidDtBAD di-tert-butyl azodicarboxylateNs nitrosulfonylT3P propylphosphonic anhydrideSPhos 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl WO 2024/199255 PCT/CN2024/083980 NIS A-iodosuccinimidemCPBA meta-chloroperbenzoic acidNMP A-methyl-2-pyrrolidoneBn benzylDMA AA-dimethylacetamideCMPI 2-chloro- 1 -methylpyridinium iodideXantphos 4,5-bis(diphenylphosphino)-9,9-dimethylxantheneCMPI 2-Chloro- 1 -methylpyridinium iodide Example 1:(R)-5-amino-N-((3',5'-difluoro-[3,4'-bipyridin]-6-yl)methyl)-N-(5,6,7,8- tetrahydroquinolin-8-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: 35'-difluoro ־r3,4'-bipyridine1-6-carbaldehyde id="p-111" id="p-111" id="p-111"
id="p-111"
[0111]To a mixture of 3,5-difluoro-4-iodopyridine (0.85 g, 3.53 mmol) in dioxane (17 mL), toluene (8.5 mL) and water (8.5 mL) was added 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)picolinaldehyde (1.64 g, 7.05 mmol), K3PO4 (2.25 g, 10.6 mmol) and Pd(dppf)C12 (258 mg, 0.35 mmol) at 20 °C. The mixture was stirred at 85 °C for 3 h. The mixture was cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatograph (PE:EtOAc=l :0 to 1:1) to give the title compound (0.70 g, 90%). LC-MS (M+H)+ =221.2.Step2:(R)-N-((3 ‘,5‘-difluoro-[3,4 ‘-bipyridin]-6-yl)methyl)-5,6,7,8-tetrahydroquinolin-8- amine WO 2024/199255 PCT/CN2024/083980 id="p-112" id="p-112" id="p-112"
id="p-112"
[0112]To a solution of (R)-5,6,7,8-tetrahydroquinolin-8-amine (525 mg, 3.54 mmol) in DCM (13 mL) was added NaBH(OAc)3 (939 mg, 4.43 mmol), MeOH (0.13 mL) and 3',5'-difluoro- [3,4'-bipyridine]-6-carbaldehyde (0.65 g, 2.95 mmol). The mixture was stirred at 20 °C for 1 h and then poured into saturated NaHCO3 (50 mL). The mixture was extracted with DCM (50 mL x 3). The combined organic layer was washed with brine (50 mL), dried over Na2S04, filtered and concentrated under vacuum. The residue was purified by prep-HPLC to give the title compound (216 mg, 21%). LC-MS (M+H)+ =353.2.Step 3: ethyl 4-amino-lH-pyrrole-2-carboxylate id="p-113" id="p-113" id="p-113"
id="p-113"
[0113]To a solution of ethyl 4-nitro-lH-pyrrole-2-carboxylate (9.0 g, 48.9 mmol) in MeOH (100 mL) was added Pd/C (10%, 5.2 g, 4.89 mmol). The mixture was stirred under hydrogen (psi) at 25 °C for 12 h. The mixture was filtered through a short pad of celite. The filtrate was concentrated under vacuum to give the title compound (7 g, 93%). LCMS (M+H)+ = 155.2.Step 4: ethyl 4-((tert-butoxycarbonyl)amino)-lH-pyrrole-2-carboxylate id="p-114" id="p-114" id="p-114"
id="p-114"
[0114]To a solution of ethyl 4-amino-lH-pyrrole-2-carboxylate (7.0 g, 45.4 mmol) in DCM (80 mL) was added B0C20 (14.9 g, 68.1 mmol) and EtzN (13.8 g, 136 mmol). The mixture was stirred at 25 °C for l h. The mixture was diluted with water (100 mL) and then extracted with DCM (50 mL x 3). The combined organic layer was washed with brine (50 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE: EtOAc = 1:0 to 1:1) to give the title compound (8.0 g, 69%). LCMS (M+H-t-Bu) + = 199.2.Step 5: ethyl 5-bromo-4-((tert-butoxycarbonyl)amino)-lH-pvn ־ole-2-carboxylate WO 2024/199255 PCT/CN2024/083980 Br NHB0C id="p-115" id="p-115" id="p-115"
id="p-115"
[0115]To a solution of ethyl 4-((tert-butoxycarbonyl)amino)-lH-pyrrole-2-carboxylate (7.0 g, 27.5 mmol) in DCM (35 mL) was added NBS (4.90 g, 27.5 mmol). The mixture was stirred at °C for 2 h. The mixture was diluted with water (50 mL) and then extracted with DCM (30 mL x 3). The combined organic layer was washed with brine (30 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE:EtOAc = 5:1) to give the title compound (6.0 g, 65%). LCMS (M+H-tBu) + = 277.1.Step 6: 4-cyano-2,5-dihydrofuran-3-yl trifluoromethanesulfonateTfO^^ JL° NC [0116]To a solution of 4-oxotetrahydrofuran-3-carbonitrile (10.0 g, 90.0 mmol) in DCM (1mL) was added DIPEA (14.0 g, 108 mmol) and Tf20 (25.4 g, 90.0 mmol) at -78 °C and the mixture was stirred at -78 °C for l h. The reaction mixture was diluted with water (100 mL), warmed to room temperature and then extracted with DCM (50 mL x 3). The combined organic layer was washed with brine (50 mL x 2), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE:EtOAc = 1:0 to 3:1) to give the title compound (10.0 g, 46%). 1H NMR (400 MHz, CDCI3) 8 4.95-4.60 (m, 4H).Step 7: ethyl 4-((tert-butoxvcarbonvDamino)-5-(4-cvano-2,5-dihvdrofuran-3-vl)-lH- pyrrole-2-carboxylate & ethyl 5-amino-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxylate id="p-117" id="p-117" id="p-117"
id="p-117"
[0117]To a solution of ethyl 5-bromo-4-((tert-butoxycarbonyl)amino)-lH-pyrrole-2- carboxylate (13.0 g, 39.0 mmol) and BPD (19.8 g, 78.0 mmol) in THE (200 mL) was added Pd2(dba)3 (1.79 g, 1.95 mmol), KO Ac (11.5 g, 117 mmol) and XPhos (1.86 g, 3.9 mmol). The mixture was stirred at 75 °C for 3 h and cooled to room temperature. Solid was filtered off and the filtrate was concentrated under vacuum. The crude was re-dissolved in dioxane (150 mL) and water (30 mL), then 4-cyano-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (17.9 g, 73.mmol), Pd(dppf)C12 (2.69 g, 3.68 mmol) and K2CO3 (12.7 g, 92.0 mmol) was added. The mixture was degassed and purged with nitrogen for 3 times, and then stirred at 80 °C for 12 h.
WO 2024/199255 PCT/CN2024/083980 The mixture was cooled to room temperature, diluted with water (400 mL), and extracted with EtOAc (300 mL x 3). The combined organic layer was washed with brine (100 mL x 2), dried over Na2S04, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (PE/EtOAc = 1/0 to 3/1) to give the following compounds: [0118]Ethyl 4-((tert-butoxycarbonyl)amino)-5-(4-cyano-2,5-dihydrofuran-3-yl)-lH-pyrrole-2- carboxylate (7.0 g, 52%). LCMS (M+H-LBu)+ = 292.1. [0119]Ethyl 5-amino-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylate (2.0 g, 21%). LCMS (M+H)+ = 248.2.Step 8: methyl 5-amino-6,8-dihydro-1H-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylate id="p-120" id="p-120" id="p-120"
id="p-120"
[0120]To ethyl 4-((tert-butoxycarbonyl)amino)-5-(4-cyano-2,5-dihydrofuran-3-yl)-1 H-pyrrole- 2-carboxylate (0.70 g, 2.02 mmol) was added HO in MeOH (3 M, 10 mL) at 25 °C and stirred for l h. The mixture was concentrated under vacuum. The residue was re-dissolved in MeOH (mL), and K2CO3 (1.28 g, 9.27 mmol) was added. The mixture was stirred at 50 °C for 2 h, cooled to room temperature and the solid was filtered off. The filtrate was concentrated under vacuum. The residue was purified by silica gel chromatography (PE/EtOAc = 2/1 to 3/1, then EtOAc/MeOH = 5/1) to give the title compound (0.40 g, 85%). 1H NMR (400 MHz, DMSO-d) 11.84 (br s, 1H), 6.85 (s, 1H), 5.70 (s, 2H), 5.19-5.09 (m, 2H), 4.97-4.88 (m, 2H), 3.85 (s, 3H). LCMS (M+H)+ = 234.2.Step 9: 5-amino-6,8-dihvdro-lH-furo[3,4-d]pvrrolo[3.2-b]pvridine-2-carboxylic acid id="p-121" id="p-121" id="p-121"
id="p-121"
[0121]To a solution of methyl 5-amino-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxylate (0.40 g, 1.72 mmol) in THE (4 mL), MeOH (0.8 mL) and water (0.8 mL) was added LiOHH2O (108 mg, 2.57 mmol). The mixture was stirred at 45 °C for 4 h and then cooled to room temperature. The mixture was diluted with H20 (10 mL) and then washed with EtOAc (mL x 3). The aqueous phase was lyophilized to give a residue. The residue was purified prep- HPLC to give the title compound (80 mg, 21%). LCMS (M+H)+ = 220.1.Step10:(R)-5-amino-N-((3 ‘,5‘-difluoro-[3,4 ‘-bipvridin]-6-yl)methyD)-N-(5,6,7.8-tetrahydroquinolin-8-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-blpyridine-2-carboxamide [0122]To a solution of 5-amino-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxylic acid (100 mg, 0.45 mmol) and (R)-N-((3',5'-difluoro-[3,4'-bipyridin]-6-yl)methyl)- WO 2024/199255 PCT/CN2024/083980 5,6,7,8-tetrahydroquinolin-8-amine (158 mg, 0.45 mmol) in DMF (2 mL) was added DIPEA (0.25 mL, 1.35 mmol) and HATU (171 mg, 0.45 mmol). The mixture was stirred at 25 °C for h. The reaction mixture was diluted with water (5 mL) and then extracted with EtOAc (20 mL x 3). The combined organic layer was washed with brine (5 mL x 2), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC to give Example 1 (15 mg, 6%). 1HNMR (500 MHz, DMSO-،/،5) 5 11.68-11.62 (m, 1H), 8.82-8.65 (m, 3H), 8.36-8.34 (m, 1H), 8.13-7.98 (m, 2H), 7.56-7.52 (m, 2H), 7.25-7.16 (m, 1H), 6.74 (s, 1H), 5.53-5.56 (m, 2H), 5.11-5.08 (m, 2H), 4.93-4.82 (m, 3H), 3.93-3.90 (m, 1H), 2.85-2.36 (m, 3H), 2.07-1.79 (m, 3H). LC-MS (M+H)+ =554.3. Example 2:(R)-5-amino-N-((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)-N-(5,6,7,8- tetrahydroquinolin-8-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: 5-(2,6-difluorophenyl)picolinaldehyde id="p-123" id="p-123" id="p-123"
id="p-123"
[0123]To a mixture of 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)picolinaldehyde (62 g, 266 mmol) and l,3-difluoro-2-iodobenzene (95.8 g, 399 mmol) in dioxane (600 mL), toluene (300 mL) and water (300 mL) was added Pd(dppf)C12 (9.73 g, 13.3 mmol) and KzPO4 (141 g, 665 mmol). The mixture was stirred at 85 °C for 16 h, cooled to room temperature and poured into water (1000 mL). The organic layer was separated. The aqueous phase was extracted with EtOAc (800 mL x 2). The combined organic layer was washed with brine (500 mL), dried with Na2SO4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (PE: EtOAc = 50:1 to 5:1) to give the title compound (30 g, 51%). LC-MS (M+H)+ =220.2.Step 2: (R)-N-((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)-5,6,7,8-tetrahydroquinolin-8- amine WO 2024/199255 PCT/CN2024/083980 id="p-124" id="p-124" id="p-124"
id="p-124"
[0124]To a solution (R)-5,6,7,8-tetrahydroquinolin-8-amine (1.35 g, 9.12 mmol) in DCM (mL) was added 5-(2,6-difluorophenyl)picolinaldehyde (2.0 g, 9.12 mmol), MeOH (2 mL) and NaBH(OAc)3 (5.80 g, 27.4 mmol). The mixture was stirred at room temperature for l h and quenched with saturated NaHCO3 (50 mL). The organic layer was separated, and the aqueous layer was extracted with DCM (50 mL x 3). The combined organic layer was washed with brine (50 mL), dried with Na2S04, filtered, and concentrated under vacuum. The residue was purified by silica gel chromatography (PE: EtOAc = 1:0 to 0:1) to give the title compound (582 mg, 18%). LC-MS (M+H)+ =352.1.Step 3: (R)-5-amino-N-((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)-N-(5,6,7,8- tetrahydroquinolin-8-yl)-6.8-dihydro-lH-furor3.4-dlpyrrolo[3,2-blpyridine-2-carboxamide [0125]To a solution of 5-amino-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxylic acid (30 mg, 0.14 mmol) and (R)-N-((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)- 5,6,7,8-tetrahydroquinolin-8-amine (48 mg, 0.14 mmol) in THE (1 mL) was added DIPEA (mg, 0.41 mmol) and BOPCI (52 mg, 0.20 mmol). The mixture was stirred at 25 °C for 12 h. The mixture was diluted with water (5 mL) and extracted with EtOAc (5 mL x 3). The combined organic layer was washed with brine (5 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude was purified by prep-HPLC to give Example 2(13 mg, 17%). 1HNMR(400 MHz, DMSO-d) 11.71 - 11.61 (m, 1 H), 8.71 - 8.34 (m, 2 H), 7.97 - 7.85 (m, H), 7.58-7.15 (m, 5 H), 6.73-6.21 (m, 1 H), 5.99-5.32 (m, 3 H), 5.25 - 5.11 (m, 2 H), 4.92 - 4.(m, 2 H), 4.84 - 3.82 (m, 1 H), 2.92 - 2.66 (m, 3 H), 2.20 - 1.95 (m, 2 H), 1.82 - 1.75 (m, 1 H). LC-MS (M+H)+ =553.0. Example 3:5-amino-N,N-bis(2,6-difluorobenzyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxamide Step 1: bis(2,6-difluorobenzyl)amine WO 2024/199255 PCT/CN2024/083980 id="p-126" id="p-126" id="p-126"
id="p-126"
[0126]To a solution of 2,6-difluorobenzaldehyde (142 mg, 1.0 mmol) and (2,6- difluorophenyl)methanamine (143 mg, 1.0 mmol) in DCM (15 mL) was added NaBH(OAc)3 (mmol, 422 mg) in portions at 0 °C. The mixture was warmed to room temperature and stirred for l h. The reaction was quenched by saturated NaHCO3 (10 mL). The organic layer was separated and the aqueous layer was extracted with EtOAc (30 mL x 2). The combine organic layer was concentrated under reduced pressure to give the title compound (256 mg, 95%). LC-MS (M+H)+ = 270.1.Step2:5-amino-N,N-bis(2,6-difluorobenzyl)-6,8-dihydro-1H-furo[3,4-d]pyrrolo[3,2-blpyridine-2-carboxamide [0127]To a solution of 5-amino-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxylic acid (100 mg, 0.45 mmol) and bis(2,6-difluorobenzyl)amine (121 mg, 0.45 mmol) in THF (4 mL) was added DIPEA (0.4 mL, 2.25 mmol) and BOPCI (171 mg, 0.67 mmol). The mixture was stirred at 25 °C for 12 h. The reaction mixture was diluted with water (5 mL) and then extracted with EtOAc (20 mL x 3). The combined organic layer was washed with brine (mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC to give the title compound (17 mg, 8%). IHNMR (500 MHz, DMSO-،/6) 11.60 (s, 1H), 7.50 - 7.34 (m, 2H), 7.17 - 6.96 (m, 4H), 6.72 - 6.53 (m, 1H), 5.58 (s, 2H), 5.- 5.10 (m, 2H), 4.95 - 4.91 (m, 2H), 4.85 (s, 4H). LC-MS (M+H)+ =471.2. Example 4:5-amino-N-((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)-N-((3R,4R)-4- methoxytetrahydro-2H-pyran-3-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide Step 1: (3R,4R)-3-(((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)amino)tetrahydro-2H- pyran-4-01 WO 2024/199255 PCT/CN2024/083980 id="p-128" id="p-128" id="p-128"
id="p-128"
[0128]To a solution of (3R,4R)-3-aminotetrahydro-2H-pyran-4-ol (120 mg, 1.02 mmol) and 5- (2,6-difluorophenyl)picolinaldehyde (224 mg, 1.02 mmol) in DCM (10 mL) was added NaBH(OAc)3 (430 mg, 2.03 mmol) at 0 °C. The mixture was warmed to room temperature and stirred for 2 h. The mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatograph (PE/EtOAc=l/l) to give the title compound (200 mg, 61%). LCMS (M+H)+= 321.1.Step 2: tert-butyl ((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)((3R,4R)-4- hydroxytetrahydro-2H-pyran-3-yl)carbamate id="p-129" id="p-129" id="p-129"
id="p-129"
[0129]To a solution of of (3R,4R)-3-(((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)amino)tetrahydro-2H-pyran-4-ol (200 mg, 0.62 mmol) in DCM (10 mL) was added Boc2O (164 mg, 0.75 mmol) and Et3N (188 mg, 1.86 mmol). The mixture was stirred at room temperature for overnight. The mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatograph (PE/EtOAc=2/l) to give the title compound (230 mg, 88%). LCMS (M+H)+ = 421.1.Step3:tert-butyl((5-(2.6-difluorophenyD)pyridin-2-yD)methyD)(3R,4R)-4-methoxvtetrahydro-2H-pvran-3-vl)carbamate id="p-130" id="p-130" id="p-130"
id="p-130"
[0130]To a mixture of tert-butyl ((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)((3R,4R)-4- hydroxytetrahydro-2H-pyran-3-yl)carbamate (230 mg, 0.55 mmol) and Mel (78 mg, 0.55 mmol) in DMF (10 mL) was added NaH (60%, 29 mg, 0.72 mmol) at 0 °C. The mixture was stirred at 87 WO 2024/199255 PCT/CN2024/083980 room temperature under nitrogen for 5 h. The mixture was diluted with iced water (20 mL) and extracted with EtOAc (20 mL x 2), The combined organic layer was washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatograph (PE/EtOAc=2/l) to give the title compound (230 mg, 96%). LCMS (M+H)+= 435.1.Step4:(3R,4R)-N-((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)-4-methoxytetrahydro-2H- pyran-3-amine hydrochloride 0 id="p-131" id="p-131" id="p-131"
id="p-131"
[0131]A mixture of tert-butyl ((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)((3R,4R)-4- methoxytetrahydro-2H-pyran-3-yl)carbamate (230 mg, 0.53 mmol) in HO (4 M in MeOH, mL) was stirred at room temperature for 2 h. The mixture was concentrated under reduced pressure to give the title compound (180 mg, 92%). LCMS (M+H)+ = 335.1.Step 5: 5-amino-N-((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)-N-((3R,4R)-4- methoxytetrahydro-2H-pyran-3-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-blpyridine-2- carboxamide [0132]A mixture of 5-amino-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid (90 mg, 0.40 mmol) in SOC12 (5 mL) was stirred at 50 °C for 3 h. Volatiles were removed in vacuo, and the residue was redissolved in DCM (10 mL). To the mixture was added (3R,4R)-N- ((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)-4-methoxytetrahydro-2H-pyran-3-amine hydrochloride (150 mg, 0.4 mmol) and DIPEA (154 mg, 1.2 mmol) at 0 °C. The mixture was stirred for 1 h then diluted with DCM (20 mL). The mixture was successively washed with water (10 mL) and brine (10 mL). The organic layer was dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM/MeOH=20/l)and then prep-HPLC to give Example 4 (11 mg, 5%). 1H NMR (500 MHz, DMSO-J6) 6 11.58 (s, 1H), 8.84-8.48 (m, 1H), 8.10-7.82 (m, 1H), 7.72 - 7.43 (m, 2H), 7.- 7.18 (m, 2H), 6.81 - 6.29 (m, 1H), 5.79 -4.18 (m, 9H), 4.14 - 3.34 (m, 5H), 3.21 - 3.03 (m, 3H), 2.26-2.13 (m, 1H), 1.47-1.19 (m, 1H). LCMS (M+H)+= 536.4. Example 5:(R)-5-amino-N-(2,6-difluorobenzyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide WO 2024/199255 PCT/CN2024/083980 Step1:(R)-N-(2,6-difluorobenzyl)-5,6,7.8-tetrahydroquinolin-8-amine F [0133]To a mixture of (R)-5,6,7,8-tetrahydroquinolin-8-amine (355 mg, 2.4 mmol) and 2,6- difluorobenzaldehyde (284 mg, 2.0 mmol) in DCM (10 mL) was added NaBH(OAc)3 (848 mg, 4.0 mmol) and the mixture was stirred at room temperature for 2 h. The mixture was diluted with DCM (30 mL) and carefully washed with saturated NaHCOa (30 mL) and brine (30 mL). The organic layer was dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM/MeOH=20/l) to give the title compound (500 mg, 91%). LC-MS (M+H)+ = 275.2.Step 2: (R)-5-amino-N-(2,6-difluorobenzyl)-N-(5.6,7.8-tetrahydroquinolin-8-yl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0134]Example 5 (2 mg, 2%) was prepared in a manner similar to that in Example 2 step from 5-amino-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and (R)-N- (2,6-difluorobenzyl)-5,6,7,8-tetrahydroquinolin-8-amine. 1H NMR (500 MHz, DMSO-J6) 11.61 (s, 1H), 8.33 (s, 1H), 7.50 (s, 1H), 7.30 (s, 1H), 7.16 (s, 1H), 6.98 (s, 2H), 6.59 (s, 1H), 5.52 (s, 2H), 5.23 - 5.04 (m, 2H), 4.91 (s, 2H), 4.74 (s, 1H), 2.79 - 2.64 (m, 3H), 2.24 -1.71 (m, 3H). LC-MS (M+H)+ =476.2. Example 6:(R)-5-amino-N-(5,6,7,8-tetrahydroquinolin-8-yl)-N-((2',3,6'-trifluoro-[l,l'- biphenyl]-4-yl)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: 2',3,6'-trifluoro-[l,l'-biphenyl]-4-carbaldehyde WO 2024/199255 PCT/CN2024/083980 id="p-135" id="p-135" id="p-135"
id="p-135"
[0135]A mixture of 4-bromo-2-fluorobenzaldehyde (609 mg, 3.0 mmol), (2,6- difluorophenyl)boronic acid (948 mg, 6.0 mmol), Pd(dppf)C12 (196 mg, 0.3 mmol) and K3PO(1.9 g, 9.0 mmol) in dioxane (15 mL) and water (3 mL) was stirred at 100 °C overnight under nitrogen and then cooled to room temperature. The mixture was extracted with EtOAc (50 mL x 3). The combined organic layer was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE/EtOAc=10/l) to give the title compound (5mg, 73%). LC-MS (M+H)+ = 237.1.Step 2: (R)-N-((2',3,6'-trifluoro-r1,l'-biphenyl1-4-yl)methyl)-5,6,7,8-tetrahydroquinolin-8- amine id="p-136" id="p-136" id="p-136"
id="p-136"
[0136]The title compound (282 mg, 76%) was prepared in a manner similar to that in Example step 1 from 2',3,6'-trifluoro-[l,r-biphenyl]-4-carbaldehyde and (R)-5,6,7,8-tetrahydroquinolin- 8-amine. LC-MS (M+H)+ = 369.3.Step 3: (R)-5-amino-N-(5,6,7,8-tetrahvdroquinolin-8-vl)-N-((2',3,6'-trifluoro-rLl'- biphenyl]-4-yl)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-blpyridine-2-carboxamide [0137]Example 6 (2 mg, 4%) was prepared in a manner similar to that in Example 2 step from 5-amino-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and (R)-N- ((2',3,6'-trifluoro-[l,l'-biphenyl]-4-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine. 1H NMR (500 MHz, DMSO-d) 8 11.72 - 11.55 (m, 1H), 8.47 - 8.32 (m, 1H), 7.65 -7.11 (m, 8H), 6.81 - 6.53 (m, 1H), 6.25 - 5.45 (m, 3H), 5.25 - 3.70 (m , 6H), 2.95 - 2.81 (m, 1H), 2.78 - 2.67 (m, 1H), 2.37 - 1.72 (m, 4H). LC-MS (M+H)+ = 570.5. Example 7:5-amino-N,N-bis((3-fluoropyridin-2-yl)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide WO 2024/199255 PCT/CN2024/083980 Step1:bis((3-fluoropyridin-2-yl)methyl)amine id="p-138" id="p-138" id="p-138"
id="p-138"
[0138]The title compound (200 mg, 87%) was prepared in a manner similar to that in Example step 1 from 3-fluoropicolinaldehyde and (3-fluoropyridin-2-yl)methanamine. LC-MS (M+H)+ = 236.2.Step 2: 5-amino-N,N-bis((3-fluoropyridin-2-yl)methyl)-6,8-dihydro-lH-furo[3,4- d1pyrrolo[3,2-b1pyridine-2-carboxamide [0139]Example 7 (5 mg, 11%) was prepared in a manner similar to that in Example 2 step from 5-amino-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and bis((3- fluoropyridin-2-yl)methyl)amine. 1HNMR (500 MHz, DMSO-،/6) 8 11.62 (s, 1H), 8.41 (s, 2H), 7.72 (s, 2H), 7.43 (s, 2H), 6.43 (d, J= 2.4 Hz, 1H), 5.52 (s, 2H), 5.35 - 4.76 (m, 8H). LC-MS (M+H)+ = 437.4. Example 8:5-amino-N-(2,6-difluorobenzyl)-N-( 1 -methoxypropan-2-yl)-6,8-dihydro- 1H- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step1:N-(2,6-difluorobenzyl)-1-methoxypropan-2-amine id="p-140" id="p-140" id="p-140"
id="p-140"
[0140]The title compound (150 mg, 49%) was prepared in a manner similar to that in Example step 1 from 2,6-difluorobenzaldehyde and l-methoxypropan-2-amine. LC-MS (M+H)+ = 216.1.Step 2: 5-amino-N-(2,6-difluorobenzvl)-N-(l-methoxvpropan-2-vl)-6,8-dihvdro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0141]Example 8 (4 mg, 7%) was prepared in a manner similar to that in Example 2 step from 5-amino-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and N-(2,6- difluorobenzyl)- l-methoxypropan-2-amine. 1H NMR (500 MHz, DMSO-،76) 8 11.49 (s, 1H), 8.16 (s, 1H), 7.36 (t, J= 7.4 Hz, 1H), 7.06 (t, J= 8.2 Hz, 2H), 6.53 (d, J = 1.9 Hz, 1H), 5.54 (s, 91 WO 2024/199255 PCT/CN2024/083980 2H), 5.11 (d, J= 2.7 Hz, 2H), 4.92 (t, J= 2.7 Hz, 2H), 4.84 (s, 1H), 3.56 - 3.49 (m, 1H), 3.15 (s, 3H), 1.19 (d, J = 6.7 Hz, 3H). LC-MS (M+H)+ = 417.2. Example 9:5-amino-N-(2,6-difluorobenzyl)-N-(l ,3-dimethoxypropan-2-yl)-6,8-dihydro- lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-142" id="p-142" id="p-142"
id="p-142"
[0142]Example 9 (2 mg, 4%) was prepared in a manner similar to that in Example 2 step 3. 1H NMR (500 MHz, DMSO-6) S 11.49 (s, 1H), 8.29 (s, 1H), 7.41 - 7.33 (m, 1H), 7.06 (t, J= 8.Hz, 2H), 6.62 (d, J= 2.0 Hz, 1H), 5.55 (s, 2H), 5.11 (s, 2H), 4.92 (d, J= 2.7 Hz, 2H), 4.80 (s, 2H), 3.64 - 3.58 (m, 2H), 3.49 - 3.44 (m, 2H), 3.15 (s, 6H). LC-MS (M+H)+ = 447.1. Example 10:(R)-5-amino-N-((3,5-difluoropyridin-4-yl)methyl)-N-(5,6,7,8- tetrahydroquinolin-8-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-143" id="p-143" id="p-143"
id="p-143"
[0143]Example 10(1 mg, 1%) was prepared in a manner similar to that in Example 2 step 3. 1H NMR (500 MHz, DMSO-d) 8 11.64 (s, 1H), 8.55-8.16 (m, 3H), 7.54 (s, 1H), 7.19 (s, 1H), 6.61 (s, 1H), 5.80 (s, 1H), 5.53 (s, 2H), 5.11 (s, 2H), 4.91 (s, 2H), 4.60 (s, 1H), 4.10 (s, 1H), 2.- 2.87 (m, 1H), 2.75 - 2.72 (m, 1H), 2.36 (s, 2H), 2.12 -1.80 (m, 2H). LC-MS (M+H)+ = 477.5. Example 11:(R)-5-amino-N-((3'-cyano-[3,4'-bipyridin]-6-yl)methyl)-N-(5,6,7,8- tetrahydroquinolin-8-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step1:6-formyl-[3,4 ‘-bipyridine]-3 ‘-carbonitrile WO 2024/199255 PCT/CN2024/083980 [0144]The title compound (160 mg, 26%) was prepared in a manner similar to that in Example step 1 from 5-bromopicolinaldehyde and 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)nicotinonitrile. LC-MS (M+H)+ = 210.1.Step 2: (R)-6-(((5,6,7,8-tetrahydroquinolin-8-yl)amino)methyl)-[3,4'-bipyridine]-3'- carbonitrile id="p-145" id="p-145" id="p-145"
id="p-145"
[0145]The title compound (88 mg, 64%) was prepared in a manner similar to that in Example step 1 from 6-formyl- [3,4'-bipyridine] -3 '-carbonitrile and (R)-5,6,7,8-tetrahydroquinolin-8- amine. LC-MS (M+H)+ = 342.2.Step 3: (R)-5-amino-N-((3'-cyano-[3,4'-bipyridin]-6-yl)methyl)-N-(5,6,7,8- tetrahydroquinolin-8-yl)-6.8-dihydro-lH-furo[3,4-d]pyrrolo[3.2-blpyridine-2-carboxamide [0146]Example 11 (8 mg, 14%) was prepared in a manner similar to that in Example 2 step from 5-amino-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and (R)-6- (((5,6,7,8-tetrahydroquinolin-8-yl)amino)methyl)-[3,4'-bipyridine]-3'-carbonitrile. ,H NMR (5MHz, DMSO-d) 8 11.78 - 11.55 (m, 1H), 9.21 - 9.11 (m, 1H), 9.03 - 8.72 (m, 2H), 8.47-8.(m, 1H), 8.25 - 8.01 (m, 1H), 7.92 - 7.75 (m, 1H), 7.70 - 7.47 (m, 2H), 7.32 - 7.11 (m, 1H), 6.- 6.22 (m, 1H), 6.03 - 3.91 (m, 9H), 2.92 - 2.71 (m, 2H), 2.32 - 1.68 (m, 4H). LC-MS (M+H)+ = 543.6. Example 12:5-amino-N-(chroman-4-yl)-N-((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)- 6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: N-((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)chroman-4-amine WO 2024/199255 PCT/CN2024/083980 [0147]The title compound (400 mg, 85%) was prepared in a manner similar to that in Example step 1 from chroman-4-amine and 5-(2,6-difluorophenyl)picolinaldehyde. LC-MS (M+H)+ = 353.2.Step 2: 5-amino-N-(chroman-4-yl)-N-((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)-6,8- dihydro-lH-furo[3,4-dlpyrrolo[3,2-blpyridine-2-carboxamide [0148]Example 12 (7 mg, 8%) was prepared in a manner similar to that in Example 2 step from 5-amino-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and N-((5- (2,6-difluorophenyl)pyridin-2-yl)methyl)chroman-4-amine. 1H NMR (400 MHz, DMSO-J6) 11.73 (br s, 1H), 8.67 - 8.56 (m, 1H), 7.91 - 7.88 (m, 1H), 7.57 - 7.49 (m, 2H), 7.29 - 7.05 (m, 4H), 6.97 - 6.36 (m, 3H), 6.11 - 6.01 (m, 1H), 5.55 (br s, 2H), 5.22 - 4.85 (m, 5H), 4.64 - 3.(m, 3H), 2.37 - 2.04 (m, 2H). LC-MS (M+H)+ = 554.2. Example 13:5-amino-N-(2,6-difluorobenzyl)-N-((5-(2,6-difluorophenyl)pyridin-2- yl)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: 1-(tert-butyl) 2-ethyl 5-(bis(tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4- d]pvrrolo[3,2-blpyridine-L2-dicarboxvlateO //^/NBocT EtO Boc /1—o [0149]To a solution of ethyl 5-amino-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxylate (2.0 g, 8.09 mmol) in THE (40 mL) was added B0C20 (5.3 g, 24.3 mmol), DMAP (99 mg, 0.81 mmol) and EtN (3.28 g, 16.2 mmol). The mixture was stirred at 45 °C for 12 h then cooled to room temperature. The mixture was diluted with water (30 mL) and then extracted with EtOAc (15 mL x 3). The combined organic layer was washed with brine (15 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 1:0 to 3:1) to give the title compound (2.4 g, 54%). LC- MS (M+H)+ = 548.4.Step2:5-((tert-butoxycarbonyl)amino)-6,8-dihydro-1H-furo[3,4-d]pyrrolo[3,2-b]pyridine- 2-carboxylic acid WO 2024/199255 PCT/CN2024/083980 [0150]To a solution of 1-(tert-butyl) 2-ethyl 5-(bis(tert-butoxycarbonyl)amino)-6,8-dihydro- lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-l,2-dicarboxylate (2.4 g, 4.38 mmol) in THF (20 mL), MeOH (4 mL) and water (4 mL) was added LiOH H20 (221 mg, 5.26 mmol). The mixture was stirred at 45 °C for 12 h. The mixture was cooled to room temperature and diluted with water (mL). The mixture was washed with EtOAc (15 mL x 3). To the aqueous phase was carefully added aqueous HC1 (0.5 M) until its pH reached 4-5. Solid was collected by filtration to give the title compound (0.90 g, 49%). LC-MS (M+H)+ = 320.2.Step 3: N-(2,6-difluorobenzyl)- 1 -(5-(2,6-difluorophenyl)pyridin-2-yl)methanamine id="p-151" id="p-151" id="p-151"
id="p-151"
[0151]The title compound (260 mg, 55%) was prepared in a manner similar to that in Example step 1 from 5-(2,6-difluorophenyl)picolinaldehyde and (2,6-difluorophenyl)methanamine. LC- MS (M+H)+ = 347.2.Step 4: tert-butyl (2-((2,6-difluorobenzyl)((5-(2,6-difluorophenyl)pyridin-2- yl)methyl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3.2-b]pyridin-5-yl)carbamate N. ^NHBoc id="p-152" id="p-152" id="p-152"
id="p-152"
[0152]To a solution of N-(2,6-difluorobenzyl)-l-(5-(2,6-difluorophenyl)pyridin-2- yl)methanamine (70 mg, 0.20 mmol) and 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid (65 mg, 0.20 mmol) in THF (3 mL) was added BOPCI (62 mg, 0.24 mmol) and DIPEA (78 mg, 0.61 mmol) at 25 °C. The mixture was stirred at 40 °C for 1 h. The mixture was cooled to room temperature and diluted with water (mL). The mixture was extracted with EtOAc (5 mL * 4). The combined organic layer was washed with brine (5 mL x 2), dried over Na2SO4, filtered, and concentrated under vacuum to give the title compound (85 mg, 66%). LC-MS (M+H)+ = 648.3.Step5:5-amino-N-(2,6-difluorobenzyl)-N-((5-(2,6-difluorophenyD)pyridin-2-yl)methyl)- 6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-blpyridine-2-carboxamide [0153]A mixture of tert-butyl (2-((2,6-difluorobenzyl)((5-(2,6-difluorophenyl)pyridin-2- yl)methyl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]py1Tolo[3,2-b]pyridin-5-yl)carbamate (85 mg, 0.13 mmol) in methanolic HC1 (3 M, 3 mL) was stirred at 25 °C for 1 h and then concentrated WO 2024/199255 PCT/CN2024/083980 under reduced pressure. The residue was purified by prep-HPLC to give Example 13 (31 mg, 44%). 1H NMR (400 MHz, CD30D) 5 11.67 (s, 1H), 8.60 (br s, 1H), 7.89 (br d, J = 7.9 Hz, 1H), 7.59 - 7.49 (m, 1H), 7.45 (d, J = 8.1 Hz, 1H), 7.40 - 7.32 (m, 1H), 7.31 - 7.23 (m, 2H), 7.09 - 7.00 (m, 2H), 6.65 - 6.26 (m, 1H), 5.55 (s, 2H), 5.13 (br s, 2H), 5.00 (br s, 3H), 4.91 (br s, 3H). LC-MS (M+H)+ = 548.2. Example 14:5-amino-N-((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)-N-((2',3,6'- trifluoro- [ 1,1 ,-biphenyl] -4-yl)methyl)-6,8-dihydro- 1 H-furo [3,4-d]pyrrolo [3,2-b]pyridine-2- carboxamide Step 1: (3R,4R)-3-(((2',3,6'-trifluoro-r 1,1 '-biphenyl]-4-yl)methyl)amino)tetrahydro-2H- pyran-4-01 id="p-154" id="p-154" id="p-154"
id="p-154"
[0154]The title compound (680 mg, 99%) was prepared in a manner similar to that in Example step 1 from (3R,4R)-3-aminotetrahydro-2H-pyran-4-ol hydrochloride and 2',3,6'-trifluoro-[l,r- biphenyl]-4-carbaldehyde. LC-MS (M+H)+ =338.2.Step 2: tert-butyl ((3R,4R)-4-hydroxytetrahydro-2H-pyran-3-yl)((2 ’,3,6'-trifluoro-[l,T-biphenyl]-4-yl)methyl)carbamate 'NBoc id="p-155" id="p-155" id="p-155"
id="p-155"
[0155]The title compound (850 mg, 97%) was prepared in a manner similar to that in Example step 2 from (3R,4R)-3-(((2',3,6'-trifluoro-[l,l'-biphenyl]-4-yl)methyl)amino)tetrahydro-2H- pyran-4-01. LC-MS (M+H)+ =438.3.Step 3: tert-butyl ((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)((2',3,6'-trifluoro-[LT-biphenyl] -4-yl)methyl)carbamate WO 2024/199255 PCT/CN2024/083980 a o-C NBoc id="p-156" id="p-156" id="p-156"
id="p-156"
[0156]The title compound (600 mg, 68%) was prepared in a manner similar to that in Example step 3 from tert-butyl ((3R,4R)-4-hydroxytetrahydro-2H-pyran-3-yl)((2',3,6'-trifluoro-[l,r- biphenyl]-4-yl)methyl)carbamate. LC-MS (M+H)+ =452.3.Step4:(3R,4R)-4-methoxy-N-((2 ‘,3,6‘-trifluoro-[1,1 ‘-biphenyl]-4-yl)methyl)tetrahydro-2H-pyran-3-amine hydrochloride id="p-157" id="p-157" id="p-157"
id="p-157"
[0157]The title compound (510 mg, 99%) was prepared in a manner similar to that in Example step 4 from tert-butyl ((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)((2',3,6'-trifluoro-[l,T- biphenyl]-4-yl)methyl)carbamate. LC-MS (M+H)+ =352.2.Step 5: tert-butyl (2-(((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)((2 ’.3.6'-trifluoro-rLT- biphenyl]-4-yl)methyl)carbamoyl)-6,8-dihydro-lH-furor3,4-d]pyrrolo[3,2-b]pyridin-5- yl)carbamate id="p-158" id="p-158" id="p-158"
id="p-158"
[0158]The title compound (15 mg, 52%) was prepared in a manner similar to that in Example step 4 from (3R,4R)-4-methoxy-N-((2',3,6'-trifluoro-[l,l'-biphenyl]-4-yl)methyl)tetrahydro- 2H-pyran-3-amine hydrochloride and 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid. LC-MS (M+H)+ =653.4.Step6:5-amino-N-((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)-N-((2 ‘,3,6‘-trifluoro- [1,1‘-biphenyl]-4-yl)methyl)-6,8-dihydro-1H-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0159]A mixture of tert-butyl (2-(((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)((2',3,6'- trifluoro-[ 1,1'-biphenyl]-4-yl)methyl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3, 2- b]pyridin-5-yl)carbamate (15 mg, 0.020 mmol) in HC1 in dioxane (4 M, 2 mL) was stirred for h at room temperature then concentrated under vacuum. The residue was purified by prep-HPLC 97 WO 2024/199255 PCT/CN2024/083980 to give Example 14 (2 mg, 19%). 1H NMR (500 MHz, DMSO- Step1:(3R,4R)-N-((3 ‘,5‘-difluoro-[3,4 ‘-bipyridin]-6-yl)methyl)-4-methoxytetrahydro-2H- pyran-3-amine F [0160]The title compound (150 mg, 85%) was prepared in a manner similar to that in Example step 1 from (3R,4R)-4-methoxytetrahydro-2H-pyran-3-amine and 3',5'-difluoro-[3,4'- bipyridine]-6-carbaldehyde. LC-MS (M+H)+ = 336.2.Step 2: 5-amino-N-((3',5'-difluoro-[3,4'-bipyridinl-6-yl)methyl)-N-((3R,4R)-4- methoxytetrahydro-2H-pyran-3-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-blpyridine-2- carboxamide [0161]Example 15(1 mg, 5%) was prepared in a manner similar to that in Example 2 step from 5-amino-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and (3R,4R)- N-((3',5'-difluoro-[3,4'-bipyridin]-6-yl)methyl)-4-methoxytetrahydro-2H-pyran-3-amine. 1H NMR (500 MHz, DMSO-t/6) 8 11.82- 11.39 (m, 1H), 9.03 -8.56 (m, 3H), 8.18-7.93 (m, 1H), 7.83 - 7.50 (m, 1H), 6.85 - 6.22 (m, 1H), 5.79 - 4.17 (m, 9H), 4.17 - 3.43 (m, 5H), 3.21 - 3.(m, 3H), 2.28-2.11 (m, 1H), 1.44- 1.27 (m, 1H). LCMS (M+H)+= 537.4. Example 16:5-amino-N-((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)-N-(l ,3- dimethoxypropan-2-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide WO 2024/199255 PCT/CN2024/083980 Step1:N-((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)-1,3-dimethoxypropan-2-amine F [0162]The title compound (0.20 g, 76%) was prepared in a manner similar to that in Example step 1 from l,3-dimethoxypropan-2-one and (5-(2,6-difluorophenyl)pyridin-2-yl)methanamine. 1H NMR (400 MHz, DMSO-،/6) 8 8.57 (s, 1H), 7.87 (d, J= 8.4 Hz, 1H), 7.60-7.48 (m, 2H), 7.32-7.22 (m, 2H), 3.94 (s, 2H), 3.34 (d, J= 5.6 Hz, 4H), 3.24 (s, 6H), 2.89 (quin, J= 5.6 Hz, 1H). LC-MS (M+H)+ = 323.2.Step 2: tert-butyl (2-(((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)(l,3-dimethoxypropan-2- yl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate id="p-163" id="p-163" id="p-163"
id="p-163"
[0163]The title compound (40 mg, 30%) was prepared in a manner similar to that in Example step 4 from 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid and N-((52,6)־-difluorophenyl)pyridin-2-yl)methyl)-l,3- dimethoxypropan-2-amine. LC-MS (M+H)+ = 624.3.Step 3: 5-amino-N-((5-(2,6-difluorophenvl)pvridin-2-vl)methvl)-N-(L3-dimethoxvpropan- 2-yl)-6,8-dihydro-1 H-furo[3,4-d]pvn ־olo[3,2-b]pvridine-2-carboxamide [0164]Example 16 (1 mg, 5%) was prepared in a manner similar to that in Example 14 step from tert-butyl (2-(((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)(l ,3-dimethoxypropan-2- yl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate. 1H NMR (4MHz, DMSO-d) 8 11.52 (s, 1H), 8.59 (brs, 1H), 7.89 (br s, 1H), 7.59 - 7.49 (m, 2H), 7.32 - 7.(m, 2H), 6.80 - 6.32 (m, 1H), 5.54 (s, 2H), 5.12 - 4.91 (m, 7H), 3.65 - 3.47 (m, 4H), 3.16 (s, 6H). LC-MS (M+H)+ = 524.2. Example 17 & 18:(S)-5-amino-N-((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)-N-(l- (pyrimidin-2-yl)ethyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (R)- 99 WO 2024/199255 PCT/CN2024/083980 5-amino-N-((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)-N-(l-(pyrimidin-2-yl)ethyl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step1:N-((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)-1-(pyrimidin-2-yl)ethan-1-amine id="p-165" id="p-165" id="p-165"
id="p-165"
[0165]To a solution of (5-(2,6-difluorophenyl)pyridin-2-yl)methanamine (0.10 g, 0.45 mmol) and l-(pyrimidin-2-yl)ethan-l-one (55 mg, 0.45 mmol) in DCM (2.7 mL) and MeOH (0.9 mL) was added NaBH(OAc)3 (192 mg, 0.91 mmol) .The mixture was stirred at 20 °C for 1 h. Saturated NaHCO3 (10 mL) was added, and the mixture was extracted with DCM (2 mL x 4). The combined organic layer was washed with brine (5 mL), dried over Na2SO4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (PE/EtOAc=l/0 to 0/1) to give the title compound (70 mg, 47%). LC-MS (M+H)+ = 327.3.Step 2: tert-butyl (2-(((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)(l-(pyrimidin-2- vl)ethvl)carbamovl)-6,8-dihvdro-lH-furor3,4-dlpvrrolor3,2-blpvridin-5-yl)carbamate id="p-166" id="p-166" id="p-166"
id="p-166"
[0166]To a solution of N-((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)-l-(pyrimidin-2- yl)ethan-l-amine (70 mg, 0.21 mmol) and 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid (72 mg, 0.23 mmol) in THE (1 mL) and DMF (0.5 mL) was added BOPCI (82 mg, 0.32 mmol) and DIPEA (139 mg, 1.07 mmol). The mixture was stirred at 40 °C for l h. The mixture was cooled to room temperature and concentrated under vacuum. The residue was purified by silica gel chromatography (PE/EtOAc=3/l to 0/1) to give the title compound (50 mg, 37%). LC-MS (M+H)+ = 628.3. 100 WO 2024/199255 PCT/CN2024/083980 Step3:(S)-5-amino-N-((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)-N-(1-(pyrimidin-2-yDethyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (R)-5-amino-N- ((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)-N-(l-(pyrimidin-2-yl)ethyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0167]A solution of tert-butyl (2-(((5-(2,6-difIuorophenyl)pyridin-2-yl)methyl)(l-(pyrimidin- 2-yl)ethyl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate (50 mg, 0.080 mol) in methanolic HC1 (4 M, 0.50 mL) was stirred at 20 °C for 12 h then concentrated under vacuum. The residue was purified by prep-HPLC and then by prep-SFC to give Example (10 mg, 24%) and Example 18 (7 mg, 17%). [0168]Analytical chiral-SFC condition as below. Column: Chiralcel OJ-3; Column size: 4.6X50 mm, 3 pm; Mobile phase: A: CO2, B: 14 mM NH3 in MeOH; Gradient: A:B=95:5 (0.min), A:B=95:5 to 50:50 (1 min), A:B=50:50 (1 min), A:B=50:50 to 95:5 (0.4 min), A:B=95:(0.4 min); Flow: 3.4 mL/min; Temperature: 35 °C. [0169]Example 17: Analytical chiral-SFC tR=l .23 min. 1H NMR (400 MHz, DMSO-d) 11.74-11.59 (m, 1H), 8.92-8.46 (m, 3H), 8.01-7.22 (m, 6H), 6.81-6.23 (m, 1H), 6.21-5.48 (m, 3H), 5.40-4.52 (m, 6H), 1.78-1.59 (m, 3H). LC-MS (M+H)+ = 528.2. [0170]Example 18: Analytical chiral-SFC tR=l .47 min. ,H NMR (400 MHz, DMSO-d) 11.75-11.59 (m, 1H), 8.92-8.44 (m, 3H), 8.01-7.22 (m, 6H), 6.81-6.23 (m, 1H), 6.21-5.49 (m, 3H), 5.40-4.52 (m, 6H), 1.78-1.58 (m, 3H). LC-MS (M+H)+ = 528.2. Example 19 & Example 20:(R)-5-amino-N-(3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)- N-((2',3,6'-trifluoro-[l,l'-biphenyl]-4-yl)methyl)-6,8-dihydro-lH-furo[3,4-d]pyn ־olo[3,2- b]pyridine-2-carboxamide & (S)-5-amino-N-(3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-N- ((2',3,6'-trifluoro-[l,r-biphenyl]-4-yl)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxamide Step 1: N-((2',3,6'-trifluoro-[l,r-biphenyll-4-yl)methyl)-3,4-dihydro-2H-pyrano[3,2- b]pyridin-4-amine 101 WO 2024/199255 PCT/CN2024/083980 id="p-171" id="p-171" id="p-171"
id="p-171"
[0171]To a mixture of 3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-amine (330 mg, 2.2 mmol) and 2’,3,6’-trifluoro-[l,l ’-biphenyl]-4-carbaldehyde (470 mg, 2.0 mmol) in DCM (20 mL) was added NaBH(0Ac)3 (848 mg, 4.0 mmol) and the mixture was stirred at room temperature for 2 h. The mixture was diluted with DCM (30 mL) and washed with saturated NaHCO3 (10 mL) and brine (10 mL), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM/MeOH=20/l) to give the title compound (620 mg, 83%). LC-MS (M+H)+ = 371.4.Step 2: tert-butyl (2-((3,4-dihydro-2H-pyranor3,2-b]pyridin-4-yl)((2',3,6'-trifluoro-[l,l'- biphenyll-4-yl)methyl)carbamoyl)-6,8-dihydro-lH-furor3,4-dlpyrrolor3,2-blpyridin-5- yl)carbamate id="p-172" id="p-172" id="p-172"
id="p-172"
[0172]The title compound (140 mg, 83%) was prepared in a manner similar to that in Example & 18 step 2 from 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid and N-((2',3,6'-trifluoro-[l,l'-biphenyl]-4-yl)methyl)-3,4-dihydro- 2H-pyrano[3,2-b]pyridin-4-amine. LC-MS (M+H)+ = 672.4.Step 3: (R)-5-amino-N-(3,4-dihvdro-2H-pvrano[3,2-b]pvridin-4-vl)-N-((2',3,6'-trifluoro- [1,1 ,-biphenyl] -4-yl)methyl)-6,8-dihydro- 1 H-furo [ 3,4-d]pyrrolo [ 3,2-b]pyridine-2-carboxamide & biphenvl]-4-vl)methvl)-6,8-dihvdro-lH-furo[3,4-d]pv1Tolo[3,2-blpvridine-2-carboxamide [0173]To a solution of tert-butyl (2-((3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)((2',3,6'- trifluoro-[ 1,1'-biphenyl]-4-yl)methyl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3, 2- b]pyridin-5-yl)carbamate (140 mg, 0.21 mmol) in DCM (3 mL) was added HC1 in dioxane (4 M, mL) and the mixture was stirred at room temperature for overnight. The mixture was concentrated under reduced pressure. The residue was purified by prep-TLC followed by chiral prep-HPLC to give Example 19 (19 mg, 16%) and Example 20 (18 mg, 15%). 102 WO 2024/199255 PCT/CN2024/083980 [0174]Analytical chiral-HPLC condition as below. Column: CHIRALPAK OD-H; Column size: 4.6X150 mm, 5 pm; Mobile phase: hexane:(0.1% diethylamine in EtOH)=9:l isocratic; Flow: 1.0 mL/min; Temperature: 25 °C. [0175]Example 19: Analytical chiral-HPLC tR=18.65 min. 1H NMR (500 MHz, DMSO-6) 13.02-12.68 (m, 1H), 8.29-7.04 (m, 9H), 7.01-6.42 (m, 2H), 6.04-3.86 (m, 11H), 2.44-2.10 (m, 2H). LC-MS (M+H)+ = 572.4. [0176]Example 20: Analytical chiral-HPLC tR=22. 16 min. 1H NMR (500 MHz, DMSO-d6) 13.02-12.68 (m, 1H), 8.29-7.04 (m, 9H), 7.01-6.42 (m, 2H), 6.04-3.86 (m, 11H), 2.44-2.10 (m, 2H). LC-MS (M+H)+ = 572.4. Example 21:(R)-5-amino-N-(4-cyano-2,6-difluorobenzyl)-N-(5,6,7,8-tetrahydroquinolin- 8-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: (R)-35״-difluoro-4-(((5,6,7,8-tetrahydroquinolin-8-yl)amino)methyl)benzonitrile CN [0177]The title compound (200 mg, 56%) was prepared in a manner similar to that in Example step 1 from (R)-5,6,7,8-tetrahydroquinolin-8-amine and 3,5-difluoro-4-formylbenzonitrile. EC- MS (M+H)+= 300.1.Step 2: tert-butyl (R)-(2-((4-cyano-2,6-difluorobenzyl)(5,6,7,8-tetrahydroquinolin-8- yl)carbamoyl)-6,8-dihydro- 1 H-furo [ 3,4-d1pvn ־olo[3,2-b]pyridin-5-yl)carbamate E N O _ ,N. .NHBoc :NA ON [0178]The title compound (30 mg, 30%) was prepared in a manner similar to that in Example & 18 step 2 from 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- 103 WO 2024/199255 PCT/CN2024/083980 b]pyridine-2-carboxylic acid and (R)-3,5-difluoro-4-(((5,6,7,8-tetrahydroquinolin-8- yl)amino)methyl)benzonitrile. LC-MS (M+H)+ = 601.3.Step3:(R)-5-amino-N-(4-cyano-2,6-difluorobenzyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)- 6,8-dihydro-1H-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0179]Example 21 (17 mg, 68%) was prepared in a manner similar to that in Example 14 step from tert-butyl (R)-(2-((4-cyano-2,6-difluorobenzyl)(5,6,7,8-tetrahydroquinolin-8- yl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate. 1H NMR (5MHz, DMSO-d6) 8 12.21 (s, 1H), 8.33 (s, 1H), 7.82 - 7.61 (m, 2H), 7.53 (s, 1H), 7.19 (s, 1H), 6.89 - 5.62 (m, 3H), 5.31 - 5.05 (m, 2H), 5.05 - 4.80 (m, 2H), 4.71 - 4.44 (m, 1H), 4.31 - 4.(m, 1H), 2.97 - 2.66 (m, 2H), 2.44 - 2.23 (m, 2H), 2.11 - 1.92 (m, 1H), 1.83 - 1.63 (m, 1H). EC- MS (M+H)+= 501.3. Example 22:5-amino-N-(4-cyano-2,6-difluorobenzyl)-N-(2,6-difluorobenzyl)-6,8-dihydro- lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step1:4-(((2,6-difluorobenzyl)amino)methyl)-3,5-difluorobenzonitrileF F id="p-180" id="p-180" id="p-180"
id="p-180"
[0180]To a mixture of 3,5-difluoro-4-formylbenzonitrile (350 mg, 2.09 mmol) and (2,6- difluorophenyl)methanamine (300 mg, 2.09 mmol) in DCM (10 mL) was added NaBH(OAc)(889 mg, 4.09 mmol) and the mixture was stirred at room temperature for 3 h. The mixture was diluted with DCM (30 mL) and washed with saturated NaHCO3 (10 mL) and brine (10 mL), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM/MeOH=20/l) to give the title compound (370 mg, 60%). LC-MS (M+H)+ = 295.2.Step 2: tert-butyl (2-((4-cvano-2,6-difluorobenzvl)(2,6-difluorobenzyl)carbamoyl)-6,8- dihydro- 1 H-furo [ 3,4-dlpyrrolo [ 3,2-blpyridin-5 -vDcarbamate 104 WO 2024/199255 PCT/CN2024/083980 [0181]The title compound (50 mg, 93%) was prepared in a manner similar to that in Example & 18 step 2 from 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid and 4-(((2,6-difluorobenzyl)amino)methyl)-3,5- difluorobenzonitrile. LC-MS (M+H)+ = 596.3.Step 3: 5-amino-N-(4-cyano-2,6-difluorobenzyl)-N-(2,6-difluorobenzyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0182]A solution of tert-butyl (2-((4-cyano-2,6-difluorobenzyl)(2,6- difluorobenzyl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate (mg, 0.084 mmol) in HCI in dioxane (4 M, 2 mL) was stirred for 3 h at room temperature. The mixture was concentrated under vacuum. The residue was purified by prep-HPLC to give Example 22 (24 mg, 58%). 1H NMR (500 MHz, DMSO-d) 8 11.62 (s, 1H), 7.89 - 7.67 (m, 2H), 7.53 - 7.34 (m, 1H), 7.17 - 6.98 (m, 2H), 6.66 (d, J= 1.7 Hz, 1H), 5.60 (s, 2H), 5.24-5.(m, 2H), 5.08 - 4.67 (m, 6H). LC-MS (M+H)+ =496.3. Example 23 & Example 24:(R)-5-amino-N-((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)- N-((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)-6-methyl-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide & (S)-5-amino-N-((5-(2,6-difluorophenyl)pyridin-2- yl)methyl)-N-((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)-6-methyl-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: 2-methyl-4-oxotetrahydrofuran-3-carbonitrile id="p-183" id="p-183" id="p-183"
id="p-183"
[0183]To a suspension of NaH (60%, 4.44 g, 0.11 mol) in THE (150 mL) was added methyl glycolate (20.0 g, 0.222 mol) at 0 °C. The mixture was stirred at 60 °C for 30 min. Crotononitrile (17.8 g, 0.266 mmol) in THE (50 mL) was added dropwise at 60 °C. The mixture was stirred at °C for 2 h. The mixture was cooled to 0 °C and acidified with aqueous HC1 (IM) until its pH reached 4-5. The mixture was extracted with EtOAc (300 mL). The organic layer washed with water (100 mL) and brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=l/l) to give the title 105 WO 2024/199255 PCT/CN2024/083980 compound (10.0 g, 36%). 1H NMR (500 MHz, CDCI) 5 4.42 - 4.27 (m, 2H), 4.26 -4.18 (m, 2H), 3.23-2.98 (m, 1H), 1.63 - 1.27 (m, 3H).Step 2: 4-cyano-5-methyl-2,5-dihydrofuran-3-yl trifluoromethanesulfonate id="p-184" id="p-184" id="p-184"
id="p-184"
[0184]To a mixture of 2-methyl-4-oxotetrahydrofuran-3-carbonitrile (5.0 g, 40 mmol) and DIPEA (6.7 g, 52 mmol) in DCM (100 mL) was added Tf20 (13.5 g, 48 mmol) dropwise at - °C and the mixture was stirred at -78 °C for 2 h. The mixture was diluted with DCM (1mL), successively washed with saturated NaHCO3 (50 mL) and brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=3/l) to give the title compound (8.5 g, 83%). ,HNMR (500 MHz, CDC13) 8 5.13-5.06 (m, 1H), 4.94 - 4.76 (m, 2H), 1.49 (d, J= 6.3 Hz, 3H).Step 3: ethyl 4-((tert-butoxycarbonyl)amino)-5-(4-cyano-5-methyl-2,5-dihydrofuran-3-yl)-H-pyrrole-2-carboxylate id="p-185" id="p-185" id="p-185"
id="p-185"
[0185]To a solution of ethyl 5-bromo-4-((tert-butoxycarbonyl)amino)-lH-pyrrole-2- carboxylate (3.0 g, 9.0 mmol) and BPD (4.6 g, 18.0 mmol) in THE (50 mL) was added Pd2(dba)(0.41 g, 0.45 mmol), KO Ac (2.65 g, 27.0 mmol) and XPhos (0.43 g, 0.90 mmol). The mixture was stirred at 75 °C for 3 h and cooled to room temperature. Solid was filtered off and the filtrate was concentrated under vacuum. The crude was re-dissolved in dioxane (100 mL) and water (mL), followed by addition of 4-cyano-5-methyl-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (3.0 g, 11.7 mmol) Pd(dppf)C12 (83 mg, 0.58 mmol) andNaHCO3 (1.96 g, 23.4 mmol). The mixture was stirred at 80 °C for 5 h. The mixture was cooled to room temperature and diluted with EtOAc (100 mL). The mixture was washed with brine (50 mL), and the aqueous layer was back-extracted with EtOAc (50 mL). The combined organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatograph (PE/EtOAc=3/l) to give the title compound (2.0 g, 62%). LC-MS (M+H)+ =362.1.Step 4: ethyl 5-amino-6-methyl-6,8-dihydro-1H-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylate 106 WO 2024/199255 PCT/CN2024/083980 id="p-186" id="p-186" id="p-186"
id="p-186"
[0186]To a solution of ethyl 4-((tert-butoxycarbonyl)amino)-5-(4-cyano-5-methyl-2,5- dihydrofuran-3-yl)-lH-pyrrole-2-carboxylate (2.0 g, 5.5 mmol) in dioxane (10 mL) was added HCI in dioxane (4 M, 10 mL) and the mixture was stirred at room temperature for 5 h. The mixture was concentrated under reduced pressure, and the crude was re-dissolved in EtOH (mL) followed by addition of K2CO3 (3.44 g, 25 mmol). The mixture was stirred at 70 °C for 4 h then cooled to room temperature. Solid was filtered off and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM/MeOH=10/l) to give the title compound (1.0 g, 69%). LC-MS (M+H)+ = 262.1.Step5:5-amino-6-methyl-6,8-dihydro-1H-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid id="p-187" id="p-187" id="p-187"
id="p-187"
[0187]A mixture of ethyl 5-amino-6-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylate (1.0 g, 3.8 mmol) and LiOHH2O (0.32 g, 7.6 mmol) in MeOH (20 mL) and water (10 mL) was stirred at 50 °C for 3 h. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by prep-HPLC to give the title compound (500 mg, 56%). LCMS (M+H)+ = 234.1.Step 6: (R)-5-amino-N-((5-(2,6-difluorophenvl)pvridin-2-vl)methyl)-N-((3R,4R)-4- methoxytetrahydro-2H-pyran-3-yl)-6-methyl-6,8-dihydro-lH-furo[3,4-dlpyrrolo[3,2-b]pyridine- 2-carboxamide & (S)-5-amino-N-((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)-N-((3R,4R)-4- methoxvtetrahvdro-2H-pvran-3-vl)-6-methvl-6,8-dihvdro-lH-furo[3,4-dlpv1Tolo[3,2-b]pvridine- 2-carboxamide [0188]To a mixture of 5-amino-6-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxylic acid (170 mg, 0.73 mmol), (3R,4R)-N-((5-(2,6-difluorophenyl)pyridin-2-yl)methyl)- 4-methoxytetrahydro-2H-pyran-3-amine hydrochloride (270 mg, 0.73 mmol) and DIPEA (4mg, 3.65 mmol) in anhydrous DMF (5 mL) under nitrogen was added HATU (832 mg, 2.mmol) and the mixture was stirred at 70 °C for 2 h. The mixture cooled to room temperature and diluted with EtOAc (20 mL). The mixture was washed with water (20 mL) and brine (20 mL). The aqueous layer was back-extracted with EtOAc (20 mL). The combined organic layer was dried over Na2S04, filtered and concentrated under reduced pressure. The crude was purified by prep-HPLC and chiral-SFC to give Example 23 (47 mg, 12%) and Example 24 (45 mg, 11%). 107 WO 2024/199255 PCT/CN2024/083980 [0189]Analytical chiral-HPLC condition as below. Column: CHIRALPAK IE-3; Column size: 4.6X50 mm, 3 pm; Mobile phase: (0.1% diethylamine in MTBE):MeOH:DCM=3:l:l isocratic; Flow: 1.0 mL/min; Temperature: 25 °C. [0190]Example 23: Analytical chiral-HPLC tR=2.26 min. 1H NMR (500 MHz, DMSO-6) 811.92 - 11.42 (m, 1H), 8.90 - 8.46 (m, 1H), 8.06 - 7.80 (m, 1H), 7.76 - 7.46 (m, 2H), 7.40 - 7.14 (m, 2H), 6.85 - 6.24 (m, 1H), 5.88 - 4.72 (m, 7H), 4.61 - 3.35 (m, 6H), 3.20 - 3.10 (m, 3H), 2.24-2.14 (m, 1H), 1.41 - 1.29 (m, 4H). LCMS (M+H)+ = 550.4. [0191]Example 24: Analytical chiral-HPLC tR=2.97 min. 1H NMR (500 MHz, DMSO-6) 811.90 - 11.46 (m, 1H), 8.82 - 8.48 (m, 1H), 8.03 - 7.76 (m, 1H), 7.74 - 7.46 (m, 2H), 7.38 - 7.19 (m, 2H), 6.85-6.26 (m, 1H), 5.81 -4.70 (m, 7H), 4.67-3.61 (m, 4H), 3.59-3.35 (m, 2H), 3.20 - 3.06 (m, 3H), 2.27 - 2.15 (m, 1H), 1.43 - 1.27 (m, 4H). LCMS (M+H)+ = 550.4. Example 25:(R)-5-amino-N-((5-( 1 -methyl- 1H-1,2,4-triazol-5-yl)pyridin-2-yl)methyl)-N- (5,6,7,8-tetrahydroquinolin-8-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide Step 1: 2-(l,3-dioxolan-2-yl)-5-(l-methyl-lH-L2,4-triazol-5-yl)pyridine id="p-192" id="p-192" id="p-192"
id="p-192"
[0192]To a mixture of (6-(l,3-dioxolan-2-yl)pyridin-3-yl)boronic acid (2.0 g, 10.3 mmol) in dioxane (20 mL), toluene (10 mL) and water (10 mL) was added 5-bromo-l-methyl-lH-l,2,4- triazole (1.66 g, 10.3 mmol), K3PO4 (6.53 g, 30.8 mmol) and Pd(dppf)C12 (751 mg, 1.0 mmol). The mixture was stirred at 80 °C for 12 h and cooled to room temperature. Solid was filtered off and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatograph (PE:EtOAc=5:l to 0:1) to give the title compound (1.3 g, 55%). LC-MS (M+H)+ = 233.3.Step 2: 5-(l-methyl-lH-L2,4-triazol-5-vl)picolinaldehyde N'N =N id="p-193" id="p-193" id="p-193"
id="p-193"
[0193]To a mixture of 2-(l,3-dioxolan-2-yl)-5-(l-methyl-lH-l,2,4-triazol-5-yl)pyridine (1.2 g, 5.17 mmol) in water (6 mL) and dioxane (12 mL) was added concentrated HC1 (6.5 mL) and the 108 WO 2024/199255 PCT/CN2024/083980 mixture was stirred at 60 °C for 3 h. The mixture was cooled to room temperature and neutralized with saturated NaHCO3 until pH reached 7-8. The mixture was diluted with water (100 mL) and extracted with EtOAc (100 mL x 3). The combined organic layer was dried with Na2S04, filtered and concentrated in vacuum to give the title compound (0.60 g, 62%). LC-MS (M+H)+= 189.3.Step3:(R)-N-((5-(1-methyl-1H-1,2.4-triazol-5-yl)pyridin-2-yl)methyD)-5,6.7.8-tetrahydroquinolin- 8-amine id="p-194" id="p-194" id="p-194"
id="p-194"
[0194]The title compound (0.28 g, 25%) was prepared in a manner similar to that in Example step 1 from (R)-5,6,7,8-tetrahydroquinolin-8-amine and 5-(l-methyl-lH-l,2,4-triazol-5- yl)picolinaldehyde. LC-MS (M+H)+ = 321.1.Step 4: tert-butyl (R)-(2-(((5-( 1 -methyl- 1H-1,2,4-triazol-5-yl)pyridin-2-yl)methyl)(5,6,7,8- tetrahydroquinolin-8-yl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b1pyridin-5- yDcarbamate id="p-195" id="p-195" id="p-195"
id="p-195"
[0195]The title compound (30 mg, 32%) was prepared in a manner similar to that in Example & 18 step 2 from 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid and (R)-N-((5-(l-methyl-lH-l,2,4-triazol-5-yl)pyridin-2- yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine. LC-MS (M+H)+ = 622.1.Step 5: (R)-5-amino-N-((5-( 1 -methyl- 1H-1,2,4-triazol-5-yl)pyridin-2-yl)methyl)-N- (5,6,7,8-tetrahydroquinolin-8-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-blpyridine-2- carboxamide [0196]Example 25 (8 mg, 30%) was prepared in a manner similar to that in Example 22 step from tert-butyl (R)-(2-(((5-(l-methyl-lH-l,2,4-triazol-5-yl)pyridin-2-yl)methyl)(5,6,7,8- tetrahydroquinolin-8-yl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-5- yl)carbamate. 1H NMR (500 MHz, DMSO-d6) 8 11.75-11.53 (m, 1H), 9.10-8.75 (m, 1H), 8.50-109 WO 2024/199255 PCT/CN2024/083980 7.90 (m, 6H), 6.81-6.17 (m, 1H), 6.00-4.76 (m, 8H), 4.10-3.87 (m, 4H), 3.05-2.39 (m, 4H), 2.30-1.68 (m, 4H). LC-MS (M+H)+ =522.4. Example 26:5-amino-N-((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)-N-((5- (trifh1oromethyl)pyridin-2-yl)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide Step 1: (3R,4R)-4-methoxy-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)tetrahydro-2H- pyran-3-amine f 3c [0197]The title compound (50 mg, 55%) was prepared in a manner similar to that in Example step 1 from (3R,4R)-4-methoxytetrahydro-2H-pyran-3-amine and 5- (trifluoromethyl)picolinaldehyde. LC-MS (M+H)+ = 291.3.Step 2: tert-butyl (2-(((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)((5-(trifh1oromethyl)pvridin-2-vl)methyl)carbamovl)-6,8-dihvdro-lH-furor3,4-d1pyrrolo[3,2- blpyridin-5-yl)carbamate id="p-198" id="p-198" id="p-198"
id="p-198"
[0198]The title compound (60 mg, 59%) was prepared in a manner similar to that in Example & 18 step 2 from 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid and (3R,4R)-4-methoxy-N-((5-(trifluoromethyl)pyridin-2- yl)methyl)tetrahydro-2H-pyran-3-amine. LC-MS (M+H)+ = 592.4.Step 3: 5-amino-N-((3R,4R)-4-methoxytetrahydro-2H-pyran-3-vl)-N-((5- (trifluoromethyl)pyridin-2-yl)methyl)-6,8-dihydro- 1 H-furo [ 3,4-d]pyrrolo [ 3,2-b]pyridine-2- carboxamide 110 WO 2024/199255 PCT/CN2024/083980 [0199]Example 26 (31 mg, 63%) was prepared in a manner similar to that in Example 22 step from tert-butyl (2-(((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)((5-(trifluoromethyl)pyridin- 2-yl)methyl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate. 1H NMR (500 MHz, DMSO-d6) S 11.73 - 11.39 (m, 1H), 9.10 - 8.79 (m, 1H), 8.30 - 8.07 (m, 1H), 7.86 - 7.54 (m, 1H), 6.82 - 6.08 (m, 1H), 5.57 (s, 2H), 5.26 - 4.73 (m, 6H), 4.67 - 3.44 (m, 5H), 3.21 - 3.04 (m, 3H), 2.32 - 2.06 (m, 1H), 1.41 - 1.20 (m, 1H). LC-MS (M+H)+ = 492.4. Example 27:5-amino-N-((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)-N-((5- phenylpyridin-2-yl)methyl)-6,8-dihydro- 1 H-furo [3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step1:(3R,4R)-4-methoxy-N-((5-phenylpyridin-2-yl)methyl)tetrahydro-2H-pyran-3-amine id="p-200" id="p-200" id="p-200"
id="p-200"
[0200]The title compound (0.050 g, 58%) was prepared in a manner similar to that in Example step 1 from 5-phenylpicolinaldehyde and (3R,4R)-4-methoxytetrahydro-2H-pyran-3-amine. LC-MS (M+H)+= 299.1.Step 2: tert-butyl (2-(((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)((5-phenylpyridin-2- yl)methyl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate id="p-201" id="p-201" id="p-201"
id="p-201"
[0201]The title compound (60 mg, 57%) was prepared in a manner similar to that in Example & 18 step 2 from 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid and (3R,4R)-4-methoxy-N-((5-phenylpyridin-2- yl)methyl)tetrahydro-2H-pyran-3-amine. LC-MS (M+H)+ = 600.2. 111 WO 2024/199255 PCT/CN2024/083980 Step 3: 5-amino-N-((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)-N-((5-phenylpyridin-2- yDmethyl)-6,8-dihydro-lH-furor3,4-d]pyrrolor3.2-b]pyridine-2-carboxamide [0202]Example 27 (23 mg, 46%) was prepared in a manner similar to that in Example 22 step from tert-butyl (2-(((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)((5-phenylpyridin-2- yl)methyl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate. 1H NMR (500 MHz, DMSO-d) 5 11.57 (s, 1H), 8.82 (s, 1H), 8.04 (s, 1H), 7.72 (s, 2H), 7.59 - 7.(m, 4H), 6.74 (s, 1H), 5.58-5.51 (m, 2H), 5.13 (s, 2H), 4.93 (s, 3H), 4.77-4.55 (m, 1H), 4.05 (s, 1H), 3.84 (d, J = 7.9 Hz, 2H), 3.51-3.26 (m, 6H), 2.20 (d, J= 10.1 Hz, 1H), 1.33 (s, 1H). EC- MS (M+H)+ = 500.2. Example 28:N-([3,4'-bipyridin]-6-ylmethyl)-5-amino-N-((3R,4R)-4-methoxytetrahydro- 2H-pyran-3-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: r3,4'-bipyridinel-6-carbaldehyde id="p-203" id="p-203" id="p-203"
id="p-203"
[0203]The title compound (1.0 g, 100%) was prepared in a manner similar to that in Example step 1 from 5-bromopicolinaldehyde and pyridin-4-ylboronic acid. LC-MS (M+H)+ = 185.0.Step 2: (3R,4R)-N-([3,4'-bipyridinl-6-vlmethyl)-4-methoxvtetrahydro-2H-pvran-3-amine id="p-204" id="p-204" id="p-204"
id="p-204"
[0204]The title compound (40 mg, 29%) was prepared in a manner similar to that in Example step 1 from [3,4'-bipyridine]-6-carbaldehyde and (3R,4R)-4-methoxytetrahydro-2H-pyran-3- amine. LC-MS (M+H)+ = 300.1. 112 WO 2024/199255 PCT/CN2024/083980 Step3:tert-butyl(2-(([3,4 ‘-bipyridin]-6-ylmethyl)((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)carbamoyl)-6.8-dihydro-lH-furor3.4-d]pyrrolor3,2-b]pyridin-5-yl)carbamate K ^NHBoc id="p-205" id="p-205" id="p-205"
id="p-205"
[0205]The title compound (35 mg, 29%) was prepared in a manner similar to that in Example & 18 step 2 from 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid and (3R,4R)-N-([3,4'-bipyridin]-6-ylmethyl)-4-methoxytetrahydro- 2H-pyran-3-amine. LC-MS (M+H)+ = 601.2.Step 4: N-(r3,4'-bipyridinl-6-ylmethyl)-5-amino-N-((3R,4R)-4-methoxytetrahydro-2H- pyran-3-yl)-6.8-dihydro-lH-furo[3.4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0206]Example 28 (2 mg, 7%) was prepared in a manner similar to that in Example 22 step from tert-butyl (2-(([3,4'-bipyridin]-6-ylmethyl)((3R,4R)-4-methoxytetrahydro-2H-pyran-3- yl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate. ,H NMR (5MHz, DMSO-d) 8 11.56 (s, 1H), 9.01 (d, J = 46.7 Hz, 1H), 8.67 (d, J = 5.2 Hz, 2H), 8.17 (s, 1H), 7.79 (s, 2H), 7.65-7.53 (m, 1H), 6.74 (s, 1H), 5.57-5.50 (m, 2H), 5.13 (s, 2H), 4.93 (s, 2H), 4.82 - 4.50 (m, 1H), 4.06 (s, 1H), 3.84 (d, J = 9.7 Hz, 2H), 3.68 (s, 1H), 3.50 (s, 1H), 3.17 (s, 3H), 2.20 (d, J = 10.0 Hz, 1H), 1.34 (s, 1H). LC-MS (M+H)+= 501.2. Example 29:N-([3,4'-bipyridin]-6-ylmethyl)-5-amino-N-(2,6-difluorobenzyl)-6,8-dihydro- lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: l-([3,4'-bipvridinl-6-vl)-N-(2,6-difluorobenzyl)methanamine id="p-207" id="p-207" id="p-207"
id="p-207"
[0207]The title compound (40 mg, 23%) was prepared in a manner similar to that in Example step 1 from [3,4'-bipyridine]-6-carbaldehyde and (2,6-difluorophenyl)methanamine. LC-MS (M+H)+= 312.1. 113 WO 2024/199255 PCT/CN2024/083980 Step2:tert-butyl(2-(([3,4 ‘-bipyridin]-6-ylmethyl)(2,6-difluorobenzyl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate id="p-208" id="p-208" id="p-208"
id="p-208"
[0208]The title compound (20 mg, 26%) was prepared in a manner similar to that in Example & 18 step 2 from 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid and l-([3,4'-bipyridin]-6-yl)-N-(2,6-difluorobenzyl)methanamine. LC-MS (M+H)+= 613.2.Step 3: N-([3,4'-bipyridinl-6-ylmethyl)-5-amino-N-(2,6-difluorobenzyl)-6,8-dihydro-lH- furo[3,4-d1pyrrolo[3,2-b]pyridine-2-carboxamide [0209]Example 29 (4 mg, 25%) was prepared in a manner similar to that in Example 22 step from tert-butyl (2-(([3,4'-bipyridin]-6-ylmethyl)(2,6-difluorobenzyl)carbamoyl)-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate. 1HNMR (500 MHz, DMSO-d6) 5 11.67 (s, 1H), 8.98 (s, 1H), 8.68 (dd, J = 4.6, 1.5 Hz, 2H), 8.20 (d, J = 7.3 Hz, 1H), 7.78 (d, J = 5.9 Hz, 2H), 7.45 (d, J = 8.2 Hz, 1H), 7.44 - 7.32 (m, 1H), 7.05 (t, J = 8.0 Hz, 2H), 6.46 (s, 1H), 5.55 (s, 2H), 5.13 (s, 2H), 5.00 (s, 2H), 4.91 (s,2H). LC-MS (M+H)+ = 513.1. Example 30:5-amino-N-((3',5'-difluoro-[3,4'-bipyridin]-6-yl)methyl)-N-(2,6- difluorobenzyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: l-(3',5'-difluoro-[3,4'-bipyridin]-6-yl)-N-(2,6-difluorobenzyl)methanamine HN X F id="p-210" id="p-210" id="p-210"
id="p-210"
[0210]The title compound (130 mg, 75%) was prepared in a manner similar to that in Example step 1 from 3',5'-difluoro-[3,4'-bipyridine]-6-carbaldehyde and (2,6- difluorophenyl)methanamine. LC-MS (M+H)+ = 348.2. 114 N. NHB0C WO 2024/199255 PCT/CN2024/083980 Step2:5-amino-N-((3 ‘,5‘-difluoro-[3,4 ‘-bipyridin]-6-yl)methyl)-N-(2,6-difluorobenzyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolor3,2-b]pyridine-2-carboxamide [0211]Example 30 (15 mg, 27%) was prepared in a manner similar to that in Example 2 step from 5-amino-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and l-(3',5'- difluoro-[3,4'-bipyridin]-6-yl)-N-(2,6-difluorobenzyl)methanamine. 1H NMR (500 MHz, DMSO-d) 5 11.72 (s, 1H), 8.78 - 8.62 (m, 3H), 8.05 - 7.95 (m, 1H), 7.55 - 7.30 (m, 2H), 7.04 (t, J = 8.0 Hz, 2H), 6.52 (s, 1H), 5.85 - 4.75 (m, 10H). LC-MS (M+H)+ = 549.3. Example 31:5-amino-N-(2,6-dichlorobenzyl)-N-((3',5'-difluoro-[3,4'-bipyridin]-6- yl)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: N-(2,6-dichlorobenzyl)-l-(3',5'-difluoro-r3,4'-bipyridin1-6-yl)methanamine id="p-212" id="p-212" id="p-212"
id="p-212"
[0212]The title compound (140 mg, 74%) was prepared in a manner similar to that in Example step 1 from 3',5'-difluoro-[3,4'-bipyridine]-6-carbaldehyde and (2,6-dichlorophenyl)methanamine. LC-MS (M+H)+ = 380.1Step 2: 5-amino-N-(2,6-dichlorobenzyl)-N-((3',5'-difluoro-[3,4'-bipyridin]-6-yl)methyl)-6,8- dihydro-lH-furo[3,4-d]pv1Tolor3,2-b]pyridine-2-carboxamide [0213]Example 31(14 mg, 24%) was prepared in a manner similar to that in Example 2 step from 5-amino-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and N-(2,6- dichlorobenzyl)-l-(3',5'-difluoro-[3,4'-bipyridin]-6-yl)methanamine. 1H NMR (500 MHz, DMSO-d) 8 11.69 (s, 1H), 8.72 - 8.53 (m, 3H), 7.94 (d, J = 8.0 Hz, 1H), 7.51 - 7.35 (m, 3H), 7.28 (t, J = 8.0 Hz, 1H), 6.52 (s, 1H), 5.56 (s, 2H), 5.47 - 4.62(m, 8H). LC-MS (M+H)+ = 581.3. Example 32:5-amino-N-((5-cyanopyridin-2-yl)methyl)-N-(2,6-difluorobenzyl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide NC 115 WO 2024/199255 PCT/CN2024/083980 Step1:6-(((2,6-difluorobenzyl)amino)methyl)nicotinonitrile F ^NH N—x X-CN id="p-214" id="p-214" id="p-214"
id="p-214"
[0214]The title compound (260 mg, 100%) was prepared in a manner similar to that in Example 3 step 1 from (2,6-difluorophenyl)methanamine and 6-formylnicotinonitrile. LC-MS (M+H)+ = 260.2.Step 2: 5-amino-N-((5-cyanopyridin-2-yl)methyl)-N-(2,6-difluorobenzyl)-6,8-dihydro-lH- furol 3,4-dlpyrrolo 13,2-blpyridine-2-carboxamide [0215]Example 32 (8 mg, 9%) was prepared in a manner similar to that in Example 2 step from 6-(((2,6-difluorobenzyl)amino)methyl)nicotinonitrile and 5-amino-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid. ,H NMR (500 MHz, DMSO-d) 8 11.64 (s, 1H), 8.95 (s, 1H), 8.27 (d, J = 7.2 Hz, 1H), 7.51 (d, J = 7.8 Hz, 1H), 7.40 - 7.30 (m, 1H), 7.13 - 6.96 (m, 2H), 6.87 - 6.11 (m, 1H), 5.55 (s, 2H), 5.27 - 4.71 (m, 8H). LC-MS (M+H)+ = 461.4. Example 33:5-amino-N-(cyclopropylmethyl)-N-(2,6-difluorobenzyl)-6,8-dihydro- 1H- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: l-cyclopropyl-N-(2,6-difluorobenzyl)methanamine f ץO^F id="p-216" id="p-216" id="p-216"
id="p-216"
[0216]The title compound (80 mg, 58%) was prepared in a manner similar to that in Example step 1 from (2,6-difluorophenyl)methanamine and cyclopropanecarbaldehyde. LC-MS (M+H)+ = 198.3.Step2:5-amino-N-(cyclopropylmethyl)-N-(2,6-difluorobenzyl)-6,8-dihydro-1H-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide [0217]Example 33 (9 mg, 16%) was prepared in a manner similar to that in Example 2 step from 5-amino-6,8-dihydro-lH-furo[3,4-d]py1Tolo[3,2-b]pyridine-2-carboxylic acid and 1- cyclopropyl-N-(2,6-difluorobenzyl)methanamine. 1H NMR (500 MHz, DMSO- WO 2024/199255 PCT/CN2024/083980 Example 34:5-amino-N-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)methyl)-N-((3R,4R)-4- methoxytetrahydro-2H-pyran-3-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide f 3cStep1:(3R,4R)-N-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)methyl)-4-methoxytetrahydro-2H-pyran-3 -amine f 3c [0218]To a mixture of 3-fluoro-5-(trifluoromethyl)picolinaldehyde (1.0 g, 5.18 mmol) and (3R,4R)-4-methoxytetrahydro-2H-pyran-3-amine (747 mg, 5.7 mmol) in DCM (50 mL) was added triethylamine (575 mg, 5.7 mmol) and then the mixture was stirred for 10 min at room temperature. NaBH(OAc)3 (2.2 g, 10.36 mmol) was added and the mixture was stirred for another 2 h at room temperature. The mixture was quenched with saturated NaHCO3, diluted with DCM (40 mL), successively washed with water (40 mL) and brine (40 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatograph to give the title compound (1.3 g, 82%). LC-MS (M+H)+ =309.2.Step 2: tert-butyl (2-(((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)methyl)((3R,4R)-4- methoxytetrahydro-2H-pyran-3-yl)carbamoyl)-6,8-dihydro-lH-furor3,4-dlpyrrolo[3,2-b]pyridin- 5-vl)carbamate id="p-219" id="p-219" id="p-219"
id="p-219"
[0219]The title compound (1.5 g, 58%) was prepared in a manner similar to that in Examplestep 4 from 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- 117 N. ^NHBoc WO 2024/199255 PCT/CN2024/083980 b]pyridine-2-carboxylic acid and (3R,4R)-N-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)methyl)- 4-methoxytetrahydro-2H-pyran-3-amine. LC-MS (M+H)+=610.3.Step3:5-amino-N-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)methyl)-N-((3R,4R)-4- methoxytetrahydro-2H-pyran-3-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-blpyridine-2- carboxamide [0220]Example 34 (970 mg, 77%) was prepared in a manner similar to that in Example 14 step from tert-butyl (2-(((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)methyl)((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin- 5-yl)carbamate. ׳HNMR (400 MHz, DMSO-d) 8 11.48 (s, 1H), 8.76 (s, 1H), 8.27 (s, 1H), 6.(s, 1H), 5.55 (s, 2H), 5.31 - 4.98 (m, 3H), 4.89 (s, 2H), 4.76 - 4.64 (m, 1H), 4.60 - 4.68 (m, 1H), 4.19 - 4.02 (m, 1H), 3.89 - 3.69 (m, 2H), 3.55 - 3.44 (m, 1H), 3.38 - 3.35 (m, 1H), 3.34 (s, 3H), 2.25-2.11 (m, 1H), 1.43 -1.30 (m, 1H). LC-MS (M+H)+=510.3. Example 35:(R)-5-amino-N-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)methyl)-N-( 1 - (pyrimidin-2-yl)ethyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide f 3cStep1:(R)-N-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)methyl)-1-(pyrimidin-2-yl)ethan-1-amine id="p-221" id="p-221" id="p-221"
id="p-221"
[0221]To a mixture of 3-fluoro-5-(trifluoromethyl)picolinaldehyde (100 mg, 0.52 mmol) and (R)-l-(pyrimidin-2-yl)ethan-l-amine dihydrochloride (122 mg, 0.62 mmol) in DCM (2 mL) and MeOH (0.2 mL) was added NaBH(OAc)3 (220 mg, 1.04 mmol). The mixture was stirred at °C for 1 h then quenched with a mixture of saturated NaHCO3 (5 mL) and water (5 mL). The mixture was extracted with EtOAc (5 mL x 3). The combined organic layer was washed with brine (5 mL), dried with Na2S04, fdtered and concentrated under reduced pressure to give the title compound (100 mg, 64%). LC-MS (M+H)+ =301.1.Step 2: tert-butyl (R)-(2-(((3-fluoro-5-(trifluoromethvl)pyridin-2-vl)methyl)(l-(pyrimidin-2- yl)ethyl)carbamovl)-6,8-dihvdro-lH-furor3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate 118 WO 2024/199255 PCT/CN2024/083980 NHBoc , ״ N id="p-222" id="p-222" id="p-222"
id="p-222"
[0222]To a mixture of (R)-N-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)methyl)-l-(pyrimidin- 2-yl)ethan-l-amine (100 mg, 0.33 mmol) and 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid (106 mg, 0.33 mmol) in THF (5 mL) was added BOPCI (170 mg, 0.67 mmol) and DIPEA (129 mg, 1.0 mmol). The mixture was stirred at °C for 1 h and cooled to room temperature. The mixture was diluted with water (15 mL) and extracted with EtOAc (5 mL x 3). The combined organic layer was washed with brine (5 mL), dried with Na2S04, filtered and concentrated under reduced pressure to give the title compound (100 mg, 50%). LC-MS (M+H-Boc) + =502.3.Step 3: (R)-5-amino-N-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)methyl)-N-(l-(pyrimidin- 2-yl)ethyl)-6,8-dihydro-lH-furor3,4-dlpyrrolor3,2-blpyridine-2-carboxamide [0223]To a solution tert-butyl (R)-(2-(((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)methyl)(l- (pyrimidin-2-yl)ethyl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-5- yl)carbamate (100 mg, 0.167 mmol) in MeOH (1 mL) was added HC1(4 M in MeOH, 1 mL, 4.mmol). The mixture was stirred at 40 °C for 1 h and cooled to room temperature. The mixture was concentrated under reduced. The residue was purified by prep-HPLC to give Example (15 mg, 18%). ،HNMR(400 MHz, DMSO-،/6) 5 11.69 - 11.47 (m, 1H), 8.98 - 8.53 (m, 3H), 8.42 - 8.05 (m, 1H), 7.62 - 7.17 (m, 1H), 6.77 - 6.20 (m, 1H), 6.20 - 5.63 (m, 1H), 5.63 - 5.(m, 3H), 5.18-4.98 (m, 3H), 4.95-4.61 (m, 3H), 1.86- 1.34 (m, 3H). LC-MS (M+H)+ =502.1. Example 36:5-amino-N-((5-cyclopropylpyridin-2-yl)methyl)-N-((3R,4R)-4- methoxytetrahydro-2H-pyran-3-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide Step 1: 5-cyclopropylpicolinaldehyde 119 WO 2024/199255 PCT/CN2024/083980 [0224]To a mixture of 5-bromopicolinaldehyde (1.0 g, 5.38 mmol), K3PO4 (2.28 g, 10.mmol), Pd(OAc)2 (120 mg, 0.54 mmol) and SPhos (440 mg, 1.08 mmol) in toluene (15 mL) and water (1.5 mL) was added cyclopropylboronic acid (550 mg, 6.46 mmol). The mixture was stirred for 3 h at 100 °C under nitrogen, then cooled to room temperature. The mixture was diluted with EtOAc (100 mL), successively washed with water (40 mL) and brine (40 mL), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatograph to give the title compound (450 mg, 57%). LC-MS (M+H)+ =148.2.Step 2: (3R,4R)-N-((5-cyclopropylpyridin-2-yl)methyl)-4-methoxytetrahydro-2H-pyran-3- amine id="p-225" id="p-225" id="p-225"
id="p-225"
[0225]The title compound (280 mg, 87%) was prepared in a manner similar to that in Example step 1 from 5-cyclopropylpicolinaldehyde and (3R,4R)-4-methoxytetrahydro-2H-pyran-3- amine. LC-MS (M+H)+=263.3.Step 3: tert-butyl (2-(((5-cyclopropylpyridin-2-yl)methyl)((3R.4R)-4-methoxytetrahydro- 2H-pyran-3-yl)carbamoyl)-6.8-dihydro-lH-furo[3.4-d]pyrrolo[3.2-b]pyridin-5-yl)carbamate id="p-226" id="p-226" id="p-226"
id="p-226"
[0226]The title compound (90 mg, 42%) was prepared in a manner similar to that in Example step 4 from 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid and (3R,4R)-N-((5-cyclopropylpyridin-2-yl)methyl)-4- methoxytetrahydro-2H-pyran-3-amine. LC-MS (M+H)+=564.4.Step4:5-amino-N-((5-cyclopropylpyridin-2-yl)methyl)-N-((3R,4R)-4-methoxytetrahydro-2H-pyran-3-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0227]Example 36 (43 mg, 58%) was prepared in a manner similar to that in Example 14 step from tert-butyl (2-(((5-cyclopropylpyridin-2-yl)methyl)((3R,4R)-4-methoxytetrahydro-2H- pyran-3-yl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate. 1H NMR (400 MHz, DMSO-d) 8 11.51 (s, 1H), 8.30 (s, 1H), 7.34 - 7.23 (m, 2H), 6.66 (s, 1H), 5.53 (s, 2H), 5.10 (s, 2H), 5.01 - 4.75 (m, 4H), 4.61 - 4.45 (m, 1H), 3.98 - 3.91 (m, 1H), 3.84 - 120 WO 2024/199255 PCT/CN2024/083980 3.70 (m, 2H), 3.65 - 3.56 (m, 1H), 3.44 - 3.35 (m, 1H), 3.11 (s, 3H),2.14(s, 1H), 1.91 (s, 1H), 1.29 (s, 1H), 0.95 (s, 2H), 0.68 (s, 2H). LC-MS (M+H)+ =464.3. Example 37:5-amino-N-(2,6-difluorobenzyl)-N-((6-(trifluoromethyl)pyridazin-3- yl)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: 6-(trifluoromethyl)pyridazine-3-carbaldehyde id="p-228" id="p-228" id="p-228"
id="p-228"
[0228]To a solution of ethyl 6-(trifluoromethyl)pyridazine-3-carboxylate (920 mg, 4.18 mmol) in DCM (10 mL) was added DIBAL-H (5.57 mL, 8.36 mmol) at -78°C under nitrogen. The mixture was stirred for 3 h at -78°C. The mixture was poured into saturated NH4C1 solution (1mL) and then extracted with DCM (100 mL x 2). The combined organic layer was washed with brine (100 mL), dried over Na2S04, filtered and concentrated under reduced pressure to give the title compound (350 mg, 48%). LC-MS (M+H)+ =177.1.Step 2: N-(2,6-difluorobenzyl)- 1 -(6-(trifluoromethyl)pyridazin-3-yl)methanamine id="p-229" id="p-229" id="p-229"
id="p-229"
[0229]The title compound (38 mg, 35%) was prepared in a manner similar to that in Example step 1 from 6-(trifluoromethyl)pyridazine-3-carbaldehyde and (2,6- difluorophenyl)methanamine. LC-MS (M+H)+ = 304.3.Step3:5-amino-N-(2,6-difluorobenzyl)-N-((6-(trifluoromethyl)pyridazin-3-yl)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0230]Example 37(18 mg, 28%) was prepared in a manner similar to that in Example 2 step from 5-amino-6,8-dihydro-lH-furo[3,4-d]py1Tolo[3,2-b]pyridine-2-carboxylic acid and N-(2,6- difluorobenzyl)-l-(6-(trifluoromethyl)py1 ־idazin-3-yl)methanamine. 1H NMR (500 MHz, DMSO- d6) 8 11.66 (s, 1H), 8.32-8.06 (m, 1H), 8.01-7.76 (m, 1H), 7.42-7.23 (m, 1H), 7.14-6.92 (m, 2H), 6.80-6.26 (m, 1H), 5.74-5.47 (m, 2H), 5.40-4.65 (m, 8H). LC-MS (M+H)+ =505.2. 121 WO 2024/199255 PCT/CN2024/083980 Example 38:(R)-5-amino-N-((3-fluoropyridin-2-yl)methyl)-6-methyl-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide Step 1: ethyl (S)-5-amino-6-methyl-6,8-dihydro-1H-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxylate and ethyl (R)-5-amino-6-methyl-6,8-dihydro-1H-furo[3,4-d]pyrrolo[3,2-b]pyridine- 2-carboxylate id="p-231" id="p-231" id="p-231"
id="p-231"
[0231]To the solution of ethyl 4-((tert-butoxycarbonyl)amino)-5-(4-cyano-5-methyl-2,5- dihydrofuran-3-yl)-lH-pyrrole-2-carboxylate (20 g, 55 mmol) in dioxane (100 mL) was added a solution of HCI in dioxane (100 mL, 4M) and the mixture was stirred at room temperature for h. The mixture was concentrated under reduced pressure. The crude was re-dissolved in EtOH (200 mL) followed by addition of K2CO3 (27.6 g, 200 mmol). The mixture was stirred at 70°C for 4 h then cooled to room temperature. Solid was filtered off and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM:MeOH=10:1) to give a racemate (5.0 g). The material was separated by SFC to give ethyl (S)-5-amino-6-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylate (2.25 g, 16%) and ethyl (R)-5-amino-6-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxylate (2.34 g, 16%). [0232]Analytical chiral-SFC condition as below. Column: CHIRALPAK IC-3; Column size: 3.0X100 mm, 3 pm; Mobile phase: 10 pM NH3 in methanol:CO2, 1:9 to 1:1 in 2 min, 1:1 for min; Flow: 2.0 mL/min; Temperature: 35 °C; backpressure: 1500 psi. [0233]ethyl (S)-5-amino-6-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxylate: Analytical SFC tR=2.01 min. LC-MS (M+H)+ = 262.1. [0234]ethyl (R)-5-amino-6-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxylate: Analytical SFC tR=2.36 min. LC-MS (M+H)+ = 262.1.Step 2: (R)-5-amino-6-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-blpyridine-2- carboxylic acid 122 WO 2024/199255 PCT/CN2024/083980 id="p-235" id="p-235" id="p-235"
id="p-235"
[0235]A mixture of ethyl (R)-5-amino-6-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylate (1.5 g, 5.7 mmol) and LiOHH2O (0.32 g, 7.6 mmol) in MeOH (20 mL) and water (10 mL) was stirred at 50 °C for 3 h. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by prep-HPLC to give the title compound (1.2 g, 90%). LC-MS (M+H)+ = 234.1.Step 3: 1 -(3-fluoropyridin-2-yl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)methanamine id="p-236" id="p-236" id="p-236"
id="p-236"
[0236]The title compound (100 mg, 60%) was prepared in a manner similar to that in Example step 1 from 5-(trifluoromethyl)picolinaldehyde and (3-fluoropyridin-2-yl)methanamine. LC- MS (M+H)+ = 286.2.Step 4: (R)-5-amino-N-((3-fluoropyridin-2-yl)methyl)-6-methyl-N-((5- (trifluoromethyl)pyridin-2-yl)methyl)-6,8-dihydro-lH-furo[3,4-d1pyrrolo[3,2-b1pyridine-2- carboxamide [0237]Example 38 (18 mg, 43%) was prepared in a manner similar to that in Example 2 step from l-(3-fluoropyridin-2-yl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)methanamine and (R)- 5-amino-6-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid. 1H NMR (400 MHz, DMSO-d) §11.63 (s, 1H),9.1 -8.75 (m, 1H), 8.5-8.1 (m, 2H), 7.8-7.56 (m, 2H), 7.42 (s, 1H), 6.6-6.1 (m, 1H), 5.44 (s, 2H), 5.37 - 4.69 (m, 7H), 1.32 (d, J= 6.1 Hz, 3H). LC-MS (M+H)+= 501.1. Example 39 & Example 40:(R)-5-amino-N-methyl-N-(7-(trifluoromethyl)isochroman-4- yl)-6,8-dihydro- lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (S)-5-amino-N-methyl- N-(7-(trifluoromethyl)isochroman-4-yl)-6,8-dihydro-lH-furo[3,4-d]py1Tolo[3,2-b]pyridine-2- carboxamide Step1:2-((allyloxy)methyl)-1-bromo-4-(trifluoromethyl)benzene 123 WO 2024/199255 PCT/CN2024/083980 f 3c [0238]To a solution of (2-bromo-5-(trifluoromethyl)phenyl)methanol (5.0 g, 19.6 mmol) in THF (100 ml) was added NaH (60%, 941 mg, 23.5 mmol) at 0 °C over a 1-hour period. Allyl bromide (3.08 g, 25.5 mmol) was added dropwise at 0 °C. The mixture was stirred at room temperature for 11 h. The mixture was diluted with water (100 mL). The mixture was extracted with ethyl acetate (100 mL x 2). The combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=l/0 to 10/1) to give the title compound (8.0 g, 69%). 1H NMR (400 MHz, DMSO-d) 8 7.84 (d, J= 8.0 Hz, 1H), 7.76 (s, 1H), 7.58 (d, J= 8.0 Hz, 1H), 6.04 - 5.88 (m, 1H), 5.37 - 5.28 (m, 1H), 5.23 - 5.16 (m, 1H), 4.55 (s, 2H), 4.16 - 4.07 (m, 2H).Step 2: 4-methylene-7-(trifluoromethyl)isochromane id="p-239" id="p-239" id="p-239"
id="p-239"
[0239]A mixture of 2-((allyloxy)methyl)-l-bromo-4-(trifluoromethyl)benzene (8.0 g, 27.mmol), Pd(OAc)2 (913 mg, 4.07 mmol), C82CO3 (10.6 g, 32.5 mmol) and PPh3 (3.20 g, 12.mmol) in DMF (80 mL) was degassed and purged with nitrogen for 3 times, and the mixture was stirred at 90 °C for 12 h. The mixture was cooled to room temperature and diluted with water (100 mL). The mixture was extracted with EtOAc (100 mL x 2). The combined organic layer was washed with brine (50 mL), dried with Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatograph (PE/EtOAc = 1/0 to 5/1) to give the title compound (5.0 g, 86%). 1H NMR (400 MHz, DMSO-d) 8 7.97 (d, J= 8.4 Hz, 1H), 7.56 (d,J=8.4 Hz, 1H), 7.52 (s, 1H), 5.87 - 5.83 (m, 1H), 5.24 - 5.18 (m, 1H), 4.80 (s, 2H), 4.41(s, 2H).Step 3: 7-(trifluoromethyl)isochroman-4-one id="p-240" id="p-240" id="p-240"
id="p-240"
[0240]To a solution of 4-methylene-7-(trifluoromethyl)isochromane (4.9 g, 22.9 mmol) in dioxane (100 mL) and water (20 mL) was added potassium osmate (VI) dihydrate (843 mg, 2.mmol), 2,6-lutidine (4.90 g, 45.8 mmol) and sodium periodate (19.6 g, 91.5 mmol). The 124 WO 2024/199255 PCT/CN2024/083980 mixture was stirred at 25 °C for 2 h. The mixture was diluted with water (100 mL) and extracted with EtOAc (100 mL x 3). The combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=l/0 to 5/1) to give the title compound (3.0 g, 61%). 1H NMR (400 MHz, DMSO-d6) S 8.13 - 8.06 (m, 1H), 7.93 - 7.78 (m, 2H), 4.99 (s, 2H), 4.44 (s, 2H).Step 4: 7-(trifluoromethyl)isochroman-4-one oxime f 3c [0241]To a solution of 7-(trifluoromethyl)isochroman-4-one (500 mg, 2.32 mmol) in MeOH (10 mL) was added hydroxylamine hydrochloride (804 mg, 11.6 mmol) and pyridine (5.4 mL). The mixture was stirred at 65 °C for l h then cooled to room temperature. The mixture was concentrated under reduced pressure and diluted with water (10 mL). Aqueous HCI (IM) was added to until the pH reached 5. The mixture was extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (10 mL), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=l/0 to 3/1) to give the title compound (500 mg, 94%). 1H NMR (400 MHz, DMSO- d6) 8 11.76 (s, 1H), 8.07 - 8.00 (m, 1H), 7.68 - 7.62 (m, 2H), 4.77-4.68 (m, 4H).Step 5: 7-(trifluoromethyl)isochroman-4-amineh2n id="p-242" id="p-242" id="p-242"
id="p-242"
[0242]To a solution of 7-(trifluoromethyl)isochroman-4-one oxime (500 mg, 2.16 mmol) in MeOH (10 mL) was added Raney-Ni (371 mg) under nitrogen. The suspension was degassed and purged with hydrogen for 3 times. The mixture was stirred under hydrogen (30 psi) at 40 °C for l h then cooled to room temperature. The solid was filtered off and the filtrate was concentrated under reduced pressure to give the title compound (400 mg, 85%). LCMS (M+H)+ = 218.1.Step 6: tert-butyl (7-(trifluoromethyl)isochroman-4-yl)carbamateBocHN 125 WO 2024/199255 PCT/CN2024/083980 [0243]To a solution of 7-(trifluoromethyl)isochroman-4-amine (350 mg, 1.61 mmol) in THF (4 mL) was added B0C20 (352 mg, 1.61 mmol) and DIPEA (417 mg, 3.22 mmol). The mixture was stirred at room temperature for 1 h and then diluted with water (10 mL). The mixture was extracted with EtOAc (5 mL x 3). The combined organic layer was washed with brine (5 mL), dried with Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/ EtOAc=l/0 to 10/1) to give the title compound (400 mg, 78%). LCMS (M+H-tBu) + = 262.0.Step 7: tert-butyl methyl(7-(trifluoromethyl)isochroman-4-yl)carbamate—NBoc id="p-244" id="p-244" id="p-244"
id="p-244"
[0244]A solution of tert-butyl (7-(trifluoromethyl)isochroman-4-yl)carbamate (350 mg, 1.mmol) in THF (5 mL) was added drop wise to a suspension of NaH (60%, 49 mg, 1.21 mmol) in THF (5 mL) at 0 °C. The resulting mixture was stirred for 10 min and Mel (172 mg, 1.21 mmol) was added dropwise at 0 °C. The mixture was warmed to room temperature and stirred for 12 h. The mixture was diluted with water (30 mL) and extracted with EtOAc (15 mL x 3). The combined organic layer was washed with brine (5 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=l/0 to 10/1) to give the title compound (300 mg, 82%). LCMS (M+H-tBu) + = 276.2.Step 8: N-methvl-7-(trifluoromethvl)isochrornan-4-amine hydrochloride id="p-245" id="p-245" id="p-245"
id="p-245"
[0245]To a solution of tert-butyl methyl(7-(trifluoromethyl)isochroman-4-y!)carbamate (3mg, 0.91 mmol) in MeOH (3 mL) was added HC1 (4 M in MeOH, 3 mL). The mixture was stirred at room temperature for 12 h. The mixture was concentrated under reduced pressure to give the title compound (200 mg, 82%). LC-MS (M+H)+ = 232.2.Step 9: tert-butyl (2-(methvl(7-(trifluoromethvl)isochroman-4-vl)carbamovl)-6,8-dihydro- H-furo [ 3,4-d]pyrrolo [ 3,2-b]pyridin-5-yl)carbamateN. NHB0C 126 WO 2024/199255 PCT/CN2024/083980 [0246]To a solution of N-methyl-7-(trifluoromethyl)isochroman-4-amine hydrochloride (2mg, 0.75 mmol) and 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid (276 mg, 0.87 mmol) in THF (5 mL) was added DIPEA (559 mg, 4.33 mmol) and BOPCI (440 mg, 1.73 mmol). The mixture was stirred at room temperature for h and then diluted with water (5 mL). The mixture was extracted with EtOAc (5.0 mL x 3). The combined organic layer was washed with brine (5.0 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give the title compound (300 mg, 75%). LC-MS (M+H)+ = 533.1.Step 10: (R)-5-amino-N-methyl-N-(7-(trifluoromethyl)isochroman-4-yl)-6,8-dihydro-lH- furo[3,4-d]pyrrolor3,2-b]pyridine-2-carboxamide & (S)-5-amino-N-methyl-N-(7- (trifluoromethyl)isochroman-4-yl)-6,8-dihydro-lH-furor3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide [0247]To a solution of tert-butyl (2-(methyl(7-(trifluoromethyl)isochroman-4-yl)carbamoyl)- 6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate (300 mg, 0.56 mmol) in MeOH (4 mL) was added HO (4 M in MeOH, 4 mL). The mixture was stirred at 25 °C for 1 h and concentrated under reduced pressure. The residue was purified by prep-HPLC and further separated by SFC to give Example 39 (21 mg, 9%) and Example 40 (20 mg, 8%). [0248]Analytical chiral-SFC condition as below. Column: CHIRALPAK AD-3; Column size: 4.6X50 mm, 3 pm; Mobile phase: 14 mM NH3 in methanol:CO2 1:1 isocratic; Flow: 4.mL/min; Temperature: 35 °C; backpressure: 1800 psi. [0249]Example 39: Analytical SFC tR=l . 11 min. 1H NMR (400 MHz, DMSO-d) 8 11.86 - 11.51 (m, 1H), 7.69-7.62 (m, 1H), 7.61 (s, 1H), 7.53 - 7.35 (m, 1H), 6.84 - 6.45 (m, 1H), 5.- 5.65 (m, 1H), 5.59 (s, 2H), 5.25 - 5.10 (m, 2H), 4.99 - 4.84 (m, 3H), 4.75 (d, J= 15.4 Hz, 1H), 4.27 - 3.99 (m, 2H), 3.18 - 2.58 (m, 3H). LC-MS (M+H)+ = 433.1. [0250]Example 40: Analytical SFC tR=2. 14 min. 1H NMR (400 MHz, DMSO-d) 8 11.88- 11.51 (m, 1H), 7.69-7.62 (m, 1H), 7.61 (s, 1H), 7.53 - 7.35 (m, 1H), 6.85 - 6.45 (m, 1H), 5.- 5.67 (m, 1H), 5.59 (s, 2H), 5.23 - 5.09 (m, 2H), 4.99 - 4.84 (m, 3H), 4.75 (d, J= 15.4 Hz, 1H), 4.27 - 3.99 (m, 2H), 3.17 - 2.59 (m, 3H). LC-MS (M+H)+ = 433.1. Example 41:(R)-5-amino-N-((5-bromo-3-fluoropyridin-2-yl)methyl)-N-(l-(py1 ־imidin-2- yl)ethyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: (R)-N-((5-bromo-3-fluoropyridin-2-yl)methyl)-l-(pyrimidin-2-yl)ethan-l-amine127 WO 2024/199255 PCT/CN2024/083980 id="p-251" id="p-251" id="p-251"
id="p-251"
[0251]The title compound (90 mg, 59%) was prepared in a manner similar to that in Example step 1 from of 5-bromo-3 -fluoropicolinaldehy de and (R)-l-(pyrimidin-2-yl)ethan-l-amine dihydrochloride. LC-MS (M+H)+ =311.1.Step 2: tert-butyl (R)-(2-(((5-bromo-3-fluoropyridin-2-yl)methyl)(l-(pyrimidin-2- yl)ethyl)carbamoyl)-6,8-dihydro-lH-furor3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate، N Oן 1 >؛ —% Br [0252]The title compound (90 mg, 57%) was prepared in a manner similar to that in Example step 2 from 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid and (R)-N-((5-bromo-3-fluoropyridin-2-yl)methyl)-l-(pyrimidin-2- yl)ethan- 1-amine. LC-MS (M+H)+ =612.2.Step 3: (R)-5-amino-N-((5-bromo-3-fluoropyridin-2-yl)methyl)-N-(l-(pyrimidin-2- yl)ethyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0253]Example 41 (30 mg, 40%) was prepared in a manner similar to that in Example 35 step from tert-butyl (R)-(2-(((5-bromo-3-fluoropyridin-2-yl)methyl)(l-(pyrimidin-2- yl)ethyl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate. 1H NMR (400 MHz, DMSO-d) 8 11.35 (s, 1H), 8.76 - 8.75 (m, 2H), 8.42 (s, 1H), 8.01 - 7.98 (m, 1H), 7.34 - 7.38 (m, 1H), 6.55 (s, 1H), 5.97 - 5.87 (m, 1H), 5.29 (s, 2H), 5.14 - 5.04 (m, 3H), 4.93 - 4.78 (m, 3H), 1.66 (d, 3H). LC-MS (M+H)+ =512.2. Example 42:5-amino-N-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)methyl)-N-(pyrimidin- 2-ylmethyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: l-(3-fluoro-5-(trifluoromethvl)pvridin-2-vl)-N-(pvrimidin-2-vlmethvl)methanamine 128 WO 2024/199255 PCT/CN2024/083980 id="p-254" id="p-254" id="p-254"
id="p-254"
[0254]The title compound (45 mg, 17%) was prepared in a manner similar to that in Example step 1 from pyrimidin-2-ylmethanamine and 3-fluoro-5-(trifluoromethyl)picolinaldehy de. EC- MS (M+H)+ = 287.0.Step 2: tert-butyl (2-(((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)methyl)(pyrimidin-2- ylmethyl)carbamoyl)-6.8-dihydro-lH-furo[3,4-d]pyrrolor3,2-b]pyridin-5-yl)carbamate id="p-255" id="p-255" id="p-255"
id="p-255"
[0255]The title compound (60 mg, 58%) was prepared in a manner similar to that in Example & 18 step 2 from 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid and l-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)-N-(pyrimidin-2- ylmethyl)methanamine. LC-MS (M+H)+ = 588.1.Step 3: 5-amino-N-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)methyl)-N-(pyrimidin-2- ylmethyl)-6,8-dihydro- 1 H-furo[3,4-d]pvrrolo[3,2-b]pyridine-2-carboxamide [0256]Example 42 (30 mg, 35%) was prepared in a manner similar to that in Example 22 step from tert-butyl (2-(((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)methyl)(pyrimidin-2- ylmethyl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate. 1H NMR (400 MHz, DMSO-d) 8 11.59 (s, 1H), 8.87-8.78 (m, 3H), 8.28 (d, J= 9.4 Hz, 1H), 7.48 (s, 1H), 6.33 (s, 1H), 5.54 (s, 2H), 5.38-5.52 (m, 2H), 5.08 (s, 4H), 4.88 (s, 2H). LC-MS (M+H)+ = 488.1. Example 43:5-amino-N-(4-cyano-2,6-difluorobenzyl)-N-((3-fluoropyridin-2-yl)methyl)- 6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide NCStep 1: 3,5-difluoro-4-((((3-fluoropyridin-2-yl)methyl)amino)methyl)benzonitrile 129 WO 2024/199255 PCT/CN2024/083980 NC [0257]The title compound (70 mg, 25%) was prepared in a manner similar to that in Example step 1 from (3-fluoropyridin-2-yl)methanamine hydrochloride and 3,5-difluoro-4- formylbenzonitrile. LC-MS (M+H)+ = 278.2.Step 2: tert-butyl (2-((4-cyano-2,6-difh1orobenzyl)((3-fluoropyridin-2-yl)methyl)carbamoyl)-6,8-dihydro-lH-furor3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate id="p-258" id="p-258" id="p-258"
id="p-258"
[0258]The title compound (35 mg, 24%) was prepared in a manner similar to that in Example & 18 step 2 from 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid and 3,5-difluoro-4-((((3-fluoropyridin-2- yl)methyl)amino)methyl)benzonitrile. LC-MS (M+H)+ = 579.3.Step 3: 5-amino-N-،4-cyano-2,6-difluorobenzvl)-N-((3-fluoropyridin-2-yl)methyl)-6,8- dihydro-lH-furo[3,4-d]pv1Tolo[3,2-b]pvridine-2-carboxamide [0259]Example 43 (8 mg, 27%) was prepared in a manner similar to that in Example 22 step from tert-butyl (2-((4-cyano-2,6-difluorobenzyl)((3-fluoropyridin-2-yl)methyl)carbamoyl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate. 1H NMR (400 MHz, DMSO) 11.61 (s, 1H), 8.36 - 8.35 (m, 1H), 7.75 - 7.69 (m, 3H), 7.43 - 7.38 (m, 1H), 6.42 (s, 1H), 5.(s, 2H), 5.25 - 4.99 (m, 4H), 4.97 - 4.78 (m, 4H). LC-MS (M+H)+ = 479.2. Example 44:(R)-5-amino-N-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)methyl)-N-(l- methoxypropan-2-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: ethyl 5-bromo-4-((tert-butoxycarbonyl)amino)-l-((2-(trimethylsilyl)ethoxy)methyl)- H-pyrrole-2-carboxylate 130 WO 2024/199255 PCT/CN2024/083980 NHBoc SEM id="p-260" id="p-260" id="p-260"
id="p-260"
[0260]To a solution of ethyl 5-bromo-4-((tert-butoxycarbonyl)amino)-lH-pyrrole-2- carboxylate (320 g, 960 mmol) in DMF (4000 mL) was added KCO3 (332 g, 2.40 mol) and SEMC1 (400 g, 2.40 mol). The mixture was stirred at 45 °C for 12 h and cooled to room temperature. Most of DMF was removed under reduced pressure. Water (1500 mL) was added, and the mixture was extracted with EtOAc (800 mL x 3). The combined organic layer was washed with brine (500 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatograph (PE:EtOAc = 1:0 to 5:1) to give the title compound (310 g, 70%). LC-MS (M+Na) + = 485.2.Step 2: ethyl 4-((tert-butoxycarbonyl)amino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- 1 -((2-(trimethylsilyl)ethoxy)methyl)- 1 H-pyrrole-2-carboxylateNHBoc id="p-261" id="p-261" id="p-261"
id="p-261"
[0261]To a mixture of ethyl 5-bromo-4-((tert-butoxycarbonyl)amino)-l-((2- (trimethylsilyl)ethoxy)methyl)-lH-pyrrole-2-carboxylate (276 g, 596 mmol) and 4,4,5,5- tetramethyl- 1,3,2-dioxaborolane (152 g, 1.19 mol) in dioxane (450 mL) was added allylpalladium chloride dimer (13.1 g, 35.7 mmol), triethylamine (301 g, 2.98 mol) and XPhos (56.8 g, 119 mmol). The mixture was stirred at 80 °C under nitrogen for 12 h. The mixture was cooled to room temperature, and the solid was filtered off. The filtrate was concentrated under reduced pressure to give the title compound (300 g, crude). The material was used in Example step 3 directly. LC-MS (M+Na) + = 533.3.Step 3: ethyl 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furor3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylate id="p-262" id="p-262" id="p-262"
id="p-262"
[0262]To a solution of ethyl 4-((tert-butoxycarbonyl)amino)-5-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-l-((2-(trimethylsilyl)ethoxy)methyl)-lH-pyrrole-2-carboxylate (300 g crude) and 4-cyano-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (214 g, 881 mmol) in dioxane (3900 mL) and water (780 mL) was added K2CO3 (244 g, 1.76 mol) and Pd(dppf)C12 CH,Cl(24.0 g, 29.4 mmol). The mixture was stirred at 80 °C under nitrogen for 12 h. The mixture was 131 N nh 2 WO 2024/199255 PCT/CN2024/083980 cooled to room temperature, and most of dioxane was removed under reduced pressure. The remainder was diluted with water (1500 mL) and extracted with EtOAc (500 mL x 3). The combined organic layer was washed with brine (500 mL x 2), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatograph (PE:EtOAc = 1:0 to 0:1) to give the title compound (100 g, 44% over 2 steps). 1H NMR (4MHz, DMSO-d) 5 6.99 (s, 1H), 5.87 (s, 2H), 5.76 (s, 2H), 5.37 - 5.32 (m, 2H), 4.97 - 4.90 (m, 2H), 4.31 (q, J= 7.0 Hz, 2H), 3.39 (t, J= 7.8 Hz, 2H), 1.32 (t, J= 7.0 Hz, 3H), 0.76 (t, J= 7.Hz, 2H), -0.12 (s, 9H). LC-MS (M+H)+ = 378.2.Step 4: 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-blpyridine-2-carboxylic acid id="p-263" id="p-263" id="p-263"
id="p-263"
[0263]To a solution of ethyl 5-amino- 1 -((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro- 1H- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylate (65 g, 172 mmol) in MeOH (150 mL), THE (450 mL) and water (150 mL) was added LiOH H2O (14.5 g, 344 mmol). The mixture was stirred at 45 °C for 12 h. Most of organic solvents were removed under reduced pressure, and the remainder was diluted with water (200 mL). The mixture was washed with MTBE (100 mL x 3). To the aqueous phase was added aqueous HC1 (1 M) until its pH reached 2-3. The solid was collected by filtration and then triturated with MTBE (500 mL) for 1 h. The solid was collected by filtration and dried under vacuum to give the title compound (49.4 g, 82%). 1H NMR (4MHz, DMSO-d) 8 6.95 (s, 1H), 5.94 (br s, 2H), 5.80 (s, 2H), 5.36 - 5.32 (m, 2H), 4.96 - 4.(m, 2H), 3.40 (t, J=8.0 Hz, 2H), 0.76 (t, J=8.0 Hz, 2H), -0.12 (s, 9H); (-COOHnot apparent). LC-MS (M+H)+ = 350.2.Step 5: (R)-N-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)methyl)- 1 -methoxypropan-2- id="p-264" id="p-264" id="p-264"
id="p-264"
[0264]To a solution of (R)-l-methoxypropan-2-amine (691 mg, 7.7 mmol) in DCM (30 mL) was added 3-fluoro-5-(trifluoromethyl)picolinaldehyde (1.5 g, 7.7 mmol), and NaBH(OAc)(3.29 g, 15.5 mmol). The mixture was stirred for 2 h at room temperature. The mixture was carefully added to into aqueous NaHCO3 (100 mL, sat.) and extracted with DCM (100 mL). The 132 WO 2024/199255 PCT/CN2024/083980 organic layer was separated, washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM:MeOH=20:l) to give the title compound (1.9 g, 91%). LC-MS (M+H)+ =267.3.Step 6: (R)-5-amino-N-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)methyl)-N-(l- methoxypropan-2-yl)-1 -((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro- 1 H-furo[3 ,4- d]pyrrolo[3.,2-blpyridine-2-carboxamide id="p-265" id="p-265" id="p-265"
id="p-265"
[0265]To a solution of (R)-N-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)methyl)-l- methoxypropan-2-amine (1.75 g, 6.6 mmol) in THF (30 mL) was added 5-amino-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid (2.3 g, 6.6 mmol), BOPCI (2.5 g, 9.9 mmol) and DIPEA (2.54 g, 19.7 mmol). The mixture was stirred for 16 h at 60 °C and then cooled to room temperature. The mixture was poured into water (100 mL) and extracted with EtOAc (100 mL x 2). The combined organic layer was washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM:MeOH=20:l) to give the title compound (3.0 g, 76%). LC-MS (M+H)+ =598.1.Step 7: (R)-5-amino-N-((3-fluoro-5-(trifluoromethvl)pvridin-2-vl)methvl)-N-(l- methoxvpropan-2-vl)-6,8-dihvdro-lH-furor3,4-dlpv1Tolor3,2-blpvridine-2-carboxamide [0266]To a solution of (R)-5-amino-N-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)methyl)-N- (l-methoxypropan-2-yl)-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide (3.0 g, 5.0 mmol) in DCM (15 mL) was added TEA (mL). The mixture was stirred for 3 h at room temperature and then concentrated under reduced pressure. MeOH (30 mL) and ammonia in water (28%, 3 mL) was added, and the mixture was stirred for 3 h at room temperature. The mixture was poured into water (100 mL) and then extracted with EtOAc (100 x 2 mL). The combined organic layer was washed with brine (1mL), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM:MeOH=10:l) to give Example 44 (1.8 g, 77%). 1H NMR (400 MHz, DMSO-d) 8 11.47 (s, 1H), 8.99-8.60 (m, 1H), 8.29-8.27 (m, 1H), 6.84-6.(m,lH), 5.79-5.38 (m, 2H), 5.29-4.37 (m, 7H), 3.68-3.51 (m, 1H), 3.49-3.37 (m, 1H), 3.29-2.(m,3H), 1.51-0.83 (m, 3H). LC-MS (M+H)+ = 468.3. 133 NSEM WO 2024/199255 PCT/CN2024/083980 Example 45:(R)-5-amino-N-((5-bromopyridin-2-yl)methyl)-N-(l -methoxypropan-2-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: (R)-N-((5-bromopyridin-2-yl)methyl)-l-methoxypropan-2-amine id="p-267" id="p-267" id="p-267"
id="p-267"
[0267]The title compound (130 mg, 94%) was prepared in a manner similar to that in Example step 5 from (R)-1 -methoxypropan-2-amine and 5-bromopicolinaldehyde. LC-MS (M+H)+ = 259.1.Step 2: tert-butyl (R)-(2-(((5-bromopyridin-2-yl)methyl)(l-methoxypropan-2- yl)carbamoyl)-6,8-dihydro-lH-furor3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate id="p-268" id="p-268" id="p-268"
id="p-268"
[0268]The title compound (174 mg, 73%) was prepared in a manner similar to that in Example & 18 step 2 from 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid and (R)-N-((5-bromopyridin-2-yl)methyl)-l-methoxypropan-2- amine. LC-MS (M+H)+ = 560.2.Step 3: (R)-5-amino-N-((5-bromopyridin-2-yl)methyl)-N-(l-methoxypropan-2-yl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0269]Example 45 (27 mg, 17%) was prepared in a manner similar to that in Example 22 step from tert-butyl (R)-(2-(((5-bromopyridin-2-yl)methyl)(l-methoxypropan-2-yl)carbamoyl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate. 1H NMR (400 MHz, DMSO-Jb) 11.52 (s, 1H), 8.65 (s, 1H), 8.01 (d,J = 6.8 Hz, 1H), 7.28 - 7.49 (m, 1H), 6.07 - 6.82 (m, 1H), 5.54 (s, 2H), 5.12 (s, 2H), 4.91 (s, 3H), 4.68 (s, 2H), 3.48 (brs, 1H), 3.34 - 3.39 (m, 1H), 3.13 (s, 3H), 1.18 (d, J = 6.2 Hz, 3H). LC-MS (M+H)+ = 460.1. Example 46:(R)-5-amino-N-(4-cyano-2,6-difluorobenzyl)-N-(l-methoxypropan-2-yl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide 134 WO 2024/199255 PCT/CN2024/083980 Step1:(R)-3,5-difluoro-4-(((1-methoxypropan-2-yl)amino)methyl)benzonitrile id="p-270" id="p-270" id="p-270"
id="p-270"
[0270]The title compound (140 mg, 97%) was prepared in a manner similar to that in Example step 5 from (R)-l-methoxypropan-2-amine and 3,5-difluoro-4-formylbenzonitrile. LC-MS (M+H)+= 241.2.Step 2: tert-butyl (R)-(2-((4-cyano-2,6-difluorobenzyl)(l-methoxypropan-2-yl)carbamoyl)- 6,8-dihydro-lH-furor3,4-d]pyrrolo[3,2-blpyridin-5-yl)carbamate N. ,NHBoc id="p-271" id="p-271" id="p-271"
id="p-271"
[0271]The title compound (33 mg, 15%) was prepared in a manner similar to that in Example & 18 step 2 from 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid and (R)-3,5-difluoro-4-(((l-methoxypropan-2- yl)amino)methyl)benzonitrile. LC-MS (M+H)+ = 542.2.Step 3: (R)-5-amino-N-(4-cyano-2,6-difluorobenzvl)-N-(l-methoxvpropan-2-vl)-6,8- dihydro-lH-furo[3,4-d]pv1Tolo[3,2-b]pvridine-2-carboxamide [0272]Example 46 (4 mg, 15%) was prepared in a manner similar to that in Example 22 step from tert-butyl (R)-(2-((4-cyano-2,6-difluorobenzyl)( 1 -methoxypropan-2-yl)carbamoyl)-6,8- dihydro-lH-furo[3,4-d]py1Tolo[3,2-b]pyridin-5-yl)carbamate . 1H NMR (400 MHz, DMSO-،/6) 11.44- 11.58 (m, 1H), 7.68 -7.83 (m, 2H). 6.58 - 6.50 (m, 1H), 5.57 (s, 2H) 5.10 (s, 2H), 4.(s, 2H), 4.51 - 4.85 (m, 3H) 3.60 - 3.49 (m, 1H), 3.36 - 3.40 (m, 1H), 3.16 (s, 3H) 1.27 (d, > 6.Hz, 3H). LC-MS (M+H)+ = 442.1. Example 47:5-amino-N-((3-fluoropy1 ־idin-2-yl)methyl)-N-(2,4,6-trifluorobenzyl)-6,8- dihydro-lH-furo[3,4-d]py1Tolo[3,2-b]pyridine-2-carboxamide 135 WO 2024/199255 PCT/CN2024/083980 Step1:1-(3-fluoropyridin-2-yl)-N-(2,4,6-trifluorobenzyl)methanamine F [0273]The title compound (180 mg, 67%) was prepared in a manner similar to that in Example step 1 from 2,4,6-trifluorobenzaldehyde and (3-fluoropyridin-2-yl)methanamine. LC-MS (M+H)+= 271.1.Step 2: tert-butyl (2-(((3-fluoropyridin-2-yl)methyl)(2,4.6-trifluorobenzyl)carbamoyl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate id="p-274" id="p-274" id="p-274"
id="p-274"
[0274]The title compound (60 mg, 42%) was prepared in a manner similar to that in Example & 18 step 2 from 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid and l-(3-fluoropyridin-2-yl)-N-(2,4,6- trifluorobenzyl)methanamine. LC-MS (M+H)+ = 572.3.Step3:5-amino-N-((3-fluoropyridin-2-yl)methyl)-N-(2,4,6-trifluorobenzyl)-6,8-dihydro-H-furo [ 3,4-dlpyrrolo [ 3,2-b]pyridine-2-carboxamide [0275]Example 47 (26 mg, 50%) was prepared in a manner similar to that in Example 22 step from tert-butyl (2-(((3-fluoropy1 ־idin-2-yl)methyl)(2,4,6-trifluorobenzyl)carbamoyl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate. 1H NMR (400 MHz, DM SO-76) 11.61 (s, 1H), 8.36 (d, 7 = 4.4 Hz, 1H), 7.70 (t,7=9.3 Hz, 1H), 7.39 (dt, J= 8.5, 4.4 Hz, 1H), 7.12 (t, J= 8.7 Hz, 2H), 6.46 (s, 1H), 5.53 (s, 2H), 5.09 (s, 2H), 4.99 (s, 2H), 4.88 (s, 4H). EC- MS (M+H)+ = 472.2. Example 48:(R)-5-amino-N-((5-cyclopropylpyridin-2-yl)methyl)-N-(l-(pyrimidin-2- yl)ethyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide 136 WO 2024/199255 PCT/CN2024/083980 Step1:(R)-N-((5-cyclopropylpyridin-2-yl)methyl)-1-(pyrimidin-2-yl)ethan-1-amine id="p-276" id="p-276" id="p-276"
id="p-276"
[0276]The title compound (60 mg, 35%) was prepared in a manner similar to that in Example step 1 from 5-cyclopropylpicolinaldehyde and (R)-l-(pyrimidin-2-yl)ethan-l-amine dihydrochloride. LC-MS (M+H)+ = 255.3.Step 2: tert-butyl (R)-(2-(((5-cyclopropylpyridin-2-yl)methyl)(l-(pyrimidin-2- yl)ethyl)carbamoyD-6,8-dihydro-lH-furor3,4-dlpyrrolor3,2-blpyridin-5-yDcarbamate id="p-277" id="p-277" id="p-277"
id="p-277"
[0277]The title compound (60 mg, 45%) was prepared in a manner similar to that in Example step 4 from 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid and (R)-N-((5-cyclopropylpyridin-2-yl)methyl)-l-(pyrimidin-2- yl)ethan-l-amine. LC-MS (M+H)+ = 556.4.Step 3: (R)-5-amino-N-((5-cvclopropvlpvridin-2-vl)methyl)-N-(l-(pyrimidin-2-vl)ethyl)- 6,8-dihydro-lH-furo[3,4-d1pv1Tolo[3,2-b1pyridine-2-carboxamide [0278]Example 48 (20 mg, 40%) was prepared in a manner similar to that in Example 14 step from tert-butyl (R)-(2-(((5-cyclopropylpyridin-2-yl)methyl)(l-(pyrimidin-2- yl)ethyl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate . 1H NMR (400 MHz, DMSO-d) 8 11.42 (s, 1H), 8.74 - 8.73 (m, 2H), 8.30 (s, 1H), 7.36 - 7.31 (m, 2H), 7.25 - 7.21 (m, 1H), 6.50 (s, 1H), 5.82 (brs, 1H), 5.25 (s, 2H), 5.12 (s, 2H),5.05 - 4.97 (m, 1H), 4.91 (s, 2H), 4.79 - 4.68 (m, 1H), 1.97 - 1.89 (m, 1H), 1.61 (d, ?? Hz, 3H), 0.99 - 0.93 (m,2H), 0.71 - 0.67 (m, 2H). LC-MS (M+H)+ =456.3. Example 49:(R)-5-amino-N-((5-bromo-3-fluoropyridin-2-yl)methyl)-N-(l - methoxypropan-2-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide 137 WO 2024/199255 PCT/CN2024/083980 Step 1: (R)-N-((5-bromo-3-fluoropyridin-2-yl)methyl)-l -methoxypropan-2-amineF id="p-279" id="p-279" id="p-279"
id="p-279"
[0279]The title compound (231 mg, 57%) was prepared in a manner similar to that in Example step 5 from (R)-1 -methoxypropan-2-amine and 5-bromo-3-fluoropicolinaldehyde. LC-MS (M+H)+= 277.1.Step2:(R)-5-amino-N-((5-bromo-3-fluoropyridin-2-yl)methyl)-N-(1-methoxypropan-2-yl)- l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furor3,4-d]pyrrolor3,2-blpyridine-2- carboxamide id="p-280" id="p-280" id="p-280"
id="p-280"
[0280]The title compound (234 mg, 43%) was prepared in a manner similar to that in Example step 6 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and (R)-N-((5-bromo-3-fluoropyridin-2-yl)methyl)- l-methoxypropan-2-amine. LC-MS (M+H)+ = 608.1.Step 3: (R)-5-amino-N-((5-bromo-3-fluoropvridin-2-vl)methvl)-N-(l-methoxvpropan-2-vl)- 6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-blpyridine-2-carboxamide [0281]Example 49 (54 mg, 18%) was prepared in a manner similar to that in Example 44 step from (R)-5-amino-N-((5-bromo-3-fluoropyridin-2-yl)methyl)-N-(l-methoxypropan-2-yl)-l- ((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide. ,HNMR(400 MHz, DMSO-d) 5 11.55 (s, 1H), 8.53 (s, 1H), 8.15 (d, J= 10.0 Hz, 1H), 6.75 - 6.23 (m, 1H), 5.82 - 5.54 (m, 2H), 5.11 (s, 2H), 5.00 - 4.39 (m, 5H), 3.56 (dd, J= 7.8, 9.7 Hz, 1H), 3.39 (dd, J= 5.2, 10.2 Hz, 1H), 3.17 (s, 3H), 1.23 (d, J= 7.6 Hz, 3H). LC-MS (M+H)+ = 478.2. Example 50:(R)-5-amino-N-((5-bromopyridin-2-yl)methyl)-N-((3-fluoropyridin-2- yl)methyl)-6-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide 138 WO 2024/199255 PCT/CN2024/083980 Step1:1-(5-bromopyridin-2-yl)-N-((3-fluoropyridin-2-yl)methyl)methanamine id="p-282" id="p-282" id="p-282"
id="p-282"
[0282]The title compound (100 mg, 65%) was prepared in a manner similar to that in Example step 1 from 5-bromopicolinaldehyde and (3-fluoropyridin-2-yl)methanamine. LC-MS (M+H)+ = 296.2.Step 2: (R)-5-amino-N-((5-bromopyridin-2-yl)methyl)-N-((3-fluoropyridin-2-yl)methyl)-6- methyl-6,8-dihydro-lH-furor3,4-dlpyrrolo[3,2-blpyridine-2-carboxamide [0283]Example 50 (52 mg, 60%) was prepared in a manner similar to that in Example 2 step from l-(5-bromopyridin-2-yl)-N-((3-fluoropyridin-2-yl)methyl)methanamine and (R)-5-amino- 6-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid. ,HNMR (4MHz, DMSO-d) 8 11.58 (s, 1H), 8.8-8.53 (m, 1H), 8.34 (brs, 1H), 8.00 (brs, 1H), 7.67 (brs, 1H), 7.38 (brs, 2H), 6.5-6.1 (m, 1H), 5.40 (s, 2H), 5.32-4.56 (m, 7H), 1.28 (d, J= 6.1 Hz, 3H). LC-MS (M+H)+= 511.4. Example 51:(R)-5-amino-N-((5-iodopyridin-2-yl)methyl)-N-(l-(pyrimidin-2-yl)ethyl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: 5-iodopicolinaldehyde id="p-284" id="p-284" id="p-284"
id="p-284"
[0284]The title compound (136 mg, 77%) was prepared in a manner similar to that in Example step 1 from methyl 5-iodopicolinate. LC-MS (M+H)+ = 233.9.Step 2: (R)-N-((5-iodopyridin-2-yl)methyl)- 1 -(pyrimidin-2-yl)ethan- 1 -amine 139 WO 2024/199255 PCT/CN2024/083980 id="p-285" id="p-285" id="p-285"
id="p-285"
[0285]The title compound (84 mg, 67%) was prepared in a manner similar to that in Example step 1 from 5-iodopicolinaldehyde and (R)-l-(pyrimidin-2-yl)ethan-l-amine dihydrochloride. LC-MS (M+H)+= 341.3.Step 3: (R)-5-amino-N-((5-iodopyridin-2-yl)methyl)-N-(l-(pyrimidin-2-yl)ethyl)-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-286" id="p-286" id="p-286"
id="p-286"
[0286]The title compound (80 mg, 48%) was prepared in a manner similar to that in Example step 6 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and (R)-N-((5-iodopyridin-2-yl)methyl)-l- (pyrimidin-2-yl)ethan- 1-amine. LC-MS (M+H)+ = 672.3.Step4:(R)-5-amino-N-((5-iodopyridin-2-yl)methyl)-N-(1-(pyrimidin-2-yl)ethyl)-6,8-dihydro-lH-furo[3.4-d1pyrrolo[3,2-b1pyridine-2-carboxamide [0287]Example 51 (20 mg, 31%) was prepared in a manner similar to that in Example 44 step from (R)-5-amino-N-((5-iodopyridin-2-yl)methyl)-N-(l-(pyrimidin-2-yl)ethyl)-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyn ־olo[3,2-b]pyridine-2- carboxamide. 1H NMR (400 MHz, DMSO-d) 8: 11.63 (s, 1H), 8.98 - 8.46 (m, 3H), 8.25 - 7.(m, 1H), 7.55 - 7.00 (m, 2H), 6.30 - 6.05 (m, 1H), 5.71 - 4.42 (m, 9H), 1.76 - 1.48 (m, 3H). EC- MS (M+H)+ = 542.2. Example 52:(R)-5-amino-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)-N-(l- (pyrimidin-2-yl)ethyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: (R)-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)- 1 -(pyrimidin-2-yl)ethan- 1 - amine 140 WO 2024/199255 PCT/CN2024/083980 id="p-288" id="p-288" id="p-288"
id="p-288"
[0288]To a solution of 5-cyclopropyl-3-fluoropicolinaldehyde (84 mg, 0.51 mmol) in DCM (mL) was added (R)-l-(pyrimidin-2-yl)ethan-l-amine dihydrochloride (100 mg, 0.51 mmol), triethylamine (103 mg, 1.02 mmol) and NaBH(OAc)3 (217 mg, 1.02 mmol). The mixture was stirred for 3 h at room temperature. The mixture was carefully added into saturated NaHCO3 (mL) and then extracted with DCM (50 mL). The organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM:MeOH=20:l) to give the title compound (61 mg, 44%). LC-MS (M+H)+ =273.4.Step 2: (R)-5-amino-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)-N-(l-(pyrimidin-2- yl)ethyl)-6.8-dihydro-lH-furo[3.4-dlpyrrolo[3.2-blpyridine-2-carboxamide [0289]Example 52 (27 mg, 25%) was prepared in a manner similar to that in Example 2 step from 5-amino-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and (R)-N- ((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)-l-(pyrimidin-2-yl)ethan-l-amine. 1H NMR (5MHz, DMSO) 8 11.71-11.39 (m, 1H), 9.02-8.58 (m, 2H), 8.46-7.86 (m, 1H), 7.61-7.08 (m, 2H), 6.74-6.23 (m, 1H), 6.19-4.36 (m, 9H), 2.12-1.85 (m, 1H), 1.85-1.43 (m, 3H), 1.05-0.89 (m, 2H), 0.89-0.64 (m, 2H). LC-MS (M+H)+ =474.4. Example 53:(R)-5-amino-N-((5-cyclopropylpyrazin-2-yl)methyl)-N-(l-methoxypropan-2- yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-290" id="p-290" id="p-290"
id="p-290"
[0290]The title compound (0.60 g, 29%) was prepared in a manner similar to that in Example step 1 from 5-chloropyrazine-2-carbaldehyde and cyclopropylboronic acid. LC-MS (M+H)+ =149.1. 141 WO 2024/199255 PCT/CN2024/083980 Step 2: (R)-N-((5-cyclopropylpyrazin-2-yl)methyl)-l -methoxypropan-2-amine id="p-291" id="p-291" id="p-291"
id="p-291"
[0291]The title compound (190 mg, 85%) was prepared in a manner similar to that in Example step 5 from (R)-l-methoxypropan-2-amine and 5-cyclopropylpyrazine-2-carbaldehyde. EC- MS (M+H)+ =222.2.Step3:(R)-5-amino-N-((5-cyclopropylpyrazin-2-yl)methyl)-N-(1-methoxypropan-2-yl)-1- ((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide id="p-292" id="p-292" id="p-292"
id="p-292"
[0292]The title compound (234 mg, 43%) was prepared in a manner similar to that in Example step 6 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and (R)-N-((5-cyclopropylpyrazin-2-yl)methyl)-l- methoxypropan-2-amine. LC-MS (M+H)+ =553.4.Step 4: (R)-5-amino-N-((5-cyclopropylpyrazin-2-yl)methyl)-N-(l -methoxypropan-2-yl)- 6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-blpyridine-2-carboxamide [0293]Example 53 (25 mg, 30%) was prepared in a manner similar to that in Example 44 step from (R)-5-amino-N-((5-cyclopropylpyrazin-2-yl)methyl)-N-(l-methoxypropan-2-yl)-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide. 1H NMR (400 MHz, DMSO-d) 8 11.48 (s, 1H), 8.54 (s, 1H), 8.46 (s, 1H), 6.75 - 6.44 (m, 1H), 5.52 (s, 2H), 5.12 (s, 2H), 5.01 - 4.59 (m, 5H), 3.50 (t, J= 9.3 Hz, 1H), 3.39 - 3.(m, 1H), 3.12 (s, 3H), 2.22 - 2.13 (m, 1H), 1.31-1.11 (m, 3H), 1.04 - 0.98 (m, 2H), 0.94 - 0.(m, 2H). LC-MS (M+H)+ = 423.2. Example 54 & Example 55:(S)-5-amino-N-ethyl-N-(7-(trifluoromethyl)isochroman-4-yl)- 6,8-dihydro-lH-furo[3,4-d]pyr ־rolo[3,2-b]pyridine-2-carboxamide & (R)-5-amino-N-ethyl-N-(7- (trifh1oromethyl)isochroman-4-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide 142 WO 2024/199255 PCT/CN2024/083980 Step1:tert-butylethyl(7-(trifluoromethyl)isochroman-4-yl)carbamate F3C NBoc id="p-294" id="p-294" id="p-294"
id="p-294"
[0294]The title compound (0.50 g, 92%) was prepared in a manner similar to that in Example 39&40 step 7 from tert-butyl (7-(trifluoromethyl)isochroman-4-yl)carbamate and Etl. LCMS (M+H-tBu) += 290.1.Step 2: N-ethyl-7-(trifluoromethyl)isochroman-4-amine hydrochloride id="p-295" id="p-295" id="p-295"
id="p-295"
[0295]The title compound (0.20 g, 62%) was prepared in a manner similar to that in Example 39&40 step 8 from tert-butyl ethyl(7-(trifluoromethyl)isochroman-4-yl)carbamate. LC-MS (M+H)+= 246.1.Step 3: tert-butyl (2-(ethvl(7-(trifluoromethvl)isochroman-4-vl)carbamovl)-6,8-dihvdro-lH- furor3,4-d1pv1Tolo[3,2-b1pvridin-5-vl)carbamate id="p-296" id="p-296" id="p-296"
id="p-296"
[0296]The title compound (0.40 g, 90%) was prepared in a manner similar to that in Example 39&40 step 9 from 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid and N-ethyl-7-(trifluoromethyl)isochroman-4-amine hydrochloride. LC-MS (M+H)+ = 547.2.Step4:(S)-5-amino-N-ethyl-N-(7-(trifluoromethyl)isochroman-4-yl)-6,8-dihydro-1H- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (R)-5-amino-N-ethyl-N-(7- 143 WO 2024/199255 PCT/CN2024/083980 (trifh1oromethyl)isochroman-4-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide [0297]Example 54 (22 mg, 14%) and Example 55 (23 mg, 14%) were prepared in a manner similar to that in Example 39 and 40 step 10 from tert-butyl (2-(ethyl(7- (trifluoromethyl)isochroman-4-yl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin- 5-yl)carbamate and N-ethyl-7-(trifluoromethyl)isochroman-4-amine hydrochloride. [0298]Analytical chiral-SFC condition as below. Column: CHIRALPAK AD-3; Column size: 4.6X50 mm, 3 pm; Mobile phase: (ethanol containing 0.2% 7 M methanolic NH3):CO2, 1:19 for 0.2 min, 1:19 to 1:1 in 1.0 min, 1:1 for 1 min, 1:1 to 1:19 in 0.4 min; Flow: 3.4 mL/min; Temperature: 35 °C; backpressure: 1800 psi. [0299]Example 54: Analytical SFC tR=l .70 min. 1H NMR (400 MHz, DMSO- Step 1: (R)-N-((5-cvclopropvl-3-fluoropvridin-2-vl)methvl)-l-methoxvpropan-2-amine id="p-301" id="p-301" id="p-301"
id="p-301"
[0301]The title compound (110 mg, 51%) was prepared in a manner similar to that in Example step 5 from (R)-l-methoxypropan-2-amine and 5-cyclopropyl-3-fluoropicolinaldehyde. EC- MS (M+H)+= 239.1. 144 WO 2024/199255 PCT/CN2024/083980 Step 2: tert-butyl (R)-(2-(((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)(l-methoxypropan-2- yl)carbamoyl)-6,8-dihydro- 1 H-furo [ 3.4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate id="p-302" id="p-302" id="p-302"
id="p-302"
[0302]The title compound (100 mg, 40%) was prepared in a manner similar to that in Example step 4 from 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid and (R)-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)-l- methoxypropan-2-amine. LC-MS (M+H)+ = 540.1.Step3:(R)-5-amino-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)-N-(1-methoxypropan- 2-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0303]Example 56 (30 mg, 37%) was prepared in a manner similar to that in Example 14 step from tert-butyl (R)-(2-(((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)(l-methoxypropan-2- yl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate. 1H NMR (4MHz, DMSO-t/6) 8 11.47 (s, 1H), 8.23 (s, 1H), 7.33 (d,J = 11.6 Hz, 1H), 6.61 -6.27 (m, 1H), 5.50 (s, 2H), 5.10 (br s, 2H), 5.05 - 4.41 (m, 5H), 3.56 (dd, J= 7.4, 9.8 Hz, 1H), 3.37 (dd, J= 5.4, 10.0 Hz, 1H), 3.17 (s, 3H), 2.03 - 1.94 (m, 1H), 1.07 - 1.27 (m, 3H), 1.05 - 0.96 (m, 2H), 0.77 (d, J= 4.9 Hz, 2H). LC-MS (M+H)+ = 440.2. Example 57 & Example 58 & Example 59 & Example 60:5-amino-N-methyl-N- ((lR,4R)-l-methyl-7-(trifluoromethyl)isochroman-4-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxamide & 5-amino-N-methyl-N-((lS,4R)-l-methyl-7- (trifluoromethyl)isochroman-4-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide & 5-amino-N-methyl-N-(( 1 S,4S)-1 -methyl-7-(trifluoromethyl)isochroman-4-yl)- 6,8-dihydro-lH-furo[3,4-d]py1Tolo[3,2-b]pyridine-2-carboxamide & 5-amino-N-methyl-N- ((lR,4S)-l-methyl-7-(trifluoromethyl)isochroman-4-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxamide 145 N., ,NHBoc WO 2024/199255 PCT/CN2024/083980 Step1:1-(2-bromo-5-(trifluoromethyl)phenyl)ethan-1-ol F3C Br id="p-304" id="p-304" id="p-304"
id="p-304"
[0304]To a solution of 2-bromo-5-(trifluoromethyl)benzaldehyde (15.0 g, 59.3 mmol) in THF (150 mL) was added MeMgBr (3 M in Et20, 19.8 mL, 59.3 mmol) at 0 °C and the mixture was stirred at 0 °C for l h. The mixture was quenched with saturated NH4C1 (100 mL) and extracted with EtOAc (80 mL x 3). The combined organic layer was washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatograph (PE/EtOAc =1/0 to 5/1) to give the title compound (12.0 g, 75% yield). 1H NMR (400 MHz, CDC13) 8 7.90 (d, J= 2.0 Hz, 1H), 7.65 (d, J= 8.4 Hz, 1H), 7.39 (dd, J= 8.4, 2.0 Hz, 1H), 5.32-5.23 (m, 1H), 2.03 (s, 1H), 1.51 (d, J= 6.4 Hz, 3H).Step 2: 2-( 1 -(allyloxy)ethyl)- 1 -bromo-4-(trifluoromethvl)benzeneBr id="p-305" id="p-305" id="p-305"
id="p-305"
[0305]The title compound (9.7 g, 70%) was prepared in a manner similar to that in Example step 1 from l-(2-bromo-5-(trifluoromethyl)phenyl)ethan-l-ol and allyl bromide. 1H NMR (400 MHz, CDC13) 8 7.81 (d, J= 2.0 Hz, 1H), 7.65 (d, J= 8.4 Hz, 1H), 7.39 (dd, J= 8.4, 2.0 Hz, 1H), 5.98-5.85 (m, 1H), 5.33-5.17 (m, 2H), 4.93-4.85 (m, 1H), 3.97-3.77 (m, 2H), 1.44 (d, J= 6.4 Hz, 3H).Step 3: l-methvl-4-methvlene-7-(trifluoromethyl)isochromane f 3c 146 WO 2024/199255 PCT/CN2024/083980 [0306]The title compound (4.6 g, 64%) was prepared in a manner similar to that in Example step 2 from 2-(l-(allyloxy)ethyl)-l-bromo-4-(trifluoromethyl)benzene. LC-MS (M+H)+ = 229.1.Step 4: l-methyl-7-(trifluoromethyl)isochroman-4-one F3C id="p-307" id="p-307" id="p-307"
id="p-307"
[0307]The title compound (3.3 g, 71%) was prepared in a manner similar to that in Example step 3 from l-methyl-4-methylene-7-(trifluoromethyl)isochromane. 1H NMR (400 MHz, CDCI) 6 8.17 (d, J= 8.0 Hz, 1H), 7.69 (d, J= 8.0 Hz, 1H), 7.53 (s, 1H), 5.03-4.94 (m, 1H), 4.57, 4.35 (ABq,J= 17.2 Hz, 2H), 1.71 (d, J= 6.8 Hz, 3H). LC-MS (M+H)+ = 231.2.Step 5: l-methyl-7-(trifluoromethyl)isochroman-4-one oximeOH N f 3c [0308]The title compound (0.75 g, 70%) was prepared in a manner similar to that in Example step 4 from l-methyl-7-(trifluoromethyl)isochroman-4-one. 1H NMR (400 MHz, CDCh) 8.03 (d, J= 8.4 Hz, 1H), 7.56 (d, J= 8.4 Hz, 1H), 7.44 (s, 1H), 5.13, 4.64 (ABq, J= 17.0 Hz, 2H), 4.73 (q, J= 6.5 Hz, 1H), 1.65 (d, J= 6.4 Hz, 3H). LC-MS (M+H)+ = 246.2.Step 6: l-methvl-7-(trifluoromethyl)isochroman-4-amine id="p-309" id="p-309" id="p-309"
id="p-309"
[0309]The title compound (0.26 g, 79%) was prepared in a manner similar to that in Examplestep 5 from l-methyl-7-(trifluoromethyl)isochroman-4-one oxime. LC-MS (M+H)+ = 232.1.Step 7: tert-butyl (l-methvl-7-(trifluoromethyl)isochroman-4-vl)carbamateBocHN id="p-310" id="p-310" id="p-310"
id="p-310"
[0310]The title compound (0.30 g, 87%) was prepared in a manner similar to that in Example step 6 from l-methyl-7-(trifluoromethyl)isochroman-4-amine. LCMS (M+H-tBu) + = 276.2.Step 8: tert-butyl methyl( l-methyl-7-(trifluoromethyl)isochroman-4-yl)carbamate 147 WO 2024/199255 PCT/CN2024/083980 BocN F3C [0311]The title compound (0.30 g, 87%) was prepared in a manner similar to that in Example step 7 from tert-butyl (l-methyl-7-(trifluoromethyl)isochroman-4-yl)carbamate. LCMS (M+H-tBu) + = 290.2.Step 9: N.l-dimethyl-7-(trifluoromethyl)isochroman-4-amine hydrochloride id="p-312" id="p-312" id="p-312"
id="p-312"
[0312]The title compound (0.20 g, 94%) was prepared in a manner similar to that in Example step 8 from tert-butyl methyl(l-methyl-7-(trifluoromethyl)isochroman-4-yl)carbamate. LC- MS (M+H)+= 246.1.Step 10: tert-butyl (2-(methyl(l-methyl-7-(trifluoromethyl)isochroman-4-yl)carbamoyl)- 6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-blpyridin-5-yl)carbamateN. ,NHBoc id="p-313" id="p-313" id="p-313"
id="p-313"
[0313]The title compound (0.15 g, 51 %) was prepared in a manner similar to that in Example step 9 from 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid and N,l-dimethyl-7-(trifluoromethyl)isochroman-4-amine hydrochloride. LC-MS (M+H)+ = 547.4.Step11:5-amino-N-methyl-N-((1R,4R)-1-methyl-7-(trifluoromethyl)isochroman-4-yl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & 5-amino-N-methyl-N-((lS,4R)- l-methyl-7-(trifluoromethyl)isochroman-4-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxamide & 5-amino-N-methyl-N-((l S,4S)-l -methyl-7- (trifh1oromethyl)isochroman-4-vl)-6,8-dihvdro-lH-furor3,4-d]pvrrolo[3,2-b]pvridine-2- carboxamide & 5-amino-N-methyl-N-((1R,4S)-1-methyl-7-(trifluoromethyl)isochroman-4-yl)- 6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-blpyridine-2-carboxamide [0314]Example 57 (3 mg, 2%), Example 58 (13 mg, 8%), Example 59 (9 mg, 6%) and Example 60 (5 mg, 3%) were prepared in a manner similar to that in Example 40 step 10 from tert-butyl (2-(methyl(l-methyl-7-(trifluoromethyl)isochroman-4-yl)carbamoyl)-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate, and the isomers were separated by chiral SEC.148 WO 2024/199255 PCT/CN2024/083980 [0315]Analytical chiral-SFC condition 1: Column: CHIRALPAK AD-3; Column size: 4.6Xmm, 3 pm; Mobile phase: (ethanol containing 0.2% 7 M methanolic NH3):CO2 1:1 isocratic;Flow: 4 mL/min; Temperature: 35 °C; backpressure: 1800 psi. [0316]Analytical chiral-SFC condition 2: Column: CHIRALPAK OJ-3; Column size: 4.6Xmm, 3 pm; Mobile phase: Mobile phase: (ethanol containing 0.2% 7 M methanolic NH3):CO2, 1:19 for 0.2 min, 1:19 to 1:1 in 1.0 min, 1:1 for 1 min, 1:1 to 1:19 in 0.4 min; Flow: 3.4 mL/min; Temperature: 35 °C; backpressure: 1800 psi. [0317]Example 57: Analytical SFC (Condition 1) tR=0.64 min. 1H NMR (400 MHz, DMSO- d6) 8 11.68 (s, 1H), 7.76-7.61 (m, 2H), 7.45 (d, J= 8.0 Hz, 1H), 6.90 - 6.60 (m, 1H), 5.99 - 5.(m, 1H), 5.64 (br s, 2H), 5.22 (s, 2H), 5.10 - 4.92 (m, 3H), 4.36 - 4.17 (m, 1H), 4.08 - 3.93 (m, 1H), 3.24 - 2.76 (m, 3H), 1.57 (d, J= 6.0 Hz, 3H). LC-MS (M+H)+ = 447.2. [0318]Example 58: Analytical SFC (Condition 2) tR=l . 18 min. ,H NMR (400 MHz, DMSO- d6) 8 11.93 (s, 1H), 7.71 - 7.65 (m, 2H), 7.55 - 7.42 (m, 1H), 6.80 - 6.62 (m, 1H), 6.38 - 6.05 (m, 2H), 5.85 - 5.60 (m, 1H), 5.20 (br s, 2H), 4.95 (s, 2H), 4.86 - 4.78 (m, 1H), 4.29 -4.17 (m, 1H), 4.13 - 4.02 (m, 1H), 3.17 - 2.76 (m, 3H), 1.59 (d, J= 6.4 Hz, 3H). LC-MS (M+H)+ = 447.2. [0319]Example 59: Analytical SFC (Condition 2) tR=l .38 min. 1H NMR (400 MHz, DMSO- d6) 8 12.50 (s, 1H), 7.74 - 7.61 (m, 2H), 7.58 -7.17 (m, 3H), 6.92 - 6.63 (m, 1H), 5.90 - 5.54 (m, 1H), 5.26 (s, 2H), 4.99 (s, 3H), 4.30 - 4.14 (m, 1H), 4.03 - 3.89 (m, 1H), 3.07 - 2.68 (m, 2H), 2.75 - 2.68 (m, 1H), 1.51 (d, J= 5.6 Hz, 3H). LC-MS (M+H)+ = 447.2. [0320]Example 60: Analytical SFC (Condition 1) tR=l .32 min. 1H NMR (400 MHz, DMSO- d6) 8 11.69 (s, 1H), 7.71-7.64 (m, 2H), 7.48 (s, 1H), 6.72 (s, 1H), 5.89-5.60 (m, 3H), 5.21-5.(m, 2H), 4.98-4.90 (m, 2H), 4.86-4.78 (m, 1H), 4.30-4.01 (m, 2H), 3.19-2.80 (m, 3H), 1.59 (d, J = 6.8 Hz, 3H). LC-MS (M+H)+ = 447.2. Example 61 & Example 62:(S)-5-amino-N-((5-bromo-3-fluoropyridin-2-yl)methyl)-N-(l- (pyrazin-2-yl)ethyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (R)-5- amino-N-((5-bromo-3-fluoropyridin-2-yl)methyl)-N-(l -(pyrazin-2-yl)ethyl)-6,8-dihydro- 1H- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step1:N-((5-bromo-3-fluoropyridin-2-yl)methyl)-1-(pyrazin-2-yl)ethan-1-amine 149 WO 2024/199255 PCT/CN2024/083980 id="p-321" id="p-321" id="p-321"
id="p-321"
[0321]The title compound (90 mg, 40%) was prepared in a manner similar to that in Example & 18 step 1 from (5-bromo-3-fluoropyridin-2-yl)methanamine and l-(pyrazin-2-yl)ethan-l- one. LC-MS (M+H)+ = 311.0.Step 2: tert-butyl (2-(((5-bromo-3-fluoropyridin-2-yl)methyl)(l-(pyrazin-2- yl)ethyl)carbamoyl)-6.8-dihydro-lH-furor3,4-dlpyrrolor3.2-blpyridin-5-yl)carbamate id="p-322" id="p-322" id="p-322"
id="p-322"
[0322]The title compound (120 mg, 76%) was prepared in a manner similar to that in Example & 18 step 2 from 5-((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid and N-((5-bromo-3-fluoropyridin-2-yl)methyl)-l-(pyrazin-2- yl)ethan-l-amine. LC-MS (M+H)+ = 612.2.Step3:(S)-5-amino-N-((5-bromo-3-fluoropyridin-2-yl)methyl)-N-(1-(pyrazin-2-yl)ethyl)- 6,8-dihvdro-lH-furor3,4-d1pv1Tolor3,2-b1pvridine-2-carboxamide & (R)-5-amino-N-((5-bromo- 3-fluoropyridin-2-yl)methyl)-N-(l-(pyrazin-2-yl)ethyl)-6,8-dihydro-lH-furo[3,4-dlpyrrolor3,2- blpyridine-2-carboxamide [0323]Example 61 (4 mg, 4%) and Example 62 (2 mg, 2%) were prepared in a manner similar to that in in Example 17 & 18 step 3 from tert-butyl (2-(((5-bromo-3-fluoropyridin-2- yl)methyl)(l-(pyrazin-2-yl)ethyl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-5- yl)carbamate, and the enantiomers were separated by chiral SEC. [0324]Analytical chiral-SFC condition as below. Column: CHIRALPAK IG-3; Column size: 4.6X50 mm, 3 pm; Mobile phase: 14 mM NH3 in isopropanol:CO2 3:2 isocratic; Flow: mL/min; Temperature: 35 °C; backpressure: 1800 psi. [0325]Example 61: Analytical SEC tR=1.28 min. *HNMR (400 MHz, DMSO- 150 N. .NHBoc WO 2024/199255 PCT/CN2024/083980 [0326]Example 62: Analytical SEC tR=2. 17 min. 1H NMR (400 MHz, DMSO- id="p-327" id="p-327" id="p-327"
id="p-327"
[0327]To a mixture of 7-bromoisochroman-4-one (500 mg, 2.2 mmol) in MeOH (20 mL) was added NaBH4 (91 mg, 2.4 mmol) at 0 °C and the mixture was stirred at room temperature for min. The mixture was diluted with water (10 mL) and MeOH was evaporated under reduced pressure. The mixture was extracted with EtOAc (20 mL). The organic layer was washed with brine (10 mL), dried over Na2SO4, filtered and concentrated to give the title compound (500 mg, 99%). LC-MS (M+H)+ = 229.1.Step 2:7-bromo-4-chloroisochromane Cl id="p-328" id="p-328" id="p-328"
id="p-328"
[0328]A mixture of 7-bromoisochroman-4-ol (500 mg, 2.2 mmol) and SOC12 (524 mg, 4.mmol) in THE (15 mL) was stirred at 60 °C for 2 h. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by silica gel chromatograph (PE/EtOAc= 20/1) to give the title compound (300 mg, 55%). LC-MS (M+H)+ = 247.1.Step 3: 7-bromo-N-methylisochroman-4-amine NH id="p-329" id="p-329" id="p-329"
id="p-329"
[0329]A mixture of 7-bromo-4-chloroisochromane (150 mg, 0.6 mmol), methylamine hydrochloride (122 mg, 1.8 mmol), K2CO3 (248 mg, 1.8 mmol) and KI (298.8 mg, 1.8 mmol) in 151 WO 2024/199255 PCT/CN2024/083980 DMAC (10 mL) was stirred at 100 °C for 15 hr and then cooled to room temperature. The mixture was diluted with EtOAc (20 mL) then successively washed with water (10 mL) and brine (10 mL), dried over Na2S04, fdtered and concentrated under reduced pressure. The residue was purified by silica gel chromatograph (DCM/MeOH= 20/1) to give the title compound (mg, 55%). LC-MS (M+H)+ = 242.1.Step 4: 5-amino-N-(7-bromoisochroman-4-yl)-N-methyl-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furor3.4-dlpyrrolor3,2-blpyridine-2-carboxamide id="p-330" id="p-330" id="p-330"
id="p-330"
[0330]The title compound (110 mg, 58%) was prepared in a manner similar to that in Example step 6 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and 7-bromo-N-methylisochroman-4-amine. LC-MS (M+H)+ = 573.2.Step 5: (S)-5-amino-N-(7-bromoisochroman-4-yl)-N-methyl-6,8-dihydro-lH-furo[3,4- d1pyrrolo[3,2-b1pyridine-2-carboxamide & (R)-5-amino-N-(7-bromoisochroman-4-yl)-N- methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0331]Example 63 (20 mg, 24%) and Example 64 (31 mg, 37%) were prepared in a manner similar to that in Example 44 step 7 from 5-amino-N-(7-bromoisochroman-4-yl)-N-methyl-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide, and the enantiomers were separated by chiral SFC. [0332]Analytical chiral-SFC condition as below. Column: CHIRALPAK AS-H; Column size: 20X250 mm, 5 pm; Mobile phase: (0.1% Et2NH in MeOH):CO2 1:2 isocratic; Flow: 40 mL/min; Temperature: 35 °C; backpressure: 1450 psi.[0333] Example 63: Analytical SFC tR=7.00 min. 1H NMR (400 MHz, DMSO-d) 8 11.59 (s, 1H), 7.58 - 7.36 (m, 2H), 7.31 - 7.05 (m, 1H), 6.95 - 6.55 (m, 1H), 5.84 - 5.36 (m, 3H), 5.30 - 5.02 (m, 2H), 5.00 - 4.55 (m, 4H), 4.20 - 3.84 (m, 2H), 3.17 - 2.68 (m, 3H). LCMS (M+H)+ = 443.2. [0334]Example 64: Analytical SFCtR=8.07 min. 1H NMR (400 MHz, DMSO- WO 2024/199255 PCT/CN2024/083980 Step 1: N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)cyclopentanamine id="p-335" id="p-335" id="p-335"
id="p-335"
[0335]The title compound (60 mg, 85%) was prepared in a manner similar to that in Example step 1 from 5-cyclopropyl-3-fluoropicolinaldehyde and cyclopentanamine. LC-MS (M+H)+ = 235.2.Step 2: 5-amino-N-cyclopentyl-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)- 1 -((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furor3,4-dlpyrrolo[3,2-blpyridine-2-carboxamide N SEM id="p-336" id="p-336" id="p-336"
id="p-336"
[0336]The title compound (120 mg, 83%) was prepared in a manner similar to that in Example step 6 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and N-((5-cyclopropyl-3-fluoropyridin-2- yl)methyl)cyclopentanamine. LC-MS (M+H)+ = 566.4.Step3:5-amino-N-cyclopentyl-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0337]Example 65 (62 mg, 67%) was prepared in a manner similar to that in Example 44 step from 5-amino-N-cyclopentyl-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide. 1H NMR (400 MHz, DMSO-d) 8 11.49 (s, 1H), 8.22 (s, 1H), 7.33 (d, J=11.6, 1H), 6.38 (s, 1H), 5.51 (s, 2H), 5.09 (s, 2H), 4.98 - 4.65 (m, 5H), 2.05 - 1.77 (m , 3H), 1.73 - 1.(m, 6H), 1.56 (d, 1=55.7, 6H), 1.07 - 0.95 (m, 2H), 0.84 - 0.73 (m, 2H). LC-MS (M+H)+ = 436.4. Example 66:5 -amino-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)-N-isopropyl-6, 8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide153 WO 2024/199255 PCT/CN2024/083980 Step 1: N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)propan-2-amine id="p-338" id="p-338" id="p-338"
id="p-338"
[0338]To a solution of 5-cyclopropyl-3-fluoropicolinaldehyde (60 mg, 0.36 mmol) and isopropylamine (32 mg, 0.54 mmol) in DCM (5 mL) was added NaBH(OAc)3 (154 mg, 0.mmol). The mixture was stirred at room temperature for 2 h and then slowly added to sat. NaHCO3 (10 mL). The mixture was extracted with EtOAc (10 mL). The organic layer was washed with brine (10 mL), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatograph (DCM:MeOH = 10:1) to give the title compound (57 mg, 75%). 1H NMR (400 MHz, DMSO-d) 8 8.32 -8.15 (m, 1H), 7.28 (dd, J= 11.3, 1.6 Hz, 1H), 3.77 (d, J = 1.8 Hz, 2H), 2.69 (hept, J = 6.2 Hz, 1H), 2.05 (br s, 1H), 2.021.91 (m, 1H), 1.11 0.91 (m, 8H), 0.88 0.69 (m, 2H). LC-MS (M+H)+= 209.1.Step 2: 5-amino-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)-N-isopropyl-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-339" id="p-339" id="p-339"
id="p-339"
[0339]To a solution of N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)propan-2-amine (mg, 0.27 mmol) in THF (5 mL) was added 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid (80 mg, 0.23 mmol), BOPCI (88 mg, 0.35 mmol) and DIPEA (148 mg, 1.15 mmol). The mixture was stirred for 2 h at 70 °C and then cooled to room temperature. The mixture was poured into water (20 mL) and extracted with EtOAc (10x2 mL). The combined organic layer was washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM:MeOH=20:l) to give the title compound (60 mg, 41%). LC- MS (M+H)+ =540.3.154 N—' SEM WO 2024/199255 PCT/CN2024/083980 Step3:5-amino-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)-N-isopropyl-6,8-dihydro-H-furo F 3,4-d] pyrrolo [ 3,2-b] pyridine-2-carboxamide [0340]To a solution of 5-amino-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)-N-isopropyl- l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide (60 mg, 0.11 mmol) in DCM (1 mL) was added TFA (1 mL). The mixture was stirred for 3 h at room temperature then concentrated under reduced pressure. The residue was re-dissolved in MeOH (I mL) and K2CO3 (46 mg, 0.33 mmol) was added. The mixture was stirred at 40 °C for 1 h, and then cooled to room temperature. The mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC to give Example 66 (28 mg, 61%). ،HNMR(400 MHz, DMSO-d) 5 11.47 (s, 1H), 8.23 (s, 1H), 7.33 (d, J= 11.7 Hz, 1H), 6.64 -6.17 (m, 1H), 5.58 - 5.41 (m, 2H), 5.17 - 5.06 (m, 2H), 4.95 - 4.49 (m, 5H), 2.07 -1.(m, 1H), 1.36 - 1.08 (m, 6H), 1.07 - 0.94 (m, 2H), 0.83 - 0.73 (m, 2H). LC-MS (M+H)+ = 410.4. Example 67:(R)-5-amino-N-(sec-butyl)-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)- 6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: (R)-N-،(5-cvclopropvl-3-fluoropvridin-2-vl)methyl)butan-2-amineH .,N id="p-341" id="p-341" id="p-341"
id="p-341"
[0341]The title compound (118 mg, 73%) was prepared in a manner similar to that in Example step 1 from 5-cyclopropyl-3-fluoropicolinaldehyde and (R)-butan-2-amine hydrochloride. LC-MS (M+H)+= 223.2.Step 2: (R)-5-amino-N-(sec-butyl)-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide 155 NSEM WO 2024/199255 PCT/CN2024/083980 [0342]The title compound (145 mg, 61%) was prepared in a manner similar to that in Example step 2 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and (R)-N-((5-cyclopropyl-3-fluoropyridin-2- yl)methyl)butan-2-amine. LC-MS (M+H)+ = 554.3.Step 3: (R)-5-amino-N-(sec-butyl)-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)-6,8- dihydro-lH-furo[3,4-d1pyrrolo[3,2-b1pyridine-2-carboxamide [0343]Example 67 (24 mg, 22%) was prepared in a manner similar to that in Example 66 step from (R)-5-amino-N-(sec-butyl)-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide. 1H NMR (400 MHz, DMSO-76) 5: 11.48 (s, 1H), 8.22 (s, 1H), 7.32 (d, J= 11.Hz, 1H), 6.42 (s, 1H), 5.51 (s, 2H), 5.10 (s, 2H), 4.98 - 4.35 (m, 5H), 2.02 - 1.92 (m, 1H), 1.75 - 1.40 (m, 2H), 1.30-1.05 (m, 3H), 1.05 - 0.95 (m, 2H), 0.85 - 0.73 (m, 5H). LC-MS (M+H)+ = 424.4. Example 68:(R)-5-amino-N,6-dimethyl-N-((S)-7-(trifluoromethyl)isochroman-4-yl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: tert-butyl (S)-(7-(trifluoromethyl)isochroman-4-yl)carbamateNHBoc id="p-344" id="p-344" id="p-344"
id="p-344"
[0344]A racemate of tert-butyl (7-(trifluoromethyl)isochroman-4-yl)carbamate (13.0 g, 41.mmol) was separated by SEC to give the title compound (5.0 g, 38%). [0345]Analytical chiral-SFC condition as below. Column: CHIRALPAK IC-3; Column size: 4.6X100 mm, 3 pm; Mobile phase: 14 mM NH3 in methanol:CO2, 1:9 for 0.2 min, 1:9 to 1:1 in 2.2 min, 1:1 for 1 min; Flow: 3.4 mL/min; Temperature: 35 °C; backpressure: 2000 psi. [0346]tert-butyl (S)-(7-(trifluoromethyl)isochroman-4-yl)carbamate: Analytical SFC tR=1.min. 1H NMR (400 MHz, DMSO-d) 8 7.59 (d, J= 8.0 Hz, 1H), 7.60-7.44 (m, 1H), 7.35 (d, J= 8.0 Hz, 1H), 4.82-4.64 (m, 3H), 3.93 (dd,7=5.2, 11.0 Hz, 1H), 3.63 (dd, 7=7.6, 11.0 Hz, 1H), 1.43 (s, 9H). LC-MS (M+H-t-Bu) + = 262.0. [0347]tert-butyl (R)-(7-(trifluoromethyl)isochroman-4-yl)carbamate: Analytical SFC tR=0.min. 156 WO 2024/199255 PCT/CN2024/083980 Step 2: tert-butyl (S)-methyl(7-(trifluoromethyl)isochroman-4-yl)carbamate BocN^ id="p-348" id="p-348" id="p-348"
id="p-348"
[0348]The title compound (1.5 g, 72%) was prepared in a manner similar to that in Example & 40 step 7 from tert-butyl (S)-(7-(trifluoromethyl)isochroman-4-yl)carbamate. LCMS (M+H-tBu) += 276.1.Step 3: (S)-N-methyl-7-(trifluoromethyl)isochroman-4-amine hydrochloride HN/ f 3c HCI id="p-349" id="p-349" id="p-349"
id="p-349"
[0349]The title compound (1.4 g, 100%) was prepared in a manner similar to that in Example & 40 step 8 from tert-butyl (S)-methyl(7-(trifluoromethyl)isochroman-4-yl)carbamate. EC- MS (M+H)+ = 232.0.Step4:(R)-5-amino-N,6-dimethyl-N-((S)-7-(trifluoromethyl)isochroman-4-yl)-6,8-dihydro- lH-furo[3,4-dlpyrrolo[3,2-b]pyridine-2-carboxamide [0350]Example 68 (46 mg, 21%) was prepared in a manner similar to that in Example 2 step from (S)-N-methyl-7-(trifluoromethyl)isochroman-4-amine hydrochloride and (R)-5-amino-6- methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid. 1H NMR (4MHz, DMSO-d) 8 11.61 (s, 1H), 7.74 - 7.38 (m, 3H), 6.72 (brs, 1H), 5.80 (s, 1H), 5.50 (s, 2H), 5.37 - 5.30 (m, 1H), 5.17 (dd, J= 13.9, 3.4 Hz, 1H), 5.06 (d, J= 13.8 Hz, 1H), 4.91 (d, J= 15.Hz, 1H), 4.74 (d, J= 15.6 Hz, 1H), 4.10 (s, 2H), 3.06 (brs, 3H), 1.36 (d, J= 6.1 Hz, 3H). LC-MS (M+H)+ = 447.4. Example 69:5-amino-N-cyclobutyl-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)cyclobutanamine 157 WO 2024/199255 PCT/CN2024/083980 id="p-351" id="p-351" id="p-351"
id="p-351"
[0351]The title compound (20 mg, 15%) was prepared in a manner similar to that in Example step 1 from 5-cyclopropyl-3-fluoropicolinaldehyde and cyclobutylamine. LC-MS (M+H)+ = 221.2.Step 2: 5-amino-N-cyclobutyl-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)- 1 -((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-352" id="p-352" id="p-352"
id="p-352"
[0352]The title compound (20 mg, 40%) was prepared in a manner similar to that in Example step 2 from N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)cyclobutanamine and 5-amino-l- ((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxylic acid. LC-MS (M+H)+ = 552.3.Step3:5-amino-N-cyclobutyl-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)-6,8-dihydro-H-furo [ 3,4-dlpyrrolo [ 3,2-b] nyrid i ne-2-carboxam ide [0353]Example 69 (3 mg, 22%) was prepared in a manner similar to that in Example 66 step from 5-amino-N-cyclobutyl-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyn ־olo[3,2-b]pyridine-2- carboxamide. ؛HNMR(400 MHz, DMSO-،/6) 5 11.51 (s, 1H), 8.20 (s, 1H), 7.33 (d, J= 11.6 Hz, 1H), 6.42 (s, 1H), 5.54 (s, 2H), 5.20 - 5.07 (m, 2H), 5.00 - 4.66 (m, 5H), 2.24 - 2.04 (m, 4H), 2.02 - 1.92 (m, 1H), 1.65 - 1.47 (m, 2H), 1.06 - 0.95 (m, 2H), 0.81 - 0.72 (m, 2H). LC-MS (M+H)+ = 422.4. Example 70:(R)-5-amino-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)-N-(3- methylbutan-2-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step1:(R)-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)-3-methylbutan-2-amine 158 WO 2024/199255 PCT/CN2024/083980 id="p-354" id="p-354" id="p-354"
id="p-354"
[0354]The title compound (110 mg, 77%) was prepared in a manner similar to that in Example step 1 from 5-cyclopropyl-3-fluoropicolinaldehyde and (R)-3-methylbutan-2-amine. LC-MS (M+H)+ = 237.0.Step 2: (R)-5-amino-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)-N-(3-methylbutan-2- yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-1H-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide id="p-355" id="p-355" id="p-355"
id="p-355"
[0355]The title compound (40 mg, 33%) was prepared in a manner similar to that in Example step 2 from (R)-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)-3-methylbutan-2-amine and 5-amino- 1 -((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro- 1 H-furo[3,4-d]pyrrolo[3,2-b]pyridine- 2-carboxylic acid. LC-MS (M+H)+ = 568.3.Step 3: (R)-5-amino-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)-N-(3-methylbutan-2- yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0356]Example 70 (31 mg, 100%) was prepared in a manner similar to that in Example 66 step from (R)-5-amino-N-((5-cyclopropyl-3-fluoropyridin-2-yl)methyl)-N-(3-methylbutan-2-yl)-l- ((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide. ؛HNMR(400 MHz, DMSO-d) 8 11.46 (s, 1H), 8.21 (s, 1H), 7.30 (d,J= 11.1 Hz, 1H), 6.58 - 6.34 (m, 1H), 5.50 (s, 2H), 5.20 - 3.87 (m, 7H), 2.06 - 1.86 (m, 2H), 1.45 - 0.94 (m, 5H), 0.91 - 0.73 (m, 8H). LC-MS (M+H)+ = 438.4. Example 71 & Example 72:(R)-5-amino-N-((R)-7-bromoisochroman-4-yl)-N,6-dimethyl- 6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (R)-5-amino-N-((S)-7- bromoisochroman-4-yl)-N,6-dimethyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide 159 WO 2024/199255 PCT/CN2024/083980 [0357]Example 71 (47 mg, 35%) and Example 72 (43 mg, 32%) were prepared in a manner similar to that in Example 124 & Example 125 step 2 from (R)-5-amino-6-methyl-6,8-dihydro- lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and 7-bromo-N-methylisochroman-4- amine, and the diastereomers were separated by chiral-HPLC. [0358]Analytical chiral-HPLC condition as below. Column: YMC Cellulose-C; Column size: 4.6X250 mm, 5 pm; Mobile phase: (0.1% 2.0 M methanolic NH3 in EtOH):hexane, 1:1 isocratic; Flow: 1.0 mL/min; Temperature: 25 °C. [0359]Example 71: Analytical chiral-HPLC tR=7.07 min. 1H NMR (400 MHz, DMSO-6) 11.59 (s, 1H), 7.56-7.36 (m, 2H), 7.29-7.08 (m, 1H), 6.70 (s, 1H), 5.70 (s, 1H), 5.49 (s, 2H), 5.4- 5.29 (m, 1H), 5.22-5.02 (m, 2H), 4.90-4.57 (m, 2H), 4.65 (d, J= 15.4 Hz, 1H), 4.06 (s, 2H), 3.- 2.66 (m, 3H), 1.36 (d, J= 6.1 Hz, 3H). LCMS (M+H)+ = 457.2. [0360]Example 72: Analytical chiral-HPLC tR=8.84 min. ,H NMR (400 MHz, DMSO-d) 811.59 (s, 1H), 7.56-7.36 (m, 2H), 7.29-7.08 (m, 1H), 6.70 (s, 1H), 5.70 (s, 1H), 5.49 (s, 2H), 5.4- 5.29 (m, 1H), 5.22-5.02 (m, 2H), 4.90-4.57 (m, 2H), 4.65 (d, J= 15.4 Hz, 1H), 4.06 (s, 2H), 3.- 2.66 (m, 3H), 1.36 (d, J= 6.1 Hz, 3H). LCMS (M+H)+ = 457.2. Example 73 & Example 74:(S)-5-amino-N-(7-chloroisochroman-4-yl)-N-ethyl-6,8- dihydro- 1 H-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (R)-5-amino-N-(7- chloroisochroman-4-yl)-N-ethyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide Step 1: methyl 2-(bromomethyl)-4-chlorobenzoateo id="p-361" id="p-361" id="p-361"
id="p-361"
[0361]To a solution of methyl 4-chloro-2-methylbenzoate (5.0 g, 27.1 mmol) in CC14 (1mL) was added NBS (5.3 g, 29.7 mmol) and AIBN (2.2 g, 13.5 mmol). The mixture was stirred at 80 °C under nitrogen overnight. The mixture was cooled to room temperature, diluted with DCM (100 mL), and washed with water (80 mL) and brine (60 mL). The organic layer was dried over Na2SO4, filtered and concentrated under vacuum. The residue was purified by purified by silica gel chromatography (PE:EtOAc=50:l) to give the title compound (6.3 g, 88%). LC-MS (M+H)+=263.1.Step 2: methyl 4-chloro-2-((2-methoxy-2-oxoethoxy)methyl)benzoate160 WO 2024/199255 PCT/CN2024/083980 0 0 id="p-362" id="p-362" id="p-362"
id="p-362"
[0362]To a mixture of methyl 2-hydroxyacetate (4.3 g, 47.9 mmol) in DMF (100 mL) was added NaH (60%, 1.92 g, 47.9 mmol) at 0 °C. The mixture was stirred for 30 min at room temperature and then cooled to 0 °C. A solution of methyl 2-(bromomethyl)-4-chlorobenzoate (6.3 g, 23.9 mmol) in DMF (10 mL) was added and the mixture was stirred for 10 min at 0 °C. Saturated NH4C1 (40 mL) was added dropwise, and then the mixture was partitioned between water (100 mL) and EtOAc (150 mL). The organic layer was washed with brine (2 x 60 mL), dried over Na2SO4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (PE:EtOAc=4:l) to give the title compound (3.8 g, 58%). LC-MS (M+Na) + =295.1.Step 3: 2-((carboxymethoxy)methyl)-4-chlorobenzoic acid id="p-363" id="p-363" id="p-363"
id="p-363"
[0363]To a solution of methyl 4-chloro-2-((2-methoxy-2-oxoethoxy)methyl)benzoate (3.8 g, 13.97 mmol) in EtOH (20 mL) was added a solution ofNaOH (2.5 g, 62.5 mmol) in water (mL). The mixture was stirred for l h at room temperature. The pH of the mixture was adjusted to 3-4 with hydrochloric acid (1 M). The mixture was extracted with DCM (80 mL). The organic layer was washed with brine (60 mL), dried over Na2S04, filtered and concentrated under vacuum to give the title compound (3.3 g, 97%). LC-MS (M+H)+ = 245.1.Step 4: acetic 7-chloro-4-oxoisochromane-3-carboxylic anhydride id="p-364" id="p-364" id="p-364"
id="p-364"
[0364]To a mixture of 2-((carboxymethoxy)methyl)-4-chlorobenzoic acid (3.3 g, 13.5 mmol) in Ac20 (60 mL) was added KO Ac (6.1 g, 62.2 mmol). The mixture was stirred for 3 h at 140 °C. The mixture was cooled to room temperature and partitioned between iced water (1mL) and EtOAc (120 mL). The aqueous phase was extracted with EtOAc (50 mL). The combined organic layer was washed with brine (60 mL), dried over Na2SO4, filtered and concentrated under vacuum to give the title compound (2.2 g, 61%).Step 5: 7-chloroisochroman-4-one 161 WO 2024/199255 PCT/CN2024/083980 [0365]To a solution of acetic 7-chloro-4-oxoisochromane-3-carboxylic anhydride (2.2 g, 8.mmol) in EtOH (60 mL) was added a solution of NaOH (1.64 g, 41.0 mmol) in water (20 mL). The mixture stirred for 15 min at room temperature and then partitioned between EtOAc (1mL) and brine (70 mL). The organic layer was dried over Na2S04, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (PE: EtOAc =10:1) to give the title compound (1.3 g, 87%). LC-MS (M+H)+ =183.1.Step 6: 7-chloroisochroman-4-ol id="p-366" id="p-366" id="p-366"
id="p-366"
[0366]To a solution of 7-chloroisochroman-4-one (1.0 g, 5.49 mmol) in EtOH (25 mL) was added NaBH4 (208 mg, 5.49 mmol) and the mixture was stirred for l h at room temperature. Saturated NH4C1 (30 mL) was added with stirring, and the mixture was successively extracted with and EA (80+50 mL). The combined organic layer was washed with brine (60 mL), dried over Na2S04, filtered and concentrated under vacuum to give the title compound (950 mg, 94%). LC-MS (M+H)+=185.1.Step 7: 4,7-dichloroisochromane id="p-367" id="p-367" id="p-367"
id="p-367"
[0367]To a mixture of 7-chloroisochroman-4-ol (950 mg, 5.16 mmol) in THF (15 mL) was added SOC12 (1.96 g, 16.5 mmol) dropwise, and the mixture was stirred for 30 min at 80 °C. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was re-dissolved in EtOAc (50 mL), successively washed with saturated NaHCO3 (30 mL) and brine (20 mL). The organic layer was dried over Na2S04, filtered and concentrated under vacuum to give the title compound (810 mg, 78%). LC-MS (M+H)+ =203.1.Step 8: 7-chloro-N-ethylisochroman-4-amine id="p-368" id="p-368" id="p-368"
id="p-368"
[0368]To a mixture of 4,7-dichloroisochromane (404 mg, 2.0 mmol) in DMA (10 mL) was added ethylamine hydrochloride (492 mg, 6.0 mmol), K2CO3 (1.1 g, 7.97 mmol) and KI (4mg, 2.41 mmol). The mixture was stirred for overnight at 100 °C. The mixture was cooled to room temperature, diluted with EtOAc (50 mL), successively washed with water (20 mL) and brine (20 mL). The organic layer was dried over Na2S04, filtered and concentrated under 162 WO 2024/199255 PCT/CN2024/083980 vacuum. The residue was purified by prep-TLC (PE: EtOAc =1:1) to give the title compound (100 mg, 24%). LC-MS (M+H)+ =212.3.Step 9: 5-amino-N-(7-chloroisochroman-4-yl)-N-ethyl-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-369" id="p-369" id="p-369"
id="p-369"
[0369]To a mixture of 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid (166 mg, 0.47 mmol) and 7-chloro-N- ethylisochroman-4-amine (100 mg, 0.47 mmol) in THE (10 mL) was added DIPEA (303 mg, 3.mmol) and BOPCI (203 mg, 0.80 mmol). The mixture was stirred for 2 h at 60 °C. The mixture was diluted with EtOAc (50 mL) and successively washed with water (20 mL) and brine (mL). The organic layer was dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC (MeOH: DCM = 1: 15) to give the title compound (160 mg, 62%). LC-MS (M+H)+ =543.3.Step10:(S)-5-amino-N-(7-chloroisochroman-4-yl)-N-ethyl-6,8-dihydro-1H-furo[3,4- d]pyrrolo[3,2-blpyridine-2-carboxamide & (R)-5-amino-N-(7-chloroisochroman-4-yl)-N-ethyl- 6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-blpyridine-2-carboxamide [0370] Amixture of 5-amino-N-(7-chloroisochroman-4-yl)-N-ethyl-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide (160 mg, 0.29 mmol) in TEA (5 mL) was stirred for 30 min at room temperature. The mixture was concentrated under reduced pressure. To the residue was added methanolic ammonia (7.M, 10 mL), and the mixture was stirred for 30 min at room temperature. The mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC and further purified by SEC to give Example 73 (27 mg, 22%) and Example 74 (28 mg, 23%). [0371]Analytical chiral-SFC condition as below. Column: CHIRALPAK IH; Column size: 4.6X100 mm, 5 pm; Mobile phase: 0.2% diethylamine in MeOH:CO2, 1:9 to 4:6 in 3 min, 4:for 2 min, 4:6 to 1:9 in 0.1 min, 1:9 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; back pressure: 1500 psi. [0372]Example 73: Analytical SEC tR=3.82 min. 1H NMR (400 MHz, DMSO- 163 WO 2024/199255 PCT/CN2024/083980 [0373]Example 74: Analytical SECtR=4.09 min. 1H NMR (400 MHz, DMSO- Step 1: (2-bromo-3,5-difluorophenyl) methanolFX Br id="p-374" id="p-374" id="p-374"
id="p-374"
[0374]To a solution of 2-bromo-3,5-difluoro-benzaldehyde (5.0 g, 22.6 mmol) in MeOH (mL) was added NaBH4 (942 mg, 24.9 mmol) at 0 °C under nitrogen. The mixture was stirred at °C for 0.5 h. Saturated NH4C1 (10 mL) was added to the reaction mixture at 0 °C, and the mixture was stirred at 25 °C for 1 h. The mixture was extracted with EtOAc (2 x 100 mL). The combined organic layer was washed with brine (50 mL), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=l/0 to 5/1) to give the title compound (4.8 g, 95%). LCMS (M+Na) + = 246.0.Step 2: l-((allyloxy)methyl)-2-bromo-3,5-difluorobenzene id="p-375" id="p-375" id="p-375"
id="p-375"
[0375]To a solution of (2-bromo-3,5-difluoro-phenyl)methanol (4.0 g, 17.9 mmol) in THE (mL) was added allyl bromide (2.82 g, 23.3 mmol) and NaH (60%, 861 mg, 21.5 mmol) at 0 °C under nitrogen. The mixture was stirred at 25 °C for 2 h. The mixture was poured into iced water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=l/0 to 5/1) to give the title compound (4.g, 91%). 1H NMR (400 MHz, CD30D) 8 7.20-7.12 (m, 1H), 7.09-7.00 (m, 1H), 6.06-5.92 (m, 164 WO 2024/199255 PCT/CN2024/083980 1H), 5.35 (dd, J= 17.2, 1.6 Hz, 1H), 5.23 (d, J= 10.4 Hz, 1H), 4.58 (s, 2H), 4.14 (d, J= 5.6 Hz, 2H).Step 3: 5,7-difluoro-4-methyleneisochromane F — F [0376]To a solution of l-(allyloxymethyl)-2-bromo-3,5-difluoro-benzene (4.5 g, 17.1 mmol) in DMF (90 mL) was added C82C03 (6.69 g, 20.5 mmol), PPh3 (1.08 g, 4.11 mmol) and Pd(OAc)(307 mg, 1.37 mmol), and the vessel was degassed and purged with N2 for 3 times. The mixture was stirred at 90 °C for 16 h under nitrogen. The mixture was cooled to room temperature and diluted with water (100 mL). The mixture was extracted with EtOAc (2 x 100 mL). The combined organic layer was washed with brine (50 mL), dried with Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 1/0 to 5/1) to give the title compound (1.5 g, 48%). 1H NMR (400 MHz, CD3OD) 6.92-6.82 (m, 1H), 6.80-6.73 (m, 1H), 5.82 (s, 1H), 5.28 (d, J= 4.4 Hz, 1H), 4.78 (s, 2H), 4.39- 4.35 (m, 2H).Step 4: 5.7-difluoroisochroman-4-oneo F [0377]To a mixture of 5,7-difluoro-4-methylene-isochromane (1.5 g, 8.23 mmol) in dioxane (20 mL) and water (4 mL) was added potassium osmate (VI) dihydrate (303 mg, 823 umol), 2,6- lutidine (1.76 g, 16.47 mmol) and sodium periodate (7.04 g, 32.9 mmol) at 25 °C under nitrogen. The mixture was stirred at 25 °C for 2 h. The mixture was quenched with saturated Na2S203 (mL), diluted with water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layer was washed with brine (50 mL), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=l/to 5/1) to give the title compound (1.0 g, 66%). 1H NMR (400 MHz, CD3OD) 8 7.10-6.96 (m, 2H), 5.88 (s, 2H), 4.29 (s, 2H).Step 5: 5,7-difluoroisochroman-4-one oxime 165 WO 2024/199255 PCT/CN2024/083980 OH id="p-378" id="p-378" id="p-378"
id="p-378"
[0378]The title compound (0.92 g, 85%) was prepared in a manner similar to that in Example & Example 40 step 4 from 5,7-difluoroisochroman-4-one. LC-MS (M+H)+ = 200.2.Step6:5,7-difluoroisochroman-4-amineHoN id="p-379" id="p-379" id="p-379"
id="p-379"
[0379]The title compound (822 mg, 96%) was prepared in a manner similar to that in Example & Example 40 step 5 from 5,7-difluoroisochroman-4-one oxime. LC-MS (M+H)+ = 186.1.Step 7: tert-butyl (57״-difluoroisochroman-4-yl)carbamateBocHN id="p-380" id="p-380" id="p-380"
id="p-380"
[0380]The title compound (820 mg, 65%) was prepared in a manner similar to that in Example & Example 40 step 6 from 5,7-difluoroisochroman-4-amine. LCMS (M+H-tBu) + = 230.1.Step 8: tert-butyl (5,7-difluoroisochroman-4-yl)(ethyl)carbamate NBoc F id="p-381" id="p-381" id="p-381"
id="p-381"
[0381]The title compound (100 mg, 91%) was prepared in a manner similar to that in Example & Example 40 step 7 from tert-butyl (5,7-difluoroisochroman-4-yl)carbamate and Etl. LCMS (M+H-tBu) += 258.1.Step 9: N-ethyl-5,7-difluoroisochroman-4-amine hydrochloride FHCI id="p-382" id="p-382" id="p-382"
id="p-382"
[0382]The title compound (125 mg, 100%) was prepared in a manner similar to that in Example 39 & Example 40 step 8 from tert-butyl (5,7-difluoroisochroman-4- yl)(ethyl)carbamate. LC-MS (M+H)+ = 214.1. 166 WO 2024/199255 PCT/CN2024/083980 Step10:5-amino-N-(5,7-difluoroisochroman-4-yl)-N-ethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide/ 0F // SEMn ؟ n / nh 2 [0383]The title compound (260 mg, 100%) was prepared in a manner similar to that in Example 73 & Example 74 step 9 from N-ethyl-5,7-difluoroisochroman-4-amine hydrochloride and 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid. LC-MS (M+H)+ = 545.3.Step11:(R)-5-amino-N-(5,7-difluoroisochroman-4-yl)-N-ethyl-6,8-dihydro-1H-furo[3,4- d1pyrrolol3,2-b1pyridine-2-carboxamide & (S)-5-amino-N-(5,7-difluoroisochroman-4-yl)-N- ethyl-6,8-dihydro-lH-furo[3,4-d1pyrrolol3,2-b1pyridine-2-carboxamide [0384]Example 75 (14 mg, 7%) and Example 76 (13 mg, 6%) were prepared in a manner similar to that in Example 73 & Example 74 step 10 from 5-amino-N-(5,7-difluoroisochroman-4- yl)-N-ethyl-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxamide, and the enantiomers were separated by chiral SFC. [0385]Analytical chiral-SFC condition as below. Column: ChiralPak IH; Column size: 4.6X100 mm, 3 pm; Mobile phase: (isopropanol containing 0.2% 7 M methanolic NH3):CO2 1; 1:9 for 0.2 min, 1:9 to 1:1 in 2.4 min, 1:1 for 1 min, 1:1 to 1:9 in 0.6 min; Flow: 3.4 mL/min; Temperature: 35 °C; back pressure: 2000 psi. [0386]Example 75: Analytical SFC tR=2.10 min. 1H NMR (400 MHz, DMSO-d) 8 11.55 (s, IH), 7.15 (t, J= 8.8 Hz, IH), 7.00 (d, J= 8.8 Hz, IH), 6.55 (s, IH), 5.68 (s, IH), 5.54 (s, 2H), 5.15 (d, J= 2.4 Hz, 2H), 4.96 - 4.88 (m, 3H), 4.63 (d, J= 15.6 Hz, IH), 4.36 - 3.94 (m, 4H), 0.(t, J=6.8 Hz, 3H). LC-MS (M+H)+= 415.1. [0387]Example 76: Analytical SFC tR=2.54 min. 1H NMR (400 MHz, DMSO-d) 8 11.55 (s, IH), 7.15 (t, J= 8.8 Hz, IH), 7.00 (d, J= 8.8 Hz, IH), 6.55 (s, IH), 5.68 (s, IH), 5.54 (s, 2H), 5.15 (d, J= 2.4 Hz, 2H), 4.96 - 4.88 (m, 3H), 4.63 (d, J= 15.6 Hz, IH), 4.36 - 3.94 (m, 4H), 0.(t, J=6.8 Hz, 3H). LC-MS (M+H)+= 415.1. Example 77:(S)-5-amino-N-ethyl-N-(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)-6,8- dihydro-lH-furo[3,4-d]py1Tolo[3,2-b]pyridine-2-carboxamide 167 WO 2024/199255 PCT/CN2024/083980 f 3cStep 1: tert-butyl (S)-(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)carbamateNHBocF3c^^^V > id="p-388" id="p-388" id="p-388"
id="p-388"
[0388]The title compound (300 mg, 99%) was prepared in a manner similar to that in Example & Example 40 step 6 from (S)-6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-amine hydrochloride. LC-MS (M+Na) + = 326.1.Step 2: tert-butyl (S)-ethyl(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)carbamate ^^NBocFaC^^^ id="p-389" id="p-389" id="p-389"
id="p-389"
[0389]The title compound (240 mg, 73%) was prepared in a manner similar to that in Example & Example 40 step 7 from tert-butyl (S)-(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3- yl)carbamate and Etl. LC-MS (M+H-tBu) + = 276.1.Step3:(S)-N-ethyl-6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-amine id="p-390" id="p-390" id="p-390"
id="p-390"
[0390]To tert-butyl (S)-ethyl(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)carbamate (2mg, 0.72 mmol) was added HC1 (4.0 M in dioxane, 5 mL), and the mixture was stirred at room temperature for 2 h. The mixture was concentrated under reduced pressure. The residue was partitioned between saturated NaHCO3 (50 mL) and EtOAc (40 mL). The aqueous layer was successively extracted with EtOAc (2 x 40 mL). The combined organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to give the title compound (120 mg, 79%). LC-MS (M+H)+ = 232.1.Step4:(S)-5-amino-N-ethyl-N-(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide 168 WO 2024/199255 PCT/CN2024/083980 id="p-391" id="p-391" id="p-391"
id="p-391"
[0391]The title compound (250 mg, 86%) was prepared in a manner similar to that in Example & Example 74 step 9 from (S)-N-ethyl-6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-amine and 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid. LC-MS (M+H)+ = 563.4.Step5:(S)-5-amino-N-ethyl-N-(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0392]Example 77 (103 mg, 60%) was prepared in a manner similar to that in Example 66 step from (S)-5-amino-N-ethyl-N-(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)- 1 -((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide. IH NMR (400 MHz, DMSO-،/6)5 11.57(s, 1H), 7.55 (d,J=7.6, 1H), 7.38-7.(m, 2H), 6.60 (d, J= 2.0 Hz, IH), 6.12 (s, IH), 5.58 (s, 2H), 5.12 (s, 2H), 4.98 - 4.78 (m, 3H), 4.72 - 4.61 (m, IH), 3.65 - 3.35 (m, 2H), 1.05 (t, J= 6.0 Hz, 3H). LC-MS (M+H)+ = 433.3. Example 78 & Example 79 & Example 80 & Example 81:5-amino-N-((lS,4R)-7- bromo- 1 -methylisochroman-4-yl)-N-methyl-6,8-dihydro- 1 H-furo[3,4-d]pyrrolo[3,2-b]pyridine- 2-carboxamide & 5-amino-N-((lR,4R)-7-bromo-l-methylisochroman-4-yl)-N-methyl-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & 5-amino-N-((lS,4S)-7-bromo- l-methylisochroman-4-yl)-N-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide & 5-amino-N-((lR,4S)-7-bromo-l-methylisochroman-4-yl)-N-methyl-6,8-dihydro- lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: l-(5-bromo-2-iodophenyl)ethan-l-ol id="p-393" id="p-393" id="p-393"
id="p-393"
[0393]The title compound (22 g, 84%) was prepared in a manner similar to that in Example 57& Example 58 & Example 59 & Example 60 step 1 from 5-bromo-2-iodo-benzaldehyde and 169 WO 2024/199255 PCT/CN2024/083980 MeMgBr. 1H NMR (400 MHz, CDC13) 8 7.72 (d, J= 1.6 Hz, 1H), 7.64 (d, J= 8.0 Hz, 1H), 7.(dd, J= 8.4, 2.4 Hz, 1H), 5.01 (q, J= 6.4 Hz, 1H), 1.99 (br s, 1H), 1.46 (d,J=6.4 Hz, 3H).Step 2: 2-( l-(allyloxy)ethyl)-4-bromo-l-iodobenzene id="p-394" id="p-394" id="p-394"
id="p-394"
[0394]The title compound (19 g, 77%) was prepared in a manner similar to that in Example & Example 40 step 1 from l-(5-bromo-2-iodophenyl)ethan-l-ol and allyl bromide. 1H NMR (400 MHz, CDC13) 5 7.64 (d, J= 8.4 Hz, 1H), 7.61 (d, J= 2.4 Hz, 1H), 7.11 (dd, J= 8.4, 2.8 Hz, 1H), 5.98-5.85 (m, 1H), 5.28-5.17 (m, 2H), 4.62 (q, J= 6.4 Hz, 1H), 3.97-3.88 (m, 1H), 3.86- 3.77 (m, 1H), 1.39 (d, J =6.4 Hz, 3H).Step 3: 7-bromo-l-methyl-4-methyleneisochromane id="p-395" id="p-395" id="p-395"
id="p-395"
[0395]The title compound (2.6 g, 21%) was prepared in a manner similar to that in Example & Example 40 step 2 from 2-( 1-(allyloxy)ethyl)-4-bromo- 1 -iodobenzene. ,H NMR (4MHz, CDC13) 8 7.53 (d,J=8.4Hz, 1H), 7.37 (dd, 8.0, 1.2 Hz, 1H), 7.29-7.26 (m, 1H), 5.(s, 1H), 5.04 (s, 1H), 4.84 (q,J=6.4 Hz, 1H), 4.54, 4.35 (ABq, J= 13.2 Hz, 2H), 1.56 (d,J= 6.Hz, 3H).Step 4: 7-bromo-l-methylisochroman-4-one id="p-396" id="p-396" id="p-396"
id="p-396"
[0396]The title compound (2.2 g, 83%) was prepared in a manner similar to that in Example & Example 40 step 3 from 7-bromo-l-methyl-4-methyleneisochromane. 1H NMR (400 MHz, CDCh) 8 7.91 (d, J= 8.0 Hz, 1H), 7.57 (d, J= 8.0 Hz, 1H), 7.43 (s, 1H), 4.91 (q, J= 6.4 Hz, 1H), 4.51, 4.29 (ABq, J= 17.2 Hz, 2H), 1.66 (d, J= 6.8 Hz, 3H). LC-MS (M+H)+ = 241.0.Step 5: 7-bromo-l-methylisochroman-4-olHO 170 WO 2024/199255 PCT/CN2024/083980 [0397]To a solution of 7-bromo-l-methylisochroman-4-one (2.2 g, 9.13 mmol) in MeOH (mL) was added NaBH4 (449 mg, 11.9 mmol) at 0 °C. The mixture was stirred at 25 °C for 1 h. The reaction mixture was quenched with saturated NH4C1 (10 mL) and extracted with EtOAc (x 30 mL). The combined organic layer was washed with brine (40 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc= 100/1 to 5/1) to give the title compound (1.9 g, 86%). LC-MS (M+H-H2O)+ = 225.0.Step 6: 4-azido-7-bromo-l-methylisochromane id="p-398" id="p-398" id="p-398"
id="p-398"
[0398]To a solution of 7-bromo-l-methylisochroman-4-ol (1.7 g, 6.99 mmol) in toluene (mL) at 0 °C was added DPP A (2.31 g, 8.39 mmol). A solution of DBU (1.60 g, 10.5 mmol) in toluene (4 mL) was added dropwise. The mixture was stirred at 25 °C for 12 h. The mixture was diluted with water (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layer was washed with brine (40 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (PE/EtOAc=l/0 to 10/1) to give the title compound (1.4 g, 75%). LC-MS (M+H-N2)+ = 240.0.Step 7: 7-bromo-l-methylisochroman-4-amine h2n Br [0399]To a solution of 4-azido-7-bromo-l-methylisochromane (1.4 g, 5.22 mmol) in THE (mL) was added PPh3 (2.74 g, 10.44 mmol) and a solution of KOH (732 mg, 13.0 mmol) in water (3 mL). The mixture was stirred at 50 °C for 1 h and 25 °C for 12 h. The pH of the mixture was adjusted to ~2 with hydrochloric acid (2 M), and the mixture was washed with EtOAc (3xmL). The pH of the aqueous layer was adjusted to ~11 with saturated KOH solution, and then the mixture was extracted with EtOAc (3 x 40 mL). The combined organic layer was washed with brine (40 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give the crude title compound (0.9 g, 71%). LC-MS (M+H)+ = 242.0.Step 8: tert-butyl (7-bromo-l-methylisochroman-4-yl)carbamate 171 WO 2024/199255 PCT/CN2024/083980 BocHN id="p-400" id="p-400" id="p-400"
id="p-400"
[0400]The title compound (1.2 g, 94%) was prepared in a manner similar to that in Example & Example 40 step 6 from 7-bromo-l-methylisochroman-4-amine. LCMS (M+H-tBu) + = 286.1.Step 9: tert-butyl (7-bromo-l-methylisochroman-4-yl)(methyl)carbamate BocN Br id="p-401" id="p-401" id="p-401"
id="p-401"
[0401]The title compound (900 mg, 72%) was prepared in a manner similar to that in Example & Example 40 step 7 from tert-butyl (7-bromo-l-methylisochroman-4-yl)carbamate and Mel. LCMS (M+H-tBu) + = 300.0.Step 10: 7-bromo-NJ-dimethylisochroman-4-amine hydrochloride / HN Br HCI [0402]The title compound (650 mg, 88%) was prepared in a manner similar to that in Example & Example 40 step 8 from tert-butyl (7-bromo-l-methylisochroman-4-yl)(methyl)carbamate. LC-MS (M+H)+= 256.1.Step 11: 5-amino-N-(7-bromo-l-methvlisochroman-4-vl)-N-methyl-l-((2- (trimethvlsilvl)ethoxv)methvl)-6,8-dihvdro-lH-furo[3,4-d]pv1Tolo[3,2-b]pvridine-2-carboxamide id="p-403" id="p-403" id="p-403"
id="p-403"
[0403]The title compound (0.6 g, 40%) was prepared in a manner similar to that in Example & Example 74 step 9 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and 7-bromo-N,l-dimethylisochroman-4- amine hydrochloride. LC-MS (M+H)+ = 587.3.Step12:5-amino-N-((1S,4R)-7-bromo-1-methylisochroman-4-yl)-N-methyl-6,8-dihydro- H-furo [3,4-dlpyrrolo [3,2-b]pyridine-2-carboxamide & 5-amino-N-(( 1 R,4R)-7-bromo- 1 - 172 WO 2024/199255 PCT/CN2024/083980 methylisochroman-4-yl)-N-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & 5-amino-N-((1S.4S)-7-bromo-1-methylisochroman-4-yl)-N-methyl-6,8-dihydro- H-furo F3,4-d]pyrrolo F3,2-blpyridine-2-carboxamide & 5-amino-N-(( 1 R,4S)-7-bromo- 1 - methylisochroman-4-yl)-N-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide [0404]Example 78 (66 mg, 14%), Example 79 (16 mg, 3%), Example 80 (21 mg, 4%) and Example 81 (73 mg, 16%) were prepared in a manner similar to that in Example 73 & Example step 10 from 5-amino-N-(7-bromo-l-methylisochroman-4-yl)-N-methyl-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide, and the isomers were separated by chiral SFC. [0405]Analytical chiral-SFC condition as below. Column: CHIRALPAK OJ-3; Column size: 4.6X50 mm, 3 pm; Mobile phase: (ethanol containing 0.2% 7 M methanolic NH3):CO2, 1:19 for 0.2 min, 1:19 to 1:1 in 1.0 min, 1:1 for 1 min, 1:1 to 1:19 in 0.4 min; 1:19 for 0.4 min; Flow: 3.mL/min; Temperature: 35 °C; backpressure: 1800 psi. [0406]Example 78: Analytical SFC tR=1.45 min. 1H NMR (400 MHz, DMSO- 173 WO 2024/199255 PCT/CN2024/083980 N NH2—N N H Step 1: 2-bromo-6-fluoro-4-(trifluoromethyl)anilineF NH2 id="p-410" id="p-410" id="p-410"
id="p-410"
[0410]To a solution of 2-fluoro-4-(trifluoromethyl)aniline (25 g, 140 mmol) in DMF (200 mL) was added NBS (26.1 g, 146.6 mmol) at 0 °C. The mixture was stirred at 25 °C for 12 h. The mixture was diluted with water (500 mL) and then extracted with ethyl acetate (3 x 150 mL). The combined organic layer was washed with brine (3 x 150 mL), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=l/0 to 10/1) to give the title compound (29 g, 80%). ,H NMR (DMSO-،/6, 4MHz) 8 7.57 (s, 1H), 7.48 (dd, J= 11.2, 0.8 Hz, 1H), 6.11 (s, 2H). LC-MS (M+H)+ = 257.9.Step 2: methyl 2-amino-3-fluoro-5-(trifluoromethyl)benzoateF nh 2 id="p-411" id="p-411" id="p-411"
id="p-411"
[0411]A mixture of 2-bromo-6-fluoro-4-(trifluoromethyl)aniline (29 g, 112.4 mmol), PdC(1.99 g, 11.2 mmol), BINAP (14.0 g, 22.5 mmol) and Et3N (22.8 g, 224.8 mmol) in MeOH (2mL) was degassed and purged with CO for 3 times. The mixture was stirred at 80 °C for 24 h under CO. Solid was filtered off and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=l/0 to 10/1) to give the title compound (15 g, 56%).^ NMR (DMSO-J8, 400 MHz) 8 7.80 (s, 1H), 7.63 (dd, J= 11.5, 1.Hz, 1H), 7.18 (br s, 2H), 3.84 (s, 3H). LC-MS (M+H)+ = 238.0.Step 3: methyl 2-bromo-3-fluoro-5-(trifluoromethyl)benzoate id="p-412" id="p-412" id="p-412"
id="p-412"
[0412]To a solution of methyl 2-amino-3-fluoro-5-(trifluoromethyl)benzoate (15 g, 63.mmol) in MeCN (100 mL) was added CuBr2 (18.4 g, 82.2 mmol), and the mixture was stirred at °C for 1 h. tert-Butyl nitrite (7.83 g, 75.9 mmol) was added, and the mixture was stirred at °C for 4 h. The mixture was diluted with water (100 mL) and extracted with EtOAc (100 mL 174 WO 2024/199255 PCT/CN2024/083980 x 2). The combined organic layer was washed with brine (50 mL), dried with Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=l/0 to 100/1) to give the title compound (12.5 g, 66%). 1H NMR (DMSO-d6, 4MHz) 8 8.10 (d, J= 8.5 Hz, 1H), 7.96 (s, 1H), 3.91 (s, 3H).Step 4: (2-bromo-3-fluoro-5-(trifluoromethyl)phenyl)methanol id="p-413" id="p-413" id="p-413"
id="p-413"
[0413]To a solution of methyl 2-bromo-3-fluoro-5-(trifluoromethyl)benzoate (12.5 g, 41.mmol) in THE (120 mL) was added LiBH4 in THE (2.0 M, 83.0 mL, 166 mmol) at 0 °C. The mixture was stirred at 20 °C for 3 h under nitrogen. The mixture was quenched by saturated NH4C1 (150 mL) and then extracted with EtOAc (3 x 150 mL). The combined organic layer was washed with brine (50 mL), dried with Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=l/0 to 10/1) to give the title compound (10.5 g, 93%). 1H NMR (DMSO-t/d, 400 MHz) 8 7.77 (d, J= 8.4 Hz, 1H), 7.66 (s, 1H), 5.80 (t, J= 5.6 Hz, 1H), 4.59 (d, J= 5.4 Hz, 2H).Step 5: l-((allyloxy)methyl)-2-bromo-3-fluoro-5-(trifluoromethyl)benzene F. Br /= id="p-414" id="p-414" id="p-414"
id="p-414"
[0414]To a solution of (2-bromo-3-fluoro-5-(trifluoromethyl)pheny !)methanol (10.5 g, 38.mmol) in DMF (100 mL) was added allyl bromide (9.31 g, 76.9 mmol) and NaH (60%, 3.08 g, 76.9 mmol) at 0 °C. The mixture was stirred at 25 °C for 12 h under nitrogen. The mixture was poured into iced water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=l/0 to 10/1) to give the title compound (10.5 g, 87%). 1H NMR (DMSO-Jd, 400 MHz) 8 7.82 (dd, J= 8.5, 1.5 Hz, 1H), 7.63 (s, 1H), 6.00 - 5.93 (m, 1H), 5.35-5.30 (m, 1H), 5.23 - 5.20 (m, 1H), 4.(s, 2H), 4.13 (td, J= 5.5, 1.4 Hz, 2H).Step 6: 5-fluoro-4-methvlene-7-(trifluoromethyl)isochromane 175 WO 2024/199255 PCT/CN2024/083980 [0415]To a solution of l-((allyloxy)methyl)-2-bromo-3-fluoro-5-(trifluoromethyl)benzene (1.g, 3.19 mmol) in DMF (100 mL) was added PPh3 (377 mg, 1.44 mmol), Pd(OAc)2 (143 mg, 6pmol) and Cs2CO3 (1.25 g, 3.83 mmol). The mixture was stirred at 90 °C for 12 h under nitrogen. The mixture was cooled to room temperature and diluted with water (100 mL). The mixture was extracted with EtOAc (2 x 100 mL). The combined organic layer was washed with brine (50 mL), dried with Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatograph (PE/EtOAc = 1/0 to 10/1) to give the title compound (0.44 g, 59%). ,H NMR (CDC13, 400 MHz) 8 7.24 (d, J= 11.6 Hz, 1H), 7.12 (s, 1H), 6.06 (s, 1H), 5.42 (d, J= 3.0 Hz, 1H), 4.85 (s, 2H), 4.42 (s, 2H).Step 7: 5-fluoro-7-(trifluoromethyl)isochroman-4-one id="p-416" id="p-416" id="p-416"
id="p-416"
[0416]To a solution of 5-fluoro-4-methylene-7-(trifluoromethyl)isochromane (5.7 g, 24.mmol) in dioxane (150 mL) and water (30 mL) was added potassium osmate (VI) dihydrate (9mg, 2.46 mmol), sodium periodate (21.0 g, 98.2 mmol) and 2,6-lutidine (5.26 g, 49.1 mmol).The mixture was stirred at 25 °C for 2 h under nitrogen. The mixture was quenched with saturated Na2S203 (20 mL), diluted with water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=l/0 to 5/1) to give the title compound (4.4 g, 77%). 1H NMR (DMSO-J6, 400 MHz) 7.77 (d, J= 10.9 Hz, 1H), 7.72 (s, 1H), 4.97 (s, 2H), 4.37 (s, 2H).Step 8: (R)-5-fluoro-7-(trifluoromethyl)isochroman-4-ol id="p-417" id="p-417" id="p-417"
id="p-417"
[0417]To a mixture of 5-fluoro-7-(trifluoromethyl)isochroman-4-one (4.4 g, 18.8 mmol) in formic acid-Et3N complex (5:2, 20 mL) in was added [(S,S)-N-(2-amino-l,2-diphenylethyl)-p- toluenesulfonamide] chloro(p-cymene)ruthenium(II) (599 mg, 940 pmol) under hydrogen. The mixture was stirred at 0 °C for 2 h, then slowly warmed to 25 °C and stirred for 12 h. The reaction mixture was diluted with water (50 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layer was washed with brine (40 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=30/l to 4/1) to give the title compound (4.1 g, 92%). ,H NMR (CDC13, 400 MHz) 176 WO 2024/199255 PCT/CN2024/083980 7.18 (d, J= 10.0 Hz, 1H), 7.05 (s, 1H), 4.82 - 4.73 (m, 2H), 4.60 (d, J= 15.6 Hz, 1H), 4.15 (dd, J = 12.4, 2.0 Hz, 1H), 3.75 (dd, J= 12.4, 2.4 Hz, 1H), 2.53 (br s, 1H).Step9:(S)-N-(5-fluoro-7-(trifluoromethyl)isochroman-4-yl)-N-methyl-2-nitrobenzenesulfonamide id="p-418" id="p-418" id="p-418"
id="p-418"
[0418]To a solution of (R)-5-fluoro-7-(trifluoromethyl)isochroman-4-ol (1.0 g, 4.23 mmol) and N-methyl-2-nitro-benzenesulfonamide (1.01 g, 4.66 mmol) in THF (16 mL) was added PPh(1.22 g, 4.66 mmol) and DIAD (941.85 mg, 4.66 mmol) at 0 °C. The mixture was stirred at°C for 1 h. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (x 20 mL). The combined organic layer was washed with brine (40 mL), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 5/1 to 1/1) to give the title compound (1.8 g, 98%). LC-MS (M+Na) += 457.1.Step 10: (S)-5-fluoro-N-methyl-7-(trifluoromethyl)isochroman-4-amineF ^NH id="p-419" id="p-419" id="p-419"
id="p-419"
[0419]To a solution of (S)-N-(5-fluoro-7-(trifluoromethyl)isochroman-4-yl)-N-methyl-2- nitrobenzenesulfonamide (6.3 g, 14.5 mmol) in THF (63 mL) and DMF (6.3 mL) was added lithium hydroxide monohydrate (3.0 g, 72.5 mmol) and dodecane- 1-thiol (14.7 g, 72.5 mmol) at °C. The mixture was stirred at 25 °C for 12 h. The pH of the mixture was adjusted to ~2 with hydrochloric acid (2 M), and the mixture was washed with EtOAc (3 x 50 mL). The pH of the aqueous layer was adjusted to -13 with aqueous NaOH (2 M), and the mixture was extracted with EtOAc (3 x 50 mL). The combined organic layer was washed with brine (70 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give the title compound (1.1 g, 30%). LC-MS (M+H)+ = 250.2.Step 11: (S)-5-amino-N-(5-fluoro-7-(trifluoromethvl)isochroman-4-vl)-N-methyl-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furor3,4-dlpyrrolo[3,2-blpyridine-2-carboxamide 177 WO 2024/199255 PCT/CN2024/083980 [0420]To a solution of (S)-5-fluoro-N-methyl-7-(trifluoromethyl)isochroman-4-amine (0.30 g, 1.20 mmol) and 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid (463 mg, 1.32 mmol) in THF (10 mL) was added BOPCI (398 mg, 1.56 mmol) and DIPEA (467 mg, 3.61 mmol). The mixture was stirred at 40 °C for 2 h and cooled to room temperature. The mixture was diluted with water (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layer was washed with brine (40 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give the title compound (0.55 g, 79%). LC-MS (M+H)+ = 581.3.Step 12: (S)-5-amino-N-(5-fluoro-7-(trifluoromethyl)isochroman-4-yl)-N-methyl-6,8- dihydro-lH-furo[3,4-d1pyrrolo[3,2-b1pyridine-2-carboxamide [0421]A solution of (S)-5-amino-N-(5-fluoro-7-(trifluoromethyl)isochroman-4-yl)-N-methyl- -((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro- 1 H-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide (0.55 g, 0.95 mmol) in TEA (4 mL) was stirred at 40 °C for 0.5 h. The mixture was cooled to room temperature and concentrated under reduced pressure. To the residue was added and methanolic ammonia (7.0 M, 4 mL) and the mixture was stirred at 25 °C for 0.5 h. The mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC to give Example 82 (390 mg, 91%). ,H NMR (400 MHz, DMSO-d) 8 11.58 (br s, 1H), 7.61 (d, J = 9.2 Hz, 1H), 7.55 (s, 1H), 6.75-6.50 (m, 1H), 5.83 (br s, 1H), 5.58 (s, 2H), 5.22 - 5.10 (m, 2H), 5.05 - 4.91 (m, 3H), 4.72 (d, J= 15.6 Hz, 1H), 4.24 - 3.99 (m, 2H), 3.19 - 2.69 (m, 3H). LC-MS (M+H)+= 451.0. Example S3:(R)-5-amino-N,6-dimethyl-N-((lR,4S)-l-methyl-7- (trifluoromethyl)isochroman-4-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide Step 1: (R)-l-(2-bromo-5-(trifluoromethyl)phenyl)ethan-l-ol OH [0422]To a mixture of l-(2-bromo-5-(trifluoromethyl)phenyl)ethan-l-one (11.2 g, 41.9 mmol) in formic acid-EtN complex (5:2, 11 mL), was added [(R,R)-N-(2-amino-l,2-diphenylethyl)-p- toluenesulfonamide]chloro(p-cymene)1 ־uthenium(II) (1.33 g, 2.1 mmol) at -18 °C under 178 WO 2024/199255 PCT/CN2024/083980 hydrogen. The mixture was stirred at 0 °C for 2 h and room temperature for 12 h. The mixture was partitioned between and saturated NaHCO3 (150 mL) and EtOAc (250 mL). The organic layer was washed with brine (100 mL), dried over Na2S04, filtered and concentrated under vacuum. The residue was purified by silica gel column chromatography (PE:EtOAc=20:l) to give the title compound (10.5 g, 93%). LC-MS (M+H)+ = 269.1.Step 2: (R)-2-(l-(allyloxy)ethyl)-l-bromo-4-(trifluoromethyl)benzene id="p-423" id="p-423" id="p-423"
id="p-423"
[0423]To a solution of (R)-l-(2-bromo-5-(trifluoromethyl)phenyl)ethan-l-ol (10.0 g, 37.mmol) in DMF (100 mL) was added NaH (60%, 1.78 g, 44.6 mmol) at 0 °C under nitrogen. After 30 min, allyl bromide (5.85 g, 48.3 mol) was added, and the mixture was stirred at 25 °C for 3 h. The reaction mixture was poured into water (150 mL) and then extracted with EtOAc (x 200 mL). The combined organic layer was washed with brine (2 x 100 mL), dried over Na2SO4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (PE:EtOAc=20: 1) to give the title compound (10.4 g, 90%). ,H NMR (4MHz, CDC13)8 7.80 (d, J= 1.1 Hz, 1H), 7.64 (d, J=S3 Hz, 1H), 7.38 (dd, J= 8.2, 1.6 Hz, 1H), 6.00 - 5.84 (m, 1H), 5.32 - 5.23 (m, 1H), 5.19 (d, J= 10.4 Hz, 1H), 4.88 (q, J= 6.4 Hz, 1H), 3.92 (dd, J= 12.6, 5.3 Hz, 1H), 3.85 (dd, J= 12.6, 5.9 Hz, 1H), 1.43 (d, J= 6 A Hz, 3H). LC-MS (M+H)+ =309.1.Step 3: (R)-l-methvl-4-methvlene-7-(trifluoromethyl)isochromane f 3c id="p-424" id="p-424" id="p-424"
id="p-424"
[0424]To a solution of (R)-2-(l-(allyloxy)ethyl)-l-bromo-4-(trifluoromethyl)benzene (10.4 g, 33.7 mmol) in DMF (250 mL) was added Pd(OAc)2 (1.13 g, 5.1 mol), Cs2CO3 (13.2 g, 40.4 mol) and PPh3 (5.3 g, 20.2 mol). The mixture solution was stirred for 16 h at 100 °C under nitrogen and cooled to room temperature. The mixture was poured into water (300 mL) and then extracted with EtOAc (2 x 400 mL). The combined organic layer was washed with brine (3 x 300 mL), dried over Na2S04, filtered and concentrated under vacuum. The crude product was purified by silica gel chromatography (PE:EtOAc = 30:1) to give the title compound (5.7 g, 74%). 1H NMR (400 MHz, CDCI) 8 7.76 (d, J= 8.2 Hz, 1H), 7.48 (d, J= 7.9 Hz, 1H), 7.37 (s, 1H), 5.69 (s, 1H), 5.13 (s, 1H), 4.89 (q,J=6.4 Hz, 1H), 4.57, 4.37 (ABq, J = 13.4 Hz, 2H), 1.60 (d, J=6.Hz, 3H).179 WO 2024/199255 PCT/CN2024/083980 Step4:(R)-1-methyl-7-(trifluoromethyl)isochroman-4-one id="p-425" id="p-425" id="p-425"
id="p-425"
[0425]To a solution of (R)-l-methyl-4-methylene-7-(trifluoromethyl)isochromane (5.7 g, mmol) in dioxane (150 mL) and water (30 mL) was added potassium osmate (VI) dihydrate (9mg, 2.5 mmol), sodium periodate (21.4 g, 100 mmol) and 2,6-lutidine (5.4 g, 50 mmol). The mixture was stirred at 25 °C for 2 h. Solid was filtered off and the filtrate was diluted with water (250 mL) then extracted with EtOAc (2 x 350 mL). The combined organic layer was successively washed with saturated Na2S203 (350 mL), hydrochloric acid (1 M, 300 mL) and brine (200 mL). The organic layer was dried over Na2S04, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (PE: EtOAc = 20:1) to give the title compound (5.6 g, 97%). 1H NMR (400 MHz, CDC13) 5 8.16 (d, J= 8.1 Hz, 1H), 7.68 (d, J= 8.0 Hz, 1H), 7.51 (s, 1H), 4.96 (q,J=6.4 Hz, 1H), 4.56, 4.33 (ABq,J= 17.1 Hz, 2H), 1.70 (d, J = 6.6 Hz, 3H). LC-MS (M+H)+ =231.3.Step5:(1R,4R)-1-methyl-7-(trifluoromethyl)isochroman-4-olOH id="p-426" id="p-426" id="p-426"
id="p-426"
[0426]To a solution of (R)-l-methyl-3,3-diphenylhexahydropyrrolo[l,2-c][l,3,2]oxazaborole (674 mg, 2.43 mmol) in THE (10 mL), was added BH3 in THE (1.0 M, 25.6 mmol, 25.6 mL) at - °C. The mixture was stirred for 10 min, and a solution of (R)-l-methyl-7- (trifluoromethyl)isochroman-4-one (5.6 g, 24.3 mmol) in THE (70 mL) was added dropwise. The mixture was stirred for l h at -10 °C under nitrogen. MeOH (10 mL) was added dropwise and the mixture was stirred for l h at room temperature. The mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE:EtOAc = 4:1) to give the title compound (5.0 g, 89%). 1H NMR (400 MHz, CDCI) 8 7.64 (d, J = 8.0 Hz, 1H), 7.53 (d, J=8.0 Hz, 1H), 7.31 (s, 1H), 4.93 (q, J=6.5Hz, 1H), 4.81 -4.71 (m, 1H), 4.20 (dd, J = 11.5,4.4 Hz, 1H), 3.67 (dd, J= 11.5, 6.7 Hz, 1H), 2.15 (d, J= 8.3 Hz, 1H), 1.53 (d,J=6.6Hz, 3H). LC-MS (M+H)+ =233.3.Step 6: N-methvl-N-((lR,4S)-l-methvl-7-(trifluoromethyl)isochroman-4-vl)-2- nitrobenzenesulfonamide 180 WO 2024/199255 PCT/CN2024/083980 id="p-427" id="p-427" id="p-427"
id="p-427"
[0427]To a solution of (lR,4R)-l-methyl-7-(trifluoromethyl)isochroman-4-ol (5.0 g, 21.mmol), N-methyl-2-nitro-benzenesulfonamide (4.66 g, 21.6 mmol) and PPh3 (6.2 g, 23.8 mmol) in THF (80 mL) was added DtBAD (5.47 g, 23.8 mmol) in portions at 0 °C under nitrogen. The mixture was stirred at 25 °C for l h and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE:EtOAc=2:l) to give the title compound (7.9 g, 86%). LC-MS (M+H)+ =431.3.Step 7: (lR,4S)-N,l-dimethyl-7-(trifluoromethyl)isochroman-4-amineMe^ NH f 3c id="p-428" id="p-428" id="p-428"
id="p-428"
[0428]A mixture of N-methyl-N-(( 1 R,4S)-1 -methyl-7-(trifluoromethyl)isochroman-4-yl)-2- nitrobenzenesulfonamide (7.9 g, 18.4 mmol), dodecane- 1-thiol (11.1 g, 55.1 mmol) and lithium hydroxide monohydrate (2.3 g, 55.1 mol) in DMF (10 mL) and THF (100 mL) was stirred at °C for 16 h. The mixture was diluted with EtOAc (250 mL), washed with brine (100 mL), dried over Na2S04, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (PE/EtOAc = 1/1 to DCM:MeOH=10:l) to give the title compound (4.3 g, 96%). 1H NMR (400 MHz, CDCL) 8 7.48 (d, J= 7.8 Hz, 1H), 7.41 (d, J= 8.0 Hz, 1H), 7.35 (s, 1H), 4.78 (q, J=6.3 Hz, 1H), 4.28 (d, J= 11.8 Hz, 1H), 3.73 (dd,J=11.8, 1.8 Hz, 1H), 3.47- 3.39 (m, 1H), 2.52 (s, 3H), 1.58 (d, J= 6.4 Hz, 3H). LC-MS (M+H)+=246.3.Step 8: 5-amino-N-methyl-N-((lR,4S)-l-methyl-7-(trifluoromethyl)isochroman-4-yl)-l-((2- (trimethvlsilvl)ethoxv)methvl)-6,8-dihydro-lH-furor3,4-dlpv1Tolor3,2-blpvridine-2-carboxamide [0429]A mixture of (lR,4S)-N,l-dimethyl-7-(trifluoromethyl)isochroman-4-amine (2.85 g, 11.6 mol) and 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid (4.25 g, 12.2 mmol) in THF (150 mL) was added DIPEA (3.0 g, 23.2 mmol) and BOPCI (3.83 g, 15.1 mmol) and the mixture was stirred at 50 °C for 4 h. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was treated with EtOAc (250 mL), successively washed with saturated NaHCO3 (mL), water (80 mL), brine (60 mL), dried over Na2S04, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (DCM:MeOH = 25:1) to give the title compound (6.0 g, 86%). LC-MS (M+H)+ =577.2. 181 WO 2024/199255 PCT/CN2024/083980 Step9:5-amino-N-methyl-N-((1R,4S)-1-methyl-7-(trifluoromethyl)isochroman-4-yl)-6,8- dihydro-lH-furo[3,4-d]pyrrolor3,2-b]pyridine-2-carboxamide [0430]To a mixture of 5-amino-N-methyl-N-((lR,4S)-l-methyl-7- (trifluoromethyl)isochroman-4-yl)- 1 -((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro- 1H- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide (6.0 g, 10.4 mmol) in DCM (15 mL) was added TFA (60 mL), and the mixture was stirred at 25 °C for l h. The mixture was concentrated under reduced pressure. Methanolic ammonia (7 M, 40 mL) was added and the mixture was stirred at 25 °C for 30 min. The mixture was concentrated under reduced pressure. The residue was treated with EtOAc (250 mL), successive washed with aqueous Na2CO3 (0.5 M, 50 mL), water (80 mL), brine (80 mL), dried over Na2S04, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (DCM:MeOH = 20:1 to 10:1) to give 5- amino-N-methyl-N-(( 1 R,4S)-1 -methyl-7-(trifluoromethyl)isochroman-4-yl)-6,8-dihydro- 1H- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide (2.6 g, 56%).Step10:(R)-5-amino-N,6-dimethyl-N-((1R,4S)-1-methyl-7-(trifluoromethyl)isochroman-4- yl)-6.8-dihydro-lH-furor3,4-dlpyrrolo[3,2-blpyridine-2-carboxamide [0431]To the mixture of (R)-5-amino-6-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid (200 mg, 0.86 mmol), (lR,4S)-N,l-dimethyl-7- (trifluoromethyl)isochroman-4-amine (210 mg, 0.86 mmol) and DIPEA (775 mg, 6.0 mmol) in anhydrous DMF (3 mL) under nitrogen was added T3P (1.36 g, 4.29 mmol) and the mixture was stirred at 60 °C for 16 h. The mixture was cooled to room temperature, hydrochloric acid (6 M, mL) was added and the mixture was stirred for 3 h at 60 °C. The mixture was cooled to room temperature, poured into saturated NaHCO3 (100 mL) and extracted with EtOAc (100 mL). The combined organic layer was washed with brine (100 mL), dried over Na2S04, filtered and concentrated under vacuum. The residue was purified by prep-HPLC to give Example 83 (1mg, 36%). 1H NMR (400 MHz, DMSO-d) 8 11.58 (s, 1H), 7.65 (s, 2H), 7.46 (s, 1H), 6.68 (s, 1H), 5.70 (s, 1H), 5.47 (s, 2H), 5.34 (s, 1H), 5.23 - 4.98 (m, 2H), 4.90 - 4.74 (m, 1H), 4.32 - 3.(m, 2H), 3.07 (s, 3H), 1.70 - 1.49 (m, 3H), 1.43 - 1.26 (m, 3H). LC-MS (M+H)+ =461.4. Example 84:(S)-5-amino-N-(7-iodoisochroman-4-yl)-N-methyl-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: (R)-7-chloroisochroman-4-ol 182 WO 2024/199255 PCT/CN2024/083980 id="p-432" id="p-432" id="p-432"
id="p-432"
[0432]To a solution of (R)-l-methyl-3,3-diphenylhexahydropyrrolo[l,2-c][l,3,2]oxazaborole (607 mg, 2.19 mmol) in THF (10 mL) at 0 °C was added BH3 Me2S (1.31 mL, 13.8 mmol) under nitrogen. The mixture was stirred at 0 °C for 30 min. A solution of 7-chloroisochroman-4-one (2.0 g, 10.95 mmol) in THF (10 mL) was added dropwise into the reaction mixture over 10 min. The mixture was stirred at 25 °C for 12 h. MeOH (9 mL) was added dropwise. Upon cease of bubbling, the mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=5/l) to give the title compound (2.0 g, 99%). 1H NMR (400 MHz, DMSO-،/6) 5 7.44 (d, J= 8.0 Hz, 1H), 7.29 (d, J= 8.0 Hz, 1H), 7.15 (s, 1H), 5.49 (d, J=6.0Hz, 1H), 4.69, 4.60 (ABq, J= 15.6 Hz, 2H), 4.55 - 4.46 (m, 1H), 3.93 - 3.82 (m, 1H), 3.66 - 3.56 (m, 1H).Step 2: (S)-4-azido-7-chloroisochromane N3 CI [0433]The title compound (1.8 g, 79%) was prepared in a manner similar to that in Example & Example 79 & Example 80 & Example 81 step 6 from (R)-7-chloroisochroman-4-ol. 1H NMR (400 MHz, DMSO-d) S 7.54 - 7.44 (m, 2H), 7.37 (s, 1H), 4.88, 4.70 (ABq, J= 15.8 Hz, 2H), 4.54-4.49 (m, 1H), 4.18 (dd, J= 12.4, 2.0 Hz, 1H), 3.95 (dd, J= 12.4, 2.8 Hz, 1H).Step 3: (S)-7-chloroisochroman-4-amineh2n ^3° CI [0434]The title compound (1.55 g, 97%) was prepared in a manner similar to that in Example & Example 79 & Example 80 & Example 81 step 7 from (S)-4-azido-7-chloroisochromane. LC-MS (M+H)+=184.1.Step 4: tert-butyl (S)-(7-chloroisochroman-4-yl)carbamateBocHN ^3° CI 183 WO 2024/199255 PCT/CN2024/083980 [0435]The title compound (0.30 g, 87%) was prepared in a manner similar to that in Example & Example 40 step 6 from (S)-7-chloroisochroman-4-amine. LCMS (M+H-tBu) + = 228.0.Step5:tert-butyl(S)-(7-chloroisochroman-4-yl)(methyl)carbamate BocN id="p-436" id="p-436" id="p-436"
id="p-436"
[0436]The title compound (1.0 g, 79%) was prepared in a manner similar to that in Example & Example 40 step 7 from tert-butyl (S)-(7-chloroisochroman-4-yl)carbamate and Mel. LCMS (M+H-tBu) + = 242.1.Step 6: tert-butyl (S)-methyl(7-(4,4,5.5-tetramethyl-L3,2-dioxaborolan-2-yl)isochroman-4- yl)carbamate id="p-437" id="p-437" id="p-437"
id="p-437"
[0437]To a solution of tert-butyl (S)-(7-chloroisochroman-4-yl)(methyl)carbamate (700 mg, 2.35 mmol) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3,2- dioxaborolane (657 mg, 2.59 mmol) in dioxane (10 mL) was added XPhos (112 mg, 235 umol), KO Ac (692 mg, 7.05 mmol) and Pd2(dba)3 (215 mg, 235 pmoly The mixture was stirred at 100 °C for 16 h under nitrogen and then cooled to room temperature. The mixture was diluted with water (30 mL) and extracted with EtOAc (3x30 mL). The combined organic layers were washed with brine (40 mL), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=l/0 to 5/1) to give the title compound (500 mg, 55%). LC-MS (M+H-tBu) + = 334.2.Step 7: tert-butyl (S)-(7-iodoisochroman-4-vl)(methyl)carbamate id="p-438" id="p-438" id="p-438"
id="p-438"
[0438]To a solution of tert-butyl (S)-methyl(7-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)isochroman-4-yl)carbamate (500 mg, 1.28 mmol) in MeOH (5 mL) and water (0.5 mL) was added Cui (245 mg, 1.28 mmol) and NIS (289 mg, 1.28 mmol) under nitrogen. The mixture was stirred at 80 °C for 1 h and then cooled to room temperature. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (3x30 mL). The combined organic layer was washed with brine (40 mL), dried over Na2S04, filtered and concentrated under reduced 184 WO 2024/199255 PCT/CN2024/083980 pressure. The residue was purified by silica gel chromatography (PE/EtOAc=l/0 to 5/1) to give the title compound (250 mg, 49%). LC-MS (M+H-tBu) + = 334.1.Step 8: (S)-7-iodo-N-methylisochroman-4-amine hydrochloride/ HN I HCI id="p-439" id="p-439" id="p-439"
id="p-439"
[0439]The title compound (66 mg, 99%) was prepared in a manner similar to that in Example & Example 40 step 8 from tert-butyl (S)-(7-iodoisochroman-4-yl)(methyl)carbamate. LC-MS (M+H)+ = 290.0.Step 9: (S)-5-amino-N-(7-iodoisochroman-4-yl)-N-methyl-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-440" id="p-440" id="p-440"
id="p-440"
[0440]The title compound (100 mg, 79%) was prepared in a manner similar to that in Example & Example 74 step 9 from (S)-7-iodo-N-methylisochroman-4-amine hydrochloride and 5- amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxylic acid. LC-MS (M+H)+ = 621.2.Step10:(S)-5-amino-N-(7-iodoisochroman-4-yl)-N-methyl-6,8-dihydro-1H-furo[3,4-d]pvrrolo[3,2-blpvridine-2-carboxamide [0441]Example 84 (50 mg, 58%) was prepared in a manner similar to that in Example 66 step from (S)-5-amino-N-(7-iodoisochroman-4-yl)-N-methyl-l-((2-(trimethylsilyl)ethoxy)methyl)- 6,8-dihydro-lH-furo[3,4-d]py1Tolo[3,2-b]pyridine-2-carboxamide. 1H NMR (400 MHz, DMSO- d6) 8 11.86 (br s, 1H), 7.65 (d, J= 8.3 Hz, 1H), 7.59 (s, 1H), 7.03 (d, J= 6.1 Hz, 1H), 6.74 (br s, 1H), 6.11 (br s, 2H), 5.69 (br s, 1H), 5.18 (s, 2H), 5.00 - 4.87 (m, 2H), 4.80 15.4 Hz, 1H),4.63 (d, J = 15.4 Hz, 1H), 4.13 - 4.01 (m, 2H), 3.04 (s, 3H) LC-MS (M+H)+ = 491.1. Example 85 & Example 86:(S)-5-amino-N-methyl-N-(2-(trifluoromethyl)-5,8-dihydro- 6H-pyrano[3,4-b]pyridin-5-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (R)-5-amino-N-methyl-N-(2-(trifluoromethyl)-5,8-dihydro-6H-pyrano[3,4-b]pyridin-5-yl)- 6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide 185 WO 2024/199255 PCT/CN2024/083980 N OHF3C id="p-442" id="p-442" id="p-442"
id="p-442"
[0442]To a solution of methyl 3-bromo-6-(trifluoromethyl)picolinate (3.2 g, 11.3 mmol) in EtOH (100 mL) was added NaBH4 (1.29 mg, 33.9 mmol) at 0 °C. The mixture was stirred at room temperature for 11 h and then concentrated under reduced pressure. The residue was partitioned between EtOAc (100 mL) and saturated NaHCO3 (100 mL). The aqueous phase was extracted with EtOAc (2 x 100 mL). The combined organic layer was washed with brine (mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc= 10/1 to 1/1) to give the title compound (3.0 g, 100%). LC-MS (M+Na) + = 278.0.Step 2: 2-((allyloxy)methyl)-3-bromo-6-(trifluoromethyl)pyridine id="p-443" id="p-443" id="p-443"
id="p-443"
[0443]The title compound (1.74 g, 63%) was prepared in a manner similar to that in Example step 5 from (3-bromo-6-(trifluoromethyl)pyridin-2-yl)methanol and allyl bromide. LC-MS (M+H)+ = 296.0.Step3:5-methylene-2-(trifluoromethyl)-5,8-dihydro-6H-pyrano[3,4-b]pyridine f 3c [0444]A mixture of 2-((allyloxy)methyl)-3-bromo-6-(trifluoromethyl)pyridine (1.74 g, 5.mmol), Pd(PPh3)4 (680 mg, 0.59 mmol), C82C03 (2.88 g, 8.8 mmol) in DMF (50 mL) was degassed and purged with nitrogen for 3 times, and the mixture was stirred at 110 °C for 12 h. The mixture was cooled to room temperature and diluted with water (100 mL). The mixture was extracted with EtOAc (2 x 100 mL). The combined organic layer was washed with brine (mL), dried with Na2S04, filtered and concentrated under reduced pressure. The residue was 186 Step1:(3-bromo-6-(trifluoromethyl)pyridin-2-yl)methanolBr WO 2024/199255 PCT/CN2024/083980 purified by silica gel chromatograph (PE/EtOAc = 1/0 to 5/1) to give the title compound (8mg, 71%). LC-MS (M+H)+ = 216.1.Step 4: 2-(trifluoromethyl)-6H-pyrano[3,4-b]pyridin-5(8H)-one f 3c [0445]To a solution of 5-methylene-2-(trifluoromethyl)-5,8-dihydro-6H-pyrano[3,4-b]pyridine (892 mg, 4.1 mmol) in dioxane (100 mL) and water (20 mL) was added potassium osmate (VI) dihydrate (147 mg, 6.2 mmol), 2,6-lutidine (439 mg, 4.1 mmol) and sodium periodate (1.33 g, 6.2 mmol). The mixture was stirred at 25 °C for 4 h. The mixture was diluted with water (1mL) and extracted with EtO Ac (3 x 100 mL). The combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=l/0 to 3/1) to give the title compound (463 mg, 51%). LC-MS (M+H)+ = 218.0.Step 5: 2-(trifluoromethyl)-5,8-dihydro-6H-pyrano[3,4-b]pyridin-5-ol f 3c [0446]To a solution of 2-(trifluoromethyl)-6H-pyrano[3,4-b]pyridin-5(8H)-one (100 mg, 0.mmol) in MeOH (1 mL) was added NaBH4 (19 mg, 0.51 mmol) at 0 °C. The mixture was stirred at room temperature for 2 h and then concentrated under reduced pressure. The residue was partitioned between EtOAc (30 mL) and saturated NaHCO3 (30 mL). The aqueous phase was extracted with EtOAc (2 x 20 mL). The combined organic layer was washed with brine (30 mL), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=10/l to 1/1) to give the title compound (101 mg, 100%). LC-MS (M+H)+ = 220.0.Step 6: di-tert-butyl (2-(trifluoromethvl)-5,8-dihvdro-6H-pv1 ־ano[3,4-b1pvridin-5- yl)iminodicarbonateBoc2N id="p-447" id="p-447" id="p-447"
id="p-447"
[0447]To a solution of 2-(trifluoromethyl)-5,8-dihydro-6H-pyrano[3,4-b]pyridin-5-ol (101 mg, 0.46 mmol), PPh3 (181 mg, 0.69 mmol) and B0C2NH (150 mg, 0,69 mmol) in THE (3 mL) was 187 WO 2024/199255 PCT/CN2024/083980 added DIAD (139 mg, 0.69 mmol) at 0 °C. The mixture was stirred at room temperature for 12 h and concentrated under reduced pressure. The residue was partitioned between EtOAc (30 mL) and saturated NaHCO3 (30 mL). The aqueous phase was extracted with EtOAc (2 x 20 mL). The combined organic layer was washed with brine (30 mL), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=l/0 to 5/1) to give the title compound (176 mg, 92%).Step 7: tert-butyl (2-(trifluoromethyl)-5,8-dihydro-6H-pyranor3,4-blpyridin-5-yl)carbamateBocHN id="p-448" id="p-448" id="p-448"
id="p-448"
[0448]To a solution of di-tert-butyl (2-(trifluoromethyl)-5,8-dihydro-6H-pyrano[3,4-b]pyridin- 5-yl)iminodicarbonate (176 mg, 0.42 mmol) in THE (1 mL), water (1 mL) and MeOH (1 mL) was added lithium hydroxide monohydrate (53 mg, 1.3 mmol). The mixture was stirred at 35 °C for 1.5 h, cooled to room temperature and then diluted with water (10 mL). The mixture was extracted with EtOAc (3 x 20 mL). The combined organic layer was washed with brine (5 mL), dried with Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/ EtOAc=l/0 to 3/1) to give the title compound (78 mg, 58%). LCMS (M+H-tBu) + = 263.1.Step 8: tert-butyl methyl(2-،trifluoromethvl)-5,8-dihvdro-6H-pvrano[3,4-b1pvridin-5- vDcarbamate—NBoc F3C [0449]To the solution of tert-butyl (2-(trifluoromethyl)-5,8-dihydro-6H-pyrano[3,4-b]pyridin- 5-yl)carbamate (780 mg, 2.45 mmol) in THE (20 mL) under nitrogen at 0 °C was added NaH (60%, 147 mg, 3.68 mmol) and stirred for 1 h. Mel (696 mg, 4.9 mmol) was added and the mixture was stirred at room temperature for 3 h. The reaction was quenched with saturated NH4C1 (20 mL). The mixture was extracted with EtOAc (3 x 20 mL). The combined organic layer was washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 1/1) to give the title compound (220 mg, 27%). LCMS (M+H)+ = 333.2.Step9:N-methyl-2-(trifluoromethyl)-5,8-dihydro-6H-pyrano[3,4-b]pyridin-5-amine hydrochloride 188 WO 2024/199255 PCT/CN2024/083980 —NH F3C id="p-450" id="p-450" id="p-450"
id="p-450"
[0450]To a solution of tert-butyl methyl(2-(trifluoromethyl)-5,8-dihydro-6H-pyrano[3,4- b]pyridin-5-yl)carbamate (220 mg, 0.66 mmol) in DCM (5 mL) was added HC1 in dioxane (4.M, 3 mL). The mixture was stirred at room temperature for 12 h. The mixture was concentrated under reduced pressure to give the title product (177 mg, 100%). LC-MS (M+H)+ = 233.2.Step10:5-amino-N-methyl-N-(2-(trifluoromethyl)-5,8-dihydro-6H-pyrano[3,4-b]pyridin-5- yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-1H-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide id="p-451" id="p-451" id="p-451"
id="p-451"
[0451]To a solution of N-methyl-2-(trifluoromethyl)-5,8-dihydro-6H-pyrano[3,4-b]pyridin-5- amine hydrochloride (177, 0.66 mmol) and 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid (232 mg, 0.66 mmol) in THF (mL) was added DIPEA (170 mg, 1.32 mmol) and BOPCI (335 mg, 1.32 mmol). The mixture was stirred at room temperature for 1 h and then diluted with water (5 mL). The mixture was extracted with EtOAc (3x5 mL). The combined organic layer was washed with brine (5 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give the title compound (370 mg, 75%). LC-MS (M+H)+ = 564.3.Step 11: (R)-5-amino-N-methyl-N-(2-(trifluoromethyl)-5,8-dihydro-6H-pyrano[3,4- b]pyridin-5-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (S)-5- amino-N-methvl-N-(2-(trifluoromethvl)-5,8-dihvdro-6H-pvrano[3,4-blpvridin-5-vl)-6,8-dihvdro- H-furo [ 3,4-d]pyrrolo [ 3,2-blpyridine-2-carboxamide [0452]To a solution of 5-amino-N-methyl-N-(2-(trifluoromethyl)-5,8-dihydro-6H-pyrano[3,4- b]pyridin-5-yl)-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxamide (370 mg, 0.65 mmol) in DCM (10 mL) was added TEA (1 mL) and the mixture was stirred at room temperature for 2 h. The mixture was concentrated under reduced pressure. The residue was dissolved in MeOH (5 mL) followed by addition of K2CO(179 mg, 1.3 mmol). The mixture was stirred at 50 °C for 2 h and then cooled to room temperature. The mixture was concentrated under reduced pressure and DCM (20 mL) was added. Solid was filtered off and the filtrate was concentrated under reduced pressure. The 189 NSEM WO 2024/199255 PCT/CN2024/083980 residue was purified by silica gel chromatography (DCM/MeOH = 15/1) followed by chiral SFC to give Example 85 (15 mg, 5%) and Example 86 (15 mg, 5%). [0453]Analytical chiral-SFC condition as below. Column: CHIRALPAK AS-H; Column size: 4.6X100 mm, 5 pm; Mobile phase: 0.1% diethylamine in methanol; Flow: 2.0 mL/min;Temperature: 35 °C; backpressure: 1800 psi. [0454]Example 85: Analytical SFC tR=2.97 min. 1H NMR (400 MHz, DMSO-d) 5 11.62 (s, 1H), 7.95 (d, J= 8.0 Hz, 1H), 7.84 (d, J= 8.1 Hz, 1H), 6.75 (s, 1H), 5.84 (s, 1H), 5.60 (s, 2H), 5.15 (s, 2H), 5.01-4.69 (m, 4H), 4.15 (s, 2H), 3.11 (s, 3H). LC-MS (M+H)+= 434.4. [0455]Example 86: Analytical SFC tR=3.26 min. 1H NMR (400 MHz, DMSO-6) S 11.68 (s, 1H), 7.95 (d, J= 8.1 Hz, 1H), 7.84 (d, J= 8.1 Hz, 1H), 6.75 (s, 1H), 5.84 (s, 1H), 5.72 (s, 2H), 5.15 (s, 2H), 4.93 -4.74 (m, 4H), 4.15 (s, 2H), 3.11 (s, 3H). LC-MS (M+H)+= 434.3. Example 87 & Example 88:(S)-5-amino-N-(2-cyclopropyl-5,8-dihydro-6H-pyrano[3,4- b]pyridin-5-yl)-N-methyl-6,8-dihydro- 1 H-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (R)-5-amino-N-(2-cyclopropyl-5,8-dihydro-6H-pyrano[3,4-b]pyridin-5-yl)-N-methyl-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step1:N-methyl-5,8-dihydro-6H-pyrano[3,4-b]pyridin-5-amine id="p-456" id="p-456" id="p-456"
id="p-456"
[0456]To a solution of 8H-pyrano[3,4-b]pyridin-5-one (1.0 g, 6.70 mmol) in CFCH2OH (mL) was added MeNH2 in THF (2.0 M, 13.4 mL, 26.8 mmol). The mixture was stirred at 25 °C for 12 h followed by addition of NaBH(OAc)3 (3.55 g, 16.8 mmol). The mixture was stirred at °C for l h. The mixture was quenched with saturated NaHCO3 (15 mL) and extracted with DCM (3x10 mL). The combined organic layer was washed with brine (15 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give the title compound (0.90 g, 82%). LC-MS (M+H)+ = 165.2.Step 2: tert-butyl (5,8-dihvdro-6H-pvrano[3,4-b1pvridin-5-vl)(methvl)carbamate 190 WO 2024/199255 PCT/CN2024/083980 BocN/ id="p-457" id="p-457" id="p-457"
id="p-457"
[0457]The title compound (0.40 g, 28%) was prepared in a manner similar to that in Example & Example 40 step 6 from N-methyl-5,8-dihydro-6H-pyrano[3,4-b]pyridin-5-amine. LC-MS (M+H)+ = 265.2.Step 3: 5-((tert-butoxycarbonyl)(methyl)amino)-5,8-dihydro-6H-pyrano[3,4-b]pyridine 1- oxide/ BocN b_ [0458]To a solution of tert-butyl (5,8-dihydro-6H-pyrano[3,4-b]pyridin-5- yl)(methyl)carbamate (0.40 g, 1.51 mmol) in DCM (4 mL) was added mCPBA (85%, 369 mg, 1.82 mmol). The mixture was stirred at 25 °C for 1 h. The mixture was quenched with saturated Na2SO3 (10 mL) and extracted with DCM (3x8 mL). The combined organic layer was washed with brine (12 mL), dried over Na2S04, fdtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EtOAc/MeOH=l/0 to 10/1) to give the title compound (0.32 g, 75%). LC-MS (M+H)+ = 281.2.Step 4: tert-butyl (2-chloro-5,8-dihvdro-6H-pvrano[3,4-b]pvridin-5-vl)(methvl)carbamate / BocN Cl [0459]A solution of 5-((tert-butoxycarbonyl)(methyl)amino)-5,8-dihydro-6H-pyrano[3,4- b]pyridine 1-oxide (0.32 g, 1.14 mmol) in POC13 (4 mL) was stirred at 50 °C for 1 h. The mixture was cooled to room temperature and concentrated under reduced pressure. To the residue was added saturated Na2CO3 (10 mL) at 0 °C, and the mixture was extracted with EtOAc (3x5 mL). The combined organic layer was washed with brine (8 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was re-dissolved in THE (2 mL) followed by addition of B0C20 (165 mg, 755 umol) and DIPEA (130 mg, 1.01 mmol). The mixture was stirred at 25 °C for 12 h and then concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=10/l to 1/1) to give the title compound (60 mg, 18%). LC-MS (M+H)+ = 299.2. 191 WO 2024/199255 PCT/CN2024/083980 Step 5: tert-butyl (2-cyclopropyl-5,8-dihydro-6H-pyrano[3,4-blpyridin-5- yl)(methyl)carbamate BocN id="p-460" id="p-460" id="p-460"
id="p-460"
[0460]To a solution of tert-butyl (2-chloro-5,8-dihydro-6H-pyrano[3,4-b]pyridin-5- yl)(methyl)carbamate (0.10 g, 335 pmol) and cyclopropylboronic acid (86 mg, 1.0 mmol) in dioxane (1 mL), toluene (1 mL) and water (0.5 mL) was added Pd(dppf)C12 (24 mg, 33 umol) and K3PO4 (142 mg, 669 pmol). The mixture was purged with N2 for 3 times and stirred at 90 °C for 12 h. The mixture was cooled to room temperature, diluted with water (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layer was washed with brine (40 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC (PE/EtOAc = 3/1) to give the title compound (50 mg, 49%). LC-MS (M+H)+ = 305.2.Step 6: 2-cyclopropyl-N-methyl-5,8-dihydro-6H-pyrano[3,4-b]pyridin-5-amine hydrochloride id="p-461" id="p-461" id="p-461"
id="p-461"
[0461]The title compound (40 mg, 100%) was prepared in a manner similar to that in Example & Example 40 step 8 from tert-butyl (2-cyclopropyl-5,8-dihydro-6H-pyrano[3,4-b]pyridin-5- yl)(methyl)carbamate. LC-MS (M+H)+ = 205.2.Step 7: 5-amino-N-(2-cvclopropvl-5,8-dihvdro-6H-pvrano[3,4-blpvridin-5-vl)-N-methvl-l- ((2-(trimethvlsilvl)ethoxv)methvl)-6,8-dihvdro-lH-furor3,4-d]pvrrolor3,2-b]pvridine-2- carboxamide id="p-462" id="p-462" id="p-462"
id="p-462"
[0462]The title compound (30 mg, 34%) was prepared in a manner similar to that in Example & Example 74 step 9 from 2-cyclopropyl-N-methyl-5,8-dihydro-6H-pyrano[3,4-b]pyridin-5- amine hydrochloride and 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid. LC-MS (M+H)+ = 536.4. 192 HCI HN WO 2024/199255 PCT/CN2024/083980 Step8:(S)-5-amino-N-(2-cyclopropyl-5,8-dihydro-6H-pyrano[3,4-b]pyridin-5-yl)-N-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolor3,2-b]pyridine-2-carboxamidecyclopropyl-5,8-dihydro-6H-pyranor3,4-b]pyridin-5-yl)-N-methyl-6,8-dihydro-lH-furor3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0463!Example 87 (2 mg, 9%) and Example 88 (1.0 mg, 4%) were prepared in a manner similar to that in Example 73 & Example 74 step 10 from 5-amino-N-(2-cyclopropyl-5,8- dihydro-6H-pyrano[3,4-b]pyridin-5-yl)-N-methyl-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide, and the enantiomers were separated by chiral SFC. [0464]Analytical chiral-SFC condition as below. Column: ChiralPak IH; Column size: 4.6X100 mm, 3 pm; Mobile phase: (isopropanol containing 0.2% 7 M methanolic NH3):CO2 1; 1:9 for 0.2 min, 1:9 to 1:1 in 2.4 min, 1:1 for 1 min, 1:1 to 1:9 in 0.6 min; Flow: 3.4 mL/min; Temperature: 35 °C; back pressure: 2000 psi. [0465]Example 87: Analytical SFC tR=2.301 min. 1H NMR (400 MHz, DMSO- f 3cStep 1: N-ethyl-N-((lR,4S)-l-methyl-7-(trifluoromethvl)isochroman-4-vl)-2- nitrobenzenesulfonamide 193 WO 2024/199255 PCT/CN2024/083980 [0467]The title compound (800 mg, 70%) was prepared in a manner similar to that in Example step 6 from (lR,4R)-l-methyl-7-(trifluoromethyl)isochroman-4-ol and N-ethyl-2- nitrobenzenesulfonamide. LC-MS (M+H)+ = 445.2.Step 2: (lR,4S)-N-ethyl-l-methyl-7-(trifluoromethyl)isochroman-4-amine^NH id="p-468" id="p-468" id="p-468"
id="p-468"
[0468]The title compound (355 mg, 90%) was prepared in a manner similar to that in Example step 7 from N-ethyl-N-((lR,4S)-l-methyl-7-(trifluoromethyl)isochroman-4-yl)-2- nitrobenzenesulfonamide. LC-MS (M+H)+ = 260.2.Step3:5-amino-N-ethyl-N-((1R,4S)-1-methyl-7-(trifluoromethyl)isochroman-4-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-469" id="p-469" id="p-469"
id="p-469"
[0469]The title compound (100 mg, 74%) was prepared in a manner similar to that in Example step 11 from (lR,4S)-N-ethyl-l-methyl-7-(trifluoromethyl)isochroman-4-amine and 5-amino- l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxylic acid. LC-MS (M+H)+ = 591.2.Step4:5-amino-N-ethyl-N-((1R,4S)-1-methyl-7-(trifluoromethyl)isochroman-4-yl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0470]Example 89 (54 mg, 58%) was prepared in a manner similar to that in Example 82 step from 5-amino-N-ethyl-N-((lR,4S)-l-methyl-7-(trifluoromethyl)isochroman-4-yl)-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyn ־olo[3,2-b]pyridine-2- carboxamide. 1H NMR (400 MHz, DMSO-d) 8 11.59 (s, 1H), 7.70 - 7.55 (m, 2H), 7.51 - 7.(m, 1H), 6.62 (s, 1H), 5.60 (s, 1H), 5.56 (s, 2H), 5.19 - 5.11 (m, 2H), 4.93 (t, J= 2.8 Hz, 2H), 4.89 - 4.82 (m, 1H), 4.35 - 4.24 (m, 1H), 4.15 - 4.01 (m, 1H), 3.87 - 3.44 (m, 2H), 1.60 (d, J= 6.5 Hz, 3H), 1.14-1.00 (m, 3H). LC-MS (M+H)+ = 461.2. Example 90:(R)-N-(l-acetyl-7-(trifluoromethyl)-l,2,3,4-tetrahydroquinolin-4-yl)-5-amino- N-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide 194 WO 2024/199255 PCT/CN2024/083980 Step1:(R)-N-(1-acetyl-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-N-methyl-2-nitrobenzenesulfonamide id="p-471" id="p-471" id="p-471"
id="p-471"
[0471]To a solution of (R)-N-methyl-2-nitro-N-(7-(trifluoromethyl)-l,2,3,4- tetrahydroquinolin-2-yl)benzenesulfonamide (574 mg, 1.38 mmol) in DCM (10 mL) was added Et3N (419 mg, 4.15 mmol), and AcCl (162 mg, 2.08 mmol) at 0 °C. The mixture was stirred for h at 25 °C. The mixture was partitioned between water (50 mL) and DCM (50 mL). The organic layers was washed with brine (50 mL), dried over Na2S04, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (DCM:MeOH=30:l) to give the title compound (507 mg, 80%). LC-MS (M+H)+ =458.2.Step 2: (R)-1 -(4-(methylamino)-7-(trifluoromethyl)-3,4-dihydroquinolin- 1 (2H)-yl)ethan- 1 - one HN/ id="p-472" id="p-472" id="p-472"
id="p-472"
[0472]The title compound (200 mg, 66%) was prepared in a manner similar to that in Example 167 & Example 168 step 9 from (R)-N-(l-acetyl-7-(trifluoromethyl)-l,2,3,4-tetrahydroquinolin- 4-yl)-N-methyl-2-nitrobenzenesulfonamide. LC-MS (M+H)+ =273.4.Step 3: (R)-N-( 1 -acetvl-7-(trifluoromethvl)- 1,2,3,4-tetrahvdroquinolin-4-yl)-5-amino-N- methyl-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-blpyridine- 2-carboxamide id="p-473" id="p-473" id="p-473"
id="p-473"
[0473]The title compound (110 mg, 83%) was prepared in a manner similar to that in Example 167 & Example 168 step 10 from (R)-l-(4-(methylamino)-7-(trifluoromethyl)-3,4- 195 WO 2024/199255 PCT/CN2024/083980 dihydroquinolin- 1 (2H)-yl)ethan-l -one and 5-amino- 1 -((2-(trimethylsilyl)ethoxy)methyl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid. LC-MS (M+H)+ =604.3.Step 4: (R)-N-(l-acetyl-7-(trifluoromethyl)-l,2,3,4-tetrahydroquinolin-4-yl)-5-amino-N- methyl-6,8-dihydro- 1 H-furo[3,4-d1 pyrrol 013,2-blpyridine-2-carboxamide [0474!Example 90 (54 mg, 62%) was prepared in a manner similar to that in Example 167 & Example 168 step 11 from (R)-N-(l-acetyl-7-(trifluoromethyl)-l,2,3,4-tetrahydroquinolin-4-yl)- 5-amino-N-methyl-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxamide. 1H NMR (400 MHz, DMSO-d6) S 11.58 (s, 1H), 8.08 (s, 1H), 7.59- 7.12 (m, 2H), 6.92-6.44 (m, 1H), 5.92-5.68 (m, 1H), 5.56 (s, 2H), 5.10 (s, 2H), 4.88 (s, 2H), 4.18-3.88 (m, 1H), 3.75-3.61 (m, 1H), 3.12-2.64 (m, 3H), 2.30-2.00 (m, 5H). LC-MS (M+H)+ =474.3. Example 91:(S)-5-amino-N-methyl-N-(7'-(trifluoromethyl)spiro[cyclopropane- 1,1'- isochroman]-4'-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: l-(2-bromo-5-(trifluoromethyl)phenyl)cyclopropan-l-ol A /0H I J id="p-475" id="p-475" id="p-475"
id="p-475"
[0475]Bis(cyclopentadienyl)zirconium dichloride (4.1 g, 14.1 mmol) was suspended in toluene (30 mL) at 0 °C. EtMgBr in THF (1.0 M, 15 mL, 15.0 mmol) was added dropwise. The mixture was stirred at 0 °C for 1 h, followed by addition of a solution of methyl 2-bromo-5- (trifluoromethyl)benzoate (2.0 g, 7.1 mmol) in toluene (10 mL) dropwise. The mixture was warmed to room temperature and stirred overnight. A solution of NaOH (1 g) in water (10 mL) was added, and the mixture was stirred at room temperature for 30 min. Solid was filtered off, and the solid was rinsed with EtOAc (20 mL). The organic layer of the filtrate was separated, and the aqueous layer was extracted with EtOAc (20 mL). The combined organic layer was washed with water (20 mL), dried with Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 30:1) to give the title compound (760 mg, 38%). LC-MS (M+H)+ = 280.9.Step 2: 2-(l-(allyloxy)cyclopropyl)-l-bromo-4-(trifluoromethyl)benzene 196 WO 2024/199255 PCT/CN2024/083980 id="p-476" id="p-476" id="p-476"
id="p-476"
[0476]To a solution of l-(2-bromo-5-(trifluoromethyl)phenyl)cyclopropan-l-ol (7.7 g, mmol) and allyl bromide (6.6 g, 54 mmol) in DMF (50 mL) was added NaH (60%, 2.2 g, mmol) at 0 °C. The mixture was warmed to room temperature and stirred for 2 h. Water (2mL) was added slowly. Upon cease of bubbling, the mixture was extracted with EtOAc (2mL). The organic layer was washed with brine (100 mL), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 50:1) to give the title compound (3.0 g, 34%).Step3:4 ‘-methylene-7 ‘-(trifluoromethyl)spiro[cyclopropane-1,1 ‘-isochromane] id="p-477" id="p-477" id="p-477"
id="p-477"
[0477]To a solution of 2-( 1-(allyloxy)cyclopropyl)- 1-bromo-4-(trifluoromethyl)benzene (8mg, 25.5 mmol) in DMF (30 mL) was added Pd(OAc)2 (90 mg, 3.8 mmol), PPh3 (312 mg, 11.mmol) and Cs2CO3 (1.0 g, 30.7 mmol) under nitrogen. The mixture was stirred at 90 °C overnight and cooled to room temperature. The mixture was concentrated under reduced pressure and the residue was partitioned between water (20 mL) and EtOAc (30 mL). The organic layer was separated, dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc =30:1) to give the title compound (5mg, 79%).Step 4: 7'-(trifluoromethyl)spiro[cyclopropane-l,l'-isochroman]-4 ’-one id="p-478" id="p-478" id="p-478"
id="p-478"
[0478]To a mixture of 4'-methylene-7'-(trifluoromethyl)spiro[cyclopropane-l,l'-isochromane] (4.1 g, 17 mmol) in dioxane (100 mL) and water (20 mL) was added potassium osmate (VI) dihydrate (620 mg, 0.17 mmol), sodium periodate (14.6 g, 68 mmol) and 2,6-lutidine (3.6 g, mmol). The mixture was stirred at room temperature for 2 h, and then solid was filtered off. The filtrate was extracted with EtOAc (20 mL). The organic layer was washed with water (20 mL), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified 197 WO 2024/199255 PCT/CN2024/083980 by silica gel chromatography (PE/EtOAc =10:1) to give the title compound (1.8 g, 43%). LC-MS (M+H)+ = 243.0.Step5:(R)-7 ‘-(trifluoromethyl)spiro[cyclopropane-1,1 ‘-isochroman]-4 ‘-ol f 3c id="p-479" id="p-479" id="p-479"
id="p-479"
[0479]To a solution of (R)-l-methyl-3,3-diphenylhexahydropyrrolo[l,2-c][l,3,2]oxazaborole (203 mg, 0.73 mmol) in THE (30 mL) was added and BH3 in THE (1.0 M, 7.7 mL, 7.7 mmol) at °C. A solution of 7'-(trifluoromethyl)spiro[cyclopropane-l,r-isochroman]-4'-one (1.77 g, 7.mmol) in THE (5 mL) was added dropwise under nitrogen. The mixture was stirred for 10 min at °C. MeOH (5 mL) was added dropwise. Upon cease of bubbling, the mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 10:1 to 5:1) to give the title compound (1.8 g, 100%). LC-MS (M+H)+ = 245.0.Step 6: (S)-N-methyl-2-nitro-N-(7'-(trifluoromethyl)spiro[cyclopropane- 1,1 ‘-isochroman]- 4'-yl)benzenesulfonamide id="p-480" id="p-480" id="p-480"
id="p-480"
[0480]To a mixture of (R)-7'-(trifluoromethy !)spiro [cyclopropane-l,l'-isochroman]-4'-ol (8mg, 3.4 mmol) in THE (30 mL) was added N-methyl-2-nitro-benzenesulfonamide (735 mg, 3.mmol), DtBAD (860 mg, 3.7 mmol) and PPh3 (980 mg, 3.7 mmol) under nitrogen. The mixture was stirred at room temperature for 1 h and then concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 10:1 to 5:1) to give the title compound, and the material (2.2 g) was used in step 7. LC-MS (M+H)+ = 443.0.Step 1: (S)-N-methyl-7Mtrifluoromethyl)spiro[cyclopropane- 1,1 '-isochromanl-4'-amine id="p-481" id="p-481" id="p-481"
id="p-481"
[0481]A mixture of (S)-N-methyl-2-nitro-N-(7'-(trifluoromethyl)spiro[cyclopropane-l,l'- isochroman]-4'-yl)benzenesulfonamide (2.2 g from step 6), lithium hydroxide monohydrate (6mg, 15 mmol) and dodecane- 1-thiol (3.0 g, 15 mmol) in THE (40 mL) and DMF (10 mL) was stirred at room temperature for overnight. The mixture was concentrated under reduced pressure. The residue was partitioned between water (30 mL) and EtOAc (30 mL). The organic layer was 198 WO 2024/199255 PCT/CN2024/083980 dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 2:1 to 0:1) to give the title compound (630 mg, 70% over two steps). LC-MS (M+H)+ = 258.2.Step 8: (S)-5-amino-N-methyl-N-(7'-(trifluoromethyl)spirorcyclopropane- 1,1 ‘-isochroman]- 4'-yl)-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-dlpyrrolo[3,2-b]pyridine-2- carboxamide nh 2 [0482]To a mixture of 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid (855 mg, 2.5 mmol) and (S)-N-methyl-7'- (trifluoromethyl)spiro[cyclopropane-l,l'-isochroman]-4'-amine (630 mg, 2.5 mmol) in THE (mL) was added BOPCI (810 mg, 3.2 mmol) and DIPEA (1.3 mL, 7.4 mmol). The mixture was stirred at 60 °C for 2 h and cooled to room temperature. The mixture was diluted with water (mL) and extracted with EtOAc (30 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM/MeOH = 30:1) to give the title compound (1.4 g, 97%). LC-MS (M+H)+ = 589.2.Step 9: (S)-5-amino-N-methyl-N-(7'-(trifluoromethyl)spiro[cyclopropane- 1,1 ‘-isochroman]- 4'-yl)-6,8-dihydro-lH-furo[3,4-dlpyrrolo[3,2-blpyridine-2-carboxamide [0483]To a solution of (S)-5-amino-N-methyl-N-(7'-(trifluoromethyl)spiro[cyclopropane-l,l'- isochroman]-4'-yl)-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxamide (1.4 g, 2.4 mmol) in DCM (10 mL) was added TEA (5 mL). The mixture was stirred at room temperature for l h. The mixture was concentrated under reduced pressure. The residue was re-dissolved in MeOH (20 mL) followed by addition of strong ammonia solution (28%, 5 mL). The mixture was stirred at room temperature for 30 min. The mixture was concentrated under reduced pressure. The residue was partitioned between EtOAc (30 mL) and water (20 mL). The organic layer was concentrated under reduced pressure and the residue was purified by silica gel chromatography (DCM:MeOH = 30:1) to give Example (554 mg, 50%). 1H NMR (400 MHz, DMSO-t/6) 5 11.61 (s, 1H), 7.59 (d,J=8.1 Hz, 1H), 7.(br s, 1H), 7.15 (s, 1H), 6.81 - 6.49 (m, 1H), 5.89 (s, 1H), 5.59 (s, 2H), 5.14 (s, 2H), 4.91 (s, 2H), 4.48 - 3.94 (m, 2H), 3.19 - 2.67 (m, 3H), 1.43 - 1.06 (m, 4H). LC-MS (M+H)+ = 459.2. 199 WO 2024/199255 PCT/CN2024/083980 Example 92:(S)-5-amino-3-cyano-N-methyl-N-(7-(trifluoromethyl)isochroman-4-yl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamideNCN NH2 f 3cStep 1: ethyl 5-(bis(tert-butoxycarbonyl)amino)-1-((2-(trimethylsilyl)ethoxy) methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylate SEM id="p-484" id="p-484" id="p-484"
id="p-484"
[0484]To a mixture of ethyl 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylate (2.2 g, 5.8 mmol) and Et3N (6.06 g, 60 mmol) and DMAP (73 mg, 0.6 mmol) in DCM (100 mL) was added (Boc)2O (13.0 g, 60 mmol). The mixture was stirred at room temperature for 12 h. Water (250 mL) was added and the organic layer was separated. The aqueous layer was extracted with DCM (2 x 100 mL). The combined organic layer was dried with Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE:EtOAc = 20:1) to give the title compound (2.4 g, 71%).Step 2: ethyl 5-(bis(tert-butoxycarbonyl)amino)-3-bromo-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylate Br°x XN.N(Boc)Hj T /—oSEM T ) id="p-485" id="p-485" id="p-485"
id="p-485"
[0485]To a mixture of ethyl 5-(bis(tert-butoxycarbonyl)amino)-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylate (2.4 g, 4.2 mmol) in MeCN (20 mL) was added NBS (756 mg, 4.2 mmol) and the mixture was stirred at 50 °C for 2 h. The mixture was cooled to room temperature and diluted with water (1mL). The mixture was extracted with DCM (2 x 100 mL). The combined organic layer was dried with Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE:EtOAc = 20:1) to give the title compound (2.4 g, 87%). LC-MS (M+H)+= 656.1. 200 N N(Boc) 2 WO 2024/199255 PCT/CN2024/083980 Step 3: ethyl 5-amino-3-cyano-1-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-1H- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylateNC N SEM id="p-486" id="p-486" id="p-486"
id="p-486"
[0486]To a mixture of ethyl 5-(bis(tert-butoxycarbonyl)amino)-3-bromo-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylate (1.7 g, 2.6 mmol) in NMP (15 mL) was added Zn(CN)2 (620 mg, 5.3 mmol) and Pd(PPh3)4 (2mg, 0.26 mmol) and the mixture was stirred at 140 °C for 3 h under nitrogen. The mixture was cooled to room temperature and diluted with water (150 mL). The mixture was extracted with EtOAc (3 x 50 mL). The combined organic layer was dried with Na2SO4, filtered and concentrated under reduced pressure to give the title compound (200 mg, 19%). LC-MS (M+H)+ = 403.2.Step 4: 5-amino-3-cyano-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- dlpyrrolo[3,2-blpyridine-2-carboxylic acid id="p-487" id="p-487" id="p-487"
id="p-487"
[0487]The title compound (350 mg, 96%) was prepared in a manner similar to that in Example step 4 from ethyl 5-amino-3-cyano-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylate. LC-MS (M+H)+ = 375.2.Step 5: (S)-5-amino-3-cyano-N-methyl-N-(7-(trifluoromethyl)isochroman-4-yl)- 1 -((2- (trimethvlsilvl)ethoxv)methvl)-6,8-dihvdro-lH-furo[3,4-d]pv1Tolo[3,2-b]pvridine-2-carboxamide N NH2 N SEM id="p-488" id="p-488" id="p-488"
id="p-488"
[0488]The title compound (50 mg, 64%) was prepared in a manner similar to that in Example step 2 from 5-amino-3-cyano-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and (S)-N-methyl-7-(trifluoromethyl)isochroman-4- amine hydrochloride. LC-MS (M+H)+ = 588.4. 201 N־^SEM WO 2024/199255 PCT/CN2024/083980 Step6:(S)-5-amino-3-cyano-N-methyl-N-(7-(trifluoromethyl)isochroman-4-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolor3,2-b]pyridine-2-carboxamide [0489]Example 92 (23 mg, 59%) was prepared in a manner similar to that in Example 66 stepfrom (S)-5-amino-3-cyano-N-methyl-N-(7-(trifluoromethyl)isochroman-4-yl)-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide. 1H NMR (400 MHz, DMSO-t/6) 5 12.69 (s, 1H), 7.75 - 7.42 (m, 3H), 6.12 (s, 2H), 5.68 (s, 1H), 5.15 (s, 2H), 4.98 - 4.62 (m, 4H), 4.13 (s, 2H), 2.86 (s, 3H). LC-MS (M+H)+ = 458.4. Example 93 & Example 94:5-amino-N-((lS,4S)-l-ethyl-7-(trifluoromethyl)isochroman- 4-yl)-N-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & 5-amino-N- ((lR,4S)-l-ethyl-7-(trifluoromethyl)isochroman-4-yl)-N-methyl-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: l-(2-bromo-5-(trifluoromethyl)phenyl)propan-l-olf 3c id="p-490" id="p-490" id="p-490"
id="p-490"
[0490]The title compound (4.8 g, 43%) was prepared in a manner similar to that in Example & Example 58 & Example 59 & Example 60 step 1 from 2-bromo-5- (trifluoromethyl)benzaldehyde and EtMgBr. LC-MS (M+H)+ =283.3.Step 2: 2-( 1 -(allyloxy)propyl)- 1 -bromo-4-(trifluoromethyl)benzene id="p-491" id="p-491" id="p-491"
id="p-491"
[0491]The title compound (5.4 g, 99%) was prepared in a manner similar to that in Example & Example 40 step 1 from l-(2-bromo-5-(trifluoromethyl)phenyl)propan-l-ol and allyl bromide. LC-MS (M+H)+ =323.1.Step 3: l-ethyl-4-methylene-7-(trifluoromethyl)isochromane 202 Nnh 2 WO 2024/199255 PCT/CN2024/083980 id="p-492" id="p-492" id="p-492"
id="p-492"
[0492]The title compound (2.5 g, 61%) was prepared in a manner similar to that in Example & Example 40 step 2 from 2-(l-(allyloxy)propyl)-l-bromo-4-(trifluoromethyl)benzene. LC- MS (M+H)+=243.3.Step 4: l-ethyl-7-(trifluoromethyl)isochroman-4-one id="p-493" id="p-493" id="p-493"
id="p-493"
[0493]The title compound (2.1 g, 84%) was prepared in a manner similar to that in Example & Example 40 step 3 from l-ethyl-4-methylene-7-(trifluoromethyl)isochromane. LC-MS (M+H)+ =245.4.Step 5: (4R)-l-ethyl-7-(trifluoromethyl)isochroman-4-ol id="p-494" id="p-494" id="p-494"
id="p-494"
[0494]The title compound (2.1 g, 100%) was prepared in a manner similar to that in Example step 5 from l-ethyl-7-(trifluoromethyl)isochroman-4-one. LC-MS (M+H)+ =247.1.Step 6: N-((4S)-l-ethvl-7-(trifluoromethvl)isochroman-4-vl)-N-methvl-2-nitrobenzenesulfonamide id="p-495" id="p-495" id="p-495"
id="p-495"
[0495]The title compound (3.8 g, 100%) was prepared in a manner similar to that in Example step 6 from (4R)-l-ethyl-7-(trifluoromethyl)isochroman-4-ol and N-methyl-2-nitro- benzenesulfonamide. LC-MS (M+H)+ =445.3.Step 1: (4S)-1 -ethyl-N-methyl-7-(trifluoromethyl)isochroman-4-amine 203 WO 2024/199255 PCT/CN2024/083980 id="p-496" id="p-496" id="p-496"
id="p-496"
[0496]The title compound (1.7 g, 77%) was prepared in a manner similar to that in Example step 7 from N-((4S)-l-ethyl-7-(trifluoromethyl)isochroman-4-yl)-N-methyl-2- nitrobenzenesulfonamide. LC-MS (M+H)+ =260.2.Step 8: 5-amino-N-((lS,4S)-l-ethyl-7-(trifluoromethyl)isochroman-4-yl)-N-methyl-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & 5-amino-N-((lR,4S)-l-ethyl-7- (trifluoromethyl)isochroman-4-yl)-N-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-blpyridine- 2-carboxamide [0497]To a mixture of 5-amino-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxylic acid (120 mg, 0.54 mmol), (4S)-l-ethyl-N-methyl-7-(trifluoromethyl)isochroman-4- amine (141 mg, 0.54 mmol) and DIPEA (492 mg, 3.82 mmol) in anhydrous DMF (5 mL) under nitrogen was added T3P (867 mg, 2.73 mmol) and the mixture was stirred at 60 °C for 16 h. The mixture was cooled to room temperature followed by addition of hydrochloric acid HC1 (6 M, mL). The mixture was stirred for 3 h at 60 °C. The mixture was cooled to room temperature and poured into saturated NaHCO3 (100 mL). The mixture was extracted with EtOAc (100 mL). The organic layer was washed with brine (100 mL), dried over Na2S04, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (DCM:MeOH = 20:1), followed by chiral SEC to give Example 93 (34 mg, 13%) and Example 94 (36 mg, 14%). [0498]Analytical chiral-SFC condition as below. Column: YMC Cellulose-C; Column size: 4.6X100 mm, 5 pm; Mobile phase: 4 mM methanolic NH3:CO2, 1:9 to 4:6 in 3 min, 4:6 for min, 4:6 to 1:9 in 0.1 min, 1:9 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; back pressure: 1500 psi. [0499]Example 93: Analytical SFC tR=4.09 min. 1H NMR (400 MHz, DMSO-d) 8 11.60 (s, 1H), 7.62 (s, 2H), 7.48 - 7.33 (m, 1H), 6.75 - 6.50 (m, 1H), 5.91 - 5.46 (m, 3H), 5.14 (s, 2H), 5.01 - 4.77 (m, 3H), 4.25 - 4.12 (m, 1H), 4.01 - 3.81 (m, 1H), 3.02 (s, 3H), 2.04 - 1.75 (m, 2H), 0.98 - 0.83 (m, 3H). LCMS (M+H)+ = 461.4. [0500]Example 94: Analytical SFC tR=4.97 min. 1H NMR (400 MHz, DMSO- WO 2024/199255 PCT/CN2024/083980 Step 1: methyl 2-amino-5-cyclopropyl-3-fluorobenzoate id="p-501" id="p-501" id="p-501"
id="p-501"
[0501]The title compound (22 g, 43%) was prepared in a manner similar to that in Example & Example 88 step 5 from methyl 2-amino-5 -bromo-3-fluoro-benzoate and cyclopropylboronic acid. LC-MS (M+H)+ = 210.2.Step 2: methyl 2-bromo-5-cyclopropyl-3-fluorobenzoate id="p-502" id="p-502" id="p-502"
id="p-502"
[0502]The title compound (22 g, 77%) was prepared in a manner similar to that in Example step 3 from methyl 2-amino-5-cyclopropyl-3-fluorobenzoate. 1H NMR (400 MHz, CDC13) 8 7.- 7.29 (m, 1H), 6.93 (dd, J=9.5, 2.1 Hz, 1H), 3.94 (s, 3H), 1.95 - 1.84 (m, 1H), 1.08 - 1.02 (m, 2H) 0.74 - 0.70 (m, 2H).Step 3: (2-bromo-5-cvclopropyl-3-fluorophenvl)methanol id="p-503" id="p-503" id="p-503"
id="p-503"
[0503]The title compound (3.55 g, 79%) was prepared in a manner similar to that in Example step 4 from methyl 2-bromo-5-cyclopropyl-3-fluorobenzoate. 1H NMR (400 MHz, CDC13) 7.05 - 7.01 (m, 1H) 6.76 (dd, J= 9.5, 2.0 Hz, 1H), 4.75 - 4.72 (m, 2H), 2.19-1.62 (m, 2H), 1.- 0.99 (m, 2H), 0.74 - 0.68 (m, 2H).Step 4: 1 -((allyloxv)methyl)-2-bromo-5-cvclopropyl-3-fluorobenzene 205 F. Br F Br WO 2024/199255 PCT/CN2024/083980 [0504]The title compound (3.37 g, 82%) was prepared in a manner similar to that in Example step 5 from (2-bromo-5-cyclopropyl-3-fluorophenyl)methanol and allyl bromide. 1H NMR (400 MHz, CDC13) 5 7.07 - 7.02 (m, 1H), 6.74 (dd, J= 9.7, 2.0 Hz, 1H), 6.05 - 5.94 (m, 1H), 5.36 (dd, 17.3, 1.6 Hz, 1H), 5.25 (dd,J=10.4, 1.3 Hz, 1H), 4.56 (s, 2H), 4.14-4.10 (m, 2H), 1.92 - 1.85 (m, 1H), 1.05 - 0.98 (m, 2H), 0.73 - 0.67 (m, 2H).Step 5: 7-cyclopropyl-5-fluoro-4-methyleneisochromane id="p-505" id="p-505" id="p-505"
id="p-505"
[0505]The title compound (3.9 g, 45%) was prepared in a manner similar to that in Example step 6 from l-((allyloxy)methyl)-2-bromo-5-cyclopropyl-3-fluorobenzene. EC-MS (M+H)+ = 205.2.Step 6: 7-cyclopropyl-5-fluoroisochroman-4-one id="p-506" id="p-506" id="p-506"
id="p-506"
[0506]The title compound (1.6 g, 53%) was prepared in a manner similar to that in Example step 7 from 7-cyclopropyl-5-fluoro-4-methyleneisochromane. 1H NMR (400 MHz, CDC13) 6.74 - 6.68 (m, 2H), 4.81 (s, 2H), 4.29 (s, 2H), 1.97 - 1.87 (m, 1H), 1.16 - 1.10 (m, 2H), 0.83 - 0.77 (m, 2H). LC-MS (M+H)+ = 207.2.Step 7: (R)-7-cyclopropyl-5-fluoroisochroman-4-olHO id="p-507" id="p-507" id="p-507"
id="p-507"
[0507]The title compound (1.6 g, 53%) was prepared in a manner similar to that in Example step 1 from 7-cyclopropyl-5-fluoroisochroman-4-one. 1H NMR (400 MHz, CDC13) 8 6.65 (d, J=10.9Hz, 1H), 6.54 (s, 1H), 4.78 - 4.67 (m, 2H), 4.65 - 4.53 (m, 1H), 4.18 (dd, J = 12.2, 1.Hz, 1H), 3.75 (dd, J= 12.2, 2.2 Hz, 1H), 1.90 - 1.81 (m, 1H), 1.07 - 0.91(m, 2H), 0.74 - 0.62 (m, 2H). LC-MS (M+H-H2O)+ =191.2.Step 8: (S)-4-azido-7-cyclopropyl-5-fluoroisochromane 206 WO 2024/199255 PCT/CN2024/083980 N3 id="p-508" id="p-508" id="p-508"
id="p-508"
[0508]The title compound (1.18 g, 81%) was prepared in a manner similar to that in Example & Example 79 & Example 80 & Example 81 step 6 from (R)-7-cyclopropyl-5- fluoroisochroman-4-ol. 1H NMR (400 MHz, CDCI3) 8 6.62 (d, J= 10.6 Hz, 1H), 6.53 (s, 1H), 4.77, 4.56 (ABq, <7=15.4 Hz, 2H), 4.35 - 4.29 (m, 1H), 4.25 - 4.14 (m, 1H), 3.72 - 3.68 (m, 1H), 1.85 - 1.75 (m, 1H), 0.97 - 0.91 (m, 2H), 0.66 - 0.60 (m, 2H).Step 9: (S)-7-cyclopropyl-5-fluoroisochroman-4-amineh2n id="p-509" id="p-509" id="p-509"
id="p-509"
[0509]The title compound (1.5 g, 99%) was prepared in a manner similar to that in Example & Example 79 & Example 80 & Example 81 step 7 from (S)-4-azido-7-cyclopropyl-5- fluoroisochromane. LC-MS (M+H)+ = 208.2.Step 10: tert-butyl (S)-(7-cvclopropyl-5-fluoroisochroman-4-yl)carbamateBocHN id="p-510" id="p-510" id="p-510"
id="p-510"
[0510]The title compound (1.4 g, 63%) was prepared in a manner similar to that in Example & Example 40 step 6 from (S)-7-cyclopropyl-5-fluoroisochroman-4-amine. LCMS (M+H- tBu) + = 252.1.Step 11: tert-butyl (S)-(7-cyclopropyl-5-fluoroisochroman-4-yl)(methyl)carbamate Body id="p-511" id="p-511" id="p-511"
id="p-511"
[0511]The title compound (360 mg, 86%) was prepared in a manner similar to that in Example & Example 40 step 7 from tert-butyl (S)-(7-cyclopropyl-5-fluoroisochroman-4-yl)carbamate and Mel. LCMS (M+H-tBu) + = 266.2. 207 WO 2024/199255 PCT/CN2024/083980 Step 12: (S)-7-cyclopropyl-5-fluoro-N-methylisochroman-4-amine hydrochloride/ HN id="p-512" id="p-512" id="p-512"
id="p-512"
[0512]The title compound (60 mg, 99%) was prepared in a manner similar to that in Example & Example 40 step 8 from tert-butyl (S)-(7-cyclopropyl-5-fluoroisochroman-4- yl)(methyl)carbamate. LC-MS (M+H)+ = 222.2.Step 13: tert-butyl (S)-(2-((7-cyclopropyl-5-fluoroisochroman-4-yl)(methyl)carbamoyl)-6,8-dihydro-lH-furor3,4-d]pyrrolo[3,2-blpyridin-5-yl)carbamate NHBoc [0513]The title compound (110 mg, 78%) was prepared in a manner similar to that in Example step 4 from (S)-7-cyclopropyl-5-fluoro-N-methylisochroman-4-amine hydrochloride and 5- ((tert-butoxycarbonyl)amino)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid. LC-MS (M+H)+ = 523.3.Step 14: (S)-5-amino-N-(7-cyclopropyl-5-fluoroisochroman-4-yl)-N-methyl-6,8-dihydro-H-furo [ 3,4-d]pyrrolo [ 3,2-b]pyridine-2-carboxamide [0514]To a solution of tert-butyl (S)-(2-((7-cyclopropyl-5-fluoroisochroman-4- yl)(methyl)carbamoyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-5-yl)carbamate (90 mg, 172 umol) in DCM (3 mL) was added ZnBr2 (388 mg, 1.72 mmol). The mixture was stirred at °C for 2 h. The mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC to give Example 95 (30 mg, 41%). 1H NMR (400 MHz, DMSO-d) 8 11.54 (br s, 1H), 6.89 - 6.42 (m, 3H), 5.71 (br s, 1H), 5.55 (s, 2H), 5.15 (s, 2H), 4.93 (s, 2H), 4.86 - 4.80 (m, 1H), 4.62 - 4.55 (m, 1H), 4.15 - 3.90 (m, 2H), 3.20 -2.70 (m, 3H), 1.98 - 1.85 (m, 1H), 0.99 - 0.87 (m, 2H), 0.76 - 0.62 (m, 2H). LC-MS (M+H)+ = 423.2. Example 96:(S)-5-amino-N-(7-bromo-5-fluoroisochroman-4-yl)-N-methyl-6,8-dihydro- lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide 208 WO 2024/199255 PCT/CN2024/083980 Step 1: methyl 4-bromo-2-(bromomethyl)-6-fluorobenzoate COMe id="p-515" id="p-515" id="p-515"
id="p-515"
[0515]To a solution of methyl 4-bromo-2-fluoro-6-methyl-benzoate (50 g, 202.38 mmol) in CC14 (500 ml) was added AIBN (3.32 g, 20.2 mmol) and NBS (39.6 g, 223 mmol). The mixture was stirred at 100 °C for 24 h and then cooled to room temperature. The mixture was concentrated under reduced pressure. n-Hexane (300 mL) was added to the residue, and then the mixture was stirred at 25 °C for 30 min. Solid was filtered off and the filtrate was concentrated in vacuum to give the title compound (42 g, 64%). 1H NMR (400 MHz, CDCI3) S 7.35 - 7.29 (m, 1H), 7.21 (dd, J=9.0, 1.8 Hz, 1H), 4.53 (s, 2H), 3.90 (s, 3H).Step 2: methyl 4-bromo-2-fluoro-6-((2-methoxy-2-oxoethoxy)methyl)benzoate CO2MeO^^CC^Me id="p-516" id="p-516" id="p-516"
id="p-516"
[0516]The title compound (22 g, 51%) was prepared in a manner similar to that in Example & Example 74 step 2 from methyl 4-bromo-2-(bromomethyl)-6-fluorobenzoate and methyl 2- hydroxyacetate. ,H NMR (400 MHz, CDCI) 8 7.71 (dd, J=9.4, 1.8 Hz, 1H), 7.62 - 7.58 (m, 1H), 4.67 (s, 2H), 4.19 (s, 2H), 3.86 (s, 3H), 3.68 (s, 3H).Step 3: methyl 7-bromo-5-fluoro-4-oxoisochromane-3-carboxylate id="p-517" id="p-517" id="p-517"
id="p-517"
[0517]A solution of LiHMDS in THE (1 M, 22.4 mL, 22.4 mmol) was diluted with THE (1mL), and to the solution was added a solution of methyl 4-bromo-2-fluoro-6-((2-methoxy-2- oxoethoxy)methyl)benzoate (5.0 g, 15 mmol) in THE (100 mL). The mixture was stirred at °C for 12 h. The reaction mixture was poured into iced water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layer was washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=l/0 to 5/1) to give the title compound (3.25 g, 72%).Step 4: 7-bromo-5-fluoroisochroman-4-one 209 CO2Me WO 2024/199255 PCT/CN2024/083980 [0518]To a solution of methyl 7-bromo-5-fluoro-4-oxoisochromane-3-carboxylate (13 g, 42.mmol) in HO Ac (100 mL) was added concentrated HC1 (33 mL) at 25 °C and the mixture was stirred at 25 °C for 12 h. The mixture was extracted with PE:EtOAc=10:l (40 mL). The organic layer was concentrated in vacuum to give the title compound (6.0 g, 57%). LC-MS (M+H)+ = 245.0.Step 5: (R)-7-bromo-5-fluoroisochroman-4-ol id="p-519" id="p-519" id="p-519"
id="p-519"
[0519]The title compound (1.0 g, 65%) was prepared in a manner similar to that in Example step 1 from 7-bromo-5-fluoroisochroman-4-one. 1HNMR (400 MHz, DMSO-t/6) 8 7.38 (d, .7=9.2 Hz, 1H), 7.21 (s, 1H), 5.45 (d, J= 6.4 Hz, 1H), 4.75 (d, J= 15.6 Hz, 1H), 4.60 - 4.46 (m, 2H), 3.91 (dd, J= 16.0, 2.0 Hz, 1H), 3.68 (dd, J= 16.0, 2.0 Hz, 1H).Step 6: (S)-4-azido-7-bromo-5-fluoroisochromane id="p-520" id="p-520" id="p-520"
id="p-520"
[0520]The title compound (0.54 g, 74%) was prepared in a manner similar to that in Example & Example 79 & Example 80 & Example 81 step 6 from (R)-7-bromo-5-fluoroisochroman-4- 01.1H NMR (400 MHz, DMSO-d) 8 7.56 (d, J= 9.2 Hz, 1H), 7.34 (s, 1H), 4.85 (d, J= 16.0 Hz, 1H), 4.62 (d, J= 16.0 Hz, 1H), 4.58 - 4.53 (m, 1H), 4.18 (d, J= 12.4 Hz, 1H), 3.84 (dd, J= 12.4, 2.6 Hz, 1H).Step 7: (S)-7-bromo-5-fluoroisochroman-4-amineH2N id="p-521" id="p-521" id="p-521"
id="p-521"
[0521]The title compound (1.5 g, 99%) was prepared in a manner similar to that in Example & Example 79 & Example 80 & Example 81 step 7 from (S)-4-azido-7-bromo-5- fluoroisochromane. LCMS (M+H)+ = 246.0.Step 8: tert-butyl (S)-(7-bromo-5-fluoroisochroman-4-yl)carbamateBocHN E '/— 210 WO 2024/199255 PCT/CN2024/083980 [0522]The title compound (0.15 g, 18%) was prepared in a manner similar to that in Example & Example 40 step 6 from (S)-7-bromo-5-fluoroisochroman-4-amine. LCMS (M+H-tBu) + = 290.1.Step 9: tert-butyl (S)-(7-bromo-5-fluoroisochroman-4-yl)(methyl)carbamate/ BocN F 7---- Br [0523]The title compound (0.10 g, 64%) was prepared in a manner similar to that in Example & Example 40 step 7 from tert-butyl (S)-(7-bromo-5-fluoroisochroman-4-yl)carbamate and Mel. LCMS (M+H-tBu) + = 304.0.Step 10: (S)-7-bromo-5-fluoro-N-methylisochroman-4-amine hydrochloride id="p-524" id="p-524" id="p-524"
id="p-524"
[0524]The title compound (130 mg, 99%) was prepared in a manner similar to that in Example & Example 40 step 8 from tert-butyl (S)-(7-bromo-5-fluoroisochroman-4- yl)(methyl)carbamate. LC-MS (M+H)+ = 260.0.Step 11: (S)-5-amino-N-(7-bromo-5-fluoroisochroman-4-yl)-N-methyl-l-((2-(trimethvlsilvl)ethoxv)methvl)-6,8-dihvdro-lH-furo[3,4-d]pv1Tolo[3,2-b]pvridine-2-carboxamide id="p-525" id="p-525" id="p-525"
id="p-525"
[0525]The title compound (100 mg, 34%) was prepared in a manner similar to that in Example & Example 74 step 9 from (S)-7-bromo-5-fluoro-N-methylisochroman-4-amine hydrochloride and 5-amino- 1 -((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro- 1 H-furo[3 ,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid. LC-MS (M+H)+ = 591.2.Step 12: (S)-5-amino-N-(7-bromo-5-fluoroisochroman-4-yl)-N-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0526]Example 96 (34 mg, 42%) was prepared in a manner similar to that in Example 66 stepfrom (S)-5-amino-N-(7-bromo-5-fluoroisochroman-4-yl)-N-methyl-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide. 1H NMR (400 MHz, DMSO-d6) 8 11.55 (s, 1H), 7.47 (d, J = 8.6 Hz, 1H), 7.35 (s, 211 WO 2024/199255 PCT/CN2024/083980 1H), 6.73 - 6.47 (m, 1H), 5.74 (br s, 1H), 5.55 (s, 2H), 5.21 - 5.09 (m, 2H), 4.96 - 4.86 (m, 3H), 4.63 (d, J= 15.4 Hz, 1H), 4.27 - 3.93 (m, 2H), 3.13 - 2.71 (m, 3H), LC-MS (M+H)+ = 461.1. Example 97:(S)-5-amino-N-(7-cyano-5-fluoroisochroman-4-yl)-N-methyl-6,8-dihydro- lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: tert-butyl (S)-(7-cyano-5-fluoroisochroman-4-yl)(methyl)carbamate NC [0527]To a solution of tert-butyl (S)-(7-bromo-5-fluoroisochroman-4-yl)(methyl)carbamate (0.10 g, 278 umol) in DMF (1 mL) was added Zn(CN)2 (49 mg, 416 umol) and Pd(PPh3)4 (mg, 28 umol). The mixture was stirred at 130 °C for 12 h and then cooled to room temperature. The mixture was poured into iced water (10 mL) and extracted with EtOAc (3x10 mL). The combined organic layer was washed with brine (10 mL), dried over Na2S04, filtered and concentrated under reduced pressure to give the title compound (20 mg, 23%). LCMS (M+H- tBu) + = 251.1.Step 2: (S)-5-fluoro-4-(methylamino)isochromane-7-carbonitrile hydrochloride HN/ NC HCI [0528]The title compound (37 mg, 79%) was prepared in a manner similar to that in Example & Example 40 step 8 from tert-butyl (S)-(7-cyano-5-fluoroisochroman-4- yl)(methyl)carbamate. LC-MS (M+H)+ = 207.2.Step 3: (S)-5-amino-N-(7-cyano-5-fluoroisochroman-4-yl)-N-methyl-l-((2- (trimethylsilyl)ethoxv)methyl)-6,8-dihvdro-lH-furo[3,4-d1pyrrolor3,2-b1pvridine-2-carboxamide 212 WO 2024/199255 PCT/CN2024/083980 [0529]The title compound (90 mg, 93%) was prepared in a manner similar to that in Example & Example 74 step 9 from (S)-5-fluoro-4-(methylamino)isochromane-7-carbonitrile hydrochloride and 5-amino- 1 -((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro- 1 H-furo[3 ,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid. LC-MS (M+H)+ = 538.3.Step4:(S)-5-amino-N-(7-cyano-5-fluoroisochroman-4-yl)-N-methyl-6,8-dihydro-1H- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0530]Example 97 (14 mg, 21%) was prepared in a manner similar to that in Example 66 step from (S)-5-amino-N-(7-cyano-5-fluoroisochroman-4-yl)-N-methyl-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide. 1H NMR (400 MHz, DMSO-t/6) 5 11.63 (br s, 1H), 7.81 - 7.72 (m, 1H), 7.64 (s, 1H), 6.71 - 6.46 (m, 1H), 5.84 - 5.75 (m, 1H), 5.56 (br s, 2H), 5.23 - 5.07 (m, 2H), 5.01 - 4.(m, 3H), 4.67 (d, J= 16.0 Hz, 1H), 4.22 - 3.97 (m, 2H), 3.12 - 2.71 (m, 3H), LC-MS (M+H)+ = 408.1. Example 98 and Example 99:(S)-N-(2-acetyl-7-(trifluoromethyl)-l,2,3,4- tetrahydroisoquinolin-4-yl)-5-amino-N-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxamide & (R)-N-(2-acetyl-7-(trifluoromethyl)- 1,2,3,4-tetrahydroisoquinolin- 4-yl)-5-amino-N-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: ethyl 2-(bromomethyl)-4-(trifluoromethyl)benzoate id="p-531" id="p-531" id="p-531"
id="p-531"
[0531]To a solution of ethyl 2-methyl-4-(trifluoromethyl)benzoate (11 g, 47.4 mmol) in CC(150 mL) was added NBS (8.43 g, 47.4mmol) and AIBN (200 mg, 1.2 mmol). The resulting mixture was heated to reflux and stirred for 16 h. The mixture was cooled to 0 °C and the solid was filtered off. The filtrate was diluted with DCM (200 mL) and successively washed with NaOH (1 M, 100 mL), saturated NaHCO (100 mL) and brine (100 mL). The organic layer was dried over anhydrous Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=10/l) to give the title compound (12 g, 82%). LC-MS (M+H)+= 311.2. 213 WO 2024/199255 PCT/CN2024/083980 Step 2: ethyl 2-((benzyl(2-ethoxy-2-oxoethyl)amino)methyl)-4-(trifluoromethyl)benzoateO BnNCOOEt [0532]To a mixture of ethyl 2-(bromomethyl)-4-(trifluoromethyl)benzoate (12 g, 38.7 mmol), ethyl benzylglycinate (11.2 g, 58 mmol) in THF (200 mL) was added Et3N (5.9 mL, 58 mmol) and the mixture was heated to reflux and stirred for 2 h. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was partitioned between EtOAc (200 mL) and saturated NaHCO3. The aqueous layer was extracted with EtOAc (2 x 2mE). The combined organic layer was concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc= 5/1) to give the title compound (10 g, 61%). LC-MS (M+H)+ = 424.2.Step 3: ethyl 2-benzyl-4-oxo-7-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylateO ^^??.COOEt r/C3C/N' F3C Bn [0533]To a solution of ethyl 2-((benzyl(2-ethoxy-2-oxoethyl)amino)methyl)-4- (trifluoromethyl)benzoate (10 g, 23.5 mmol) in toluene (50 mL) was added NaOEt in EtOH (20%, 12 g, 35.3 mmol). The mixture was stirred at refluxing temperature for 5 h. The mixture was cooled to room temperature and diluted with EtOAc (100 mL) and water (100 mL). The pH of the aqueous layer was adjusted to ~7 with hydrochloric acid (1 M). The organic layer was separated, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc= 5/1) to give the title compound (8.5 g, 96%). LC-MS (M+H)+ = 378.2.Step 4: 2-benzyl-7-(trifluoromethyl)-2,3-dihydroisoquinolin-4(lH)-one O XXXF3C Bn [0534]To a mixture of ethyl 2-benzyl-4-oxo-7-(trifluoromethyl)-l,2,3,4- tetrahydroisoquinoline-3-carboxylate (8.5 g, 22.5 mmol) in EtOH (70 mL) was added concentrated hydrochloric acid (100 mL). The mixture was stirred at refluxing temperature for h and then cooled to room temperature. The mixture was concentrated under reduced pressure. To the residue was added saturated NaHCO3 (150 mL) and the mixture was extracted214 WO 2024/199255 PCT/CN2024/083980 with DCM (2 x 150 mL). The combined organic layer was washed with brine (150 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=3/l) to give the title compound (3.5 g, 51%). LC-MS (M+H)+ = 306.2.Step 5: 7-(trifluoromethyl)-l,2,3,4-tetrahydroisoquinolin-4-ol id="p-535" id="p-535" id="p-535"
id="p-535"
[0535]To a mixture of 2-benzyl-7-(trifluoromethyl)-2,3-dihydroisoquinolin-4(lH)-one (3.5 g, 11.5 mmol) in AcOH (10 mL) and EtOH (10 mL) was added 10% Pd/C (300 mg) under nitrogen. The mixture was purged with hydrogen and stirred under a hydrogen atmospheres for h. Solid was filtered off and the filtrate was concentrated to give the title compound (2.2 g, 88%). LC-MS (M+H)+= 218.2.Step 6: tert-butyl 4-hydroxy-7-(trifluoromethyl)-3.4-dihydroisoquinoline-2(lH)-carboxylate id="p-536" id="p-536" id="p-536"
id="p-536"
[0536]To a solution of 7-(trifluoromethyl)- 1,2,3,4-tetrahydroisoquinolin-4-ol (2.2 g, 10.mmol) in DCM (40 mL) was added BocO (2.2 g, 10.1 mmol), Et3N (4.37 mL, 30.3 mmol). The reaction mixture was stirred room temperature for 5 h. The reaction mixture was concentrated and purified by silica gel chromatography (PE/EtOAc= 4/1) to give the title compound (2.8 g, 87%). LC-MS (M+H)+ = 318.2.Step 7: tert-butyl 4-((N-methyl-2-nitrophenyl)sulfonamido)-7-(trifluoromethyl)-3,4- dihydroisoquinoline-2(lH)-carboxylate id="p-537" id="p-537" id="p-537"
id="p-537"
[0537]To a solution of tert-butyl 4-hydroxy-7-(trifluoromethyl)-3,4-dihydroisoquinoline- 2(lH)-carboxylate (2.8 g, 8.8 mmol), N-methyl-2-nitro-benzenesulfonamide (1.9 g, 8.8 mmol) and PPh3 (2.99 g, 11.4 mmol) in THE (50 mL) was added DtBAD (2.64 g, 11.4 mmol) in portions at 0 °C under nitrogen. The final mixture was stirred at room temperature for 3 h. The mixture was concentrated under reduced pressure and the residue was purified by silica gel 215 OH WO 2024/199255 PCT/CN2024/083980 chromatography (PE/EtOAc = 3/1) to give the title compound (4.2 g, 93%). LC-MS (M+H)+ =516.1.Step 8: tert-butyl 4-(methylamino)-7-(trifluoromethyl)-3,4-dihydroisoquinoline-2(lH)- carboxylate^NH id="p-538" id="p-538" id="p-538"
id="p-538"
[0538]To a solution of tert-butyl 4-((N-methyl-2-nitrophenyl)sulfonamido)-7- (trifluoromethyl)-3,4-dihydroisoquinoline-2(lH)-carboxylate (4.2 g, 8.15 mmol) in DMF (mL) and THE (50 mL) was added dodecane- 1-thiol (4.9 g, 24.4 mmol) and lithium hydroxide monohydrate (1.0 g, 24.4 mmol). The mixture was stirred at room temperature for 16 h. The mixture was concentrated under reduced pressure, and the residue was partitioned between water (100mL) and EtOAc (100mL). The organic layer was dried with Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM:MeOH = 10:1) to give the title compound (2.5 g, 93%). LC-MS (M+H)+ =331.1.Step 9: tert-butyl 4-(5-amino-N-methyl-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro- lH-furor3,4-dlpyrrolor3,2-blpyridine-2-carboxamido)-7-(trifluoromethyl)-3,4- dihydroisoquinoline-2( 1 H)-carboxylate id="p-539" id="p-539" id="p-539"
id="p-539"
[0539]To a solution of tert-butyl 4-(methylamino)-7-(trifluoromethyl)-3,4- dihydroisoquinoline-2( lH)-carboxylate (2.0 g, 6.1 mmol) and 5-amino- 1-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid (2.1 g, 6.0 mmol) in THE (50 mL) was added BOPCI (2.29 g, 9.0 mmol) and DIPEA (1.g, 12.0 mmol). The mixture was stirred at 60 °C for 16 h and cooled to room temperature. The residue was partitioned between water (50 mL) and EtOAc (50 mL). The organic layer was dried with Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM:MeOH = 20:1) to give the title compound (3.0 g, 76%). LC- MS (M+H)+ =662.2.Step 10: 5-amino-N-methyl-N-(7-(trifluoromethyl)-L2,3,4-tetrahydroisoquinolin-4-yl)-l- ((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide 216 WO 2024/199255 PCT/CN2024/083980 n,,nh 2N SEM id="p-540" id="p-540" id="p-540"
id="p-540"
[0540]To a solution of tert-butyl 4-(5-amino-N-methyl-l-((2-(trimethylsilyl)ethoxy )methyl)- 6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamido)-7-(trifluoromethyl)-3,4- dihydroisoquinoline-2(lH)-carboxylate (1.0 g, 1.78 mmol) in dioxane (10 mL) was added HCI in dioxane (4.0 M, 10 mL). The mixture was stirred for 2 h at room temperature. The precipitate was collected by filtration. To the solid was added saturated NaHCO3, and the mixture was extracted with DCM (2 x 30 mL). The combined organic layer was washed with brine (30 mL), dried over Na2S04, filtered and concentrate under reduced pressure to give the title compound (850 mg, 85%). LC-MS (M+H)+ = 562.2.Step11:N-(2-acetyl-7-(trifluoromethyl)-1,2,3.4-tetrahydroisoquinolin-4-yl)-5-amino-N- methyl-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furor3,4-dlpyrrolo[3,2-blpyridine- 2-carboxamide id="p-541" id="p-541" id="p-541"
id="p-541"
[0541]To a mixture of 5-amino-N-methyl-N-(7-(trifluoromethyl)-l,2,3,4- tetrahydroisoquinolin-4-yl)-1 -((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro- 1 H-furo[3 ,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide (200 mg, 0.356 mmol ), HO Ac (64 mg, 1.07 mmol) and DIPEA (92 mg, 0.71 mmol) in DMF (5 mL) was added HATU (203 mg, 0.53 mmol). The mixture was stirred at 25 °C for 16 h. The mixture was partitioned between water (20 mL) and EtOAc (20 mL). The organic layer was dried with Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC (DCM:MeOH = 20:1) to give the title compound (206 mg, 96%). LC-MS (M+H)+ =604.2.Step12:(S)-N-(2-acetyl-7-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinolin-4-yl)-5-amino- N-methvl-6,8-dihvdro-lH-furo[3,4-d]pv1Tolo[3,2-b]pyridine-2-carboxamide & (R)-N-(2-acetyl- 7-(trifluoromethyl)-L2,3,4-tetrahydroisoquinolin-4-yl)-5-amino-N-methyl-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0542]To a mixture of N-(2-acetyl-7-(trifluoromethyl)-l,2,3,4-tetrahydroisoquinolin-4-yl)-5- amino-N-methyl-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxamide (206 mg, 0.34 mmol) in DCM (5 mL) was added and TEA (1 mL). The mixture was stirred at room temperature for 2 h. The mixture was concentrated under 217 N SEM WO 2024/199255 PCT/CN2024/083980 reduced pressure and the residue was re-dissolved in MeOH (5 mL). Strong ammonia solution (28%, 1 mL) was added and the mixture was stirred room temperature for 1 h. The mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC and chiral SFC to give Example 98 (53 mg, 33%) and Example 99 (54 mg, 33%). [0543]Analytical chiral-SFC condition as below. Column: CHIRALPAK IH; Column size: 4.6X100 mm, 5 pm; Mobile phase: 4 mM methanolic NH3:CO2, 1:9 to 1:1 in 3 min, 1:1 for min, 1:1 to 1:9 in 0.1 min, 1:9 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; back pressure: 1500 psi. [0544]Example 98: Analytical SFC tR=3.12 min. 1H NMR (400 MHz, DMSO-d6) 8 11.63 (s, IH), 7.78 - 7.69 (m, IH), 7.66 - 7.56 (m, IH), 7.48 - 7.32 (m, IH), 6.85 - 6.60 (m, IH), 5.76 (s, IH), 5.57 (s, 2H), 5.14 (s, 2H), 5.03 - 4.50 (m, 4H), 4.30 - 3.53 (m, 2H), 3.15 - 2.70 (m, 3H), 2.15 - 2.05 (m, 3H). LCMS (M+H)+ = 474.3. [0545]Example 99: Analytical SFC tR=3.73 min. 1H NMR (400 MHz, DMSO-،/6) 8 11.63 (s, IH), 7.7 8- 7.69 (m, IH), 7.66 - 7.56 (m, IH), 7.48 - 7.32 (m, IH), 6.85 - 6.60 (m, IH), 5.76 (s, IH), 5.57 (s, 2H), 5.14 (s, 2H), 5.03 - 4.50 (m, 4H), 4.30 - 3.53 (m, 2H), 3.15 - 2.70 (m, 3H), 2.15 - 2.05 (m, 3H). LCMS (M+H)+ = 474.3. Example 100 & Example 101:(S)-5-amino-N-(2-(cyclopropanecarbonyl)-7- (trifluoromethyl)- 1,2,3,4-tetrahydroisoquinolin-4-yl)-N-methyl-6,8-dihydro- 1 H-furo [3,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide & (R)-5-amino-N-(2-(cyclopropanecarbonyl)-7- (trifluoromethyl)- 1,2,3,4-tetrahydroisoquinolin-4-yl)-N-methyl-6,8-dihydro- 1 H-furo [3,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: 5-amino-N-(2-(cyclopropanecarbonyl)-7-(trifluoromethyl)-L2,3,4-tetrahydroisoquinolin-4-yl)-N-methyl-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide N SEM id="p-546" id="p-546" id="p-546"
id="p-546"
[0546]The title compound (80 mg, 71%) was prepared in a manner similar to that in Example & Example 99 step 11 from (5-amino-N-methyl-N-(7-(trifluoromethyl)-l,2,3,4-218 WO 2024/199255 PCT/CN2024/083980 tetrahydroisoquinolin-4-yl)-1 -((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro- 1 H-furo[3 ,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide and cyclopropanecarboxylic acid. LC-MS (M+H)+ = 630.2.Step2:(S)-5-amino-N-(2-(cyclopropanecarbonyl)-7-(trifluoromethyl)-1,2,3,4- tetrahydroisoquinolin-4-yl)-N-methyl-6,8-dihydro-lH-furo[3,4-dlpyrrolo[3,2-blpyridine-2- carboxamide & (R)-5-amino-N-(2-(cyclopropanecarbonyl)-7-(trifluoromethyl)-1,2,3,4- tetrahydroisoquinolin-4-yl)-N-methyl-6,8-dihydro-lH-furor3,4-dlpyrrolo[3,2-blpyridine-2- carboxamide [0547]Example 100 (8 mg, 13%) and Example 101 (10 mg, 15%) was prepared in a manner similar to that in Example 98 & Example 99 step 12 from 5-amino-N-(2- (cyclopropanecarbonyl)-7-(trifluoromethyl)-l,2,3,4-tetrahydroisoquinolin-4-yl)-N-methyl-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide, and the enantiomers were separated by chiral SFC. [0548]Analytical chiral-SFC condition as below. Column: YMC Cellulose-C; Column size: 4.6X100 mm, 5 pm; Mobile phase: 4 mM methanolic NH3:CO2, 1:9 to 1:1 in 3 min, 1:1 for min, 1:1 to 1:9 in 0.1 min, 1:9 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; back pressure: 1500 psi. [0549]Example 100: Analytical SFC tR=3.96 min. 1H NMR (400 MHz, DMSO- 219 WO 2024/199255 PCT/CN2024/083980 Step1:5-amino-N-(2-isobutyryl-7-(trifluoromethyl)-1,2,3.4-tetrahydroisoquinolin-4-yl)-N-methyl-l-((2-(trimethylsilyl)ethoxy)rnethyl)-6.8-dihydro-lH-furo[3.4-d]pyrrolo[3,2-blpyridine- 2-carboxamide id="p-551" id="p-551" id="p-551"
id="p-551"
[0551]The title compound (80 mg, 71%) was prepared in a manner similar to that in Example & Example 99 step 11 from (5-amino-N-methyl-N-(7-(trifluoromethyl)-l,2,3,4- tetrahydroisoquinolin-4-yl)-1 -((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro- 1 H-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide and isobutyric acid. LC-MS (M+H)+ = 632.2.Step 2: (S)-5-amino-N-(2-isobutyryl-7-(trifluoromethyl)-1.2,3.4-tetrahydroisoquinolin-4- yl)-N-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (R)-5-amino- N-(2-isobutyryl-7-(trifluoromethyl)-l,2,3,4-tetrahydroisoquinolin-4-yl)-N-methyl-6,8-dihydro- H-furo [ 3,4-d]pyrrolo [ 3,2-blpyridine-2-carboxamide [0552]Example 102 (6 mg, 9%) and Example 103 (7 mg, 10%) was prepared in a manner similar to that in Example 98 & Example 99 step 12 from 5-amino-N-(2-isobutyryl-7- (tri fluoromethyl)- 1,2,3,4-tetrahydroisoquinolin-4-yl)-N-methyl- 1 -((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide, and the enantiomers were separated by chiral SFC. [0553]Analytical chiral-SFC condition as below. Column: YMC Cellulose-C; Column size: 4.6X100 mm, 5 pm; Mobile phase: 4 mM methanolic NH3:CO2, 1:9 to 1:1 in 3 min, 1:1 for min, 1:1 to 1:9 in 0.1 min, 1:9 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; back pressure: 1500 psi. [0554]Example 102: Analytical SFC tR=3.52 min. 1H NMR (400 MHz, DMSO- 220 WO 2024/199255 PCT/CN2024/083980 Step 1: (S)-N-methyl-7-(pyridin-3-yl)isochroman-4-amine—NH id="p-556" id="p-556" id="p-556"
id="p-556"
[0556]The title compound (100mg, 83%) was prepared in a manner similar to that in Example & Example 88 step 5 from (S)-7-bromo-N-methylisochroman-4-amine and pyridin-3- ylboronic acid. LC-MS (M+H)+ = 241.1.Step 2: (S)-5-amino-N-methyl-N-(7-(pyridin-3-yl)isochroman-4-yl)-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-dlpyrrolor3,2-blpyridine-2-carboxamide id="p-557" id="p-557" id="p-557"
id="p-557"
[0557]The title compound (198 mg, 83%) was prepared in a manner similar to that in Example & Example 74 step 9 from (S)-N-methyl-7-(pyridin-3-yl)isochroman-4-amine and 5-amino-l- ((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxylic acid. LC-MS (M+H)+ =572.4.Step 3: (S)-5-amino-N-methyl-N-(7-(pyridin-3-yl)isochroman-4-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0558]Example 104 (114 mg, 75%) was prepared in a manner similar to that in Example step 3 from (S)-5-amino-N-methyl-N-(7-(pyridin-3-yl)isochroman-4-yl)-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide. ,H NMR (400 MHz, DMSO-d) 8 11.58 (s, 1H), 8.87 (d, J= 1.6 Hz, 1H), 8.(dd, J= 4.8, 1.2 Hz, 1H), 8.09 - 8.01 (m, 1H), 7.63 (d, J= 7.6 Hz, 1H), 7.53 (s, 1H) 7.49 - 7.(m, 2H), 6.69 (s, 1H), 5.78 (s, 1H), 5.53 (s, 2H), 5.13 (s, 2H), 4.95 - 4.68 (m, 4H), 4.08 (s, 2H), 3.09 - 2.69 (m, 3H). LC-MS (M+H)+ = 442.3. 221 N SEM WO 2024/199255 PCT/CN2024/083980 Example 105:5-amino-N-(4-cyclopropyl-2,6-difluorobenzyl)-N-(pentan-3-yl)-6,8-dihydro- lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamideN NH2 Step 1: 4-cyclopropyl-2,6-difluorobenzaldehyde0, id="p-559" id="p-559" id="p-559"
id="p-559"
[0559]The title compound (1.2 g, 61 %) was prepared in a manner similar to that in Examplestep 1 from 4-bromo-2,6-difluorobenzaldehyde and cyclopropylboronic acid. LC-MS (M+H)+ =183.1.Step2:N-(4-cyclopropyl-2,6-difluorobenzyl)pentan-3-amine id="p-560" id="p-560" id="p-560"
id="p-560"
[0560]The title compound (230 mg, 92%) was prepared in a manner similar to that in Example step 1 from 4-cyclopropyl-2,6-difluorobenzaldehyde and pentan-3-amine. LC-MS (M+H)+ =254.2.Step 3: 5-amino-N-(4-cyclopropvl-2,6-difluorobenzvl)-N-(pentan-3-vl)-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-561" id="p-561" id="p-561"
id="p-561"
[0561]The title compound (90 mg, 65%) was prepared in a manner similar to that in Example step 2 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and N-(4-cyclopropyl-2,6-difluorobenzyl)pentan-3- amine. LC-MS (M+H)+ = 585.4.222 N N>SEM WO 2024/199255 PCT/CN2024/083980 Step4:5-amino-N-(4-cyclopropyl-2,6-difluorobenzyl)-N-(pentan-3-yl)-6,8-dihydro-1H- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0562]Example 105 (10 mg, 17%) was prepared in a manner similar to that in Example 66 step from 5-amino-N-(4-cyclopropyl-2,6-difluorobenzyl)-N-(pentan-3-yl)-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide. 1H NMR (400 MHz, DMSO-t/6) 5: 11.50 (s, 1H), 6.80 (d, J= 9.2 Hz, 2H), 6.47 (s, 1H), 5.53 (s, 2H), 5.12 (s, 2H), 4.92 (s, 2H), 4.88 - 3.62 (m, 3H), 1.97 - 1.88 (m, 1H), 1.72 - 1.(m, 4H), 1.02 - 0.91 (m, 2H), 0.82 - 0.67 (m, 8H). LC-MS (M+H)+ = 455.2. Example 106:(R)-5-amino-N-((5-cyclopropylpyridin-2-yl)methyl)-N-isopropyl-6-methyl- 6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide N NH2 Step 1: N-((5-cyclopropylpyridin-2-yl)methyl)propan-2-amine id="p-563" id="p-563" id="p-563"
id="p-563"
[0563]The title compound (70 mg, 90%) was prepared in a manner similar to that in Example step 1 from 5-cyclopropylpicolinaldehyde and propan-2-amine. LC-MS (M+H)+ = 191.2.Step 2: (R)-5-amino-N-((5-cyclopropylpyridin-2-yl)methyl)-N-isopropyl-6-methyl-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0564]Example 106 (41 mg, 27%) was prepared in a manner similar to that in Example 2 step from N-((5-cyclopropylpyridin-2-yl)methyl)propan-2-amine and (R)-5-amino-6-methyl-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid. 1H NMR (400 MHz, DMSO- d6) 8 11.56 (s, 1H), 8.38 (s, 1H), 7.46 - 7.33 (m, 1H), 7.28 - 7.14 (m, 1H), 6.66 - 5.97 (m, 1H), 5.42 (s, 2H), 5.36 - 5.28 (m, 1H), 5.22 - 4.98 (m, 2H), 4.74 (br s, 3H), 2.07 - 1.85 (m, 1H), 1.(d, J= 6.1 Hz, 3H), 1.22 - 1.08 (m, 6H), 1.04 - 0.92 (m, 2H), 0.80 - 0.62 (m, 2H). LC-MS (M+H)+ = 406.5. Example 107:(R)-5-amino-N-(sec-butyl)-N-((5-cyclobutylpyridin-2-yl)methyl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide 223 WO 2024/199255 PCT/CN2024/083980 Step 1: 5-bromo-2-(L3-dioxolan-2-yl)pyridine id="p-565" id="p-565" id="p-565"
id="p-565"
[0565]To a solution of 5-bromopicolinaldehyde (5.0 g, 27 mmol) in toluene (250 mL) was added ethylene glycol (3.3 g, 54 mmol) and p-toluenesulfonic acid (465 mg, 2.7 mmol) at room temperature, and the mixture was stirred at 110 °C for 12 h equipped with a Dean-Stark trap. The mixture was cooled to room temperature, diluted with water (150 mL) and extracted with EtOAc (3 x 150 mL). The combined organic layer was washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc=l/0 to 5/1) to give the title compound (5.0 g, 81%). LC-MS (M+H)+ = 230.0.Step2:5-cyclobutyl-2-(1,3-dioxolan-2-yl)pyridine id="p-566" id="p-566" id="p-566"
id="p-566"
[0566]Ten batches of the reaction described herein were set up. To a solution of 5-bromo-2- (l,3-dioxolan-2-yl)pyridine (0.10 g, 0.435 mmol) in DMA (1 mL) was added potassium cyclobutyltrifluoroborate (70 mg, 0.435 mmol), (4,4'-di-tert-butyl-2,2'-bipyridine)bis[3,5- difluoro-2-[5-trifluoromethyl-2-py1 ־idinyl-under at blue light (34 W) at 25 °C for 12 h.The ten batches of reaction mixture were combined and diluted with water (100 mL). The mixture was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE:EtOAc=10:l to 0:1) to give the title compound (0.40 g, 45%). LC-MS (M+H)+ = 206.1.Step 3: 5-cyclobutylpicolinaldehyde 224 WO 2024/199255 PCT/CN2024/083980 id="p-567" id="p-567" id="p-567"
id="p-567"
[0567]To a mixture of 5-cyclobutyl-2-(l,3-dioxolan-2-yl)pyridine (0.37 g, 1.8 mmol) in water (8.4 mL) was added concentrated HC1 (1.6 mL) dropwise. The mixture was stirred at 80 °C for h and then cooled to room temperature. The mixture was poured into aqueous NaOH solution (M, 12 mL), and the mixture was extracted with EtOAc (20 mL). The combined organic layer was washed with brine (20 mL), dried over Na2S04, fdtered and concentrated under reduced pressure to give the title compound (290 mg, 99%). LC-MS (M+H)+ =162.1.Step 4: (R)-N-((5-cyclobutylpyridin-2-yl)methyl)butan-2-amine y ״nh id="p-568" id="p-568" id="p-568"
id="p-568"
[0568]The title compound (100 mg, 92%) was prepared in a manner similar to that in Example step 1 from 5-cyclobutylpicolinaldehyde and (R)-butan-2-amine. LC-MS (M+H)+ = 219.2.Step 5: (R)-5-amino-N-(sec-butyl)-N-((5-cyclobutylpyridin-2-yl)methyl)- 1 -((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-569" id="p-569" id="p-569"
id="p-569"
[0569]The title compound (10 mg, 40%) was prepared in a manner similar to that in Example step 2 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and (R)-N-((5-cyclobutylpyridin-2-yl)methyl)butan- 2-amine. LC-MS (M+H)+ = 550.4.Step 6: (R)-5-amino-N-(sec-butyl)-N-((5-cyclobutylpyridin-2-yl)methyl)-6,8-dihydro-lH- furo[ 3,4-d]pyrrolo [ 3,2-b]pyridine-2-carboxamide [0570]Example 107 (26 mg, 43%) was prepared in a manner similar to that in Example 66 step from (R)-5-amino-N-(sec-butyl)-N-((5-cyclobutylpyridin-2-yl)methyl)- 1 -((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide. ,H NMR (400 MHz, DMSO-d6) 8 11.55 (s, 1H), 8.40 (s, 1H), 7.66 (d, J= 8.0 Hz,225 WO 2024/199255 PCT/CN2024/083980 1H), 7.30 (d, J= 8.0 Hz, 1H), 6.65 - 6.25 (m, 1H), 5.50 (s, 2H), 5.15 - 5.11 (m, 2H), 4.93 - 4.(m, 3H), 4.65 - 4.37 (m, 2H), 3.58 - 3.49 (m, 1H), 2.33 - 2.25 (m, 2H), 2.16 - 2.07 (m, 2H), 2.- 1.93 (m, 1H), 1.87 - 1.78 (m, 1H), 1.72 - 1.61 (m, 1H), 1.55 - 1.44 (m, 1H), 1.25-1.10 (m, 3H), 0.83 - 0.74 (m, 3H). LC-MS (M+H)+ = 420.3. Example 108:(R)-5-amino-N-(sec-butyl)-N-((5-cyclopropyl-6-methylpyridin-2- yl)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step1:(R)-N-((5-bromo-6-methylpyridin-2-yl)methyl)butan-2-amine id="p-571" id="p-571" id="p-571"
id="p-571"
[0571]The title compound (490 mg, 95%) was prepared in a manner similar to that in Example step 1 from 5-bromo-6-methylpicolinaldehyde and (R)-butan-2-amine. LC-MS (M+H)+ = 257.1.Step 2: (R)-N-((5-cyclopropyl-6-methylpyridin-2-yl)methyl)butan-2-amine 1NH id="p-572" id="p-572" id="p-572"
id="p-572"
[0572]The title compound (350 mg, 94%) was prepared in a manner similar to that in Example step 1 from (R)-N-((5-bromo-6-methylpyridin-2-yl)methyl)butan-2-amine and cyclopropylboronic acid. LC-MS (M+H)+ = 219.2.Step 3: (R)-5-amino-N-(sec-butyl)-N-((5-cyclopropyl-6-methylpyridin-2-yl)methyl)- 1 -((2- (trimethvlsilvl)ethoxv)methvl)-6,8-dihvdro-lH-furo[3,4-d]pv1Tolo[3,2-b]DV11dine-2-carboxamide 226 WO 2024/199255 PCT/CN2024/083980 [0573]The title compound (150 mg, 60%) was prepared in a manner similar to that in Example step 2 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and (R)-N-((5-cyclopropyl-6-methylpyridin-2- yl)methyl)butan-2-amine. LC-MS (M+H)+ = 550.4.Step 4: (R)-5-amino-N-(sec-butyl)-N-((5-cyclopropyl-6-methylpyridin-2-yl)methyl)-6,8- dihydro-lH-furo[3,4-d1pyrrolo[3,2-b1pyridine-2-carboxamide [0574]Example 108 (35 mg, 32%) was prepared in a manner similar to that in Example 66 step from (R)-5-amino-N-(sec-butyl)-N-((5-cyclopropyl-6-methylpyridin-2-yl)methyl)- 1 -((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide. 1H NMR (400 MHz, DMSOV5) 5: 11.66 (br s, 1H), 8.19 (br s, 1H), 7.29 (br s, 1H), 7.08 (br s, 1H), 6.66 - 6.21 (m, 1H), 5.52 (br s, 2H), 5.12 (br s, 2H), 4.91 (br s, 2H), 4.76 (br s, 1H), 4.43 (brs, 2H), 2.57 (br s, 3H), 1.92 (brs, 1H), 1.65 (td,J= 14.3, 7.4 Hz, 1H), 1.49(td, J = 14.0, 7.1 Hz, 1H), 1.17 (brs, 3H), 0.93 (br d, J= 7.1 Hz, 2H), 0.81 -0.73 (m, 3H), 0.60 (br d, J = 2.7 Hz, 2H). LC-MS (M+H)+ = 420.2. Example 109:5-amino-N-((5-cyclopropyl-4-methylpyridin-2-yl)methyl)-N-(pentan-3 -yl)- 6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step1:5-bromo-2-(1,3-dioxolan-2-yl)-4-methylpyridine VonVOBr id="p-575" id="p-575" id="p-575"
id="p-575"
[0575]The title compound (1.9 g, 78%) was prepared in a manner similar to that in Example 107 step 1 from 5-bromo-4-methylpicolinaldehyde and ethylene glycol. LC-MS (M+H)+ = 244.0.Step 2: 5-cyclopropyl-2-(L3-dioxolan-2-vl)-4-methvlpyridine 227 WO 2024/199255 PCT/CN2024/083980 [0576]The title compound (1.6 g, 95%) was prepared in a manner similar to that in Example step 1 from 5-bromo-2-(l,3-dioxolan-2-yl)-4-methylpyridine and cyclopropylboronic acid. LC-MS (M+H)+ =206.1.Step 3: 5-cyclopropyl-4-methylpicolinaldehyde id="p-577" id="p-577" id="p-577"
id="p-577"
[0577]The title compound (1.0 g, 80%) was prepared in a manner similar to that in Example107 step 3 from 5-cyclopropyl-2-(l,3-dioxolan-2-yl)-4-methylpyridine. LC-MS (M+H)+ =162.1.Step 4: N-((5-cyclopropyl-4-methylpyridin-2-yl)methyl)pentan-3-amine id="p-578" id="p-578" id="p-578"
id="p-578"
[0578]The title compound (300 mg, 83%) was prepared in a manner similar to that in Example step 1 from 5-cyclopropyl-4-methylpicolinaldehyde and pentan-3-amine. LC-MS (M+H)+ = 233.1.Step 5: 5-amino-N-((5-cvclopropvl-4-methvlpvridin-2-vl)methyl)-N-(pentan-3-vl)- 1 -((2- (trimethvlsilyl)ethoxv)methyl)-6,8-dihvdro-lH-furo[3,4-d]pyrrolo[3,2-b]pvridine-2-carboxamide id="p-579" id="p-579" id="p-579"
id="p-579"
[0579]The title compound (240 mg, 33%) was prepared in a manner similar to that in Example step 2 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and N-((5-cyclopropyl-4-methylpyridin-2- yl)methyl)pentan-3-amine. LC-MS (M+H)+ = 564.3.Step 6: 5-amino-N-((5-cyclopropyl-4-methylpyridin-2-yl)methyl)-N-(pentan-3-yl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0580]Example 109 (60 mg, 33%) was prepared in a manner similar to that in Example 66 step from 5-amino-N-((5-cyclopropyl-4-methylpyridin-2-yl)methyl)-N-(pentan-3-yl)-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- 228 N N>SEM WO 2024/199255 PCT/CN2024/083980 carboxamide. 1H NMR (400 MHz, DMSO-،/6) 8: 11.86 - 11.40 (m, 1H), 8.26 - 7.96 (m, 1H), 7.16 ( s, 1H), 6.50 (s, 1H), 5.62- 5.39 (m, 2H), 5.12 (s, 2H), 4.91 (s, 2H), 4.81 - 4.45 (m, 2H), 4.40 - 4.20 (m, 1H), 2.34 (s, 3H), 1.85 (s, 1H), 1.70 - 1.43 (m, 4H), 0.92 (d, J= 7.6 Hz, 2H), 0.(t, J= 13 Hz, 6H), 0.67 (s, 2H). LC-MS (M+H)+ = 434.0. Example 110 & Example 111:(R)-5-amino-N-ethyl-N-(l-(3-fluoro-5- (trifluoromethyl)pyridin-2-yl)ethyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide & (S)-5-amino-N-ethyl-N-(l-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethyl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamideN NH2 Step 1: l-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethan-l-olHO id="p-581" id="p-581" id="p-581"
id="p-581"
[0581]To a solution of 3-fluoro-5-(trifluoromethyl)picolinaldehyde (4.0 g, 20.7 mmol) in THF (40 mL) was added MeMgBr in diethyl ether (3.0 M, 8.29 mL, 24.9 mmol) at -78 °C under nitrogen. The mixture was slowly warmed to room temperature and stirred for 2 h. The reaction mixture was slowly added to saturated NH4C1 (50 mL) with stirring. The mixture was extracted with EtOAc (3 x 30 mL). The combined organic layer was washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 100/0 to 20/1) to give the title compound (3.3 g, 76%). 1H NMR (400 MHz, DMSO-d) 8: 8.81 (s, 1H), 8.25 (d, J= 10.0 Hz, 1H), 5.48 (d, J= 5.7 Hz, 1H), 5.23 - 5.03 (m, 1H), 1.43 (d, J= 6.5 Hz, 3H). LC-MS (M+H)+ = 210.2.Step 2: 2-(l-azidoethyl)-3-fluoro-5-(trifluoromethyl)pyridine id="p-582" id="p-582" id="p-582"
id="p-582"
[0582]To a solution of l-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethan-l-ol (3.3 g, 15.8mmol) in toluene (45 mL) was added DBU (3.6 g, 23.7 mmol) and DPP A (5.2 g, 18.9 mmol) at 229 WO 2024/199255 PCT/CN2024/083980 °C. The mixture was warmed to room temperature and stirred for 12 h. The mixture was diluted with water (50 mL) and extracted with EtOAc (3 x 40 mL). The combined organic layer was washed with brine (100 mL), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 100/0 to 20/1) to give the title compound (2.5 g, 68%). 1H NMR (400 MHz, DMSO-6) 8: 8.91 (s, 1H), 8.40 (d, J = 9.8 Hz, 1H), 5.04 (q, J= 6.8 Hz, 1H), 1.59 (d, J= 6.8 Hz, 3H). LC-MS (M+H)+ = 235.1.Step 3: tert-butyl (l-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethyl)carbamateBocHN f 3c id="p-583" id="p-583" id="p-583"
id="p-583"
[0583]To a solution of 2-(l-azidoethyl)-3-fluoro-5-(trifluoromethyl)pyridine (2.5 g, 10.mmol) in MeOH (60 mL) was added BocO (3.77 g, 17.3 mmol) and 10% Pd/C (675 mg) under nitrogen. The mixture was degassed and purged with hydrogen for 3 times, then stirred under H(30 psi) at 30 °C for 4 h. The mixture was filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 100/0 to 20/1) to give the title compound (3.0 g, 91%). 1H NMR (400 MHz, DMSO-d) 8: 8.80 (s, 1H), 8.25 (d, J= 9.9 Hz, 1H), 7.41 (d, J=7.2 Hz, 1H), 5.04-4.93 (m, 1H), 1.49-1.25 (m, 12H). LC-MS (M+H)+= 309.2.Step 4: tert-butyl ethyl( l-(3-fluoro-5-(trifluoromethvl)pvridin-2-vl)ethvl)carbamate Boel/ N= f 3c [0584]To a solution of tert-butyl (1 -(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethy!)carbamate (1.0 g, 3.24 mmol) in Etl (10.5 mL, 130 mmol) was added NaH (60%, 519 mg, 13.0 mmol) under nitrogen in a sealed tube. After cease of bubbling, the vessel was sealed and the mixture was stirred at 80 °C for 12 h. The mixture was cooled to room temperature and slowly added to saturated NH4Cl (20 mL). The mixture was extracted with EtOAc (3x15 mL). The combined organic layer was washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 100/0 to 20/1) to give the title compound (440 mg, 40%). LC-MS (M+H)+ = 337.3.Step 5: N-ethyl-1-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethan-1-amine hydrochloride 230 WO 2024/199255 PCT/CN2024/083980 f 3c [0585]To tert-butyl ethyl( 1 -(3 -fluoro-5 -(trifluoromethyl)pyridin-2-yl)ethyl)carbamate (2mg, 0.71 mmol) was added HCI in MeOH (3.0 M, 3 mL). The mixture was stirred at room temperature for 3 h. The mixture was concentrated under reduced pressure to give the title compound (150 mg, 77%). LC-MS (M+H)+ = 237.1.Step 6: 5-amino-N-ethyl-N-(l-(3-fluoro-5-(trifIuoromethyl)pyridin-2-yl)ethyl)-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-586" id="p-586" id="p-586"
id="p-586"
[0586]To a solution of N-ethyl-l-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethan-l-amine hydrochloride (127 mg, 466 umol) and 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid (163 mg, 466 umol) in DMF (mL) was added DIPEA (150 mg, 1.16 mmol) and CMPI (131 mg, 512 umol). The mixture was stirred at 40 °C for 6 h and then cooled to room temperature. The mixture was diluted with water (20 mL) and extracted with EtOAc (3x10 mL). The combined organic layer was washed with brine (3 x 20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 100/0 to 1/4) to give the title compound (200 mg, 76%). LC-MS (M+H)+ = 568.3.Step 7: (R)-5-amino-N-ethyl-N-(l-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethyl)-6,8- dihydro-lH-furo[3,4-d]pv1Tolo[3,2-b]pvridine-2-carboxamide & (S)-5-amino-N-ethyl-N-(l-(3- fluoro-5-(trifluoromethvl)pyridin-2-vl)ethyl)-6,8-dihvdro-lH-furo[3,4-d1pvn ־olo[3,2-b1pyridine- 2-carboxamide [0587]To a solution of 5-amino-N-ethyl-N-(l-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethyl)- l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide (180 mg, 317 umol) in DCM (2 mL) was added TEA (2 mL). The mixture was stirred at room temperature for 1 h and then concentrated under reduced pressure. The residue was diluted with methanolic ammonia (7.0 M, 5 mL) and stirred at room temperature for 0.5 h. Solid was filtered off and the filtrate was concentrated under reduced pressure. The residue was 231 WO 2024/199255 PCT/CN2024/083980 purified by prep-HPLC and further separated by SFC to give Example 110 (7 mg, 5%) andExample 111 (10 mg, 7%). [0588]Analytical chiral-SFC condition as below. Column: CHIRALPAK IH-3; Column size: 4.6X100 mm, 3 pm; Mobile phase: (ethanol containing 0.2% 7 M methanolic NH3):CO2, 1:9 for 0.2 min, 1:9 to 1:1 in 2.2 min, 1:1 for 1 min, 1:1 to 1:9 in 0.6 min; Flow: 3.5 mL/min;Temperature: 35 °C; back pressure: 2000 psi. [0589]Example 110: Analytical SFC tR=1.39 min. 1H NMR (400 MHz, DMSO- id="p-592" id="p-592" id="p-592"
id="p-592"
[0592]To a solution of l-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethan-l-one (1.0 g, 4.mmol) in formic acid-Et3N complex (5:2, 20 mL) was added [(S,S)-N-(2-amino-l,2- diphenylethyl)-p-toluenesulfonamide]chloro(p-cymene)ruthenium(II) (156 mg, 0.24 mmol) at - °C under hydrogen. The mixture was stirred at 0 °C for 2 h and at room temperature for 12 h. The mixture was diluted with saturated NaHCO3 (150 mL) and extracted with EtOAc (150 mL). The organic layer was washed with brine (150 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE:EtOAc = 10:1) to give the title compound (680 mg, 67%). LC-MS (M+H)+ = 210.1.Step 2: (R)-N-(l-(3-fluoro-5-(trifluoromethvl)pvridin-2-vl)ethvl)-N-ethyl-2- nitrobenzenesulfonamide id="p-593" id="p-593" id="p-593"
id="p-593"
[0593]To a mixture of (S)-l-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethan-l-ol (680 mg, 3.25 mmol), N-ethyl-2-nitro-benzenesulfonamide (748 mg, 3.25 mmol) and PPh3 (936 mg, 3.58232 WO 2024/199255 PCT/CN2024/083980 mmol) in THF (30 mL) was added DtBAD (823 mg, 3.58 mmol) in portions at 0 °C under nitrogen. The mixture was stirred at room temperature for 3 h. The mixture was diluted water (100 mL) and then extracted with EtOAc (100 mL). The organic layer was washed with brine (100 mL), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE:EtOAc = 3:1) to give the title compound (1.3 g, 95%). LC-MS (M+H)+= 422.1.Step 3: (R)-N-ethyl-l-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethan-l-amine id="p-594" id="p-594" id="p-594"
id="p-594"
[0594]To a mixture of (R)-N-(l-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethyl)-N-ethyl-2- nitrobenzenesulfonamide (1.3 g, 3.09 mmol), dodecane- 1-thiol (1.94 g, 9.58 mmol) in DMF (mL) and THF (40 mL) was added LiOHH2O (402 mg, 9.58 mmol), and the mixture was stirred at room temperature for 16 h. Volatiles were removed under reduced pressure and the residue was partitioned between water (50 mL) and EtOAc (50 mL). The organic layer was separated, dried with Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 1/1 to DCM:MeOH=10:1) to give the title compound (560 mg, 76%). LC-MS (M+H)+ = 237.1.Step 4: (R)-5-amino-N-ethyl-N-(l-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethyl)-l-((2- (trimethvlsilvl)ethoxv)methvl)-6,8-dihvdro-lH-furo[3,4-d1pvn ־olo[3,2-b1pvridine-2-carboxamide id="p-595" id="p-595" id="p-595"
id="p-595"
[0595]The title compound (105 mg, 59%) was prepared in a manner similar to that in Example step 2 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and l-(5-cyclopropylpyridin-2-yl)-N-ethylethan-l- amine. LC-MS (M+H)+ = 568.3.Step5:(R)-5-amino-N-ethyl-N-(1-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethyl)-6,8-dihvdro-lH-furo[3,4-d]pv1Tolo[3,2-b]pvridine-2-carboxamide [0596]Example 110 (40 mg, 49%) was prepared in a manner similar to that in Example 110 & Example ill step 7 from (R)-5-amino-N-ethyl-N-(l-(3-fluoro-5-(trifluoromethyl)pyridin-2- yl)ethyl)-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-fi1ro[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxamide.233 N N).... SEM WO 2024/199255 PCT/CN2024/083980 Example 112 & Example 113:(R)-5-amino-N-(l-(5-cyclopropylpyridin-2-yl)ethyl)-N- ethyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (S)-5-amino-N-(l-(5- cyclopropylpyridin-2-yl)ethyl)-N-ethyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide id="p-597" id="p-597" id="p-597"
id="p-597"
[0597]The title compound (990 mg, 61%) was prepared in a manner similar to that in Example step l from l-(5-bromopyridin-2-yl)ethan-l-one and cyclopropylboronic acid. LC-MS (M+H)+= 162.2.Step 2: l-(5-cyclopropylpyridin-2-yl)-N-ethylethan-l-amine id="p-598" id="p-598" id="p-598"
id="p-598"
[0598]To a solution of l-(5-cyclopropylpyridin-2-yl)ethan-l-one (0.30 g, 1.86 mmol) in ethylamine (2.10 g, 46.5 mmol) was added Ti(OEt)4 (425 mg, 1.86 mmol) and the mixture was stirred at 60 °C for 12 h in a sealed tube. The mixture was cooled to room temperature and NaBHCN (468 mg, 7.44 mmol) in THE (3 mL) was added. The tube was re-sealed and the mixture reacted with stirring at room temperature for 12 h. The reaction mixture was fully quenched with saturated NaHCOs (30 mL) and then extracted with DCM (3x5 mL). The combined organic layer was washed with brine (5 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 1/0 to 0/1) to give the title compound (267 mg, 75%). LC-MS (M+H)+ = 191.2.Step 3: 5-amino-N-(l-(5-cyclopropylpyridin-2-yl)ethyl)-N-ethyl-l-((2- (trimethvlsilvl)ethoxv)methvl)-6,8-dihvdro-lH-furo[3,4-d1pvn ־olo[3,2-blDvridine-2-carboxamide 234 Step1:1-(5-cyclopropylpyridin-2-yl)ethan-1-one WO 2024/199255 PCT/CN2024/083980 id="p-599" id="p-599" id="p-599"
id="p-599"
[0599]The title compound (66 mg, 16%) was prepared in a manner similar to that in Example step 2 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and l-(5-cyclopropylpyridin-2-yl)-N-ethylethan-l- amine. LC-MS (M+H)+ = 522.2.Step 4: (R)-5-amino-N-(l-(5-cyclopropylpyridin-2-yl)ethyl)-N-ethyl-6,8-dihydro-lH- furol 3,4-dlpyrrolo 13,2-blpyridine-2-carboxamide & (S)-5 -amino-N-( 1 -(5-cyclopropylpyridin-2- yl)ethyl)-N-ethyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0600]Example 112 (6 mg, 9%) and Example 113 (6 mg, 9%) were prepared in a manner similar to that in Example 110 & Example 111 step 7 from 5-amino-N-(l-(5-cyclopropylpyridin- 2-yl)ethyl)-N-ethyl-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxamide, and the enantiomers were separated by chiral SFC. [0601]Analytical chiral-SFC condition as below. Column: Chiralcel OD-3; Column size: 4.6X50 mm, 3 pm; Mobile phase: 14 mM ammonia in MeOH:CO2, 1:19 for 0.2 min, 1:19 to 1:in 1 min, 1:1 for 1 min, 1:1 to 1:19 in 0.4 min, 1:19 for 0.4 min; Flow: 3.4 mL/min;Temperature: 35 °C; backpressure: 1800 psi. [0602]Example 112: Analytical SFC tR=1.49 min. 1H NMR (400 MHz, DMSO-d) 5 11.54 (s, 1H), 8.40 (d, J= 1.9 Hz, 1H), 7.42 (dd, J= 8.1, 2.1 Hz, 1H), 7.24 (d, J= 8.1 Hz, 1H), 6.54 (s, 1H), 5.79 - 5.70 (m, 1H), 5.51 (s, 2H), 5.13 (s, 2H), 4.92 (s, 2H), 3.68 - 3.44 (m, 2H), 1.99 - 1.(m, 1H), 1.65 (d, J= 7.0 Hz, 3H), 1.03 - 0.97 (m, 5H), 0.75 - 0.69 (m, 2H). LCMS (M+H)+ = 392.2. [0603]Example 113: Analytical SFC tR=1.68 min. 1H NMR (400 MHz, DMSO-d) 8 11.54 (s, 1H), 8.39 (d, J= 1.8 Hz, 1H), 7.42 (dd, J= 8.2, 1.9 Hz, 1H), 7.24 (d, J= 8.3 Hz, 1H), 6.54 (s, 1H), 5.79 - 5.70 (m, 1H), 5.51 (s, 2H), 5.13 (s, 2H), 4.92 (s, 2H), 3.68 - 3.44 (m, 2H), 1.99 - 1.(m, 1H), 1.65 (d, J = 7.0 Hz, 3H), 1.03 - 0.97 (m, 5H), 0.75 - 0.69 (m, 2H). LCMS (M+H)+ = 392.2. Example 114 & Example 115:(S)-5-amino-N-ethyl-N-(l-(5-(trifluoromethyl)pyridin-2- yl)ethyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (R)-5-amino-N- ethyl-N-(l-(5-(trifluoromethyl)py1 ־idin-2-yl)ethyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxamide 235 WO 2024/199255 PCT/CN2024/083980 Step 1: 1-(5-(trifluoromethyl) pyridin-2-yl)ethan-1-one oximeOHN N=• F3C id="p-604" id="p-604" id="p-604"
id="p-604"
[0604]To a solution of l-(5-(trifluoromethyl)pyridin-2-yl)ethan-l-one (2.0 g, 10.6 mmol) in pyridine (25 mL) was added hydroxylamine hydrochloride (1.84 g, 26.4 mmol). The mixture was stirred at 50 °C for 1.5 h. The mixture was diluted with water (50 mL) and extracted with EtOAc (3 x 40 mL). The combined organic layer was washed with saturated NH4C1 (3 x 100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 100/0 to 50/1). to give the title compound (2.0 g, 93%). 1H NMR (400 MHz, DMSO-،/6) 8: 1 L90 (s, 1H), 8.97 (s, 1H), 8.18 (dd, J = 8.6, 2.1 Hz, 1H), 8.06 (d, J= 8.5 Hz, 1H), 2.24 (s, 3H). LC-MS (M+H)+ = 205.1.Step 2: tert-butyl (l-(5-(trifluoromethyl)pyridin-2-yl)ethyl)carbamateBocHN id="p-605" id="p-605" id="p-605"
id="p-605"
[0605]To a solution of l-(5-(trifluoromethyl)pyridin-2-yl)ethan-l-one oxime (2.0 g, 9.mmol) in MeOH (30 mL) was added Boc2O (4.3 g, 19.6 mmol) and Raney-Ni (84 mg, 0.mmol) under argon. The suspension was degassed and purged with hydrogen for 3 times. The mixture was stirred under hydrogen (40 psi) at 40 °C for 12 h. Solid was filtered off and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 100/0 to 2/1) to give the title compound (2.3 g, 81%). 1H NMR (400 MHz, DMSO-d) 8: 8.88 (s, 1H), 8.19 (d, J= 7.0 Hz, 1H), 7.58 - 7.47 (m, 2H), 4.79 - 4.(m, 1H), 1.43 - 1.28 (m, 12H). LC-MS (M+H)+ = 291.1.Step 3: tert-butyl ethyl(l-(5-(trifluoromethyl)pyridin-2-yl)ethyl)carbamate 236 WO 2024/199255 PCT/CN2024/083980 BocN F3C id="p-606" id="p-606" id="p-606"
id="p-606"
[0606]The title compound (430 mg, 39%) was prepared in a manner similar to that in Example 110 & Example 111 step 4 from tert-butyl (l-(5-(trifluoromethyl)pyridin-2-yl)ethyl)carbamate and Etl. LC-MS (M+H)+ = 319.1.Step 4: N-ethyl-1-(5-(trifluoromethyl)pyridin-2-yl)ethan-1-amine hydrochloride f 3c [0607]The title compound (300 mg, 87%) was prepared in a manner similar to that in Example 110 & Example 111 step 5 from tert-butyl ethyl(l-(5-(trifluoromethyl)pyridin-2- yl)ethyl)carbamate. LC-MS (M+H)+ = 219.1.Step 5: 5-amino-N-ethyl-N-( 1 -(5-(trifluoromethyl)pyridin-2-yl)ethyl)- 1 -((2-(trimethylsilyl)ethoxy)methyl)-6.8-dihydro-lH-furo[3.4-d]pyrrolo[3,2-b]pyridine-2-carboxamideN nh 2 SEM F3C [0608]The title compound (190 mg, 75%) was prepared in a manner similar to that in Example 110 & Example 111 step 6 fromN-ethyl-1 -(5-(trifluoromethyl)pyridin-2-yl)ethan-l-amine hydrochloride and 5-amino- 1 -((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro- 1 H-fi1ro[3 ,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid . LC-MS (M+H)+ = 550.3.Step5:(S)-5-amino-N-ethyl-N-(1-(5-(trifluoromethyl)pyridin-2-yl)ethyl)-6,8-dihydro-1H- furo 3,4-d] pvrro lo [3,2-b1pvridine-2-carboxamide & (R)-5-amino-N-ethyl-N-( 1 -(5 - (trifluoromethyl)pyridin-2-yl)ethyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide [0609]Example 114(16 mg, 12%) and Example 115 (20 mg, 15%) were prepared in a manner similar to that in Example 110 & Example 111 step 7 from 5-amino-N-ethyl-N-(l-(5- (trifluoromethyl)pyridin-2-yl)ethyl)-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide, and the enantiomers were separated by chiral SEC.237 WO 2024/199255 PCT/CN2024/083980 [0610]Analytical chiral-SFC condition as below. Column: Chiralpak IC-3; Column size: 4.6X100 mm, 3 pm; Mobile phase: (ethanol containing 0.2% 7 M methanolic NH3):CO2, 1:isocratic; Flow: 4 mL/min; Temperature: 35 °C; backpressure: 2000 psi. [0611]Example 114: Analytical SFC tR=1.03 min. 1H NMR (400 MHz, DMSO-d6) 8 11.65 - 11.43 (m, 1H), 8.97 (s, 1H), 8.20 (d, J= 1A Hz, 1H), 7.62 (d, J= 8.4 Hz, 1H), 6.68 - 6.44 (m, 1H), 5.90 - 5.50 (m, 3H), 5.12 (s, 2H), 4.92 (s, 2H), 3.90 - 3.42 (m, 2H), 1.74 (d, J= 7.0 Hz, 3H), 1.22 - 1.08 (m, 3H). LCMS (M+H)+ = 420.2. [0612]Example 115: Analytical SFC tR=1.29 min. 1H NMR (400 MHz, DMSO-d6) 11.65 - 11.43 (m, 1H), 8.97 (s, 1H), 8.20 (d, J= 1A Hz, 1H), 7.62 (d, J= 8.4 Hz, 1H), 6.68 - 6.44 (m, 1H), 5.90 - 5.50 (m, 3H), 5.12 (s, 2H), 4.92 (s, 2H), 3.90 - 3.42 (m, 2H), 1.74 (d, J= 7.0 Hz, 3H), 1.22 - 1.08 (m, 3H). LCMS (M+H)+ = 420.2. Example 116:(R)-5-amino-N-(2,6-difluoro-4-(trifluoromethyl)benzyl)-6-methyl-N- (pentan-3-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: (2,6-difluoro-4-(trifluoromethyl)phenyl)methanol .OH CF3 id="p-613" id="p-613" id="p-613"
id="p-613"
[0613]To a solution of 2,6-difluoro-4-(trifluoromethyl)benzoic acid (800 mg, 3.54 mmol) in THF (10 mL) was added borane in THF (1.0 M, 14.1 mL, 14.1 mmol) dropwise. The mixture was stirred at 60 °C for 3 h and then cooled to room temperature. The mixture was completely quenched with MeOH (10 mL) and then concentrated under vacuum. The residue was purified by silica gel chromatography (PE:EtOAc=2:l) to give the title compound (700 mg, 93%). LC- MS (M+H)+=213.1.Step 2: N-(2,6-difluoro-4-(trifluoromethvl)benzyl)pentan-3-amine 238 cf 3 WO 2024/199255 PCT/CN2024/083980 [0614]To a solution of (2,6-difluoro-4-(trifluoromethyl)phenyl)methanol (700 mg, 3.3 mmol) in THF (10 mL) was added SOC12 (2.4 mL, 33 mmol). The mixture was stirred at refluxing temperature for 3 h and then cooled to room temperature. Volatiles were removed under reduced pressure. The residue was re-dissolved in MeCN (10 mL) in a sealed tube, followed by addition of pentan-3-amine (376 mg, 4.3 mmol) and DIPEA (0.8 mL, 4.3 mmol). The tube was sealed and the mixture was stirred at 100 °C for 12 h. The mixture was cooled to room temperature and diluted with water (20 mL). The mixture was extracted with EtOAc (50 mL). The organic layer was washed with brine (50 mL), dried over Na2S04, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (DCM:MeOH=20:l) to give the title compound (50 mg, 5%). LC-MS (M+H)+ =281.2.Step3:(R)-5-amino-N-(2,6-difluoro-4-(trifluoromethyl)benzyl)-6-methyl-N-(pentan-3-yl)- 6,8-dihydro-lH-furo[3,4-dlpyrrolo[3,2-blpyridine-2-carboxamide [0615]To a mixture of (R)-5-amino-6-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid (72 mg, 0.31 mmol), N-(2,6-difluoro-4- (trifluoromethyl)benzyl)pentan-3-amine (87 mg, 0.31 mmol) and DIPEA (0.60 ml, 3.1 mmol) in anhydrous DMF (3 mL) under nitrogen was added T3P in EtOAc (50%, 1.0 g, 1.6 mmol) and the mixture was stirred at 60 °C for 16 h. After cooling to room temperature, hydrochloric acid (6 M, mL) was added and the mixture was stirred for 3 h at 60 °C. The mixture was cooled to room temperature and quenched with saturated NaHCO (100 mL). The mixture was extracted with EtOAc (100 mL). The organic layer was washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC to give the title compound (40 mg, 26%). 1H NMR (400 MHz, DMSO-d) 8 11.52 (s, 1H), 7.59 - 7.57 (m, 1H), 6.44 (s, 1H), 5.46 (s, 2H), 5.12 (s, 1H), 5.09 - 4.98 (m, 2H), 4.67 (s, 2H), 1.67 - 1.58 (m, 4H), 1.21 (s, 3H), 0.81 - 0.80 (m, 6H). LC-MS (M+H)+ = 497.4. Example 117:5-amino-N-((3-fluoro-5-morpholinopyridin-2-yl)methyl)-N-(pentan-3-yl)- 6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: N-((5-bromo-3-fluoropyridin-2-yl)methyl)pentan-3-amine 239 WO 2024/199255 PCT/CN2024/083980 id="p-616" id="p-616" id="p-616"
id="p-616"
[0616]The title compound (11.5 g, 85%) was prepared in a manner similar to that in Example step 1 from 5 -bromo-3 -fluoropicolinaldehy de and pentan-3-amine. LC-MS (M+H)+ = 275.0.Step 2: tert-butyl ((5-bromo-3-fluoropyridin-2-yl)methyl)(pentan-3-yl)carbamate id="p-617" id="p-617" id="p-617"
id="p-617"
[0617]The title compound (12.0 g, 98%) was prepared in a manner similar to that in Example & Example 40 step 6 from N-((5-bromo-3-fluoropyridin-2-yl)methyl)pentan-3-amine. LC- MS (M+H)+= 375.1.Step 3: tert-butyl ((3-fluoro-5-morpholinopyridin-2-yl)methyl)(pentan-3-yl)carbamate id="p-618" id="p-618" id="p-618"
id="p-618"
[0618]To a solution of tert-butyl ((5-bromo-3-fluoropyridin-2-yl)methyl)(pentan-3- yl)carbamate (100 mg, 0.266 mmol) and morpholine (46 mg, 0.533 mmol) in toluene (2 mL) was added t-BuONa (38 mg, 0.40 mmol), Xantphos (31 mg, 53 umol) and Pd2(dba)3 (24 mg, umol) under nitrogen and the mixture was stirred at 100 °C for 12 h. The mixture was cooled to room temperature, diluted with water (5 mL) and extracted with EtOAc (3x5 mL). The combined organic layer was washed with brine (10 mL), dried over Na2S04, filtered and concentrated under reduced pressure to give the title compound (90 mg, 89%). LC-MS (M+H)+ = 382.3.Step 4: N-((3-fluoro-5-morpholinopyridin-2-yl)methyl)pentan-3-amine hydrochloride 240 WO 2024/199255 PCT/CN2024/083980 [0619]The title compound (60 mg, 80%) was prepared in a manner similar to that in Example110 & Example 111 step 5 from tert-butyl ((3-fluoro-5-morpholinopyridin-2-yl)methyl)(pentan- 3-yl)carbamate. LC-MS (M+H)+ = 282.3.Step 5: 5-amino-N-((3-fluoro-5-morpholinopyridin-2-yl)methyl)-N-(pentan-3-yl)- 1 -((2- (trimethylsilyl)ethoxy)methyl)-6.8-dihydro-lH-furo[3.4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-620" id="p-620" id="p-620"
id="p-620"
[0620]The title compound (100 mg, 76%) was prepared in a manner similar to that in Example step 2 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and N-((3-fluoro-5-morpholinopyridin-2- yl)m ethyl )pentan-3-amine hydrochloride. LC-MS (M+H)+ = 613.3.Step 6: 5-amino-N-((3-fluoro-5-morpholinopyridin-2-yl)methyl)-N-(pentan-3-yl)-6.8- dihydro-lH-furo[3.4-d]pyrrolo[3.2-b]pyridine-2-carboxamide [0621]Example 117 (34 mg, 48%) was prepared in a manner similar to that in Example 66 step from 5-amino-N-((3-fluoro-5-morpholinopyridin-2-yl)methyl)-N-(pentan-3-yl)- 1 -((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide. 1H NMR (400 MHz, DMSO-d) 8: 11.71 - 11.30 (m, 1H), 8.28 - 8.00 (m, 1H), 7.32 - 7.16 (m, 1H), 6.80 - 6.35 (m, 1H), 5.61 - 5.42 (m, 2H), 5.20 - 5.04 (m, 2H), 4.94 - 4.47 (m, 4H), 4.39 - 4.02 (m, 1H), 3.81 - 3.61 (m, 4H), 3.28 - 3.10 (m, 4H), 1.80 - 1.32 (m, 4H), 0.95 - 0.68 (m, 6H). LC-MS (M+H)+ = 483.3. Example 118 & Example 119:(S)-5-amino-N-(l-(5-cyclopropyl-3-fluoropyridin-2- yl)ethyl)-N-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (R)-5- amino-N-(l-(5-cyclopropyl-3-fluoropyridin-2-yl)ethyl)-N-methyl-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide 241 WO 2024/199255 PCT/CN2024/083980 Br HO id="p-622" id="p-622" id="p-622"
id="p-622"
[0622]To a solution of 5-bromo-3-fluoropicolinaldehyde (10.0 g, 49.0 mmol) in THF (1mL) was added MeMgBr in diethyl ether (3.0 M, 18.0 mL, 54.0 mmol) at -78 °C. The mixture was stirred at 0 °C for l h and then quenched with water (120 mL). The mixture was extracted with EtOAc (3 x 50 mL). The combined organic layer was washed with brine (2 x 20 mL), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 100/1 to 10/1). to give the title compound (7.53 g, 70%). LC-MS (M+H)+= 220.1.Step 2: 2-(l-azidoethyl)-5-bromo-3-fluoropyridine Br n 3 id="p-623" id="p-623" id="p-623"
id="p-623"
[0623]The title compound (5.0 g, 60%) was prepared in a manner similar to that in Example 110 & Example 111 step 2 from l-(5-bromo-3-fluoropyridin-2-yl)ethan-l-ol. ,H NMR (4MHz, CDCb) 8: 8.55 - 8.49 (m, 1H), 7.62 (dd, J= 8.93, 1.83 Hz, 1H), 4.82 (q, J= 6.8 Hz, 1H), 1.64 (d, J = 6.8 Hz, 3H).Step 3: tert-butyl (l-(5-bromo-3-fluoropyridin-2-yl)ethyl)carbamateBocHN id="p-624" id="p-624" id="p-624"
id="p-624"
[0624]To a solution of 2-(l-azidoethyl)-5-bromo-3-fluoropyridine (2.5 g, 10.2 mmol) in THF (30 mL) and water (6 mL) was added KOH (1.43 g, 25.5 mmol) and PPh3 (5.35 g, 20.4 mmol). The mixture was stirred at 50 °C for 1 h and room temperature for 11 h. The mixture was concentrated under reduced pressure. To the residue was added THF (20 mL), B0C20 (2.49 g, 11.4 mmol) and DIPEA (2.95 g, 22.8 mmol). The mixture was stirred at room temperature for h and then concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 100/1 to 10/1) to give the title compound (2.4 g, 74%). 1H NMR (400 MHz, CDCb) 8: 8.47 - 8.41 (m, 1H), 7.57 (dd, J= 8.7, 1.8 Hz, 1H), 5.78 - 5.58 (m, 1H), 5.23 - 5.11 (m, 1H), 1.50 - 1.35 (m, 12H).Step 4: tert-butyl (l-(5-cyclopropvl-3-fLuoropvridin-2-vl)ethyl)carbamate 242 WO 2024/199255 PCT/CN2024/083980 BocHN id="p-625" id="p-625" id="p-625"
id="p-625"
[0625]The title compound (1.3 g, 62%) was prepared in a manner similar to that in Example step 1 from tert-butyl (l-(5-bromo-3-fluoropyridin-2-yl)ethyl)carbamate and cyclopropylboronic acid. LC-MS (M+H-tBu) + = 225.0.Step 5: tert-butyl (l-(5-cyclopropyl-3-fluoropyridin-2-yl)ethyl)(methyl)carbamate id="p-626" id="p-626" id="p-626"
id="p-626"
[0626]The title compound (0.30 g, 95%) was prepared in a manner similar to that in Example & Example 40 step 7 from tert-butyl (l-(5-cyclopropyl-3-fluoropyridin-2-yl)ethyl)carbamate and Mel. LC-MS (M+H)+ = 295.2.Step 6: l-(5-cyclopropyl-3-fluoropyridin-2-yl)-N-methylethan-l-amine hydrochloride —NH N= % // F HCI id="p-627" id="p-627" id="p-627"
id="p-627"
[0627]The title compound (0.20 g, 85%) was prepared in a manner similar to that in Example110 & Example 111 step 5 from tert-butyl (l-(5-cyclopropyl-3-fluoropyridin-2- yl)ethyl)(methyl)carbamate. LC-MS (M+H)+ =195.3.Step 7: 5-amino-N-( 1 -(5-cvclopropvl-3-fLuoropvridin-2-vl)ethyl)-N-methyl- 1 -((2- (trimethylsilyl)ethoxy)methyl)-6 18-dihydro-lH-furo[3 14-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-628" id="p-628" id="p-628"
id="p-628"
[0628]The title compound (0.20 g, 49%) was prepared in a manner similar to that in Example step 2 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and l-(5-cyclopropyl-3-fluoropyridin-2-yl)-N- methylethan-l-amine hydrochloride. LC-MS (M+H)+ =526.4.Step 8: (S)-5-amino-N-، 1 -(5-cyclopropyl-3-fluoropyridin-2-vl)ethyl)-N-methyl-6,8- dihydro-lH-furo[3,4-d]pv1Tolo[3,2-b]pvridine-2-carboxamide & (R)-5-amino-N-(l-(5- 243 NSEM WO 2024/199255 PCT/CN2024/083980 cyclopropyl-3-fluoropyridin-2-yl)ethyl)-N-methyl-6,8-dihydro-lH-furor3,4-dlpyrrolo[3,2- blpyridine-2-carboxamide [0629]Example 118 (40 mg, 27%) and Example 119 (43 mg, 29%) were prepared in a manner similar to that in Example 110 & Example 111 step 7 from 5-amino-N-(l-(5-cyclopropyl-3- fluoropyridin-2-yl)ethyl)-N-methyl- 1 -((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro- 1H- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide, and the enantiomers were separated by chiral SFC. [0630]Analytical chiral-SFC condition as below. Column: Chiralpak IC-3; Column size: 4.6X50 mm, 3 pm; Mobile phase: (0.1% isopropylamine in 1:1 v/v EtOH/MeCN):CO2, 45:isocratic; Flow: 4 mL/min; Temperature: 35 °C; backpressure: 1800 psi. [0631]Example 118: Analytical SFC tR=1.87 min. 1H NMR (400 MHz, DMSO- id="p-634" id="p-634" id="p-634"
id="p-634"
[0634]The title compound (0.15 g, 86%) was prepared in a manner similar to that in Example step 2 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]py1T010[3,2-b]pyridine-2-carb0xylic acid and (R)-l-(5-cyclopropyl-3-fluoropyridin-2-yl)-N- methylethan-l-amine. LC-MS (M+H)+ =526.4.Step 2: (R)-5-amino-N-(l-(5-cyclopropyl-3-fluoropyridin-2-yl)ethyl)-N-methyl-6,8- dihydro-lH-furo[3,4-d]pv1Tolo[3,2-b]pvridine-2-carboxamide [0635]Example 119 (49 mg, 43%) was prepared in a manner similar to that in Example 110 & Example ill step 7 from (R)-5-amino-N-(l-(5-cyclopropyl-3-fluoropyridin-2-yl)ethyl)-N- methyl-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine- 2-carboxamide.244 NSEM WO 2024/199255 PCT/CN2024/083980 Example 120 & Example 121:(R)-5-amino-N-(l-(5-cyclopropyl-3-fluoropyridin-2- yl)ethyl)-N-ethyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (S)-5- amino-N-(l-(5-cyclopropyl-3-fluoropyridin-2-yl)ethyl)-N-ethyl-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: tert-butyl (l-(5-cyclopropyl-3-fluoropyridin-2-yl)ethyl)(ethyl)carbamate Boc id="p-636" id="p-636" id="p-636"
id="p-636"
[0636]The title compound (0.10 g, 23%) was prepared in a manner similar to that in Example & Example 40 step 7 from tert-butyl (l-(5-cyclopropyl-3-fluoropyridin-2-yl)ethyl)carbamate and Etl. LC-MS (M+H)+ = 309.3.Step 2: l-(5-cvclopropvl-3-fluoropvridin-2-vl)-N-ethvlethan-l-amine hydrochloride id="p-637" id="p-637" id="p-637"
id="p-637"
[0637]The title compound (54 mg, 100%) was prepared in a manner similar to that in Example 110 & Example 111 step 5 from tert-butyl (l-(5-cyclopropyl-3-fluoropyridin-2- yl)ethyl)(ethyl)carbamate. LC-MS (M+H)+ = 209.2.Step 3: 5-amino-N-(l-(5-cyclopropyl-3-fluoropyridin-2-yl)ethyl)-N-ethyl-l-((2- (trimethvlsilyl)ethoxv)methyl)-6,8-dihvdro-lH-furo[3,4-d]pyrrolor3,2-b]Dvridine-2-carboxamide id="p-638" id="p-638" id="p-638"
id="p-638"
[0638]The title compound (0.10 g, 48%) was prepared in a manner similar to that in Example 110 & Example 111 step 6 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH- 245 NSEM WO 2024/199255 PCT/CN2024/083980 furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and l-(5-cyclopropyl-3-fluoropyridin-2-yl)- N-ethylethan-l-amine hydrochloride. LC-MS (M+H)+ = 540.4.Step4:(R)-5-amino-N-(1-(5-cyclopropyl-3-fluoropyridin-2-yl)ethyl)-N-ethyl-6,8-dihydro- lH-furo[3,4-dlpyrrolo[3,2-b]pyridine-2-carboxamide & (S)-5-amino-N-(l-(5-cyclopropyl-3- fluoropyridin-2-yl)ethyl)-N-ethyl-6,8-dihydro- 1 H-furo[3,4-d]pyrrolo 13,2-b]pyridine-2- carboxamide [0639]Example 120 (13 mg, 21%) and Example 121 (11 mg, 18%) were prepared in a manner similar to that in Example 110 & Example 111 step 7 from 5-amino-N-(l-(5-cyclopropyl-3- fluoropyridin-2-yl)ethyl)-N-ethyl- 1 -((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro- 1 H-furo[3 ,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide, and the enantiomers were separated by chiral SFC. [0640]Analytical chiral-SFC condition as below. Column: CHIRALPAK IH-3; Column size: 4.6X100 mm, 3 pm; Mobile phase: (isopropanol containing 0.2% 7 M methanolic NH3):CO2, 1:for 0.2 min, 1:9 to 1:1 in 2.2 min, 1:1 for 1 min, 1:1 to 1:9 in 0.6 min; Flow: 3.4 mL/min; Temperature: 35 °C; back pressure: 2000 psi. [0641]Example 120: Analytical SFC tR=2.23 min. 1H NMR (400 MHz, DMSO- Step 1: tert-butyl (l-(4-bromo-2,6-difluorophenyl)ethyl)carbamate 246 WO 2024/199255 PCT/CN2024/083980 HNBoc id="p-643" id="p-643" id="p-643"
id="p-643"
[0643]The title compound (350 mg, 99%) was prepared in a manner similar to that in Example step 2 from l-(4-bromo-2,6-difluorophenyl)ethan-l -amine. 1H NMR (400 MHz, DMSO-،/6) 5: 7.50 - 7.29 (m, 3H), 4.92 - 4.75 (m, 1H), 1.42 - 1.29 (m, 12H).Step 2: tert-butyl (l-(4-bromo-2,6-difluorophenyl)ethyl)(methyl)carbamateBoc—N Br [0644]The title compound (104 mg, 100%) was prepared in a manner similar to that in Example 39 & Example 40 step 7 from tert-butyl (l-(4-bromo-2,6- difluorophenyl)ethyl)carbamate and Mel. LC-MS (M+H-t-Bu) + = 294.1.Step 3: l-(4-bromo-2,6-difluorophenyl)-N-methylethan-l-amine hydrochloride—NH Br HCI id="p-645" id="p-645" id="p-645"
id="p-645"
[0645]The title compound (95 mg, 100%) was prepared in a manner similar to that in Example 110 & Example 111 step 5 from tert-butyl (l-(4-bromo-2,6- difluorophenyl)ethyl)(methyl)carbamate. LC-MS (M+H)+ = 250.0.Step 4: 5-amino-N-(l-(4-bromo-2,6-difluorophenyl)ethyl)-N-methyl-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-646" id="p-646" id="p-646"
id="p-646"
[0646]The title compound (150 mg, 87%) was prepared in a manner similar to that in Example step 2 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]py1T010[3,2-b]pyridine-2-carb0xylic acid and l-(4-bromo-2,6-difluorophenyl)-N-methylethan- 1-amine hydrochloride. LC-MS (M+H)+ = 581.2.Step 4: (S)-5-amino-N-(l-(4-bromo-2,6-difluorophenyl)ethyl)-N-methyl-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (R)-5-amino-N-(l-(4-bromo-2,6- 247 WO 2024/199255 PCT/CN2024/083980 difh1orophenyl)ethyl)-N-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide [0647]Example 122 (24 mg, 13%) and Example 123 (23 mg, 12%) were prepared in a manner similar to that in Example 110 & Example 111 step 7 from 5-amino-N-(l-(4-bromo-2,6- difluorophenyl)ethyl)-N-methyl-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide, and the enantiomers were separated by chiral SFC. [0648]Analytical chiral-SFC condition as below. Column: Chiralcel OD-3; Column size: 4.6X50 mm, 3 pm; Mobile phase: (isopropanol containing 0.2% 7 M methanolic NH3):CO2, 1:for 0.2 min, 1:19 to 1:1 in 1 min, 1:1 for 1 min, 1:1 to 1:19 in 0.4 min, 1:19 for 0.4 min; Flow: 3.4 mL/min; Temperature: 35 °C; back pressure: 1800 psi. [0649]Example 122: Analytical SFC tR=1.48 min. 1H NMR (400 MHz, DMSO- Step 1: l-(4-bromo-2-fluorophenvl)-N-ethylethan-l -amine id="p-651" id="p-651" id="p-651"
id="p-651"
[0651]To a solution of l-(4-bromo-2-fluorophenyl)ethan-l-one (500 mg, 2.31 mmol) in MeOH (10 mL) was added ethylamine in THF (2.0 M, 2.3 mL, 4.62 mmol) and NaBHJCN (2mg, 4.62 mmol). The mixture was stirred for 16 h at 60 °C and then cooled to room temperature The mixture was quenched with saturated NaHCO3 (50 mL) and then extracted with EtOAc (mL). The organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and 248 WO 2024/199255 PCT/CN2024/083980 concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM:MeOH=20:l) to give the title compound (300 mg, 53%). LC-MS (M+H)+ =246.3.Step2:(R)-5-amino-N-((R)-1-(4-bromo-2-fluorophenyl)ethyl)-N-ethyl-6-methyl-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & ((R)-5-amino-N-((S)-l-(4- bromo-2-fluorophenyl)ethyl)-N-ethyl-6-methyl-6,8-dihydro-lH-fi1ro[3,4-d1pyrrolo[3,2- blpyridine-2-carboxamide [0652]To a mixture of (R)-5-amino-6-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid (40 mg, 0.17 mmol), l-(4-bromo-2-fluorophenyl)-N-ethylethan-l- amine (42 mg, 0.17 mmol) and DIPEA (155 mg, 1.2 mmol) in anhydrous DMF (3 mL) under nitrogen was added T3P in EtOAc (50%, 546 mg, 0.86 mmol) and the mixture was stirred at °C for 16 h. After cooling to room temperature, 6 M HC1 (9 mL) was added and the mixture was stirred for 3 h at 60 °C. The mixture was cooled to room temperature and quenched with saturated NaHCO3 (100 mL). The mixture was extracted with EtOAc (100 mL). The organic layer was washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC and further separated by SFC to give Example 124 (12 mg, 16%) and Example 125 (12 mg, 16%). [0653]Analytical chiral-SFC condition as below. Column: YMC Cellulose-C; Column size: 4.6X100 mm, 5 pm; Mobile phase: 4 mM methanolic NH3:CO2, 1:9 to 4:6 in 3 min, 4:6 for min, 4:6 to 1:9 in 0.1 min, 1:9 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; back pressure: 1500 psi. [0654]Example 124: Analytical SFC tR=4.20 min. 1H NMR (400 MHz, DMSO-d) 8 11.52 (s, 1H), 7.66 - 7.39 (m, 3H), 6.51 (s, 1H), 5.96 - 5.81 (m, 1H), 5.44 (s, 2H), 5.32 (s, 1H), 5.21 - 5.(m, 1H), 5.06 - 4.95 (m, 1H), 3.52 - 3.34 (m, 2H), 1.75 - 1.58 (m, 3H), 1.40 - 1.30 (m, 3H), 0.- 0.85 (m, 3H). LC-MS (M+H)+ = 461.3. [0655]Example 125: Analytical SFC tR=4.60 min. 1H NMR (400 MHz, DMSO-d) 8 11.52 (s, 1H), 7.59 - 7.33 (m, 3H), 6.51 (s, 1H), 5.97 - 5.79 (m, 1H), 5.44 (s, 2H), 5.32 (s, 1H), 5.19 - 5.(m, 1H), 5.07 - 4.89 (m, 1H), 3.63 - 3.32 (m, 2H), 1.73 - 1.52 (m, 3H), 1.39 - 1.28 (m, 3H), 0.- 0.87 (m, 3H). LC-MS (M+H)+ = 461.3. Example 126 & Example 127:(R)-5-amino-N-ethyl-N-((R)-l-(2-fluoro-4- (trifluoromethyl)phenyl)ethyl)-6-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide & (R)-5-amino-N-ethyl-N-((S)- 1 -(2-fluoro-4-(trifluoromethyl)phenyl)ethyl)-6- methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide 249 WO 2024/199255 PCT/CN2024/083980 N NH2 N NH2 Step1:N-ethyl-1-(2-fluoro-4-(trifluoromethyl)phenyl)ethan-1-amine id="p-656" id="p-656" id="p-656"
id="p-656"
[0656]The title compound (400 mg, 70%) was prepared in a manner similar to that in Example 124 & Example 125 step 1 from l-(2-fluoro-4-(trifluoromethyl)phenyl)ethan-l-one and ethylamine. LC-MS (M+H)+ = 236.2.Step 2: (R)-5-amino-N-ethyl-N-((R)-l -(2-fluoro-4-(trifluoromethyl)phenyl)ethyl)-6-methyl- 6,8-dihydro-lH-furor3,4-dlpyrrolor3,2-blpyridine-2-carboxamide & (R)-5-amino-N-ethyl-N- ((S)-1-(2-fluoro-4-(trifluoromethyl)phenyl)ethyl)-6-methyl-6.8-dihydro-1H-furo[3.4- dlpyrrolo 13,2-blpyridine-2-carboxamide [0657]Example 126 (6 mg, 7%) and Example 127 (8 mg, 11 %) were prepared in a manner similar to that in Example 124 & Example 125 step 2 from (R)-5-amino-6-methyl-6,8-dihydro- lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and N-ethyl-l-(2-fluoro-4- (trifluoromethyl)phenyl)ethan-l-amine, and the diastereomers were separated by chiral SFC. [0658]Analytical chiral-SFC condition as below. Column: YMC Cellulose-C; Column size: 4.6X100 mm, 5 pm; Mobile phase: 4 mM methanolic NH3:CO2, 1:9 to 4:6 in 3 min, 4:6 for min, 4:6 to 1:9 in 0.1 min, 1:9 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; back pressure: 1500 psi. [0659]Example 126: Analytical SFC tR=3.06 min. 1H NMR (400 MHz, DMSO-d) 8 11.54 (s, 1H), 7.86 - 7.73 (m, 1H), 7.70 - 7.53 (m, 2H), 6.52 (s, 1H), 5.96 - 5.88 (m, 1H), 5.47 (s, 2H), 5.36 - 5.28 (m, 1H), 5.19 - 5.07 (m, 1H), 5.06 - 4.97 (m, 1H), 3.62 - 3.33 (m, 2H), 1.74 - 1.60 (m, 3H), 1.37 - 1.31 (m, 3H), 1.02 - 0.89 (m, 3H). LCMS (M+H)+ = 451.3. [0660]Example 127: Analytical SFC tR=3.32 min. 1H NMR (400 MHz, DMSO- 250 WO 2024/199255 PCT/CN2024/083980 (R)-5-amino-N-((S)-l-(5-brorno-3-fluoropyridin-2-yl)ethyl)-N-ethyl-6-methyl-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-661" id="p-661" id="p-661"
id="p-661"
[0661]To a solution of l-(5-bromo-3-fluoropyridin-2-yl)ethan-l-one (300 mg, 1.38 mmol) in MeOH (10 mL) was added EtNH 2 in THF (2.0 M, 1.37 mL, 2.76 mmol) and NaBH 3CN (174 mg, 2.76 mmol). The mixture was stirred for 16 h at 60 °C. The reaction mixture was cooled to room temperature and quenched with saturated NaHCOa (50 mL). The mixture was extracted with EtOAc (50 mL). The organic layer was washed with brine (50 mL), dried over Na 2SO4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (DCM:MeOH=20:1) to give the title compound (150 mg, 44%). LC-MS (M+H)+ =247.1.Step 2: (R)-5-amino-N-((R)-l-(5-bromo-3-fluoropyridin-2-yf)ethyl)-N-ethyl-6-methyl-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (R)-5-amino-N-((S)-l-(5- bromo-3-fluoropvridin-2-vl)ethvl)-N-ethvl-6-methvl-6,8-dihvdro-lH-furor3,4-dlpvn ־olor3,2- b1pyridine-2-carboxamide [0662]Example 129 (16 mg, 16%) and Example 130 (19 mg, 19%) were prepared in a manner similar to that in Example 124 & Example 125 step 2 from (R)-5-amino-6-methyl-6,8-dihydro- lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and l-(5-bromo-3-fluoropyridin-2-yl)- N-ethylethan-l-amine, and the diastereomers were separated by chiral SEC. [0663]Analytical chiral-SFC condition as below. Column: Lux Cellulose-4; Column size: 4.6X100 mm, 5 pm; Mobile phase: 4 mM methanolic NH3:CO2, 45:55 for 5 min, 45:55 to 1:1 in 0.1 min, 1:1 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; backpressure: 1500 psi. [0664]Example 129: Analytical SFC tR=3.83 min. 1H NMR (400 MHz, DMSO- 251 WO 2024/199255 PCT/CN2024/083980 [0665]Example 130: Analytical SEC tR=4.92 min. 1H NMR (400 MHz, DMSO- id="p-666" id="p-666" id="p-666"
id="p-666"
[0666]The title compound (100 mg, 35%) was prepared in a manner similar to that in Example 124 & Example 125 step 1 from l-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethan-l-one and ethylamine. LC-MS (M+H)+ = 237.4.Step 2: (R)-5-amino-N-ethyl-N-((R)-l-(3-fluoro-5-(trifluoromethvl)pvridin-2-vl)ethvl)-6- methyl-6,8-dihvdro-lH-furo[3,4-d]pvrrolor3,2-b]pvridine-2-carboxamide & (R)-5-amino-N- ethyl-N-((S)-l-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethyl)-6-methyl-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0667]Example 130 (17 mg, 18%) and Example 131 (18 mg, 18%) were prepared in a manner similar to that in Example 124 & Example 125 step 2 from (R)-5-amino-6-methyl-6,8-dihydro- lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and N-ethyl-l-(3-fluoro-5- (trifluoromethyl)pyridin-2-yl)ethan-l-amine, and the diastereomers were separated by chiral SEC. [0668]Analytical chiral-SFC condition as below. Column: Lux Cellulose-4; Column size: 4.6X100 mm, 5 pm; Mobile phase: 4 mM methanolic NH3:CO2, 1:9 to 1:1 in 3 min, 1:1 for min, 1:1 to 1:9 in 0.1 min, 1:9 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; back pressure: 1500 psi. [0669]Example 130: Analytical SEC tR=3.33 min. 1H NMR (400 MHz, DMSO- WO 2024/199255 PCT/CN2024/083980 (m, 1H), 5.21 - 5.06 (m, 1H), 5.06 - 4.91 (m, 1H), 3.78 - 3.32 (m, 2H), 1.75 - 1.59 (m, 3H), 1.- 1.27 (m, 3H), 1.05 - 0.92 (m, 3H). LCMS (M+H)+ = 452.3. [0670]Example 131: Analytical SEC tR=3.64 min. 1HNMR (400 MHz, DMSO- Step 1: N-ethyl- 1 -(3-fluoro-5-morpholinopvridin-2-yl)ethan- 1 -amine id="p-673" id="p-673" id="p-673"
id="p-673"
[0673]The title compound (20 mg, 36%) was prepared in a manner similar to that in Example 124 & Example 125 step 1 from l-(3-fluoro-5-morpholinopyridin-2-yl)ethan-l-one and ethylamine. LC-MS (M+H)+ = 254.2.Step 2: 5-amino-N-ethyl-N-(l-(3-fluoro-5-morpholinopvridin-2-vl)ethvl)-l-((2- (trimethylsilyl)ethoxv)methvl)-6,8-dihydro-lH-furo[3,4-d1pyn ־olo[3,2-blDyridine-2-carboxamide 253 WO 2024/199255 PCT/CN2024/083980 [0674]The title compound (10 mg, 21%) was prepared in a manner similar to that in Example step 2 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and N-ethyl-l-(3-fluoro-5-morpholinopyridin-2- yl)ethan-l-amine. LC-MS (M+H)+ = 585.4.Step 3: 5-amino-N-ethyl-N-(l-(3-fluoro-5-morpholinopyridin-2-yl)ethyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0675]Example 132 (3 mg, 38%) was prepared in a manner similar to that in Example 66 stepfrom 5-amino-N-ethyl-N-( 1 -(3 -fluoro-5 -morpholinopyridin-2-y !)ethyl)- 1 -((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide. 1H NMR (400 MHz, DMSO-t/6) 5 11.52 (s, 1H), 7.25 - 7.22 (m, 1H), 6.55 (s, 1H), 6.03 (s, 1H), 5.54 (s, 2H), 5.12 (s, 2H), 4.91 (s, 2H), 3.71 (s, 4H), 3.20 (s, 4H), 1.61 (s, 3H), 0.- 0.80 (m, 3H). LC-MS (M+H)+ = 455.4. Example 133 & Example 134:(R)-5-amino-N-(l-(4-bromo-2-fluorophenyl)ethyl)-N-ethyl- 6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (S)-5-amino-N-(l-(4- bromo-2-fluorophenyl)ethyl)-N-ethyl-6, 8 -dihydro- 1 H-furo [3,4-d]pyrrolo [3,2-b]pyridine-2- carboxamide id="p-676" id="p-676" id="p-676"
id="p-676"
[0676]Example 133 (6 mg, 8%) and Example 134 (6 mg, 7%) were prepared in a manner similar to that in Example 124 & Example 125 step 2 from 5-amino-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and l-(5-bromo-3-fluoropyridin-2-yl)-N-ethylethan- 1-amine, and the enantiomers were separated by chiral SEC. [0677]Analytical chiral-SFC condition as below. Column: CHIRALPAK AS-H; Column size: 4.6X100 mm, 5 pm; Mobile phase: 4 mM methanolic NH3:CO2, 1:9 to 1:1 in 3 min, 1:1 for min, 1:1 to 1:9 in 0.1 min, 1:9 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; back pressure: 1500 psi. [0678]Example 133: Analytical SEC tR=2.74 min. 1H NMR (400 MHz, DMSO- WO 2024/199255 PCT/CN2024/083980 Example 135 & Example 136:(R)-5-amino-N-ethyl-N-(l-(2-fluoro-4-(trifluoromethyl)phenyl)ethyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide& (S)-5-amino-N-ethyl-N-(l-(2-fh1oro-4-(trifluoromethyl)phenyl)ethyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-680" id="p-680" id="p-680"
id="p-680"
[0680]Example 135 (13 mg, 17%) and Example 136 (11 mg, 14%) were prepared in a manner similar to that in Example 124 & Example 125 step 2 from 5-amino-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and l-(4-bromo-2-fluorophenyl)-N-ethylethan-l- amine, and the enantiomers were separated by chiral SFC. [0681]Analytical chiral-SFC condition as below. Column: CHIRALPAK AS-H; Column size: 4.6X100 mm, 5 pm; Mobile phase: 4 mM methanolic NH3:CO2, 1:9 to 1:1 in 3 min, 1:1 for min, 1:1 to 1:9 in 0.1 min, 1:9 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; back pressure: 1500 psi. [0682]Example 135: Analytical SFC tR=1.96 min. ,HNMR (400 MHz, DMSO-،/6) 8 11.53 (s, 1H), 7.83 - 7.71 (m, 1H), 7.71 - 7.56 (m, 2H), 6.54 (s, 1H), 5.96 - 5.88 (m, 1H), 5.55 (s, 2H), 5.11 (s, 2H), 4.90 (s, 2H), 3.57 - 3.42 (m, 2H), 1.76 - 1.59 (m, 3H), 1.02 - 0.91 (m, 3H). LCMS (M+H)+= 437.3. [0683]Example 136: Analytical SFC tR=2.21 min. 1H NMR (400 MHz, DMSO-d) 8 11.56 (s, 1H), 7.86 - 7.75 (m, 1H), 7.70 - 7.49 (m, 2H), 6.54 (s, 1H), 5.97 - 5.88 (m, 1H), 5.59 (s, 2H), 5.11 (s, 2H), 4.90 (s, 2H), 3.55 - 3.41 (m, 2H), 1.78 - 1.59 (m, 3H), 0.99 - 0.91 (m, 3H). LCMS (M+H)+= 437.3. Example 137 & Example 138:(R)-5-amino-N-(l-(4-bromo-2-fluorophenyl)ethyl)-N- methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (S)-5-amino-N-(l- (4-bromo-2-fluorophenyl)ethyl)-N-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide Step 1: l-(4-bromo-2-fluorophenvl)-N-methvlethan-l-amine 255 WO 2024/199255 PCT/CN2024/083980 Br [0684]To a solution of l-(4-bromo-2-fluorophenyl)ethan-l-one (4.32 g, 20.0 mmol), MeNHin THF (2.0 M, 20 mL, 40.0 mmol) in DCM (80 mL) was added NaH(OAc)3 (8.44 g, 40.mmol) in portions. The mixture was stirred at room temperature for 48 h and then quenched with saturated NaHCO3 (200 mL). The mixture was extracted with DCM (3 x 50 mL). The combined organic layer was dried with Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM:MeOH = 30:1) to give the title compound (820 mg, 18%). LC-MS (M+H)+ =232.1.Step 2: 5-amino-N-(l-(4-bromo-2-fluorophenyl)ethyl)-N-methyl-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furor3,4-dlpyrrolor3,2-blpyridine-2-carboxamide id="p-685" id="p-685" id="p-685"
id="p-685"
[0685]The title compound (170 mg, 76%) was prepared in a manner similar to that in Example 110 & Example 111 step 6 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and l-(4-bromo-2-fluorophenyl)-N- methylethan-l-amine. LC-MS (M+H)+ =563.4.Step3:(R)-5-amino-N-(1-(4-bromo-2-fluorophenyl)ethyl)-N-methyl-6,8-dihydro-1H- furor3,4-d1pv1Tolo[3,2-b1pvridine-2-carboxamide & (S)-5-amino-N-(l-(4-bromo-2- fluorophenyl)ethyl)-N-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-blpyridine-2-carboxamide [0686]Example 137 (43 mg, 33%) and Example 138 (44 mg, 34%) were prepared in a manner similar to that in Example 110 & Example 111 step 7 from 5-amino-N-(l-(4-bromo-2- fluorophenyl)ethyl)-N-methyl-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide, and the enantiomers were separated by chiral SEC. [0687]Analytical chiral-SFC condition as below. Column: CHIRALPAK AS-H; Column size: 4.6X100 mm, 5 pm; Mobile phase: 4 mM methanolic NH3:CO2, 1:9 to 1:1 in 3 min, 1:1 for min, 1:1 to 1:9 in 0.1 min, 1:9 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; back pressure: 1500 psi. [0688]Example 137: Analytical SFC tR=2.88 min. 1H NMR (400 MHz, DMSO- 256 WO 2024/199255 PCT/CN2024/083980 [0689]Example 138: Analytical SEC tR=3.17 min. 1H NMR (400 MHz, DMSO- id="p-690" id="p-690" id="p-690"
id="p-690"
[0690]To a mixture of (R)-5-amino-6-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid (117 mg, 0.50 mmol), l-(4-bromo-2-fluorophenyl)-N-methylethan- 1-amine (116 mg, 0.50 mmol) and DIPEA (516 mg, 4.0 mmol) in anhydrous DMF (6 mL) under nitrogen was added T3P in DMF (50%, 1.59 g, 2.5 mmol) and the mixture was stirred at 60 °C for 2 h. After cooling to room temperature, HC1 in MeOH (4.0 M, 6 mL) was added and the mixture was stirred for 6 h at 60 °C. The mixture was cooled to room temperature and quenched with saturated NaHCOa (100 mL). The mixture was extracted with EtOAc (4 x 50 mL). The combined organic layer was washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (DCM:MeOH = 15:1) and further separated by SFC to give Example 139 (35 mg, 16%) and Example 140 (36 mg, 16%). [0691]Analytical chiral-SFC condition as below. Column: CHIRALPAK AS-H; Column size: 4.6X100 mm, 5 pm; Mobile phase: 4 mM methanolic NH3:CO2, 1:9 to 1:1 in 3 min, 1:1 for min, 1:1 to 1:9 in 0.1 min, 1:9 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; back pressure: 1500 psi. [0692]Example 139: Analytical SFC tR=2.71 min. 1H NMR (400 MHz, DMSO-،Z6) 8 11.53 (s, 1H), 7.54 (d, J= 10.1 Hz, 1H), 7.50 - 7.41 (m, 2H), 6.70 - 6.46 (m, 1H), 6.02 - 5.86 (m, 1H), 5.60 - 5.39 (m, 2H), 5.38 - 5.27 (m, 1H), 5.14 (dd, J= 14.0, 3.2 Hz, 1H), 5.02 (d, J= 13.9 Hz, 1H), 3.16 - 2.71 (m, 3H), 1.57 (d, J= 5.0 Hz, 3H), 1.34 (d, J= 6.1 Hz, 3H). LCMS (M+H)+ = 447.3. [0693]Example 140: Analytical SFC tR=2.93 min. 1H NMR (400 MHz, DMSO- 257 N nh 2 WO 2024/199255 PCT/CN2024/083980 2H), 5.37 - 5.26 (m, 1H), 5.13 (dd, J= 13.9, 3.3 Hz, 1H), 5.03 (d, J= 14.0 Hz, 1H), 3.14 - 2.(m, 3H), 1.57 (d, J= 5.0 Hz, 3H), 1.34 (d, J= 6.1 Hz, 3H). LCMS (M+H)+= 447.3. Example 141:(S)-(5-amino-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-2-yl)(3-(4- (trifluoromethyl)phenyl)morpholino)methanone Step1:(S)-(5-amino-1-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-1H-furo[3,4-d]pyrrolo[3,2-blpyridin-2-yl)(3-(4-(trifluoromethyl)phenyl)morpholino)methanone id="p-694" id="p-694" id="p-694"
id="p-694"
[0694]To a mixture of 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid (151 mg, 0.43 mmol) and DIPEA (0.23 ml, 1.mmol) in THE (10 mL) was added BOPC1 (164 mg, 0.65 mmol) and (S)-3-(4- (trifluoromethyl)phenyl)morpholine (100 mg, 0.43 mmol). The mixture was stirred at 60 °C for h and then cooled to room temperature. The mixture was diluted with water (10 mL) and then extracted with EtOAc (50 mL). The organic layer was washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep- TLC to give the title compound (100 mg, 41%). LC-MS (M+H)+=563.3.Step 2: (S)-(5-amino-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridin-2-yl)(3-(4- (trifluoromethvl)phenvl)morpholino)methanone [0695]To (S)-(5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridin-2-yl)(3-(4-(trifluoromethyl)phenyl)morpholino)methanone (100 mg, 0.18 mmol) was added TEA (2 mL), and the mixture was stirred at room temperature for 0.5 h. The mixture was concentrated under reduced pressure, and the residue was re-dissolved in THE (4 mL), and then strong ammonia solution (28%, 1 mL) was added. The mixture was stirred at room temperature for 2 h and concentrated under reduced pressure. The residue was purified by prep-HPLC to give Example 141 (30 mg, 39%). 1H NMR (400 MHz, DMSO-<76) 8 12.16 (s, 1H), 7.77 - 7.75 (m, 2H), 7.65 - 7.63 (m, 2H), 6.65 (s, 2H), 5.66 (s, 1H), 5.17 (s, 2H), 4.92 (s, 2H), 4.48 (s, 1H), 4.25 (s, 1H), 3.83 - 3.85 (m, 2H), 3.56 - 3.54 (m, 1H). LC-MS (M+H)+ = 433.4. 258 f 3c N n>SEM WO 2024/199255 PCT/CN2024/083980 Example 142:(R)-5-amino-N-((R)-l-(5-cyclopropyl-3-fluoropyridin-2-yl)ethyl)-N,6- dimethyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step1:1-(5-cyclopropyl-3-fluoropyridin-2-yl)ethan-1-one0, id="p-696" id="p-696" id="p-696"
id="p-696"
[0696]To a solution of l-(5-bromo-3-fluoropyridin-2-yl)ethan-l-one (5.0 g, 22.9 mmol) in dioxane (100 mL) and water (20 mL) was added cyclopropylboronic acid (2.96 g, 34.4 mmol), K2CO3 (6.32 g, 45.8 mmol) and Pd(dppf)C12 (1.68 g, 2.29 mmol). The mixture was stirred for h at 100 °C under nitrogen and then cooled to room temperature. The mixture was diluted with water (150 mL) and then extracted with EtOAc (150 mL). The organic layer was washed with brine (2 x 150 mL), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE:EtOAc = 10:1) to give the title compound (1.0 g, 24%). LC-MS (M+H)+ = 180.3.Step 2: (S)-l-(5-cvclopropvl-3-fluoropvridin-2-yl)ethan-l-ol id="p-697" id="p-697" id="p-697"
id="p-697"
[0697]To a solution of l-(5-cyclopropyl-3-fluoropyridin-2-yl)ethan-l-one (440 mg, 2.mmol) in formic acid-Et3N complex (5:2, 10 mL) was added [(S,S)-N-(2-amino-l,2- diphenylethyl)-p-toluenesulfonamide]chloro(p-cymene)ruthenium(II) (78 mg, 0.12 mmol) at - °C under hydrogen. The mixture was stirred at 0 °C for 2 h and at room temperature for 12 h. The mixture was diluted with saturated NaHCO3 (150 mL) and extracted with EtOAc (150 mL). The organic layer was washed with brine (150 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE:EtOAc = 10:1) to give the title compound (382 mg, 86%). LC-MS (M+H)+ = 182.1.Step3:(R)-N-(1-(5-cyclopropyl-3-fluoropyridin-2-yl)ethyl)-N-methyl-2- nitrobenzenesulfonamide259 WO 2024/199255 PCT/CN2024/083980 F [0698]To a mixture of (S)-l-(5-cyclopropyl-3-fluoropyridin-2-yl)ethan-l-ol (350 mg, 1.mmol), N-methyl-2-nitro-benzenesulfonamide (415 mg, 1.92 mmol) and PPh (604 mg, 2.mmol) in THF (15 mL) was added DtBAD (529 mg, 2.30 mmol) in portions at 0 °C under nitrogen. The mixture was stirred at room temperature for 3 h. The mixture was diluted water (100 mL) and then extracted with EtOAc (100 mL). The organic layer was washed with brine (100 mL), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE:EtOAc = 3:1) to give the title compound (720 mg, 100%). LC-MS (M+H)+ = 380.4.Step 4: (R)-1 -(5-cyclopropyl-3-fluoropyridin-2-yl)-N-methylethan- 1 -amine—NH N= id="p-699" id="p-699" id="p-699"
id="p-699"
[0699]To a mixture of (R)-N-(l-(5-cyclopropyl-3-fluoropyridin-2-yl)ethyl)-N-methyl-2- nitrobenzenesulfonamide (720 mg, 1.92 mmol), dodecane- 1-thiol (1.23 g, 6.09 mmol) in DMF (mL) and THF (20 mL) was added LiOHH2O (256 mg, 6.09 mmol), and the mixture was stirred at room temperature for 16 h. Volatiles were removed under reduced pressure and the residue was partitioned between water (50 mL) and EtOAc (50 mL). The organic layer was separated, dried with Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 1/1 to DCM:MeOH=10:l) to give the title compound (300 mg, 81%). LC-MS (M+H)+ =195.1.Step 5: (R)-5-amino-N-((R)-l-(5-cyclopropvl-3-fluoropvridin-2-vl)ethvl)-N,6-dimethvl-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0700]To a mixture of (R)-5-amino-6-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid (50 mg, 0.21 mmol), (R)-l-(5-cyclopropyl-3-fluoropyridin-2-yl)-N- methylethan-1-amine (42 mg, 0.21 mmol) and DIPEA (194 mg, 1.5 mmol) in anhydrous DMF (mL) under nitrogen was added T3P in EtOAc (50%, 682 mg, 1.07 mmol) and the mixture was stirred at 60 °C for 16 h. After cooling to room temperature, 6 M HC1 (9 mL) was added and the mixture was stirred for 3 h at 60 °C. The mixture was cooled to room temperature and quenched with saturated NaHCO3 (100 mL). The mixture was extracted with EtOAc (100 mL). The organic layer was washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC and SFC to give Example 1 260 WO 2024/199255 PCT/CN2024/083980 (23 mg, 27%). 'HNMR(400 MHz, DMSO-،/6) 8 11.51 (s, 1H), 8.29 (s, 1H), 7.33 (d, J= 11.Hz, 1H), 6.79 - 6.43 (m, 1H), 6.20 - 5.93 (m, 1H), 5.56 - 5.40 (m, 2H), 5.38 - 5.26 (m, 1H), 5.13 (dd, J= 14.0, 2.9 Hz, 1H), 5.02 ^J= 13.6 Hz, 1H), 3.21-2.61 (m, 3H), 2.05-1.91 (m, 1H), 1.72 - 1.40 (m, 3H), 1.34 (d, J= 6.1 Hz, 3H), 1.10 - 0.90 (m, 2H), 0.83 - 0.67 (m, 2H). LC-MS (M+H)+= 410.4. Example 143 & Example 144:(R)-5-amino-N-(l-(5-bromo-3-fluoropyridin-2-yl)ethyl)-N- ethyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (S)-5-amino-N-(l-(5- bromo-3-fluoropyridin-2-yl)ethyl)-N-ethyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide Step1:5-amino-N-(1-(5-bromo-3-fluoropyridin-2-yl)ethyl)-N-ethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-701" id="p-701" id="p-701"
id="p-701"
[0701]The title compound (2.0 g, 43%) was prepared in a manner similar to that in Example step 2 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and l-(5-bromo-3-fluoropyridin-2-yl)-N-ethylethan- 1-amine. LC-MS (M+H)+ = 578.3.Step 2: (R)-5-amino-N-(l-(5-bromo-3-fluoropvridin-2-vl)ethyl)-N-ethvl-6,8-dihydro-lH- furor3,4-d1py1Tolo[3,2-b1pyridine-2-carboxamide & (S)-5-amino-N-(l-(5-bromo-3- fluoropyridin-2-yl)ethyl)-N-ethyl-6,8-dihydro- 1 H-furo[3,4-d]pyrrolo [ 3,2-b1pyridine-2- carboxamide [0702]Example 143 (78 mg, 5%) and Example 144 (91 mg, 6%) were prepared in a manner similar to that in Example 110 & Example 111 step 7 from 5-amino-N-(l-(5-bromo-3- fluoropyridin-2-yl)ethyl)-N-ethyl-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide, and the enantiomers were separated by chiral SEC. [0703]Analytical chiral-SFC condition as below. Column: Chiralcel OZ-3; Column size: 4.6X50 mm, 3 pm; Mobile phase: 14 mM NH3 in MeOH:CO2, 1:19 for 0.2 min, 1:19 to 1:1 in 1 261 WO 2024/199255 PCT/CN2024/083980 min, 1:1 for 1 min, 1:1 to 1:19 in 0.4 min, 1:19 for 0.4 min; Flow: 3.4 mL/min; Temperature: °C; back pressure: 1800 psi. [0704]Example 143: Analytical SFC tR=1.89 min. 1H NMR (400 MHz, DMSO- Step 1: l-(2-fluoro-4-(trifluoromethyl)phenyl)-N-methylethan-l-amine—NH F F3C id="p-706" id="p-706" id="p-706"
id="p-706"
[0706]The title compound (420 mg, 16%) was prepared in a manner similar to that in Example 137 & Example 138 step 1 from l-(2-fluoro-4-(trifluoromethyl)phenyl)ethan-l-one andMeNH2. LC-MS (M+H)+= 222.1Step2:5-amino-N-(1-(2-fluoro-4-(trifluoromethyl)phenyl)ethyl)-N-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-707" id="p-707" id="p-707"
id="p-707"
[0707]The title compound (173 mg, 78%) was prepared in a manner similar to that in Example 110 & Example 111 step 6 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH- 262 WO 2024/199255 PCT/CN2024/083980 furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and l-(2-fluoro-4-(trifluoromethyl)phenyl)- N-methylethan-l-amine. LC-MS (M+H)+ = 553.2.Step3:(R)-5-amino-N-(1-(2-fluoro-4-(trifluoromethyl)phenyl)ethyl)-N-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (S)-5-amino-N-(l-(2-fluoro-4- (trifluoromethyl)phenyl)ethyl)-N-methyl-6,8-dihydro-lH-furo[3,4-dlpyrrolo[3,2-b]pyridine-2- carboxamide [0708]Example 145 (48 mg, 37%) and Example 146 (49 mg, 37%) were prepared in a manner similar to that in Example 110 & Example 111 step 7 from 5-amino-N-(l-(2-fluoro-4- (trifluoromethyl)phenyl)ethyl)-N-methyl-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide, and the enantiomers were separated by chiral SFC. [0709]Analytical chiral-SFC condition as below. Column: CHIRALPAK AS-H; Column size: 4.6X100 mm, 5 pm; Mobile phase: 4 mM methanolic NH3:CO2, 1:9 to 1:1 in 3 min, 1:1 for min, 1:1 to 1:9 in 0.1 min, 1:9 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; back pressure: 1500 psi. [0710]Example 145: Analytical SFC tR=2.02 min. ,H NMR (400 MHz, DMSO-،/6) 8 11.56 (s, 1H), 7.83 - 7.51 (m, 3H), 6.69 - 6.45 (m, 1H), 6.13 - 5.86 (m, 1H), 5.63 (s, 2H), 5.12 (s, 2H), 4.91 (s, 2H), 3.14 - 2.62 (m, 3H), 1.81 - 1.45 (m, 3H).LCMS (M+H)+ = 423.4. [0711]Example 146: Analytical SFC tR=2.24 min. 1H NMR (400 MHz, DMSO- id="p-713" id="p-713" id="p-713"
id="p-713"
[0713]The title compound (730 mg, 99%) was prepared in a manner similar to that in Example 110 & Example 111 step 9 from (S)-l-(3-fluoro-5-(trifluoromethyl)pyridine-2-yl)ethan-l-ol and N-methyl-2-nitro-benzenesulfonamide. LC-MS (M+H)+ = 408.1.Step 2: (R)-1 -(3 -fluoro-5-(trifluoromethvl)pvridin-2-vl)-N-methylethan- 1 -amine —NH f 3c 263 WO 2024/199255 PCT/CN2024/083980 [0714]The title compound (250 mg, 63%) was prepared in a manner similar to that in Example 110 & Example 111 step 10 from (R)-N-(l-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethyl)-N- methyl-2-nitrobenzenesulfonamide. LC-MS (M+H)+ = 223.1.Step3:(R)-5-amino-N-(1-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethyl)-N-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-6.8-dihydro-lH-furo[3.4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-715" id="p-715" id="p-715"
id="p-715"
[0715]The title compound (90 mg, 52%) was prepared in a manner similar to that in Example step 2 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and (R)-l-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)- N-methylethan-1-amine. LC-MS (M+H)+ = 554.3.Step4:(R)-5-amino-N-(1-(2-fluoro-4-(trifluoromethyl)phenyl)ethyl)-N-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0716]Example 145 (33 mg, 48%) was prepared in a manner similar to that in Example 110 & Example ill step 7 from (R)-5-amino-N-(l-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethyl)-N- methyl- 1 -((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro- 1 H-furo[3,4-d]pyrrolo[3,2-b]pyridine- 2-carboxamide. Example 147 & Example 148:(R)-5-amino-N-((S)-l-(2-fluoro-4-(trifluoromethyl)phenyl)ethyl)-N,6-dimethyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine- 2-carboxamide & (R)-5-amino-N-((R)- 1 -(2-fluoro-4-(trifluoromethyl)phenyl)ethyl)-N,6- dimethyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-717" id="p-717" id="p-717"
id="p-717"
[0717]Example 147 (24 mg, 18%) and Example 148 (24 mg, 18%) were prepared in a manner similar to that in Example 124 & Example 125 step 2 from (R)-5-amino-6-methyl-6,8-dihydro- lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and l-(2-fluoro-4- (trifluoromethyl)phenyl)-N-methylethan-l-amine, and the diastereomers were separated by chiral SEC. 264 NSEM WO 2024/199255 PCT/CN2024/083980 [0718]Analytical chiral-SFC condition as below. Column: CHIRALPAK AD-H; Column size: 4.6X100 mm, 5 pm; Mobile phase: 4 mM methanolic NH3:CO2, 1:9 to 1:1 in 3 min, 1:1 for min, 1:1 to 1:9 in 0.1 min, 1:9 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; back pressure: 1500 psi. [0719]Example 147: Analytical SFC tR=4.03 min. 1H NMR (400 MHz, DMSO-d6) 8 11.51 (s, 1H), 7.85 - 7.58 (m, 3H), 6.72 - 6.45 (m, 1H), 6.11 - 5.91 (m, 1H), 5.45 (s, 2H), 5.39 - 5.27 (m, 1H), 5.13 (dd, J= 13.9, 3.2 Hz, 1H), 5.03 (d, J= 13.8 Hz, 1H), 3.16 - 2.65 (m, 3H), 1.62 (d, J= Hz, 3H), 1.34 (d, J= 6.1 Hz, 3H).. LCMS (M+H)+ = 437.4. [0720]Example 148: Analytical SFC tR=4.98 min. 1H NMR (400 MHz, DMSO-d6) 8 11.51 (s, 1H), 7.83 - 7.55 (m, 3H), 6.74 - 6.43 (m, 1H), 6.00 (q, J= 6.7 Hz, 1H), 5.45 (s, 2H), 5.38 - 5.(m, 1H), 5.14 (dd,J= 13.9, 3.2 Hz, 1H), 5.02 (d,J=13.8Hz, 1H), 3.15 - 2.68 (m, 3H), 1.62 (d, J= 63 Hz, 3H), 1.34 (d, J= 6.1 Hz, 3H). LCMS (M+H)+ = 437.4. Example 149 & Example 150:(S)-5-amino-N-(l-(2,6-difluoro-4-(trifluoromethyl)phenyl)ethyl)-N-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide & (R)-5-amino-N-(l-(2,6-difluoro-4-(trifluoromethyl)phenyl)ethyl)-N-methyl-6,8- dihydro- 1 H-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamideN NH2 Step1:N-(2,6-difluoro-4-(trifluoromethyl)benzylidene)-2-methylpropane-2-sulfinamide id="p-721" id="p-721" id="p-721"
id="p-721"
[0721]To a solution of 2,6-difluoro-4-iodobenzaldehyde (0.50 g, 1.87 mmol) in DMF (5 mL) was added methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (2.15 g, 11.19 mmol) and Cui (533 mg, 2.80 mmol). The mixture was stirred at 100 °C for 16 h and then cooled to room temperature.The mixture was diluted with water (15 mL) and extracted with DCM (3x5 mL). The combined organic layer was washed with brine (3x5 mL), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was re-dissolved in DCM (5 mL) followed by addition of tert-butanesulfinamide (577 mg, 4.76 mmol), PPTS (30 mg, 119 umol) and CuSO4 (1.90 g, 11.mmol). The mixture was stirred at 30 °C for 12 h. Water (15 mL) was added and the mixture was265 WO 2024/199255 PCT/CN2024/083980 extracted with DCM (3x5 ml). The combined organic layer was washed with brine (5 mL), dried over Na2S04, filtered and concentrated under reduced pressure to give the title compound. The residue was purified by silica gel chromatography (PE/EtOAc = 1/0 to 50/1) to give the title compound (122 mg, 21%) 1H NMR (400 MHz, CDCI3) 5 8.82 (s, 1H), 7.30 (d, 2H, J= 8.0 Hz), 1.30 (s, 9H).Step 2: N-(l-(2,6-difluoro-4-(trifluoromethyl)phenyl)ethyl)-2-methylpropane-2-sulfinamide id="p-722" id="p-722" id="p-722"
id="p-722"
[0722]To a solution of N-(2,6-difluoro-4-(trifluoromethyl)benzylidene)-2-methylpropane-2- sulfinamide (122 mg, 390 umol) in DCM (2 mL) was added MeMgBr in Et2O (3.0 M, 207 pL, 0.62 mmol) at -20 °C. The mixture was stirred at -20 °C for 2 h and then saturated NH4C1 (6 mL) was added. The mixture was extracted with DCM (3x2 mL). The combined organic layer was washed with brine (2 mL), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC (PE:EtOAc = 3:1) to give the title compound (0.10 g, 77%). LCMS (M+H)+ = 330.0.Step 3: N-( 1 -(2,6-difluoro-4-(trifluoromethyl)phenyl)ethyl)-N,2-dimethylpropane-2- sulfinamide id="p-723" id="p-723" id="p-723"
id="p-723"
[0723]To a solution of N-(l-(2,6-difluoro-4-(trifluoromethyl)phenyl)ethyl)-2-methylpropane- 2-sulfinamide (0.10 g, 304 umol) in THE (2 mL) was added NaH (60%, 24 mg, 607 pmol) at °C. The mixture was stirred at 25 °C for 30 min followed by addition of Mel (86 mg, 6pmol). The mixture was stirred at 25 °C for 3 h and then diluted with water (8 mL). The mixture was extracted with EtOAc (3x3 mL). The combined organic layer was washed with brine (mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC (PE:EtOAc = 3:1) to give the title compound (80 mg, 76%). LC-MS (M+H)+= 344.1.Step 4: 1-(2,6-difluoro-4-(trifluoromethyl)phenyl)-N-methylethan-1-amine hydrochloride 266 WO 2024/199255 PCT/CN2024/083980 —NH id="p-724" id="p-724" id="p-724"
id="p-724"
[0724]To a flask charged with N-(l-(2,6-difluoro-4-(trifluoromethyl)phenyl)ethyl)-N,2- dimethylpropane-2-sulfinamide (80 mg, 233 umol) was added HC1 in MeOH (3.0 M, 2 mL). The mixture was stirred at room temperature for l h and then concentrated under reduced pressure to give the title compound (64 mg, 100%). LC-MS (M+H)+ =240.0.Step 5: 5-amino-N-( 1 -(2,6-difluoro-4-(trifluoromethyl)phenyl)ethyl)-N-methyl- 1 -((2- (trimethylsilyl)ethoxy)methyl)-6.8-dihydro-lH-furor3.4-d]pyrrolo[3,2-b]pyridine-2-carboxamide —N F. )— SEM yjF f 3c [0725]The title compound (150 mg, 95%) was prepared in a manner similar to that in Example step 2 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and l-(2,6-difluoro-4-(trifluoromethyl)phenyl)-N- methylethan-1-amine hydrochloride. LC-MS (M+H)+ = 571.2.Step 6: (S)-5-amino-N-( 1 -(2,6-difluoro-4-(trifluoromethyl)phenyl)ethyl)-N-methyl-6,8- dihydro-lH-furo[3,4-d1pyn ־olo[3,2-b1pvridine-2-carboxamide & (R)-5-amino-N-(l-(2,6- difluoro-4-(trifluoromethyl)phenyl)ethyl)-N-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- blpyridine-2-carboxamide [0726]Example 149 (12 mg, 10%) and Example 150 (10 mg, 9%) were prepared in a manner similar to that in Example 110 & Example 111 step 7 from 5-amino-N-(l-(2,6-difluoro-4- (trifluoromethyl)phenyl)ethyl)-N-methyl-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide, and the enantiomers were separated by chiral SEC. [0727]Analytical chiral-SFC condition as below. Column: Chiralpak AD-3; Column size: 4.6X50 mm, 3 pm; Mobile phase: 14 mM NH3 in MeOH:CO2, 1:19 for 0.2 min, 1:19 to 1:1 in min, 1:1 for 1 min, 1:1 to 1:19 in 0.4 min, 1:19 for 0.4 min; Flow: 3.4 mL/min; Temperature: °C; back pressure: 1800 psi. [0728]Example 149: Analytical SEC tR=l .44 min. 1H NMR (400 MHz, DMSO- 267 WO 2024/199255 PCT/CN2024/083980 [0729]Example 150: Analytical SEC tR=l .65 min. 1H NMR (400 MHz, DMSO- Step 1: l-(4-bromo-2-fluoro-5-methylphenyl)ethan-l-one Br id="p-730" id="p-730" id="p-730"
id="p-730"
[0730]To a solution of 2-bromo-4-fluoro- 1 -methylbenzene (2.0 g, 10.6 mmol) in DCM (mL) was added AlC13 (1.55 g, 11.6 mmol) at room temperature. The mixture was stirred for min, and then AcCl (878 mg, 11.1 mmol) was added dropwise at 0 °C. The mixture was warmed to room temperature and stirred overnight. The mixture was slowly quenched with addition of water (1 mL) dropwise at 0 °C, and the mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 30:1) to give the title compound (280 mg, 12%). LC-MS (M+H)+ = 230.9.Step 2: l-(4-cvclopropvl-2-fluoro-5-methvlphenyl)ethan-l-one id="p-731" id="p-731" id="p-731"
id="p-731"
[0731]The title compound (220 mg, 95%) was prepared in a manner similar to that in Example step 1 from l-(4-bromo-2-fluoro-5-methylphenyl)ethan-l-one and cyclopropylboronic acid. LC-MS (M+H)+= 193.1.Step 3: 1 -(4-cyclopropyl-2-fluoro-5-methylphenyl)-N-methylethan- 1 -amine 268 WO 2024/199255 PCT/CN2024/083980 HN id="p-732" id="p-732" id="p-732"
id="p-732"
[0732]The title compound (90 mg, 38%) was prepared in a manner similar to that in Example 137 & Example 138 step 1 from l-(4-cyclopropyl-2-fluoro-5-methylphenyl)ethan-l-one and MeNH2. LC-MS (M+H)+ = 208.1Step 4: 5-amino-N-(l-(4-cyclopropyl-2-fluoro-5-methylphenyl)ethyl)-N-methyl-l-((2- (trimethylsilyl)ethoxy)methyl)-6.8-dihydro-lH-furo[3.4-d1pyrrolol3.2-b1pyridine-2-carboxamide id="p-733" id="p-733" id="p-733"
id="p-733"
[0733]The title compound (200mg, 78%) was prepared in a manner similar to that in Example 110 & Example 111 step 6 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and l-(4-cyclopropyl-2-fluoro-5- methylphenyl)-N-methylethan-l-amine. LC-MS (M+H)+ = 539.2.Step 5: (R)-5-amino-N-(l-(4-cyclopropyl-2-fluoro-5-methylphenyl)ethyl)-N-methyl-6,8- dihydro-lH-furo[3,4-d]py1Tolo[3,2-b]pvridine-2-carboxamide & (S)-5-amino-N-(l-(4- cyclopropyl-2-fluoro-5-methylphenyl)ethyl)-N-methyl-6,8-dihydro-lH-furo[3,4-d1pyrrolo[3,2- b]pyridine-2-carboxamide [0734]Example 151 (12 mg, 8%) and Example 152 (12 mg, 8%) were prepared in a manner similar to that in Example 110 & Example 111 step 7 from 5-amino-N-(l-(4-cyclopropyl-2- fluoro-5-methylphenyl)ethyl)-N-methyl-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide, and the enantiomers were separated by chiral SEC. [0735]Analytical chiral-SFC condition as below. Column: CHIRALPAK AS-H; Column size: 4.6X100 mm, 5 pm; Mobile phase: 4 mM methanolic NH3:CO2, 1:9 to 1:1 in 3 min, 1:1 for min, 1:1 to 1:9 in 0.1 min, 1:9 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; back pressure: 1500 psi. [0736]Example 151: Analytical SEC tR=2.72 min. 1H NMR (400 MHz, DMSO- 269 NSEM WO 2024/199255 PCT/CN2024/083980 5.53 (s, 2H), 5.11 (s, 2H), 4.90 (s, 2H), 2.89 (s, 3H), 2.35 (s, 3H), 1.88 (s, 1H), 1.55 (s, 3H), 0.(d, J= 8.6 Hz, 2H), 0.63 - 0.59 (m, 2H). LCMS (M+H)+ = 409.2. [0737]Example 152: Analytical SECtR=3.06 min. 1H NMR (400 MHz, DMSO- Step1:N-(1-(5-cyclopropyl-3-fluoropyridin-2-yl)ethyl)cyclobutanamine id="p-738" id="p-738" id="p-738"
id="p-738"
[0738]The title compound (200 mg, 77%) was prepared in a manner similar to that in Example 124 & Example 125 step 1 from l-(5-cyclopropyl-3-fluoropyridin-2-yl)ethan-l-one and cyclobutanamine. LC-MS (M+H)+ = 235.2.Step 2: 5-amino-N-cyclobutyl-N-(l-(5-cyclopropyl-3-fluoropyridin-2-yl)ethyl)-l-((2- (trimethvlsilyl)ethoxv)rnethyl)-6,8-dihvdro-lH-furo[3,4-d]pyrrolo[3,2-b]pvridine-2-carboxamide id="p-739" id="p-739" id="p-739"
id="p-739"
[0739]The title compound (100 mg, 20%) was prepared in a manner similar to that in Example 110 & Example 111 step 6 from N-(l-(5-cyclopropyl-3-fluoropyridin-2-yl)ethyl)cyclobutanamine and 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH- furo[3,4-d]py1Tolo[3,2-b]pyridine-2-carboxylic acid. LC-MS (M+H)+ = 566.2. 270 WO 2024/199255 PCT/CN2024/083980 Step3:(R)-5-amino-N-cyclobutyl-N-(1-(5-cyclopropyl-3-fluoropyridin-2-yl)ethyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolor3,2-b1pyridine-2-carboxamide & (S)-5-amino-N-cyclobutyl-N- (l-(5-cyclopropyl-3-fluoropyridin-2-yl)ethyl)-6,8-dihydro-lH-furor3,4-dlpyrrolo[3,2-b]pyridine- 2-carboxamide [0740]Example 153 (17 mg, 22%) and Example 154 (18 mg, 23%) were prepared in a manner similar to that in Example 110 & Example 111 step 7 from 5-amino-N-cyclobutyl-N-(l-(5- cyclopropyl-3-fluoropyridin-2-yl)ethyl)-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide, and the enantiomers were separated by chiral SFC. [0741]Analytical chiral-SFC condition as below. Column: YMC Cellulose-C; Column size: 4.6X100 mm, 5 pm; Mobile phase: 4 mM methanolic NH3:CO2, 1:9 to 1:1 in 3 min, 1:1 for min, 1:1 to 1:9 in 0.1 min, 1:9 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; back pressure: 1500 psi. [0742]Example 153: Analytical SFC tR=3.76 min. 1H NMR (400 MHz, DMSO- Step 1: N-(l-(3-fluoro-5-(trifluoromethvl)pyridin-2-yl)ethvl)cyclobutanamine 271 WO 2024/199255 PCT/CN2024/083980 HN CF3 [0744]The title compound (150 mg, 47%) was prepared in a manner similar to that in Example 124 & Example 125 step 1 from l-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethan-l-one and cyclobutanamine. LC-MS (M+H)+ = 263.2.Step2:5-amino-N-cyclobutyl-N-(1-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethyl)-1-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-745" id="p-745" id="p-745"
id="p-745"
[0745]The title compound (100 mg, 20%) was prepared in a manner similar to that in Example 110 & Example 111 step 6 from N-(l-(3-fluoro-5-(trifluoromethyl)pyridin-2- yl)ethyl)cyclobutanamine and 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid. LC-MS (M+H)+ = 594.2.Step3:(R)-5-amino-N-cyclobutyl-N-(1-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethyl)- 6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-blpyridine-2-carboxamide & (S)-5-amino-N-cyclobutyl- N-( 1 -(3 -fLuoro-5-(trifluoromethyl)pyridin-2-yl)ethyl)-6,8-dihydro- 1 H-furo [ 3,4-d]pyrrolo [3,2- b]pyridine-2-carboxamide [0746]Example 155 (7 mg, 9%) and Example 156 (7 mg, 8%) were prepared in a manner similar to that in Example 110 & Example 111 step 7 from 5-amino-N-cyclobutyl-N-(l-(3- fluoro-5-(trifluoromethyl)pyridin-2-yl)ethyl)-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro- lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide, and the enantiomers were separated by chiral SEC. [0747]Analytical chiral-SFC condition as below. Column: YMC Cellulose-C; Column size: 4.6X100 mm, 5 pm; Mobile phase: 4 mM methanolic NH3:CO2, 1:9 to 1:1 in 3 min, 1:1 for min, 1:1 to 1:9 in 0.1 min, 1:9 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; back pressure: 1500 psi. [0748]Example 155: Analytical SEC tR=2.94 min. 1H NMR (400 MHz, DMSO- WO 2024/199255 PCT/CN2024/083980 [0749]Example 156: Analytical SEC tR=3.12 min. 1H NMR (400 MHz, DMSO- Step 1: 1-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethan-1-amine hydrochlorideH2N f 3c id="p-750" id="p-750" id="p-750"
id="p-750"
[0750]The title compound (1.02 g, 100%) was prepared in a manner similar to that in Example 110 & Example 111 step 5 from tert-butyl (l-(3-fluoro-5-(trifluoromethyl)pyridin-2- yl)ethyl)carbamate. LC-MS (M+H)+ = 209.1.Step 2: 1 -(3-fluoro-5-(trifluoromethvl)pvridin-2-vl)-N-(2-methoxvethvl)ethan- 1 -amine 0^ f 3c [0751]To a solution of l-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethan-l-amine hydrochloride (1.02 g, 3.64 mmol) in DMF (20 mL) was added K2CO3 (1.24 g, 8.99 mmol), 1- bromo-2-methoxyethane (688 mg, 4.95 mmol) and KI (149 mg, 0.90 mmol).The mixture was stirred at 90 °C for 12 h and then cooled to room temperature. The mixture was diluted with water (50 mL) and extracted with EtOAc (3x30 mL). The combined organic layer was washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC to give the title compound (300 mg, 31%). LC-MS (M+H)+ = 267.0. 273 WO 2024/199255 PCT/CN2024/083980 Step 3: 5-amino-N-(l-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethyl)-N-(2-methoxyethyl)- l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furor3,4-d]pyrrolor3,2-blpyridine-2- carboxamide id="p-752" id="p-752" id="p-752"
id="p-752"
[0752]The title compound (200 mg, 36%) was prepared in a manner similar to that in Example 110 & Example 111 step 6 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and l-(3-fluoro-5-(trifluoromethyl)pyridin- 2-yl)-N-(2-methoxyethyl)ethan-l-amine. LC-MS (M+H)+ = 598.2.Step 4: (R)-5-amino-N-( 1 -(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethyl)-N-(2- methoxyethyl)-6,8-dihydro-lH-furor3,4-dlpyrrolor3,2-blpyridine-2-carboxamide & (S)-5- amino-N-(l-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)ethyl)-N-(2-methoxyethyl)-6,8-dihydro- lH-furo[3,4-d1pyrrolo[3,2-b1pyridine-2-carboxamide [0753]Example 157 (25 mg, 16%) and Example 158 (26 mg, 16%) were prepared in a manner similar to that in Example 110 & Example 111 step 7 from 5-amino-N-(l-(3-fluoro-5- (trifluoromethyl)pyridin-2-yl)ethyl)-N-(2-methoxyethyl)-l-((2-(trimethylsilyl)ethoxy )methyl)- 6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide, and the enantiomers were separated by chiral SFC. [0754]Analytical chiral-SFC condition as below. Column: Chiralcel OX-3;Column size: 4.6X50 mm, 5 pm; Mobile phase: (EtOH containing 0.2% 7 M methanolic NH3):CO2, 1:19 for 0.2 min, 1:19 to 1:1 in 1 min, 1:1 for 1 min, 1:1 to 1:19 in 0.4 min, 1:9 for 0.4 min; Flow: 3.mL/min; Temperature: 35 °C; backpressure: 1800 psi. [0755]Example 157: Analytical SFC tR=L43 min. 1H NMR (400 MHz, DMSO- 274 WO 2024/199255 PCT/CN2024/083980 cyclobutyl-N-(l-(5-cyclopropylpyridin-2-yl)ethyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxamideN nh 2 Step 1: N-(l-(5-cyclopropylpyridin-2-yl)ethyl)cyclobutanamine id="p-757" id="p-757" id="p-757"
id="p-757"
[0757]The title compound (160mg, 29%) was prepared in a manner similar to that in Example 124 & Example 125 step 1 from l-(5-cyclopropylpyridin-2-yl)ethan-l-one and cyclobutanamine. LC-MS (M+H)+= 217.3.Step 2: 5-amino-N-cyclobutyl-N-( 1 -(5-cyclopropylpyridin-2-yl)ethyl)- 1 -((2-(trimethylsilyl)ethoxY)methyl)-6,8-dihydro-lH-furo[3,4-dlpyrrolor3,2-blpyridine-2-carboxamide id="p-758" id="p-758" id="p-758"
id="p-758"
[0758]The title compound (90 mg, 14%) was prepared in a manner similar to that in Example 110 & Example 111 step 6 from N-(l-(5-cyclopropylpyridin-2-yl)ethyl)cyclobutanamine and 5- amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyn ־olo[3,2-b]pyridine-2- carboxylic acid. LC-MS (M+H)+ = 548.3.Step 3: (R)-5-amino-N-cyclobutyl-N-(l-(5-cyclopropylpyridin-2-yl)ethyl)-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (S)-5-amino-N-cyclobutyl-N-(l-(5- cvclopropvlpv1 ־idin-2-vl)ethvl)-6,8-dihvdro-lH-furo[3,4-d1pvrrolo[3,2-b1pvridine-2-carboxamide [0759]Example 159 (19 mg, 28%) and Example 160 (18 mg, 27%) were prepared in a manner similar to that in Example 110 & Example 111 step 7 from 5-amino-N-cyclobutyl-N-(l-(5- cyclopropylpyridin-2-yl)ethyl)-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide, and the enantiomers were separated by chiral SEC. [0760]Analytical chiral-SFC condition as below. Column: CHIRALPAK Cellulose-C; Column size: 4.6X100 mm, 5 pm; Mobile phase: 4 mM methanolic NH3:CO2, 1:9 to 1:1 in 3 min, 1:1 for275 WO 2024/199255 PCT/CN2024/083980 min, 1:1 to 1:9 in 0.1 min, 1:9 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; back pressure: 1500 psi. [0761]Example 159: Analytical SFC tR=3.82 min. 1H NMR (400 MHz, DMSO- f 3cStep1:(S)-N-ethyl-2-nitro-N-(7 ‘-(trifluoromethyl)spiro[cyclopropane-1,l ‘-isochroman]-4 ‘- yl)benzenesulfonamidecf 3 id="p-763" id="p-763" id="p-763"
id="p-763"
[0763]The title compound (100 mg, 67%) was prepared in a manner similar to that in Example step 6 from (R)-7'-(trifluoromethyl)spiro[cyclopropane-l,l'-isochroman]-4'-ol and N-ethyl-2- nitro-benzenesulfonamide. LC-MS (M+H)+ = 457.1.Step 2: (S)-N-ethyl-7'-(trifluoromethyl)spiro[cyclopropane- 1,1 '-isochromanl-4'-amine 276 WO 2024/199255 PCT/CN2024/083980 [0764]The title compound (100 mg, 84%) was prepared in a manner similar to that in Example step 7 from (S)-N-ethyl-2-nitro-N-(7'-(trifluoromethyl)spiro[cyclopropane- 1,1 ,-isochroman]- 4'-yl)benzenesulfonamide. LC-MS (M+H)+ = 272.2.Step 3: (S)-5-amino-N-ethyl-N-(7'-(trifluoromethyl)spiro[cyclopropane- 1,1 ,-isochroman]- 4,-yl)-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-dlpyrrolo[3,2-b]pyridine-2- carboxamide id="p-765" id="p-765" id="p-765"
id="p-765"
[0765]The title compound (50 mg, 90%) was prepared in a manner similar to that in Example step 8 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and (S)-N-ethyl-7'-(trifluoromethyl)spiro[cyclopropane-l,l ,-isochroman]-4 ,-amine. LC-MS (M+H)+ = 603.2.Step4:(S)-5-amino-N-ethyl-N-(7 ‘-(trifluoromethyl)spiro[cyclopropane-1,1 ‘-isochroman]- 4,-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0766]Example 161 (12 mg, 31%) was prepared in a manner similar to that in Example 91 step from (S)-5-amino-N-ethyl-N-(7'-(trifluoromethyl)spiro[cyclopropane- 1,1 ,-isochroman]-4'-yl)- l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide. 1H NMR (400 MHz, DMSO-d) 8 11.60 (s, 1H), 7.56 (d, J= 7.5 Hz, 1H), 7.41 (d, J= 7.6 Hz, 1H), 7.11 (s, 1H), 6.62 (s, 1H), 5.70 (s, 1H), 5.56 (s, 2H), 5.12 (s, 2H), 4.91 (s, 2H), 4.19 (s, 2H), 4.00 - 3.50 (m, 2H), 1.35 - 1.20 (m, 4H), 1.12 (s, 3H). LC-MS (M+H)+ = 473.1. Example 162:(R)-5-amino-N-methyl-N-(7-(trifluoromethyl)chroman-4-yl)-6,8-dihydro- lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: (S)-7-(trifluoromethyl)chroman-4-ol 277 WO 2024/199255 PCT/CN2024/083980 [0767]The title compound (600 mg, 99%) was prepared in a manner similar to that in Example step 5 from 7-(trifluoromethyl)chroman-4-one.Step 2: (R)-N-methyl-2-nitro-N-(7-(trifluoromethyl)chroman-4-yl)benzenesulfonamide id="p-768" id="p-768" id="p-768"
id="p-768"
[0768]The title compound (1.1 g, 88%) was prepared in a manner similar to that in Example step 9 from (S)-7-(trifluoromethyl)chroman-4-ol andN-methyl-2-nitro-benzenesulfonamide. LC-MS (M+Na) += 439.1.Step 3: (R)-N-methyl-7-(trifluoromethyl)chroman-4-amineMe-NH F3C id="p-769" id="p-769" id="p-769"
id="p-769"
[0769]The title compound (458 mg, 76%) was prepared in a manner similar to that in Example step 10 from (R)-N-methyl-2-nitro-N-(7-(trifluoromethyl)chroman-4-yl)benzenesulfonamide. LC-MS (M+H)+= 232.1.Step 4: (R)-5-amino-N-methyl-N-(7-(trifluoromethyl)chroman-4-yl)- 1 -((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-770" id="p-770" id="p-770"
id="p-770"
[0770]The title compound (332 mg, 84%) was prepared in a manner similar to that in Example & Example 74 step 9 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and (R)-N-methyl-7- (trifluoromethyl)chroman-4-amine. LC-MS (M+H)+ = 563.4.Step5:(R)-5-amino-N-methyl-N-(7-(trifluoromethyl)chroman-4-yl)-6,8-dihydro-1H- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide [0771]Example 162 (214 mg, 84%) prepared in a manner similar to that in Example 66 step from (R)-5-amino-N-methyl-N-(7-(trifluoromethyl)chroman-4-yl)- 1 -((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide. 1H NMR (400 MHz, DMSO-d6) 8 11.62 (s, 1H), 7.37 - 7.11 (m, 3H), 6.76 (s, 1H), 278 SEM WO 2024/199255 PCT/CN2024/083980 5.97 (s, 1H), 5.58 (s, 2H), 5.14 (s, 2H), 4.91 (s, 2H), 4.51 - 4.28 (m, 2H), 3.15 - 2.68 (m, 3H), 2.31 - 2.05 (m, 2H). LC-MS (M+H)+ = 433.3 Example 163 & Example 164:(R)-5-amino-N-methyl-N-(3-(trifluoromethyl)-7,8-dihydro- 5H-pyrano[4,3-b]pyridin-8-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (S)-5-amino-N-methyl-N-(3-(trifluoromethyl)-7,8-dihydro-5H-pyrano[4,3-b]pyridin-8-yl)-6,8- dihydro-1 H-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-772" id="p-772" id="p-772"
id="p-772"
[0772]The title compound (2.0 g, 95%) was prepared in a manner similar to that in Example & Example 76 step 1 from 2-chloro-5-(trifluoromethyl)nicotinaldehyde. LC-MS (M+H)+ = 212.2Step 2: 3-((allyloxy)methyl)-2-chloro-5-(trifluoromethyl)pyridine id="p-773" id="p-773" id="p-773"
id="p-773"
[0773]The title compound (1.6 g, 71%) was prepared in a manner similar to that in Example & Example 40 step 1 from (2-chloro-5-(trifluoromethyl)pyridin-3-y!)methanol and allyl bromide. LC-MS (M+H)+ = 252.2.Step3:8-methylene-3-(trifluoromethyl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine 279 Step1:(2-chloro-5-(trifluoromethyl)pyridin-3-yl)methanolCI OH WO 2024/199255 PCT/CN2024/083980 [0774]The title compound (630 mg, 46%) was prepared in a manner similar to that in Example & Example 40 step 2 from 3-((allyloxy)methyl)-2-chloro-5-(trifluoromethyl)pyridine. LC-MS (M+H)+= 216.3.Step 4: 3-(trifluoromethyl)-5H-pyrano[4,3-b]pyridin-8(7H)-one id="p-775" id="p-775" id="p-775"
id="p-775"
[0775]The title compound (308 mg, 49%) was prepared in a manner similar to that in Example & Example 40 step 3 from 8-methylene-3-(trifluoromethyl)-7,8-dihydro-5H-pyrano[4,3- b]pyridine. LC-MS (M+H)+ = 218.0Step5:3-(trifluoromethyl)-7.8-dihydro-5H-pyrano[4,3-b]pyridin-8-olOH id="p-776" id="p-776" id="p-776"
id="p-776"
[0776]To a solution of 3-(trifluoromethyl)-5H-pyrano[4,3-b]pyridin-8(7H)-one (88 mg, 0.mmol) in THE (3 mL) was added BH3 in THE (1.0 M, 0.50 mL, 0.50 mmol) dropwise at 0 °C. The mixture was stirred at room temperature for 0.5 h, and then MeOH (0.5 mL) was added. Upon cease of bubbling, the mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography to give the title compound (80 mg, 91%). LC-MS (M+H) = 220.1.Step6:N-methyl-2-nitro-N-(3-(trifluoromethyl)-7,8-dihydro-5H-pyrano[4,3-b]pyridin-8- yl)benzenesulfonamide id="p-777" id="p-777" id="p-777"
id="p-777"
[0777]The title compound (142 mg, 93%) was prepared in a manner similar to that in Example step 6 from 3-(trifLuoromethyl)-7,8-dihydro-5H-pyrano[4,3-b]pyridin-8-ol and N-methyl-2- nitro-benzenesulfonamide. LC-MS (M+H)+ = 418.1.Step 7: N-methyl-3-(trifluoromethyl)-7,8-dihydro-5H-pyrano[4,3-b]pyridin-8-amine 280 WO 2024/199255 PCT/CN2024/083980 [0778]The title compound (69 mg, 88%) was prepared in a manner similar to that in Example step 7 from N-methyl-2-nitro-N-(3-(trifluoromethyl)-7,8-dihydro-5H-pyrano[4,3-b]pyridin-8- yl)benzenesulfonamide. LC-MS (M+H)+ = 233.1.Step8:5-amino-N-methyl-N-(3-(trifluoromethyl)-7,8-dihydro-5H-pyrano[4,3-b]pyridin-8- yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-1H-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide id="p-779" id="p-779" id="p-779"
id="p-779"
[0779]The title compound (142 mg, 84%) was prepared in a manner similar to that in Example step 8 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and N-methyl-3-(trifluoromethyl)-7,8-dihydro-5H- pyrano[4,3-b]pyridin-8-amine. LC-MS (M+H)+ = 564.4.Step 9: (R)-5-amino-N-methyl-N-(3-(trifluoromethyl)-7,8-dihydro-5H-pyrano[4.,3- b]pyridin-8-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (S)-5- amino-N-methyl-N-(3-(trifluoromethyl)-7,8-dihydro-5H-pyrano[4.3-blpyridin-8-yl)-6.8-dihydro- H-furo [ 3,4-dlpyrrolo [ 3,2-b]pyridine-2-carboxamide [0780]Example 163 (20 mg, 15%) and Example 164 (22 mg, 17%) were prepared in a manner similar to that in Example 110 & Example 111 step 7 from 5-amino-N-methyl-N-(3- (trifluoromethyl)-7,8-dihydro-5H-pyrano[4,3-b]pyridin-8-yl)-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide, and the enantiomers were separated by chiral SEC. [0781]Analytical chiral-SFC condition as below. Column: Lux Cellulose-3; Column size: 4.6X100 mm, 5 pm; Mobile phase: 4 mM methanolic NH3:CO2, 1:9 to 1:1 in 3 min, 1:1 for min, 1:1 to 1:9 in 0.1 min, 1:9 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; back pressure: 1500 psi. [0782]Example 163: Analytical SEC tR=2.95 min. 1H NMR (400 MHz, DMSO- 281 SEM WO 2024/199255 PCT/CN2024/083980 Example 165:(R)-5-amino-N,6-dimethyl-N-((S)-7'-(trifluoromethyl)spiro[cyclopropane- l,r-isochroman]-4'-yl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-784" id="p-784" id="p-784"
id="p-784"
[0784]Example 165 (37 mg, 37%) was prepared in a manner similar to that in Example 124 & Example 125 step 2 from (R)-5-amino-6-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid and (S)-N-methyl-7'-(trifluoromethyl)spiro[cyclopropane-l,l'- isochroman]-4'-amine. 1H NMR (400 MHz, DMSO-d6) 8 11.61 (s, 1H), 7.60 (d, J= 7.8 Hz, 1H), 7.51-7.31 (m, 1H), 7.15 (s, 1H), 6.82 - 6.47 (m, 1H), 6.00 5.66 (m, 1H), 5.49 (s, 2H), 5.40- 5.29 (m, 1H), 5.22-5.11 (m, 1H), 5.11 -5.01 (m, 1H), 4.32 - 3.94 (m, 2H), 3.19 - 2.69 (m, 3H), 1.40- 1.15 (m, 7H). LC-MS (M+H)+= 473.3. Example 166:(R)-5-amino-N-ethyl-6-methyl-N-((S)-7'- (trifluoromethyl)spiro[cyclopropane- 1,1 '-isochroman]-4'-yl)-6,8-dihydro- 1 H-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-785" id="p-785" id="p-785"
id="p-785"
[0785]Example 166 (55 mg, 53%) was prepared in a manner similar to that in Example 124 & Example 125 step 2 from (R)-5-amino-6-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid and (S)-N-ethyl-7'-(trifluoromethyl)spiro[cyclopropane-l,l'- isochroman]-4'-amine. 1H NMR (400 MHz, DMSO-d) 8 11.59 (s, 1H), 7.56 (d, J= 7.5 Hz, 1H), 7.41 (d, J=7.9 Hz, 1H), 7.11 (s, 1H), 6.76 - 6.45 (m, 1H), 5.87 - 5.54 (m, 1H), 5.47 (s, 2H), 5.37 - 5.26 (m, 1H), 5.21 - 5.08 (m, 1H), 5.08 - 4.99 (m, 1H), 4.33 - 4.02 (m, 2H), 3.95 - 2.(m, 2H), 1.34 (d, J = 6.0 Hz, 3H), 1.31-0.97 (m, 7H). LC-MS (M+H)+= 487.3. Example 167 & Example 168:(R)-5-amino-N-(5'-fluoro-7'- (trifluoromethyl)spiro[cyclopropane-l,r-isochroman]-4'-yl)-N-methyl-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide & (S)-5-amino-N-(5'-fluoro-7'- (trifluoromethyl)spiro[cyclopropane-l,r-isochroman]-4'-yl)-N-methyl-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide 282 WO 2024/199255 PCT/CN2024/083980 N NH2 Step 1: methyl 2-amino-3-fluoro-5-(trifluoromethyl)benzoate cf 3 [0786]To a solution of 2-fluoro-4-(trifluoromethyl)aniline (24.9 g, 139 mmol) in DMF (1mL) was added NBS (25.0 g, 146 mmol) at room temperature and the mixture was stirred for h. The mixture was partitioned between water (300 mL) and EtOAc (300 mL). The organic layer was washed with brine (200 mL), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was re-dissolved in MeOH (400 mL) followed by addition of Pd(dppf)C(5.7 g, 7.8 mmol) and Et3N (47.0 g, 465 mmol). The vessel was flushed with CO and the mixture was stirred at 100 °C under CO (20 bar) overnight. The mixture was cooled to room temperature and concentrated under reduced pressure. The crude was purified by silica gel chromatography (PE/EtOAc = 5:1) to give the title compound (21.4 g, 65%). LC-MS (M+H)+ = 238.0.Step 2: methyl 2-bromo-3-fluoro-5-(trifluoromethvl)benzoate id="p-787" id="p-787" id="p-787"
id="p-787"
[0787] Amixture of methyl 2-amino-3-fluoro-5-(trifluoromethyl)benzoate (21.4 g, 90 mmol), t-BuONO (10.2 g, 99 mmol) and CuBr2 (22.1 g, 99 mmol) in MeCN (200 mL) was stirred for 2 h at room temperature. The mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 10:1) to give the title compound (24.0 g, 88%).Step 3: 1 -(2-bromo-3-fluoro-5-(trifluoromethyl)phenyl)cyclopropan- 1 -01 id="p-788" id="p-788" id="p-788"
id="p-788"
[0788]Bis(cyclopentadienyl)zirconium dichloride (3.9 g, 13.3 mmol) was suspended in toluene (20 mL) at 0 °C, EtMgBr in Et20 (3.0 M, 6.6 mL, 19.9 mmol) was added dropwise. The mixture was stirred at 0 °C for 1 h, followed by addition of methyl 2-bromo-3-fluoro-5- 283 & F3C WO 2024/199255 PCT/CN2024/083980 (trifluoromethyl)benzoate (2.0 g, 6.6 mmol) in toluene (10 mL) dropwise. The mixture was warmed to room temperature and stirred overnight. A solution of NaOH (1 g) in water (10 mL) was added, and the mixture was stirred at room temperature for 30 min. Solid was fdtered off, and the solid was rinsed with EtOAc (20 mL). The organic layer of the filtrate was separated, and the aqueous layer was extracted with EtOAc (20 mL). The combined organic layer was washed with water (20 mL), dried with Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 30:1) to give the title compound (660 mg, 33%). 1H NMR (400 MHz, DMSO-6) S 7.81 (d, J= 8.4 Hz, 1H), 7.(s, 1H), 6.03 (s, 1H), 1.10 - 1.02 (m, 2H), 0.95 - 0.89 (m, 2H). LC-MS (M+H)+ = 298.9.Step 4: l-(l-(allyloxy)cyclopropyl)-2-bromo-3-fluoro-5-(trifluoromethyl)benzene id="p-789" id="p-789" id="p-789"
id="p-789"
[0789]To a solution of l-(2-bromo-3-fluoro-5-(trifluoromethyl)phenyl)cyclopropan-l-ol (6mg, 2.2 mmol) and allyl bromide (534 mg, 4.4 mmol) in DMF (10 mL) was added NaH (60%, 176 mg, 4.4 mmol) at 0 °C. The mixture was warmed to room temperature and stirred at room temperature for 2 h. Water (50 mL) was added, and the mixture was extracted with EtOAc (mL). The organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 50:1) to give the title compound (610 mg, 81%).Step 5: 5'-fluoro-4'-methylene-7'-(trifluoromethyl)spiro[cyclopropane- 1,1 ,-isochromane] id="p-790" id="p-790" id="p-790"
id="p-790"
[0790]To a mixture of l-(l-(allyloxy)cyclopropyl)-2-bromo-3-fluoro-5- (trifluoromethyl)benzene (2.1 g, 6.2 mmol) in DMF (50 mL) was added Pd(OAc)2 (138 mg, 0.mmol), XantPhos (710 mg, 1.24 mmol) and C82CO3 (2.4 g, 7.4 mmol) under nitrogen. The mixture was heated to 100 °C overnight. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was partitioned between water (20 mL) and EtOAc (30 mL). The organic layer was dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc =30:1) to the title compound (1.5 g, 94%). LC-MS (M+H)+ = 259.1.Step6:5 ‘-fluoro-7 ‘-(trifluoromethyl)spiro[cyclopropane-1,1 ‘-isochroman]-4 ‘-one 284 WO 2024/199255 PCT/CN2024/083980 F 0 id="p-791" id="p-791" id="p-791"
id="p-791"
[0791]To a mixture of 5'-fluoro-4'-methylene-7'-(trifluoromethyl)spiro[cyclopropane-l,T- isochromane] (580 mg, 2.2 mmol) in dioxane (10 mL) and water (2 mL) was added potassium osmate (VI) dihydrate (82 mg, 0.22 mmol), 2,6-lutidine (480 mg, 4.4 mmol) and sodium periodate (1.9 g, 8.8 mmol). The mixture was stirred at room temperature for 2 h. Solid was filtered off, then the filtrate was diluted with EtOAc (20 mL). The organic layer was washed with water (20 mL), dried over Na2S04, filtered and concentrated under reduced pressure. The residue was was purified by silica gel chromatography (PE/EtOAc =10:1) to give the title compound (84 mg, 14%). LC-MS (M+H)+ = 261.0.Step7:5 ‘-fluoro-7 ‘-(trifluoromethyl)spiro[cyclopropane-1,1 ‘-isochroman]-4 ‘-ol id="p-792" id="p-792" id="p-792"
id="p-792"
[0792]To a solution of 5 '-fluoro-7'-(trifluoromethyl)spiro [cyclopropane- 1, T-isochroman] -4'- one (84 mg, 0.32 mmol) in methanol (5 mL) was added NaBH4 (25 mg, 0.64 mmol) at 0 °C. The mixture was warmed to room temperature and stirred for l h. The mixture was concentrated under reduced pressure and purified by silica gel chromatography (PE/EtOAc = 5:1) to give the title compound (80 mg, 95%). LC-MS (M+H)+ = 263.0.Step 8: N-(5'-fluoro-7'-(trifluoromethvl)spiro[cyclopropane- 1,1 '-isochromanl-4'-yl)-N- methyl-2-nitrobenzenesulfonamide id="p-793" id="p-793" id="p-793"
id="p-793"
[0793]To a solution of 5'-fluoro-7'-(trifluoromethyl)spiro[cyclopropane- 1, T-isochroman]-4'-ol (80 mg, 0.31 mmol) and N-methyl-2-nitro-benzenesulfonamide (66 mg, 0.34 mmol) in THF (mL) was added DtBAD (77 mg, 0.34 mmol) and PPh3 (88 mg, 0.34 mmol) under nitrogen, and the mixture was stirred at room temperature for 1 h. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (PE/EtOAc =10:to 5:1) to give the title compound (130 mg, 92%). LC-MS (M+H)+ = 461.0.Step 9: 5'-fluoro-N-methyl-7'-(trifluoromethyl)spiro[cyclopropane- 1,1 ‘-isochroman]-4 ‘- amine 285 F OH WO 2024/199255 PCT/CN2024/083980 F NH id="p-794" id="p-794" id="p-794"
id="p-794"
[0794]To a mixture of N-(5'-fluoro-7'-(trifluoromethyl)spiro[cyclopropane-l,l'-isochroman]- 4'-yl)-N-methyl-2-nitrobenzenesulfonamide (130 mg, 0.28 mmol) in THF (4 mL) and DMF (mL) was added lithium hydroxide monohydrate (36 mg, 0.86 mmol) and dodecane- 1-thiol (1mg, 0.86 mmol), and the mixture was stirred at room temperature overnight. The mixture was concentrated under reduced pressure, and the residue was partitioned between water (10 mL) and EtOAc (10 mL). The organic layer was separated and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EtOAc = 2:1 to 0:1) to give the title compound (46 mg, 59%). LC-MS (M+H)+ = 276.0.Step 10: 5-amino-N-(5'-fluoro-7'-(trifluoromethyl)spirorcyclopropane- 1,1 '-isochromanl-4'- yl)-N-methyl- 1 -((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro- 1 H-furo[3,4-dlpyrrolor3 ,2- blpyridine-2-carboxamide id="p-795" id="p-795" id="p-795"
id="p-795"
[0795]To a mixture of 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid (34 mg, 0.10 mmol) and 5'-fluoro-N-methyl-7'- (trifluoromethyl)spiro[cyclopropane-l,r ־isochroman]-4'-amine (24 mg, 0.09 mmol) in THF (mL) was added BOPC1 (29 mg, 0.13 mmol) and DIPEA (34 mg, 0.26 mmol). The mixture was stirred at 60 °C for 2 h. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was partitioned between water (10 mL) and EtOAc (10 mL). The organic layer was separated, dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM/MeOH = 30 :1) to give the title compound (50 mg, 94%). LC-MS (M+H)+ = 607.2.Step 11: (R)-5-amino-N-(5'-fluoro-7'-(trifluoromethyl)spirorcvclopropane-Ll'- isochroman]-4'-yl)-N-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (S)-5-amino-N-(5'-fluoro-7'-(trifluoromethyl)spiro[cyclopropane- 1,1 '-isochroman]-4'-yl)-N- methyl-6,8-dihydro-1 H-furo[3,4-d]pvrrolo[3,2-b]pvridine-2-carboxamide [0796]To a solution of 5-amino-N-(5'-fluoro-7'-(trifluoromethyl)spiro[cyclopropane-l,l'- isochroman]-4'-yl)-N-methyl-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide (50 mg, 0.083 mmol) in DCM (2 mL) was added TFA (1 mL) and the mixture was stirred at room temperature for 1 h. The mixture was concentrated 286 N SEM WO 2024/199255 PCT/CN2024/083980 under reduced pressure. The residue was dissolved in MeOH (5 mL) followed by addition of strong ammonia solution (28%, 1 mL). The mixture was stirred at room temperature for 30 min and concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM/MeOH = 30/1) followed by chiral SFC to give Example 167 (5 mg, 13%) and Example 168 (10 mg, 25%). [0797]Analytical chiral-SFC condition as below. Column: YMC Cellulose-C; Column size: 4.6X100 mm, 5 pm; Mobile phase: 4 mM methanolic NH3:CO2, 1:9 to 1:1 in 3 min, 1:1 for min, 1:1 to 1:9 in 0.1 min, 1:9 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; back pressure: 1500 psi. [0798]Example 167: Analytical SFC tR=3.46 min. 1H NMR (400 MHz, DMSO- id="p-800" id="p-800" id="p-800"
id="p-800"
[0800]To the mixture of (R)-5-amino-6-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxylic acid (23 mg, 0.10 mmol), 5'-fluoro-N-methyl-7'-(trifluoromethyl)spiro[cyclopropane-l,l'-isochroman]-4'-amine (25 mg, 0.11 mmol) and DIPEA (79 mg, 0.46 mmol) in anhydrous DMF (3 mL) under nitrogen was added T3P (289 mg, 0.mmol, 50% in DMF) and the mixture was stirred at 60 °C for 16 h. The mixture was cooled to room temperature, hydrochloric acid (6 M, 9 mL) was added and the mixture was stirred for 3 h at 60 °C. The mixture was cooled to room temperature, poured into saturated NaHCO3 (100 mL) and extracted with EtOAc (100 mL). The combined organic layer was washed with brine (1mL), dried over Na2SO4, filtered and concentrated under vacuum. The residue was purified by287 WO 2024/199255 PCT/CN2024/083980 silica gel chromatography (DCM/MeOH =30 :1) followed by chiral SFC to give Example 169 (mg, 8%) and Example 170 (8 mg, 16%). [0801]Analytical chiral-SFC condition as below. Column: YMC Cellulose-C; Column size: 4.6X100 mm, 5 pm; Mobile phase: 4 mM methanolic NH3:CO2, 1:9 to 1:1 in 3 min, 1:1 for min, 1:1 to 1:9 in 0.1 min, 1:9 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; back pressure: 1500 psi. [0802]Example 169: Analytical SFC tR=3.17 min. 1H NMR (400 MHz, DMSOA6) 5 11.55 (s, 1H), 7.64 - 7.42 (m, 1H), 7.07 (s, 1H), 6.72 - 6.43 (m, 1H), 5.97 - 5.70 (m, 1H), 5.54 - 5.42 (m, 2H), 5.36 - 5.25 (m, J = 5.2 Hz, 1H), 5.19 - 4.98 (m, 2H), 4.55 - 3.95 (m, 2H), 3.17 - 2.66 (m, 3H), 1.66 - 1.52 (m, 1H), 1.42 - 1.28 (m, 4H), 1.28 - 1.19 (m, 1H), 1.09 - 0.94 (m, 1H). LC-MS (M+H)+= 491.1. [0803]Example 170: Analytical SFC tR=3.72 min. ,H NMR (400 MHz, DMSO-،/6) 8 11.55 (s, 1H), 7.63 - 7.41 (m, 1H), 7.07 (s, 1H), 6.72 - 6.44 (m, 1H), 5.96 - 5.73 (m, 1H), 5.46 (s, 2H), 5.36 - 5.25 (m, 1H), 5.14 (dd, J= 14.0, 3.3 Hz, 1H), 5.01 (d, J= 13.4 Hz, 1H), 4.49 - 3.98 (m, 2H), 3.19-2.67 (m, 3H), 1.66-1.51 (m, 1H), 1.47- 1.27 (m, 4H), 1.27-1.18 (m, 1H), 1.09- 0.90 (m, 1H). LC-MS (M+H)+ = 491.1. Example 171:(R)-5-amino-N-((S)-7'-cyclopropylspiro[cyclopropane- 1,1 '-isochroman]-4'- yl)-N,6-dimethyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: l-(2-bromo-5-cyclopropylphenyl)cyclopropan-l-olA/OH id="p-804" id="p-804" id="p-804"
id="p-804"
[0804]The title compound (1.5 g, 45%) was prepared in a manner similar to that in Example 167 & Example 168 step 3 from methyl 2-bromo-5-cyclopropylbenzoate. LC-MS (M+H)+ = 253.0.Step 2: 2-( l-(allyloxv)cyclopropyl)-l-bromo-4-cyclopropy !benzene 288 WO 2024/199255 PCT/CN2024/083980 [0805]The title compound (1.35 g, 79%) was prepared in a manner similar to that in Example 167 & Example 168 step 4 from l-(2-bromo-5-cyclopropylphenyl)cyclopropan-l-ol and allyl bromide.Step3:7 ‘-cyclopropyl-4 ‘-methylenespiro[cyclopropane-1,l ‘-isochromane] id="p-806" id="p-806" id="p-806"
id="p-806"
[0806]The title compound (630 mg, 64%) was prepared in a manner similar to that in Example167 & Example 168 step 5 from 2-(l-(allyloxy)cyclopropyl)-l-bromo-4-cyclopropylbenzene.Step 4: 7'-cyclopropylspiro[cyclopropane-l,l'-isochroman]-4'-one id="p-807" id="p-807" id="p-807"
id="p-807"
[0807]The title compound (285 mg, 45%) was prepared in a manner similar to that in Example 167 & Example 168 step 6 from 7'-cyclopropyl-4'-methylenespiro[cyclopropane-l,T- isochromane]. LC-MS (M+H)+ = 215.1.Step5:(R)-7 ‘-cyclopropylspiro[cyclopropane-1,1 ‘-isochroman]-4 ‘-ol OH id="p-808" id="p-808" id="p-808"
id="p-808"
[0808]The title compound (186 mg, 65%) was prepared in a manner similar to that in Example step 1 from 7'-cyclopropylspiro[cyclopropane-l,r ־isochroman]-4'-one. EC-MS (M+H)+ = 217.1.Step6:(S)-N-(7 ‘-cyclopropylspiro[cyclopropane-1,l ‘-isochroman]-4 ‘-yl)-N-methyl-2-nitrobenzenesulfonamide id="p-809" id="p-809" id="p-809"
id="p-809"
[0809]The title compound (355 mg, 100%) was prepared in a manner similar to that in Example 167 & Example 168 step 8 from (R)-7'-cyclopropylspiro[cyclopropane-l,l'- isochroman]-4'-ol and N-methyl-2-nitro-benzenesulfonamide. LC-MS (M+H)+ = 415.1.Step 7: (S)-7'-cvclopropvl-N-methylspiro [cyclopropane- 1,1 '-isochromanl-4'-amine 289 WO 2024/199255 PCT/CN2024/083980 [0810]The title compound (124 mg, 56%) was prepared in a manner similar to that in Example 167 & Example 168 step 9 from (S)-N-(7'-cyclopropylspiro[cyclopropane-l,l'-isochroman]-4'- yl)-N-methyl-2-nitrobenzenesulfonamide. LC-MS (M+H)+ = 230.1.Step 8: (R)-5-amino-N-((S)-7'-cyclopropylspiro[cyclopropane-l,l'-isochromanl-4'-yl)-N,6- dimethyl-6,8-dihydro-1 H-furo[3,4-d]pyrrolo[3,2-blpyridine-2-carboxamide [0811]Example 171 (5 mg, 5%) was prepared in a manner similar to that in Example 169 & Example 170 from (S)-7'-cyclopropyl-N-methylspiro[cyclopropane-l,l'-isochroman]-4'-amine and (R)-5-amino-6-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid. 1H NMR (400 MHz, DMSO-6) S 11.67 (s, 1H), 7.04 (s, 1H), 6.87 (d, J= 8.1 Hz, 1H), 6.67 (s, 1H), 6.48 (s, 1H), 5.74-5.67 (m, 2H), 5.33 (d, J= 3.7 Hz, 1H), 5.20 - 5.00 (m, 2H), 4.03 (s, 2H), 3.01 (s, 3H), 1.87-1.81 (m, 1H), 1.33 (d,J=6.1 Hz, 3H), 1.30- 1.07 (m, 4H), 0.98 (s, 1H), 0.(td, J= 6.1,4.0 Hz, 2H), 0.64 (t, J= 4.5 Hz, 2H). LC-MS (M+H)+ = 445.2. Example 172:(S)-5-amino-N-(7'-cyclopropylspiro[cyclopropane- 1,1 '-isochroman]-4'-yl)- N-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide Step 1: (S)-5-amino-N-(7'-cyclopropvlspiro [cyclopropane- 1,1 ‘-isochroman] -4'-yl)-N - methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-1H-furo[3,4-d]pyrrolo[3,2-b]pyridine- 2-carboxamide id="p-812" id="p-812" id="p-812"
id="p-812"
[0812]The title compound (100 mg, 60%) was prepared in a manner similar to that in Example 167 & Example 168 step 10 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and (S)-7'-cyclopropyl-N- methylspiro[cyclopropane-l,l'-isochroman]-4'-amine. LC-MS (M+H)+ = 561.2.Step 2: (S)-5-amino-N-(7'-cyclopropylspiro[cyclopropane- 1,1 '-isochromanl-4'-yl)-N- methyl-6,8-dihydro-1 H-furo[3,4-d]pvrrolo[3,2-b1pyridine-2-carboxamide [0813]Example 172 (10 mg, 7%) was prepared in a manner similar to that in Example 167 & Example 168 step 11 from (S)-5-amino-N-(7'-cyclopropylspiro[cyclopropane-l,l'-isochroman]- 4'-yl)-N-methyl-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-290 WO 2024/199255 PCT/CN2024/083980 b]pyridine-2-carboxamide. 1H NMR (400 MHz, DMSO-،/6) 8 11.59 (s, 1H), 7.03 (s, 1H), 6.(d, J = 8.0 Hz, 1H), 6.66 (s, 1H), 6.47 (s, 1H), 5.80-5.70 (m, 1H), 5.63 (s, 2H), 5.11 (s, 2H), 4.(s, 2H), 4.10-3.95 (m, 2H), 3.01 (s, 3H), 1.81 (dd, J= 9.1, 4.1 Hz, 1H), 1.14 (d, J = 3.2 Hz, 3H), 1.01 - 0.91 (m, 1H), 0.87 - 0.75 (m, 2H), 0.65 - 0.49 (m, 2H). LC-MS (M+H)+ = 431.2. Example 173 & Example 174:(R)-5-amino-N-(l-(4-cyclopropyl-2-fluorophenyl)ethyl)-N- methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (S)-5-amino-N-(l- (4-cyclopropyl-2-fluorophenyl)ethyl)-N-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxamide F [0814]The title compound (730 mg, 89%) was prepared in a manner similar to that in Example step l from l-(4-bromo-2-fluorophenyl)ethan-l-one and cyclopropylboronic acid. LC-MS (M+H)+= 179.2.Step 2: l-(4-cvclopropvl-2-fluorophenvl)-N-methvlethan-l-amine /= NH F [0815]The title compound (90 mg, 28%) was prepared in a manner similar to that in Example 137 & Example 138 step 1 from l-(4-cyclopropyl-2-fluorophenyl)ethan-l-one andMeNH2. LC- MS (M+H)+= 194.1.Step 3: 5-amino-N-(l-(4-cyclopropyl-2-fluorophenyl)ethyl)-N-methyl-l-((2- (trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-816" id="p-816" id="p-816"
id="p-816"
[0816]The title compound (220 mg, 76%) was prepared in a manner similar to that in Example 110 & Example 111 step 6 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH- 291 WO 2024/199255 PCT/CN2024/083980 furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and l-(4-cyclopropyl-2-fluorophenyl)-N- methylethan-l-amine. LC-MS (M+H)+ = 525.2.Step 4: (R)-5-amino-N-(l-(4-cyclopropyl-2-fluorophenyl)ethyl)-N-methyl-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (S)-5-amino-N-(l-(4-cyclopropyl-2- fluorophenyl)ethyl)-N-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-blpyridine-2-carboxamide [0817]Example 173 (4 mg, 2%) and Example 174 (8 mg, 5%) were prepared in a manner similar to that in Example 110 & Example 111 step 7 from 5-amino-N-(l-(4-cyclopropyl-2- fh1orophenyl)ethyl)-N-methyl-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide, and the enantiomers were separated by chiral SFC. [0818]Analytical chiral-SFC condition as below. Column: CHIRALPAK AS-H; Column size: 4.6X100 mm, 5 pm; Mobile phase: 4 mM methanolic NH3:CO2, 1:9 to 1:1 in 3 min, 1:1 for min, 1:1 to 1:9 in 0.1 min, 1:9 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; back pressure: 1500 psi. [0819]Example 173: Analytical SFC tR=2.83 min. 1H NMR (400 MHz, DMSO- Step1:1-(4-cyclopropyl-2-fluorophenyl)-N-ethylethan-1-amineh 292 WO 2024/199255 PCT/CN2024/083980 [0821]The title compound (300 mg, 52%) was prepared in a manner similar to that in Example 137 & Example 138 step 1 from l-(4-cyclopropyl-2-fluorophenyl)ethan-l-one and EtNH2. EC- MS (M+H)+ = 208.2.Step 2: (R)-5-amino-N-((R)-l-(4-cyclopropyl-2-fluorophenyl)ethyl)-N-ethyl-6-methyl-6,8- dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (R)-5-amino-N-((S)-l-(4- cyclopropyl-2-fluorophenyl)ethyl)-N-ethyl-6-methyl-6,8-dihydro-lH-furor3,4-dlpyrrolor3,2- blpyridine-2-carboxamide [0822]Example 175 (7 mg, 7%) and Example 176 (4 mg, 4%) were prepared in a manner similar to that in Example 124 & Example 125 step 2 from (R)-5-amino-6-methyl-6,8-dihydro- lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and l-(4-cyclopropyl-2-fluorophenyl)- N-ethylethan-l-amine, and the diastereomers were separated by chiral SFC. [0823]Analytical chiral-SFC condition as below. Column: CHIRALPAK Cellulose-3; Column size: 4.6X100 mm, 5 pm; Mobile phase: 4 mM methanolic NH3:CO2, 1:9 to 1:1 in 3 min, 1:1 for min, 1:1 to 1:9 in 0.1 min, 1:9 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; back pressure: 1500 psi. [0824]Example 175: Analytical SFC tR=2.71 min. ,H NMR (400 MHz, DMSO-،/6) 8 11.51 (s, 1H), 7.47-7.33 (m, 1H), 6.95 (d, J = 8.0 Hz, 1H), 6.85 (d, J= 12.0 Hz, 1H), 6.49 (s, 1H), 6.5.86 (m, 1H), 5.44 (s, 2H), 5.37 - 5.25 (m, 1H), 5.20 - 5.09 (m, 1H), 5.02 (d, J= 13.9 Hz, 1H), 3.55-3.23 (m, 2H), 2.03 - 1.85 (m, 1H), 1.70-1.51 (m, 3H), 1.34 (d,V=6.1Hz, 3H), 1.01- 0.91 (m, 2H), 0.86 (t, J= 6.8 Hz, 3H), 0.74 - 0.62 (m, 2H). LCMS (M+H)+ = 423.5. [0825]Example 176: Analytical SFC tR=3.62 min. 1H NMR (400 MHz, DMSO-d) 8 11.51 (s, 1H), 7.39 (t, J= 8.1 Hz, 1H), 6.95 (d, J= 7.9 Hz, 1H), 6.85 (d, J= 12.2 Hz, 1H), 6.50 (s, 1H), 6.00 - 5.82 (m, 1H), 5.44 (s, 2H), 5.39 - 5.28 (m, 1H), 5.13 (dd, J= 13.9, 3.2 Hz, 1H), 5.04 (d, J = 13.9 Hz, 1H), 3.42 - 3.06 (m, 2H), 2.01 - 1.86 (m, 1H), 1.69 - 1.52 (m, 3H), 1.34 (d, J= 6.Hz, 3H), 0.98 - 0.90 (m, 2H), 0.86 (t, J= 6.8 Hz, 3H), 0.72 - 0.63 (m, 2H). LCMS (M+H)+ = 423.5. Example 177 & Example 178:(R)-5-amino-N-(l-(4-cyclopropyl-2-fluorophenyl)ethyl)-N- ethyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide & (S)-5-amino-N-(l-(4- cyclopropyl-2-fluorophenyl)ethyl)-N-ethyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide 293 WO 2024/199255 PCT/CN2024/083980 Step1:5-amino-N-(1-(4-cyclopropyl-2-fluorophenyl)ethyl)-N-ethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furor3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-826" id="p-826" id="p-826"
id="p-826"
[0826]The title compound (30 mg, 39%) was prepared in a manner similar to that in Example 110 & Example 111 step 6 from 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid and l-(4-cyclopropyl-2-fluorophenyl)-N- ethylethan- 1-amine. LC-MS (M+H)+ =538.2.Step2:(R)-5-amino-N-(1-(4-cyclopropyl-2-fluorophenyl)ethyl)-N-ethyl-6,8-dihydro-1H- furo[3,4-d]pyrrolor3,2-b]pyridine-2-carboxamide & (S)-5-amino-N-(l-(4-cyclopropyl-2- fluorophenyl)ethyl)-N-ethyl-6,8-dihydro-lH-furor3,4-dlpyrrolor3,2-blpyridine-2-carboxamide [0827]Example 177 (1 mg, 3%) and Example 178 (1 mg, 3%) were prepared in a manner similar to that in Example 110 & Example 111 step 7 from 5-amino-N-(l-(4-cyclopropyl-2- fluorophenyl)ethyl)-N-ethyl-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide, and the enantiomers were separated by chiral SFC. [0828]Analytical chiral-SFC condition as below. Column: CHIRALPAK AS-H; Column size: 4.6X100 mm, 5 pm; Mobile phase: 4 mM methanolic NH3:CO2, 1:9 to 1:1 in 3 min, 1:1 for min, 1:1 to 1:9 in 0.1 min, 1:9 for 1.9 min; Flow: 2.0 mL/min; Temperature: 35 °C; back pressure: 1500 psi. [0829]Example 177: Analytical SFC tR=2.66 min. 1H NMR (400 MHz, DMSO- 294 WO 2024/199255 PCT/CN2024/083980 Step 1: l-(5-bromo-2-iodophenyl)cyclopropan-l-ol HO id="p-831" id="p-831" id="p-831"
id="p-831"
[0831]The title compound (8.5 g, 29%) was prepared in a manner similar to that in Example 167 & Example 168 step 3 from methyl 5-bromo-2-iodobenzoate. LC-MS (M+H)+ = 338.8.Step 2: 2-( 1-(allyloxy)cyclopropyl)-4-bromo- 1-iodobenzeneBr id="p-832" id="p-832" id="p-832"
id="p-832"
[0832]The title compound (9.4 g, 99%) was prepared in a manner similar to that in Example 167 & Example 168 step 4 from l-(5-bromo-2-iodophenyl)cyclopropan-l-ol and allyl bromide. LC-MS (M+H)+= 379.1.Step 3: 7'-bromo-4'-methylenespiro[cyclopropane-LT-isochromane]Br id="p-833" id="p-833" id="p-833"
id="p-833"
[0833]The title compound (4.6 g, 72%) was prepared in a manner similar to that in Example 167 & Example 168 step 5 from 2-(l-(allyloxy)cyclopropyl)-4-bromo-l -iodobenzene.Step 4: 7'-bromospiro[cyclopropane-Ll'-isochromanl-4'-oneBr id="p-834" id="p-834" id="p-834"
id="p-834"
[0834]The title compound (3.5 g, 75%) was prepared in a manner similar to that in Example 167 & Example 168 step 6 from 7'-bromo-4'-methylenespiro[cyclopropane-l,r ־isochromane] . 1H NMR (400 MHz, DMSO-d) 8 7.88-7.82 (m, 1H), 7.70-7.63 (m, 1H), 7.38 (d, J= 1.7 Hz, 1H), 4.43 (s, 2H), 1.45-1.31 (m, 4H). LC-MS (M+H)+ = 253.1.Step5:(R)-7 ‘-bromospiro[cyclopropane-1,1 ‘-isochroman]-4 ‘-ol 295 WO 2024/199255 PCT/CN2024/083980 OH id="p-835" id="p-835" id="p-835"
id="p-835"
[0835]The title compound (2.4 g, 95%) was prepared in a manner similar to that in Example step 1 from 7'-bromospiro[cyclopropane-l,T-isochroman]-4'-one. LC-MS (M+H)+ = 255.1.Step 6: (S)-N-(7'-bromospiro[cyclopropane-l,T-isochroman]-4'-yl)-N-methyl-2-nitrobenzenesulfonamide id="p-836" id="p-836" id="p-836"
id="p-836"
[0836]The title compound (1.0 g, 93%) was prepared in a manner similar to that in Example 167 & Example 168 step 8 from (R)-7'-bromospiro[cyclopropane-l,T-isochroman]-4'-ol andN- methyl-2-nitro-benzenesulfonamide. LC-MS (M+H)+ = 453.1.Step 7: (S)-7'-bromo-N-methylspiro[cyclopropane-l J'-isochroman]-4'-amine id="p-837" id="p-837" id="p-837"
id="p-837"
[0837]The title compound (550 mg, 93%) was prepared in a manner similar to that in Example 167 & Example 168 step 9 from (S)-N-(7'-bromospiro[cyclopropane-l,T-isochroman]-4'-yl)-N- methyl-2-nitrobenzenesulfonamide. LC-MS (M+H)+ = 268.1.Step 8: (S)-5-amino-N-(7'-bromospirorcvclopropane-Ll'-isochroman]-4'-vl)-N-methyl-l- ((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxamide id="p-838" id="p-838" id="p-838"
id="p-838"
[0838]The title compound (130 mg, 84%) was prepared in a manner similar to that in Example 167 & Example 168 step 10 from (S)-7'-bromo-N-methylspiro[cyclopropane-l,r ־isochroman]- 4'-amine and 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxylic acid. LC-MS (M+H)+ = 599.1.Step9:(S)-5-amino-N-(7 ‘-bromospiro[cyclopropane-1,1 ‘-isochroman]-4 ‘-yl)-N-methyl-6,8-dihydro-lH-furo[3,4-d]pv1Tolo[3,2-b]pvridine-2-carboxamide 296 WO 2024/199255 PCT/CN2024/083980 [0839]Example 179 (53 mg, 52%) was prepared in a manner similar to that in Example 167 & Example 168 step 11 from (S)-5-amino-N-(7'-bromospiro[cyclopropane-l,r-isochroman]-4'-yl)- N-methyl-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2- b]pyridine-2-carboxamide. 1H NMR (400 MHz, DMSO-d6) S 11.56 (s, 1H), 7.39 (dd, J= 8.3, 1.7 Hz, 1H), 7.17-7.04 (m, 1H), 7.01 (d,J=1.7Hz, 1H), 6.72 - 6.43 (m, 1H), 5.83 - 5.59 (m, 1H), 5.54 (s, 2H), 5.10 (s, 2H), 4.88 (s, 2H), 4.26 - 3.88 (m, 2H), 3.15-2.64 (m, 3H), 1.33 - 1.00 (m, 4H). LC-MS (M+H)+ = 469.1. Example 180:(R)-5-amino-N-((S)-7'-bromospiro[cyclopropane-l,l'-isochroman]-4'-yl)- N,6-dimethyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide id="p-840" id="p-840" id="p-840"
id="p-840"
[0840]Example 180 (54 mg, 50%) was prepared in a manner similar to that in Example 1& Example 125 step 2 from (S)-7'-bromo-N-methylspiro[cyclopropane-l,l'-isochroman]-4'- amine and (R)-5-amino-6-methyl-6,8-dihydro-lH-furo[3,4-d]pyrrolo[3,2-b]pyridine-2- carboxylic acid. 1H NMR (400 MHz, DMSO-d) 8 11.55 (s, 1H), 7.40 (dd, J= 8.3, 1.8 Hz, 1H), 7.21 - 7.06 (m, 1H), 7.01 (d, J= 1.7 Hz, 1H), 6.79 - 6.38 (m, 1H), 5.86 - 5.52 (m, 1H), 5.44 (s, 2H), 5.36 - 5.23 (m, 1H), 5.12 (dd, J= 13.9, 3.4 Hz, 1H), 5.02 (d, J= 13.0 Hz, 1H), 4.30 - 3.(m, 2H), 3.13-2.57 (m, 3H), 1.32 (d, J= 6.1 Hz, 3H), 1.30- 1.10 (m, 4H). LC-MS (M+H)+= 483.1. Example 181:(R)-5-amino-N-methyl-N-(l-methyl-7-(trifluoromethyl)-l,2,3,4-tetrahydroquinolin-4-yl)-6,8-dihydro-lH-furo[3,4-d]pyn ־olo[3,2-b]pyridine-2-carboxamide f 3cStep 1: tert-butyl 7-iodo-4-oxo-3,4-dihydroquinoline-l(2H)-carboxylate id="p-841" id="p-841" id="p-841"
id="p-841"
[0841]To a solution of tert-butyl 7-bromo-4-oxo-3,4-dihydroquinoline-l(2H)-carboxylate (3 g, 9.2 mmol) in 1,4-dioxane (100 mL) was added Nai (5.52 g, 36.8 mmol), Cui (876 mg, 4.6 mmol) and trans-N,N'-dimethy!cyclohexane-1,2-diamine (654 mg, 4.6 mmol). The mixture was stirred 297 WO 2024/199255 PCT/CN2024/083980 at 100 °C for 16 h under nitrogen, then cooled to room temperature. Solid was filtered off and the filtrate was concentrated under vacuum. The residue was partitioned between water (200 mL) and EtOAc (200 mL). The organic layer was washed with brine (2 x 100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE:EtOAc=10:l) to give the title compound (2.2 g, 64%). LC-MS (M+H)+ =374.1.Step 2: tert-butyl 4-oxo-7-(trifluoromethyl)-3,4-dihydroquinoline-l(2H)-carboxylate o y—' BocF3C [0842]To a solution of tert-butyl 7-iodo-4-oxo-3,4-dihydroquinoline-l(2H)-carboxylate (2.2 g, 5.9 mmol) in DMF (50 mL) was added Cui (1.13 g, 5.9 mmol) and methyl 2,2-difluoro-2- (fluorosulfonyl)acetate (4.53 g, 23.6 mmol). The mixture was stirred for 16 h at 100 °C under nitrogen and cooled to room temperature. The mixture was filtered off and the filtrate was partitioned between saturated NaHCO3 solution (100 mL) and EtOAc (100 mL). The organic layer was washed with brine (2 x 100 mL), dried over Na2SO4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (PE:EtOAc=10:l) to give the title compound (1.5 g, 81%). LC-MS (M+H)+ =316.4.Step 3: tert-butyl (S)-4-hvdroxv-7-،trifluoromethvl)-3,4-dihvdroquinoline-l(2H)- carboxylateHO y—' Bocf 3c [0843]The title compound (1.5 g, 99%) was prepared in a manner similar to that in Example step 1 from tert-butyl 4-oxo-7-(trifluoromethyl)-3,4-dihydroquinoline-l(2H)-carboxylate. LC- MS (M+H)+ =318.2.Step 4: tert-butyl (R)-4-((N-methyl-2-nitrophenyl)sulfonamido)-7-(trifluoromethyl)-3,4- dihydroquinoline- 1 (2H)-carboxylate 298 WO 2024/199255 PCT/CN2024/083980 [0844]The title compound (3.0 g, 100%) was prepared in a manner similar to that in Example step 6 from tert-butyl (S)-4-hydroxy-7-(trifluoromethyl)-3,4-dihydroquinoline-l(2H)- carboxylate and N-methyl-2-nitro-benzenesulfonamide. LC-MS (M+H)+ =516.3.Step5:(R)-N-methyl-2-nitro-N-(7-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-4- id="p-845" id="p-845" id="p-845"
id="p-845"
[0845]To a solution of tert-butyl (R)-4-((N-methyl-2-nitrophenyl)sulfonamido)-7- (trifluoromethyl)-3,4-dihydroquinoline-l(2H)-carboxylate (3.0 g, 5.82 mmol) in DCM (20 mb) was added HC1 in dioxane (4 M, 20 mL). The mixture was stirred at 25 °C for 3 h. The mixture was concentrated under vacuum. The residue was partitioned between saturated NaHCOa solution (100 mL) and EtOAc (100 mL). The organic layer was washed with brine (100 mL), dried over Na2S04, fdtered and concentrated under vacuum. The residue was purified by silica gel chromatography (DCM:MeOH=20:l) to give the title compound (1.4 g, 58 %). LC-MS (M+H)+=416.1.Step 6: (R)-N-methyl-N-( 1 -methyl-7-(trifluoromethyl)- 1,2,3,4-tetrahydroquinolin-4-yl)-2- nitrobenzenesulfonamide 'S^ NO, —N 0 f 3c [0846]To a solution of (R)-N-methyl-2-nitro-N-(7-(trifluoromethyl)-l,2,3,4- tetrahydroquinolin-4-yl)benzenesulfonamide (520 mg, 1.25 mmol) in MeOH (10 mL) was added paraformaldehyde (188 mg, 6.26 mmol), NaBHJCN (237 mg, 3.76 mmol) and AcOH (376 mg, 6.26 mmol). The mixture was stirred for 16 h at 60 °C then cooled to room temperature. The reaction was quenched with saturated NaHCO3 solution (100 mL) and then extracted with EtOAc (100 mL). The organic layer was washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM:MeOH=30:l) to give the title compound (535 mg, 100%). LC-MS (M+H)+ =430.3.Step 7: (R)-N, 1 -dimethyl-7-(trifluoromethyl)- 1,2,3,4-tetrahydroquinolin-4-amine 299 WO 2024/199255 PCT/CN2024/083980 FSC / HN id="p-847" id="p-847" id="p-847"
id="p-847"
[0847]The title compound (150 mg, 49%) was prepared in a manner similar to that in Example 167 & Example 168 step 9 from (R)-N-methyl-N-(l-methyl-7-(trifIuoromethyl)-l,2,3,4- tetrahydroquinolin-4-yl)-2-nitrobenzenesulfonamide LC-MS (M+H)+ =245.1.Step 8: (R)-5-amino-N-methyl-N-( 1 -methyl-7-(trifluoromethyl)- 1,2,3,4-tetrahydroquinolin- 4-yl)-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4-dlpyrrolo[3,2-b]pyridine-2- carboxamide id="p-848" id="p-848" id="p-848"
id="p-848"
[0848]The title compound (105 mg, 69%) was prepared in a manner similar to that in Example 167 & Example 168 step 10 from (R)-N,l-dimethyl-7-(trifluoromethyl)-l,2,3,4- tetrahydroquinolin-4-amine and 5-amino-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH- furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxylic acid. LC-MS (M+H)+=576.2.Step 9: (R)-5-amino-N-methyl-N-( 1 -methyl-7-(tri fluoromethyl)- 1,2,3,4-tetrahydroquinolin- 4-yl)-6,8-dihydro-1 H-furo[3,4-d]pvn ־olo[3,2-b]pyridine-2-carboxamide [0849]Example 181 (51 mg, 63%) was prepared in a manner similar to that in Example 167 & Example 168 step 11 from (R)-5-amino-N-methyl-N-(l-methyl-7-(trifluoromethyl)-l,2,3,4- tetrahydroquinolin-4-yl)-l-((2-(trimethylsilyl)ethoxy)methyl)-6,8-dihydro-lH-furo[3,4- d]pyrrolo[3,2-b]pyridine-2-carboxamide. 1HNMR (400 MHz, DMSO-d6) 8 11.59 (s, 1H), 7.18- 6.78 (m, 2H), 6.80-6.23 (m, 2H), 5.94-5.68 (m, 1H), 5.58 (s, 2H), 5.20-5.03 (m, 2H), 4.88 (s, 2H), 3.57-3.31 (m, 2H), 3.14-2.69 (m, 6H), 2.27-1.94 (m, 2H). LC-MS (M+H)+ =446.37. Cell killing in HCT116 isogenic pair [0850]HCT116 cell line (ATCC, CCL-247) was isolated from the colon of an adult male with colon cancer. It has a mutation in codon 13 of the ras proto-oncogene and can be used as a positive control for PCR assays of mutation in this codon. HCT116-MTAP-KO was knocked- out-MTAP-gene based HCT116, and a single clone was passed for this assay. HCT116-mock- RNA-KO was knocked-out-mock-gene based HCT116 with MTAP wildtype genotype. The base medium for HCT116 isogenic pair is RPMI 1640, HEPES (Gibco, 22400105). To make the complete growth medium, added the following components to the base medium: fetal bovine serum to a final concentration of 10% (Gibco, 10099-141C). The cell line was grown in a 300 WO 2024/199255 PCT/CN2024/083980 humidified 5% CO2 atmosphere at 37 °C and regularly tested for the presence of mycoplasma with MycoAlertTM PLUS Mycoplasma Detection Kit (Lonza, LT07-710). [0851]Experimental• Seeded HCT116-mock-RNA-KO (4E2/well) or HCT116-MTAP-KO (4E2/well) cells into a 96-well plate (Greiner: 655090), 100 pL/well.• Incubated at 37 °C, 5% CO2, overnight.• Added 50 pL fresh growth medium containing serial dilution of test compounds for a final test compound concentration of 0-10 pM to each well.• Incubated at 37 °C, 5% CO2, 6 days.• The cell viability was detected by Cell Titer-Gio (Promega, G7573). Added pL of CellTiter-Glo® reagent in each well.• Incubated at room temperature for 10 minutes to stabilize luminescent signal.• Analyzed with Microplate Reader (TECAN, SPARK) and fit IC50 using Prism® 9. [0852]The compounds disclosed herein showed cell killing activity values as in Table 1.
Table 1: Cell killing IC50 (nM) for the compounds disclosed herein Example Cell killingIC50 (nM) inHCT116-MTAP-KO Cell killingIC50 (nM) inHCT116-mock-RNA-KO Example Cell killingIC50 (nM) inHCT116-MTAP-KO Cell killingIC50 (nM) inHCT116- mock-RNA-KO 1 <1.5* 4.6 2 3.3 23 3 2.4 221 4 2.3 99 5 4.0 76 6 11 40 7 30 3143 8 34 2746 9 46 3445 10 4.6 247 11 3.8 69 12 29 1906 13 4.6 251 14 <1.5* 554 15 8.1 225 16 1.0 165 17 8.2 1054 18 1.8 96 19 <1.5* 185 20 658 4004 21 <1.5* 7.0 22 <1.5* 11 23 4.8 81 24 103 8538 301 WO 2024/199255 PCT/CN2024/083980 Example Cell killing IC50 (nM) in HCT116- MTAP-KO Cell killing IC50 (nM) in HCT116- mock-RNA- KO Example Cell killing IC50 (nM) in HCT116- MTAP-KO Cell killing IC50 (nM) in HCT116- mock-RNA- KO 25 96 2002 26 14 1873 27 2.4 284 28 11 1903 29 1.3 81 30 0.8 22 31 1.2 7.1 32 3.9 451 33 210 >10000 34 7.4 1346 35 11 1530 36 5.8 445 37 13 1685 38 6.3 665 39 1174 >10000 40 13 2491 41 6.6 586 42 24 2498 43 2.9 207 44 8.2 568 45 7.2 856 46 9.0 854 47 4.4 605 48 8.4 625 49 6.1 835 50 8.6 1360 51 7.8 558 52 4.6 419 53 34 >10000 54 12 1362 55 1643 >10000 56 5.0 146 57 958 >10000 58 1077 >10000 59 110 >10000 60 7.3 857 61 808 >10000 62 17 2084 63 22 2502 64 362 >10000 65 17 2455 66 20 2519 67 4.2 453 68 9.0 1693 69 26 2704 70 12 1184 71 728 6155 72 8.2 1007 73 34 2490 74 1066 >10000 75 41 >10000 76 2108 >10000 77 51 >10000 78 624 2931 79 525 3280 80 351 >10000 81 9.7 1025 82 13 1841 302 WO 2024/199255 PCT/CN2024/083980 Example Cell killing IC50 (nM) in HCT116- MTAP-KO Cell killing IC50 (nM) in HCT116- mock-RNA- KO Example Cell killing IC50 (nM) in HCT116- MTAP-KO Cell killing IC50 (nM) in HCT116- mock-RNA- KO 83 7.2 556 84 10 2202 85 113 >10000 86 1903 >10000 87 67 >10000 88 1412 >10000 89 4.1 446 90 29 5446 91 32 3877 92 49 2049 93 165 >10000 94 3.8 578 95 18 1779 96 7.2 1933 97 17 2886 98 11 1858 99 722 >10000 100 1.4 136 101 339 2091 102 1.1 77 103 272 2448 104 18 2730 105 13 930 106 11 2631 107 20 1094 108 31 3422 109 24 1790 110 12 2488 ill 2200 >10000 112 59 >10000 113 1609 >10000 114 3629 >10000 115 43 6815 116 6.9 269 117 6.5 609 118 2246 >10000 119 9.8 1591 120 5.6 992 121 586 >10000 122 2224 5780 123 46 4912 124 22 2472 125 365 7457 126 11 1719 127 236 5896 128 6.0 1054 129 1182 >10000 130 8.5 1093 131 1834 >10000 132 45 >10000 133 13 1337 134 336 2883 135 26 2133 136 245 3518 137 44 3023 138 913 3240 139 12 2397 140 270 3026 303 WO 2024/199255 PCT/CN2024/083980 * More than 50% viability inhibition at tested concentration without a full curve for IC50 Example Cell killing IC50 (nM) in HCT116- MTAP-KO Cell killing IC50 (nM) in HCT116- mock-RNA- KO Example Cell killing IC50 (nM) in HCT116- MTAP-KO Cell killing IC50 (nM) in HCT116- mock-RNA- KO 141 149 >10000 142 2.6 477 143 11 1381 144 543 >10000 145 26 3426 146 316 >10000 147 1229 5422 148 19 2437 149 2678 >10000 150 32 2793 151 85 >10000 152 1277 >10000 153 10 610 154 1626 8516 155 19 2253 156 523 >10000 157 64 >10000 158 2018 >10000 159 36 2577 160 598 >10000 161 39 2799 162 186 >10000 163 >10000 >10000 164 145 >10000 165 17 2573 166 19 2150 167 697 3325 168 8.4 2108 169 565 2112 170 4.4 1012 171 39 3034 172 33 5050 173 67 5920 174 478 6070 175 14 704 176 452 1785 177 74 2687 178 1039 3269 179 24 4388 180 20 3567 181 15 1796 determination id="p-853" id="p-853" id="p-853"
id="p-853"
[0853]The foregoing examples and description of certain embodiments should be taken as illustrating, rather than as limiting the present invention as defined by the claims. As will be readily appreciated, numerous variations and combinations of the features set forth above can be utilized without departing from the present invention as set forth in the claims. All such 304 WO 2024/199255 PCT/CN2024/083980 variations are intended to be included within the scope of the present invention. All references cited are incorporated herein by reference in their entireties. [0854]It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art in any country. 305
Claims (76)
1. WO 2024/199255 PCT/CN2024/083980 What is claimed is: 1. A compound of Formula (1): or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof, wherein:L is a single bond or -C(R8R9)-;R1 andR 2 are each independently selected from hydrogen, -C1-8alkyl, -C3-C8cycloalkyl, -C3-C12cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12-membered heteroaryl, wherein each of said -C1-8alkyl, -C3-C8cycloalkyl, 3- to 12-membered heterocyclyl, - C6-C12aryl and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent Rla ; orR1 and R2 together with the nitrogen atom to which they are attached, form a 3- to 8- membered unsaturated or saturated ring, said ring comprising 0-3 additional heteroatoms independently selected from nitrogen, oxygen or sulfur and said ring is optionally substituted with at least one substituent Rla ;Rla is independently hydrogen, halogen, deuterium, -C1-8alkyl, -C3-C8cycloalkyl, -C3-C!2cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C!2aryl, 5- to 12-membered heteroaryl, -ORlb, -SO2Rlb, -SO2NRlbRlc , -CORlb, -CO2Rlb, -CONRlbRlc , -NRlbRlc , - NRlbCORlc , -NRlbCO2Rlc ,NRlbSO2Rlc , oxo, or -CN, wherein each of said -C!-8alkyl, -C3-C8cycloalkyl, -C3- C!2cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C!2aryl and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent Rld; ortwo Rla together with the atom(s) to which they are attached, form a 3- to 8-membered unsaturated or saturated ring, said ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur and said ring is optionally substituted with at least one substituent Rld;Rlb and Rlc are each independently selected from hydrogen, -C1-8alkyl, -C3-C8cycloalkyl, 3- to12-membered heterocyclyl, -C6-C12aryl and 5- to 12-membered heteroaryl, wherein each of said -C!-8alkyl, -C3-C8cycloalkyl, 3- to 12-membered heterocyclyl, -C6-C!2aryl and 5- to 12- membered heteroaryl is optionally substituted with at least one substituent Rle;Rld and Rle are each independently hydrogen, halogen, -C1-8alkyl, -C3-C8cycloalkyl, 306 WO 2024/199255 PCT/CN2024/083980 -C3-C12cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C12aryl, 5- to 12-membered heteroaryl, -ORlf ,-SO2Rlf , -SO2NRlf Rlg, -CORlf , -CO2R11', -CONRlf Rlg, -NRlf Rlg, -NRlf CORlg, -NRlf CO2Rlg, -NRlf SO2Rlg, oxo, or -CN, wherein each of said -Cnsalkyl, -C3-C8cycloalkyl, -C3- C12cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent Rlh ;Rlf and Rlg are each independently selected from hydrogen, -Cnsalkyl, -C3-Cscycloalkyl, 3- to12-membered heterocyclyl, -C6-C12aryl and 5- to 12-membered heteroaryl, wherein each of said -Cnsalkyl, -C3-C8cycloalkyl, 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12- membered heteroaryl is optionally substituted with at least one substituent R11;R,h andR 1' are each independently hydrogen, halogen, -Cnsalkyl, -C3-C8cycloalkyl, -C3-C12cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C12aryl, 5- to 12-membered heteroaryl, -OR1׳, -SO2Rlj , -S02NR1'Rlk, -COR1', -C02R1j, -C0NRljRlk, -NRljRlk, -NRljC0Rlk, -NRljC02Rlk, - NR’jSO2R ,k, oxo, or -CN, wherein each of said -C1-salkyl, -C3-C8cycloalkyl, -C3- C12cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent selected from the group consisting of halogen, -Cnsalkyl, -Cnsalkoxy, -C2-8alkenyl, -C2-8alkynyl, -C3-C8cycloalkyl, 3- to 8-membered heterocyclyl, -C6-C12aryl, 5- to 12-membered heteroaryl, -CN, -OH, -NH2 or oxo;Rlj and Rlk are each independently selected from hydrogen, -Cnsalkyl, -C3-C8cycloalkyl, 3- to12-membered heterocyclyl, -C6-C!2aryl and 5- to 12-membered heteroaryl, wherein each of said -Cnsalkyl, -C3-C8cycloalkyl, 3- to 12-membered heterocyclyl, -C6-C!2aryl and 5- to 12- membered heteroaryl is optionally substituted with at least one substituent selected from the group consisting of halogen, -Cnsalkyl, -Cnsalkoxy, -C2-salkenyl, -C2-8alkynyl, -C3-C8cycloalkyl, 3- to 8-membered heterocyclyl, -C6-C!2aryl, 5- to 12-membered heteroaryl, -CN, -OH, -NH2 or oxo;R3 is selected from hydrogen, halogen, -Cnsalkyl, -C3-C8cycloalkyl, -CN, -OH, or -NH2, wherein each of said -Cnsalkyl and -C3-C8cycloalkyl is optionally substituted with at least one substituent selected from the group consisting of halogen, -Cnsalkoxy, -Cnsalkyl, -C3- Cgcycloalkyl, and 3- to 8-membered heterocyclyl;R4, R5, R6, R7, R8 and R9 are each independently selected from hydrogen, halogen, -Cn salkyl or 307 WO 2024/199255 PCT/CN2024/083980 -C3-C8cycloalkyl, wherein each of said -C!-8alkyl and -C3-C8cycloalkyl is optionally substituted with at least one substituent selected from the group consisting of halogen, -Cnsalkoxy, -Cn 8alkyl, -C3-C8cycloalkyl, 3- to 8-membered heterocyclyl, C6-C12aryl, 5- to 12-membered heteroaryl, oxo, -CN,-0R4a , -SO2R4a , -SO2NR4a R4b, -COR4a , -CO2R4a , -CONR4a R4b, -NR4a R4b, -NR4a COR4b, - NR4a CO2R4b, or-NR4a SO2R4b;R4a and R4b are each independently hydrogen, -C1-8alkyl, C3-C8cycloalkyl, 3- to 8- membered heterocyclyl, -C6-C12aryl, or 5- to 12-membered heteroaryl; each of said -C1-8alkyl, C3-C8cycloalkyl, 3- to 8-membered heterocyclyl, -C6-C12aryl, or 5- to 12-membered heteroaryl is optionally substituted with at least one halogen, -OH, -Cusalkyl, -Cnsalkoxy, Cn8alkoxy-Cn salkyl-, -C2-8alkenyl, -C2-8alkynyl, -C3-C8cycloalkyl, 3- to 8-membered heterocyclyl, -C6-C12aryl, or 5- to 12-membered heteroaryl.
2. The compound of claim 1, wherein the compound is of formula (11a) or (11b): or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof.
3. The compound of claim 2, wherein the compound is of formula (11c) or (lid): or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof.
4. The compound of claim 3, wherein the compound is of formula (lie), (Ilf), (Ilg) or (Ilh): 308 WO 2024/199255 PCT/CN2024/083980 or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof.
5. The compound of claim 1, wherein the compound is of formula (Illa):R3 or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof, wherein nl is 0, 1, 2 or 3.
6. The compound of claim 5, wherein nl is 1 or 2.
7. The compound of claim 6, wherein nl is 1.
8. The compound of any one of claims 5-7, wherein the compound is of formula (111b): or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof.
9. The compound of any one of claims 5-8, wherein the compound is of formula (IIIc) : or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof.
10. The compound of any one of claims 5-9, wherein the compound is of formula (Hid), (Ilie), (Ulf), or (Illg): 309 WO 2024/199255 PCT/CN2024/083980 (Hid), (Illf), (Ilie), (Hlg),or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof.
11. The compound of any one of claims 5-10, wherein the compound is of formula (Illh), (Ulk), or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof ; .
12. The compound of claim 1, wherein the compound is of formula (IVa), (IVb), (IVc), (IVd), (IVe), (IVf), (IVg), or (IVh): 310 WO 2024/199255 PCT/CN2024/083980 or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof, wherein n2 is 0, 1, 2 or 3.
13. The compound of claim 12, wherein n2 is 0, 1 or 2.
14. The compound of claim 12 or 13, wherein the compound is of formula (IVi), (IVj), (IVk), (IVI), (IVm), (IVn), (IVo), (IVp), (IVq), (IVr), (IVs), (IVt), (IVu), or (IVv): (IVi); (IVj); 311 ZIE ■(AA1) ( n Al ؛) ( SA1 ؛) ( JA1 ؛) -(bAl) ( UA1 ؛) 086£80/1־Z0ZN3/13d SSZ661/+707 OM WO 2024/199255 PCT/CN2024/083980 or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof,.
15. The compound of claim 1, wherein the compound is of formula (Va): (Va),or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof, wherein:n3 is 0, 1, 2, 3 or 4; andeach occurrence of X is independently N or CH.
16. The compound of claim 15, wherein n3 is 1, 2 or 3.
17. The compound of claim 15 or 16, wherein zero, one or two occurrences of X are N, and the rest are CH.
18. The compound of claim 16, wherein the compound is of formula (Vb), (Vc), (Vd), (Ve),or (Vf): (Vf); (Vc), (Ve), or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a313 WO 2024/199255 PCT/CN2024/083980 deuterated analog thereof.
19. The compound of any one of claims 15-18, wherein n3 is 1 or 2.
20. The compound of claim 19, wherein n3 is 1.
21. The compound of any one of claims 15-20, wherein the compound is of formula (Vg), (Vh), (Vi), (Vj), (Vk), (VI), (Vm), (Vn), or (Vo): (Vo);or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof.
22. The compound of claim 21, wherein the compound is of formula (Vp), (Vq), (Vr), (Vs),314 WO 2024/199255 PCT/CN2024/083980 (Vt), (Vu) , (Vv), (Vw), (Vx), (Vy), or (Vz): (Vz),or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof.
23. A compound of Formula (VI):315 WO 2024/199255 PCT/CN2024/083980 or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof, wherein:R1 and R2 are each independently selected from hydrogen, -C1-8alkyl, -C3-C8cycloalkyl, -C3-C12cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12-membered heteroaryl, wherein each of said -Cusalkyl, -C3-C8cycloalkyl, 3- to 12-membered heterocyclyl, - C6-C12aryl and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent Rla ; orR1 and R2 together with the nitrogen atom to which they are attached, form a 3- to 8- membered unsaturated or saturated ring, said ring comprising 0-3 additional heteroatoms independently selected from nitrogen, oxygen or sulfur and said ring is optionally substituted with at least one substituent Rla ;R,a is independently hydrogen, halogen, deuterium, -Cusalkyl, -C3-C8cycloalkyl, -C3-C12cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C12aryl, 5- to 12-membered heteroaryl, -ORlb, -SO2Rlb, -SO2NRlbRlc , -CORlb, -CO2Rlb, -CONRlbRlc , -NRlbRlc , - NRlbCORlc , -NRlbCO2Rlc , -NRlbSO2Rlc , oxo, or -CN, wherein each of said -Cusalkyl, -C3-C8cycloalkyl, -C3- C!2cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C!2aryl and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent Rld; ortwo Rla together with the atom(s) to which they are attached, form a 3- to 8-membered unsaturated or saturated ring, said ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur and said ring is optionally substituted with at least one substituent Rld;Rlb and Rlc are each independently selected from hydrogen, -Cusalkyl, -C3-C8cycloalkyl, 3- to12-membered heterocyclyl, -C6-C12aryl and 5- to 12-membered heteroaryl, wherein each of said -Cusalkyl, -C3-C8cycloalkyl, 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12- membered heteroaryl is optionally substituted with at least one substituent Rle;Rld and Rle are each independently hydrogen, halogen, -Cusalkyl, -C3-C8cycloalkyl, -C3-C12cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C12aryl, 5- to 12-membered heteroaryl, -ORlf , -SO2Rlf , -SO2NRlf Rlg, -CORlf , -CO2Rlf , -CONRlf Rlg, -NRlf Rlg, -NRlf CORlg, -NRlf CO2Rlg, -NRlf SO2Rlg, oxo, or -CN, wherein each of said -Ci-salkyl, -C3-C8cycloalkyl, -C3- C12cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12-membered heteroaryl316 WO 2024/199255 PCT/CN2024/083980 is optionally substituted with at least one substituent Rlh ;Rlf and Rlg are each independently selected from hydrogen, -Ci-galkyl, -C3-C8cycloalkyl, 3- to12-membered heterocyclyl, -C6-C12aryl and 5- to 12-membered heteroaryl, wherein each of said -C!-8alkyl, -C3-C8cycloalkyl, 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12- membered heteroaryl is optionally substituted with at least one substituent R11;Rlh and R״ are each independently hydrogen, halogen, -Cnsalkyl, -C3-C8cycloalkyl, -C3-C12cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C12aryl, 5- to 12-membered heteroaryl, -OR1, -SO2Rlj , -SO2NRljRlk, -CORlj , -CO2R1j, -CONRljRlk, -NRljRlk, -NRljCORlk, -NRljCO2Rlk, - NRljSO2Rlk, oxo, or -CN, wherein each of said -C1-8alkyl, -C3-C8cycloalkyl, -C3- C12cycloalkenyl, 3- to 12-membered heterocyclyl, -C6-C12aryl and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent selected from the group consisting of halogen, -C1-8alkyl, -C1-8alkoxy, -C2-8alkenyl, -C2-8alkynyl, -C3-C8cycloalkyl, 3- to 8-membered heterocyclyl, -C6-C12aryl, 5- to 12-membered heteroaryl, -CN, -OH, -NH2 or oxo;R'j and R,k are each independently selected from hydrogen, -C1-8alkyl, -C3-C8cycloalkyl, 3- to12-membered heterocyclyl, -C6-C12aryl and 5- to 12-membered heteroaryl, wherein each of said -C!-8alkyl, -C3-C8cycloalkyl, 3- to 12-membered heterocyclyl, -C6-C!2aryl and 5- to 12- membered heteroaryl is optionally substituted with at least one substituent selected from the group consisting of halogen, -C1-8alkyl, -C1-8alkoxy, -C2-8alkenyl, -C2-8alkynyl, -C3-C8cycloalkyl, 3- to 8-membered heterocyclyl, -C6-C12aryl, 5- to 12-membered heteroaryl, -CN, -OH, -NH2 or oxo; andR6 and R7 are each independently selected from hydrogen or methyl.
24. The compound of claim 23, wherein the compound is of formula (Vila): or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof, wherein:n4 is 0, 1, 2, 3 or 4; andeach occurrence of Y is independently N or CH. 317 WO 2024/199255 PCT/CN2024/083980
25. The compound of claim 24, wherein n4 is 0, 1, 2 or 3.
26. The compound of claim 25, wherein n4 is 1, 2 or 3.
27. The compound of any one of claims 24-26, wherein zero, one or two occurrences of Y are N, and the rest are CH.
28. The compound of any one of claims 25-27, wherein the compound is of formula (VIIb),(Vile), (Vlld), (Vile), or (Vllf): (Vile), (VIIb), (Vile), (Vllf); or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof.
29. The compound of any one of claims 25-28, wherein n4 is 1 or 2.
30. The compound of claim 29, wherein n4 is 1.
31. The compound of any one of claims 23-30, wherein the compound is of formula (Vllg),(Vllh), (Vlli), (Vllj), (VHk), (VIII), (Vllm), (Vlln), (VIIo), (VIIp), or (Vllq): (Vllg), (Vllh), 318 WO 2024/199255 PCT/CN2024/083980 R1d (Vlli), (VUj), (Vllk), R1d(Vlln), (Vllm), (VHp), (VIIo), (Vllq),or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof.
32. The compound of claim 23, wherein the compound is of formula (Villa): (Villa),or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof, wherein: 319 WO 2024/199255 PCT/CN2024/083980 n5 is 0, 1, 2, 3 or 4;Z1 and Z2 are each independently selected from O or CH2; andZ3 and Z4 are each independently selected from N or CH.
33. The compound of claim 32, wherein the compound is of formula (Vlllb), (VIIIc), (Vllld), (Ville), (Vlllf), (Vlllg), (Vlllh), (Villi), (Vlllj), (VlUk), (VIIII), (VIHm), (Vllln) or (VIIIo): (VTITc) (Ville) (Vllld) (Vlllg)(Vlllf) (Villi) (VIHk) 320 WO 2024/199255 PCT/CN2024/083980 (VIIIo), or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof.
34. The compound of claim 32 or 33, wherein n5 is 1, 2 or 3.
35. The compound of claim 34, wherein n5 is 1 or 2.
36. The compound of any one of claims 1-35, wherein R1 and R2 are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C3-C12cycloalkenyl, 3- to 12-membered heterocyclyl, phenyl and 5- to 12-membered heteroaryl, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 12-membered heterocyclyl, phenyl and 5- to 12- membered heteroaryl is optionally substituted with at least one substituent Rla ; orR1 and R2 together with the nitrogen atom to which they are attached, form a 3-, 4-, 5-, 6-, 7- or 8-membered unsaturated or saturated ring, said ring comprising 0, 1, 2 or 3 additional heteroatoms independently selected from nitrogen, oxygen or sulfur and said ring is optionally substituted with at least one substituent Rla ;Rla is independently hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C3- C!2cycloalkenyl, 3- to 12-membered heterocyclyl, phenyl, 5- to 12-membered heteroaryl, -ORlb, -SO2Rlb, -SO2NRlbRlc , -CORlb, -CO2Rlb, -CONRlbRlc , -NRlbRlc , -NRlbCORlc , -NRlbCO2Rlc , - NRlbSO2Rlc , oxo, or -CN, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C3- C!2cycloalkenyl, 3- to 12-membered heterocyclyl, phenyl or 5- to 12-membered heteroaryl is 321 WO 2024/199255 PCT/CN2024/083980 optionally substituted with at least one substituent Rld; ortwo Rla together with the atom(s) to which they are attached, form a 3-, 4-, 5-, 6-, 7- or 8- membered unsaturated or saturated ring, said ring comprising 0, 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur and said ring is optionally substituted with at least one substituent Rld;Rlb and Rlc are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 12-membered heterocyclyl, phenyl or 5- to 12-membered heteroaryl, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 12-membered heterocyclyl, phenyl or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent Rle;R,dandR ,eare each independently hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C3-C12cycloalkenyl, 3- to 12-membered heterocyclyl, phenyl, 5- to 12-membered heteroaryl, -ORlf , -SO2Rlf , -SO2NRlf Rlg, -CORlf , -CO2Rlf , -CONR,f R,g, -NR1fR1g, -NR1f COR,g, -NRlf CO2R,g, NR,f SO2R,g, oxo, or -CN, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C3-C12cycloalkenyl, 3- to 12-membered heterocyclyl, phenyl, and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent Rlh ;Rlf and Rlg are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 12-membered heterocyclyl, phenyl or 5- to 12-membered heteroaryl, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 12-membered heterocyclyl, phenyl or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent R11;Rlh and R״ are each independently hydrogen, -F, -Cl, -Br, -1, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C3-C12cycloalkenyl, 3- to 12-membered heterocyclyl, phenyl, 5- to 12-membered heteroaryl, -ORlj , -SO2R1j, -S02NRljRlk, -C0Rlj , -CO2Rlj , -C0NRljRlk, -NRljRlk, -NRljC0Rlk, -NRljC02Rlk, -NRljS02Rlk, oxo, or -CN, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C3-C12cycloalkenyl, 3- to 12-membered heterocyclyl, phenyl and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent -F, -Cl, -Br, -1, methyl, ethyl, propyl, butyl, 322 WO 2024/199255 PCT/CN2024/083980 pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, hepthoxy, octoxy, -C2-8alkenyl, -C2-8alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, 5- to 12-membered heteroaryl, -CN, -OH, - NH2 or oxo;R1J andR lk are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 12-membered heterocyclyl, phenyl and 5- to 12-membered heteroaryl,wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 12-membered heterocyclyl, phenyl and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent - F, -Cl, -Br, -1, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, hepthoxy, octoxy, -C2-8alkenyl, -C2-8alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, 5- to 12-membered heteroaryl, -CN, -OH, -NH2 or oxo.
37. The compound of any one of claims 1-36, wherein R1 and R2 are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl, pyrimidinyl, tetrahydro- 2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo[d]thiazolyl, triazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl, wherein each of said methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl, pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo[d]thiazolyl, triazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rla ; orR1 and R2 together with the nitrogen atom to which they are attached, form a 3-, 4-, 5-, 6-, 7- or 8-membered unsaturated or saturated ring, said ring comprising 0, 1, 2 or 3 additional heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent Rla ;Rla is independently hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl, pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo [d] thiazolyl, triazolyl, pyridinyl, quinolinyl, 323 WO 2024/199255 PCT/CN2024/083980 isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, tetrahydrofuropyridinyl -ORlb, -SO2Rlb, -SO2NRlbRlc , -CORlb, -CO2Rlb, - CONRlbRlc , -NRlbRlc , -NRlbCORlc , -NRlbCO2Rlc , -NRlbSO2Rlc , oxo, or -CN, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl, pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo[d]thiazolyl, triazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rld; ortwo Rla together with the atom(s) to which they are attached, form a 3-, 4-, 5- or 6- membered unsaturated or saturated ring, said ring comprising 0, 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent R,d;Rlb and Rlc are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl, pyrimidinyl, tetrahydro- 2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo[d]thiazolyl, triazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl, pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo[d]thiazolyl, triazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rle;Rld and Rle are each independently hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl, pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo[d]thiazolyl, triazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl, tetrahydrofuropyridinyl, -ORlf , - SO2Rlf ,-CORlf , -CO2Rlf , -C0NRlf Rlg, -NRlf Rlg, -NRlf CORlg, -NRlf C02Rlg, oxo, or -CN, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, 324 WO 2024/199255 PCT/CN2024/083980 cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl, pyrimidinyl, tetrahydro- 2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo[d]thiazolyl, triazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rlh ;Rlf and Rlg are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl, pyrimidinyl, tetrahydro- 2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo[d]thiazolyl, triazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl, pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo [d]thiazolyl, triazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent R11;Rlh and R״ are each independently hydrogen, -F, -Cl, -Br, -1, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl, pyrimidinyl, tetrahydro- 2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo[d]thiazolyl, triazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl, tetrahydrofuropyridinyl, -ORlj , -CORlj , -CO2R1j, -CONRljRlk, -NRljRlk, -NRljCORlk, - NRljCO2Rlk, oxo, or -CN, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl, pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo [d]thiazolyl, triazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, hepthoxy, octoxy, -C2-8alkenyl, -C2-8alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, 325 WO 2024/199255 PCT/CN2024/083980 tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl, tetrahydrofuropyridinyl, -CN, -OH, -NH2 or oxo; andRlj and Rlk are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl, pyrimidinyl, tetrahydro- 2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo[d]thiazolyl, triazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl, pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo[d]thiazolyl, triazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent -F,-Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, hepthoxy, octoxy, -C2-8alkenyl, -C2-8alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl, tetrahydrofuropyridinyl, -CN, -OH, -NH2 or oxo.
38. The compound of claim 37, wherein R1 and R2 are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl, pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo [d]thiazolyl, triazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl, wherein each of said methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl, pyrimidinyl, tetrahydro- 2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo[d]thiazolyl, triazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rla ; orR1 and R2 together with the nitrogen atom to which they are attached, form a 3-, 4-, 5-, 6-, 7- or 8-membered unsaturated or saturated ring, said ring comprising 0, 1, 2 or 3 additional heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally 326 WO 2024/199255 PCT/CN2024/083980 substituted with at least one substituent Rla ;Rla is independently hydrogen, -F, -Cl, -Br, -1, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl, pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo[d]thiazolyl, triazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl, tetrahydrofuropyridinyl, -ORlb or -CN, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl, pyrimidinyl, tetrahydro- 2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo[d]thiazolyl, triazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent R,d; ortwo Rla together with the atom(s) to which they are attached, form a 3-, 4-, 5- or 6- membered unsaturated or saturated ring, said ring comprising 0, 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent R,d;Rlb is each independently hydrogen, methyl, ethyl, propyl, cyclopropyl or cyclobutyl;Rld is each independently hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl , butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl , pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo [d] thiazolyl, triazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl, tetrahydrofuropyridinyl, -ORlf , -NRlf Rlg, - NRlf CORlg, oxo, -SO2Rlf or -CN, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl, pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo[d]thiazolyl, triazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rlh ;Rlf and Rlg are each independently selected from hydrogen, methyl, ethyl, , butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl, pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo [d] thiazolyl, triazolyl, pyridinyl, quinolinyl, 327 WO 2024/199255 PCT/CN2024/083980 isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl, pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo [d]thiazolyl, triazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent R11; andRlh andR 1' are each independently hydrogen, -F, -Cl, -Br, -1, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl, pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo[d]thiazolyl, triazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl, tetrahydrofuropyridinyl, -OH, or -CN.
39. The compound of claim 38, wherein R1 and R2 are each independently selected from hydrogen, methyl, ethyl, propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl, pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo[d]thiazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl, wherein each of said methyl, ethyl, propyl, phenyl, chromanyl, isochromanyl, dihydropyranopyridinyl, pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, tetrahydronaphthalenyl, benzo[d]thiazolyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rla ; orR1 and R2 together with the nitrogen atom to which they are attached, form a 6-membered unsaturated or saturated ring, said ring is optionally substituted with at least one substituent Rla ;Rla is independently hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyrimidinyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, benzo[d]thiazolyl, pyridinyl, quinolinyl, isoquinolinyl, thiazolyl, -ORlb or -CN wherein each of said methyl, ethyl, propyl, phenyl, pyrimidinyl, pyridazinyl, pyrazinyl, dihydrofuropyridinyl, benzo[d]thiazolyl, pyridinyl, quinolinyl, isoquinolinyl or thiazolyl is optionally substituted with at least one substituent Rld; 328 WO 2024/199255 PCT/CN2024/083980 Rlb is each independently hydrogen, methyl, ethyl, propyl, cyclopropyl or cyclobutyl;Rld is each independently hydrogen, -F, -Cl, -Br, -1, methyl, ethyl, propyl, butyl, phenyl, pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, triazolyl, pyridinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl, tetrahydrofuropyridinyl, -ORlf , -SO2Rlf or -CN, wherein each of said methyl, ethyl, propyl, butyl, phenyl, pyrimidinyl, tetrahydro-2H-pyranyl, pyridazinyl, pyrazinyl, triazolyl, pyridinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rlh ;Rlf is each independently selected from hydrogen, methyl, ethyl, propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or phenyl, wherein each of said methyl, ethyl, propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or phenyl is optionally substituted with at least one substituent R1;Rlh and R״ are each independently hydrogen, -F, -Cl, -Br, -1, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -OH, or -CN.
40. The compound of any one of claims 1 -35, wherein R1 and R2 are each independently selected from -C1-8alkyl, -C3-C8cycloalkyl, -C3-C12cycloalkenyl and 3- to 12-membered heterocyclyl, wherein each of said -C1-8alkyl, -C3-C8cycloalkyl, -C3-C12cycloalkenyl and 3- to 12-membered heterocyclyl is optionally substituted with at least one substituent Rla ; orR1 and R2 together with the nitrogen atom to which they are attached, form a 3- to 8- membered unsaturated or saturated ring, said ring comprising 0-3 additional heteroatoms independently selected from nitrogen, oxygen or sulfur and said ring is optionally substituted with at least one substituent Rla ;Rla is independently hydrogen, halogen, deuterium, -C!-8alkyl, -C3-C8cycloalkyl, -C6- C!2aryl, 5- to 12-membered heteroaryl, -ORlb or -CN, wherein each of said -C!-8alkyl, -C3- Cgcycloalkyl, -C6-C12aryl and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent Rld; ortwo Rla together with the atom(s) to which they are attached, form a 3- to 8-membered unsaturated or saturated ring, said ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur and said ring is optionally substituted with at least one substituent Rld;Rlb is each independently selected from hydrogen, -C1-8alkyl, wherein said -C1-8alkyl is optionally substituted with at least one substituent Rle;Rld and Rle are each independently hydrogen, halogen, -C!-8alkyl, -C3-C8cycloalkyl, -C6- C12aryl, 5- to 12-membered heteroaryl, -ORlf , -SO2Rlf or -CN, wherein each of said -C1-8alkyl, - C6-C12aryl and 5- to 12-membered heteroaryl is optionally substituted with at least one 329 WO 2024/199255 PCT/CN2024/083980 substituent Rlh ;Rlf is each independently selected from hydrogen, -Cnsalkyl and -C3-C8cycloalkyl, wherein each of said -C-galkyl and -C3-C8cycloalkyl is optionally substituted with at least one substituent R11; andRlh andR 1' are each independently hydrogen, halogen, -C1-8alkyl or -CN.
41. The compound of claim 40, wherein R1 and R2 are each independently selected from methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, chromanyl, isochromanyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl, wherein each of said methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, chromanyl, isochromanyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rla ; orR1 and R2 together with the nitrogen atom to which they are attached, form a 3-, 4-, 5-, 6-, 7- or 8-membered unsaturated or saturated ring, said ring comprising 0, 1, 2 or 3 additional heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent Rla ;Rla is independently hydrogen, -F, -Cl, -Br, -1, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl, tetrahydrofuropyridinyl -ORlb or -CN, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rld; ortwo Rla together with the atom(s) to which they are attached, form a 3-, 4-, 5- or 6- membered unsaturated or saturated ring, said ring comprising 0, 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent Rld;Rlb is each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl and octyl, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl and octyl is optionally substituted with at least one substituent Rle;Rld and Rle are each independently hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyridinyl, quinolinyl, 330 WO 2024/199255 PCT/CN2024/083980 isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl, tetrahydrofuropyridinyl, -OR11, -SO2R11 or -CN, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, pyridinyl, quinolinyl, isoquinolinyl, pyrazolyl, imidazolyl, thiazolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydronaphthyl, dihydrofuropyridinyl or tetrahydrofuropyridinyl is optionally substituted with at least one substituent Rlh ;Rlf is each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl is optionally substituted with at least one substituent R11;R,h andR 1' are each independently hydrogen, -F, -Cl, -Br, -T, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl or -CN.
42. The compound of any one of claims 1-41, wherein R1 and R2 are each independently 331 WO 2024/199255 PCT/CN2024/083980 332 PCT/CN2024/083980 ;or N n atom to «h. ־h they land ^together -b= mtro g=o atom / 6x,__ ל < > , or X .
43. The compound of any one of claims 1, 5-10, 12, 13, 15-21, and 36-42, wherein L is a 333 WO 2024/199255 PCT/CN2024/083980 single bond.
44. The compound of any one of claims 1-41 and 43, wherein Rla is independently selected from hydrogen, methyl, ethyl, propyl, halo, methyl substituted with one or more halo, C3- 5cycloalkyl, or -CN, or two Rla attached to the same atom form C3-5cycloalkyl.
45. The compound of claim 44, wherein Rla is independently selected from hydrogen, methyl, ethyl, -F, -Cl, -Br, -1, -CF3, cyclopropyl, or -CN, or two Rla attached to the same atom form cyclopropyl.
46. The compound of any one of claims 1-41 and 43-45, wherein Rld is independently selected from hydrogen, halo, C1-4alkyl, C1-4alkyl substituted with one or more halo, C1-4alkyl substituted with -OH,-O-C1-4alkyl, -O-C1-4alkyl substituted with one or more halo, C3-5cycloalkyl optionally substituted with fluoro, -SO2-C1-4alkyl, or -CN.
47. The compound of claim 46, wherein Rld is independently selected from hydrogen, -F, - Br, -Cl,-1, methyl, ethyl, propyl, butyl, -CF3, hydroxypropyl, methoxy, trifluoromethoxy, cyclopropyl, fluorocyclopropyl, cyclobutyl, -SO2CH3, or -CN.
48. The compound of any one of claims 1-47, wherein R2 is C1-8alkyl.
49. The compound of claim 48, wherein R2 is methyl, ethyl, propyl, or butyl.
50. The compound of any one of claims 1, 2, 5-22, and 36-49, wherein R3 is selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -CN, -OH or -NH2.
51. The compound of claim 50, wherein R3 is selected from hydrogen, -F, -Cl, -Br, -1, methyl, ethyl, propyl , butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -CN, or-OH.
52. The compound of claim 51, wherein R3 is selected from hydrogen, -F, -Cl, methyl, ethyl, propyl, butyl.
53. The compound of claim 52, wherein R3 is hydrogen.
54. The compound of any one of claims 1-3 and 5-53, wherein R4, R5, R6, R7, Rs and R9 are each independently selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl is optionally substituted with at least one substituent selected from -F, -Cl, -Br, -I, methoxy, ethoxy, propoxy, butoxy, pentoxy, 334 WO 2024/199255 PCT/CN2024/083980 hexoxy, hepthoxy, octoxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, 5- to 12-membered heteroaryl, oxo, -CN, -0R4a ,-SO2R4a , -SO2NR4a R4b, -C0R4a , -CO2R4a , -CONR4a R4b, -NR4a R4b, -NR4a COR4b, -NR4a CO2R4b, -NR4a SO2R4b; andR4a and R4b are each independently hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8- membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl is optionally substituted with at least one -F, -Cl, -Br, -I, -OH, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, hepthoxy, octoxy, C1-8alkoxy-C1-8alkyl-, -C2-8alkenyl, -C2-8alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12- membered heteroaryl.
55. The compound of claim 54, wherein R4, R5, R6, R7, R8 and R9 are each independently selected from hydrogen, -F, -Cl, -Br, -1, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl.
56. The compound of claim 55, wherein R4, R5, R6, R7, R8 and R9 are each independently selected from hydrogen, -F, -Cl, -Br, -1, methyl, ethyl, propyl, cyclopropyl, or cyclobutyl.
57. The compound of claim 56, wherein R4, R5, R6, R7, R8 and R9 are each independently selected from hydrogen, -F, -Cl, -Br, -1, or methyl.
58. The compound of claim 57, wherein R4, R5, R6, R7, R8 and R9 are each independently selected from hydrogen or methyl.
59. The compound of any one of claims 1, 32, and 36-58, wherein the compound is of formula (VIIIp): (VIIIp),or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereofor an N-oxide thereof, or a pharmaceutically acceptable salt thereof, or 335 WO 2024/199255 PCT/CN2024/083980 a stereoisomer thereof, or a tautomer thereof, or a deuterated analog thereof, wherein:Rla ’ is independently selected from hydrogen, methyl or ethyl; Rla ” is hydrogen; or Rla ’ and Rla ” together with the atom to which they are attached, form a C3-5cycloalkyl; andn5 ’ is 0, 1 or 2.
60. The compound of claim 59, wherein:Rla is independently selected from halo, methyl substituted with one or more halo, C3- scycloalkyl or -CN;R2 is C1-8alkyl;R6 is hydrogen or methyl; andR7 is hydrogen.
61. The compound of claim 59 or 60, wherein Rla is independently selected from -F, -Cl, -Br, -1,-CF3, cyclopropyl or -CN.
62. The compound of any one of claims 59-63, wherein: (i) Rla ’ is methyl; or (iii) Rla ’ and Rla ” together with the atom to which they are attached, form a cyclopropyl.
63. The compound of any one of claims 59-62, wherein R2 is methyl.
64. The compound of any one of claims 59-63, wherein R6 is hydrogen.
65. The compound of any one of claims 1, 24, and 36-58, wherein the compound is of formula (Vllr): or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof, wherein Y’ is N or C(Rld).
66. The compound of claim 65, wherein:Rla is hydrogen or methyl;Rld is independently selected from hydrogen, halo, methyl substituted with one or more halo, C3-5cycloalkyl optionally substituted with fluoro, or -CN;R2 is Cl-salkyl;R6 is hydrogen or methyl; andR7 is hydrogen.
67. The compound of claim 65 or 66, wherein Rld is independently selected from hydrogen, -F, -Br, -I, -CF3, cyclopropyl, fluorocyclopropyl, cyclobutyl or -CN.
68. The compound of any one of claims 65-67, wherein Y’ is N. 336 WO 2024/199255 PCT/CN2024/083980
69. The compound of any one of claims 65-68, wherein Y’ is C(Rld).
70. A compound, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a tautomer thereof, or a deuterated analog thereof, selected from: O jjJyNH2Q״n 1& fXF J7 JlF O w! VHOn ״ F J/ vOF /*52'b/Fo /-^N^NH2XX hI lF O H x> Example 1 Example 2 Example 3Xo O /^N^NHrA y—Vj hI''NFX/ F J'n 0 NH2 b -b :11b F^/k/F XX XX wtntNH0״N X/f Example 4 Example 5 Example 6 Kmxx o 1 O 7^N<^NH2< X hoF^/k/F XO O _,N NH2( Hl JXoV ן h X> O’ Example 7 Example 8 Example 90N 0 N.NH2M )—0I O״y 1C סN 2 סס!"" 0 <^X1 b^CN o xhtx^2°' / N h^H/ __ / 0 VJ^F Example 10 Example 11 Example 12 CX >XI1/ — N N '^F J ' o vXF x o °a/^ynyNH2( y ״N0^ ץ H L /u _ / L0X/fF =/ XXf nh2 ؟ n ^؟ ^ 0 Xo( ״NvJ H H yJf Example 13 Example 14 Example 15 337 WO 2024/199255 PCT/CN2024/083980 XO O _,N NH2( hI 1 /־N N ^JV > H L / u _ / 1—o 0/ F 4 NOn4 j T/ N H^/O — ؛ / V0Fv0F Example 16 Example 17 Example 18 H י «X" F /=/ 4 NO z־../N>^H T° / N__ / o z 0■■* RC 0^ CN Example 19 Example 20 Example 21pCHO" WNC J) O _,N NH2W J J< ) "NH L /u __ / 0NF 4=^V0F XO 0 _,N NH2AX W J J ( >"N N '-^'. ״,,H L /— ؛ / u001 C7 F Example 22 Example 23 Example 24 N=L N--N' XO 0 /^/N NH2H Mj J Vj H T> f3c XO 0 _,N NH2Hi J ( > ״N0<> H L> CN W Example 25 Example 26 Example 27Xo oaX W I I( ) "N N ^> H A /u __ / Oo yCHip״׳ >0 p IjHN^ Example 28 Example 29 Example 30 338 WO 2024/199255 PCT/CN2024/083980 kJ W J I /Cl H /__ / Oouxp dNC ־ NH ؛ y^Ps Example 31 Example 32 Example 33 > 0HJjf‘Z NO FC,NH2yl TX0 0 NNH2H HT 1q1 3׳TO FaC 7—N f3c < )1״N N^^V0^ 7 H L /؛- / __ u)( Example 34 Example 35 Example 36PP-Fq nh 2O Hi ךd^N 0 NH2kJd J JInh 2 ؟ n ^؟ 0 F > H u p f3c 1 N N^p_F J H uf3c —N/ O/^-V° f3c Example 37 Example 38 Example 390 ^^n^nh 2d N O /-^n^nh 2M=Z — 1 TN^/NH2 /^؟ 0 XN ،mJ — f3c Jn N^pd Br ^n n^HHj1f F3c Example 40 Example 41 Example 42 M h 1 JF N N '_^f 7 H L /o — ؛ / _ yl/ FNC }3-g /Nkx °d^Ff3c | Br Example 43 Example 44 Example 45 0 O NH2 NC d NO /^^n^nh 2M Hl 1F ^N N^p^xF 7 H L /— ؛ / ___ ry^FF Q > •pr <1 N Example 46 Example 47 Example 48339 WO 2024/199255 PCT/CN2024/083980 p O NH2 /RR nV 0( / F Br R? vp: d " Br 4 N o x NH2־ Example 49 Example 50 Example 51NH2 ^ >؛ N 0 /^,N ،nX — 0 /^/Nx/NH2 HI I/ ،0 Cv °f3c Example 52 Example 53 Example 54NH2 W J I / H f3c p 0 nh 2> RR nV °^Vf 0 /N^ /NH2EXIT—M N'XRR/ '—0 f3c Example 55 Example 56 Example 57_/N^/NH2HJ I—N X )/ HOx f3c 0 /^/NX/-NH2Hl T—N— ؛ / f3c 0 /^/n x/nh 2HI T—N— ؛ / cS־^f3c Example 58 Example 59 Example 60X X OM OxT ¥)-N N^: Br n'^^'n nh 2*On n1r1 Br O /^^Nx^NH2—N N^XH // 1—o cS0^־Br Example 61 Example 62 Example 63 340 WO 2024/199255 PCT/CN2024/083980 O /^,N NH2—N N^YY__ , H /o ؛~ / Br WJ Y>—N N^^ V-€l Y An n^^ / n /nJ Y^7 F Example 64 Example 65 Example 66 —a yJY T )"N N 'A / H /nJVjJf 0 /^_/N nh 2hi Y—n/ Y cS־^f3c Z^N N^YY nJ ' L° Y^f Example 67 Example 68 Example 69 nY nh 2 ؟ n ^؟ 0—N N Y^Y-/ Y cS־^Br n,.^nh 2 ^'؟ 0—N NY:" Br Example 70 Example 71 Example 72NH2 Hj J / Y Cl O /^^N^NH2 W J! I 0 — ؛ / cS־^Cl NH2 ؟ O /^^N hI TfvJ^h J xS־^FExample 73 Example 74 Example 75NH2 HY TK M-Y F f3c N V N H2—N N^YY __ _ H / BrExample 76 Example 77 Example 78O //N/NHhI j—N YYY/ 0 Br 0 /-^N^NH2wj Y—N/ 0 Br 0 __^N. ^NH2y —A(—n Y''Y')/ Y cS־^°Br Example 79 Example 80 Example 81 341 WO 2024/199255 PCT/CN2024/083980 Z^Ywj T—N f3c 0 __ /N NH2Hl T—N F3C 0 __ /N NH2wj T—N Example 82 Example 83 Example 84n^nh 2 ^؟ ^ 0 —N h/ 0/p°/ Nf3c n^nh 2 ^؟ 0—N nHA/ H/p°/Nf3c HI 1—N h H— ؛ /Zyvo/ N Example 85 Example 86 Example 87O Z^Y'-YWJ I—N / N 0 /^N^NH2n/ 0 f3c HI T—N h I'')— ؛ /Ihn >؛f3c 6^ Example 88 Example 89 Example 90,^,N NH2— I— ؛ / f3c NCV^N NH2Hi J—N ')؛- /cS^0F3C 0^ NY N H2—n/ H f3c / Example 91 Example 92 Example 93/^N^NH2—1/ fl 5ך)/ 0 f3c / Hi T—N N^Y'fv^h 0 /^/N^/NH2—N N^HH FvYn X° V7Br Example 94 Example 95 Example 96n^nh 2 ^؟—N nAA V7NC 0—N j^hH° f3c nh 2 ؟. n ^؟ 0—N N^YxHHHo f3c Example 97 Example 98 Example 99 342 WO 2024/199255 PCT/CN2024/083980 nh 2 ؟. n ^؟—N NH n / 0—N N^H 1H" n^nh 2 ^؟ O—N/ ،־ל H Example 100 Example 101 Example 102NH2Hl TM 0 /-_/N^NH2Hi T—n [{ך)/ ^—o!IM M O / ..../N../NH2"A MI J / N h^M/ ozF7־= Example 103 Example 104 Example 105 N=In 0 NH2y.N ° N y N H2Yun n^A N=־aa Example 106 Example 107 Example 108 -a HI I/ N 1 ')/ ON= Mj T J. H u N= f3c n^nh 2 ^؟ OHn___ H /M 0 f3c Example 109 Example 110 Example 111O /--A HI T). H UN 0 NH2 HI T h '1)O — ؛ /־N M J TH /־N= f3c Example 112 Example 113 Example 114NH2 HI TJ.H uNA F3C NH2 ؟ O /^^N־A Hi I 1 r f3c -X Hl TAn r ׳rY-M H UN= mn Example 115 Example 116 Example 117 343 WO 2024/199255 PCT/CN2024/083980 Hi 1 n4،h l° yv f 0 /-./HI T—N N ~Y ... hn4 ° y^F 0 /-./ wj TN^Yx.. h y?n4 °Vv F Example 118 Example 119 Example 120/--Y'xVx wj TNY) L° 0 N Y n h 2—N nAv^F YH L /r L 0(37 F Br nh 2 ؟ n ^؟ O—N N^YxFy> .... H Y yv FBr Example 121 Example 122 Example 123nh 2 ؟. n ^؟ 0Yn nA^X J.. ' M (37 f Br ؛ 0 ^ YVHX—NY"3y FBr 0 ^^NyNH; N^YY-— J.... " U Ff3c Example 124 Example 125 Example 126N/NH2 /~؟ ONN^YY— , H // Y^37 F f3c ؛ 0 ^ xv NV N HN^^Yx^•J.... H WN= ^^F Br 0 /-^N^NH2N^Yy^•N=^H L° fBr Example 127 Example 128 Example 129O /^^Nx/ NH2'X—NY.... h^a^^F f3c O //Nx/MH2''''—N N^YY-—N=^H L° ff3c 0 y-VN^NH2N־Y^ Example 130 Example 131 Example 132nh 2 ؟. n ^؟ 0X—N AA, J...H M (37 F Br n^nh 2 ^؟ 0 h 'Y"(3yfBr 0^ xv NY N H2N^YXJ.... H u Ff3c Example 133 Example 134 Example 135 344 WO 2024/199255 PCT/CN2024/083980 /-■■Y'Y )—I TN^Y f3c 0 /Y'xYHi T—N N^Y Br NH2 ؟ O /^^NWj T—M— ؛ /־־■ G^fBr Example 136 Example 137 Example 138 hI l—N nYY,p. ' Br 0 NH2Yy j T—N YlY / "3y f Br F3CO °^1NYNH2Yn/ h^? / —o Example 139 Example 140 Example 141 h! T—N N 'Y->...h ך ynY ° n^nh 2 ^؟ 0Yn nYYxJ.H uN=^^FBr °/y/NyNH2Ynn4،hVy FBr Example 142 Example 143 Example 144zYY^—N N'YpA J.... H M^37 ff3c N Y N H2—NH /־־" ^37 Ff3c N Y N H2—N N^YrYx.— ؛ H1 Ff3c Example 145 Example 146 Example 147NH2MT l—N rYY).H - -Y Ff3c NH2 ؟ O /^_xN—Nf h L /y^F f3c H^YY N Y N H2 O. H u yY F f3c Example 148 Example 149 Example 150NN H2—N H'-pYx v،> .... H w 0 p-p/ Np/ N H2—N N^HpF WH L / NH2 ؟ O /^^N/x wj T< Yn n-^Yv ...h 2 ץnY 0Vy F Example 151 Example 152 Example 153 345 WO 2024/199255 PCT/CN2024/083980 NH2/x H j TN N '^L° 0 //N/NH2z MJ I < J-N N.... H uN= f3c 0 N=^H L° y^F f3c Example 154 Example 155 Example 156 O NH2M; j TN N ^J.. H uN= f3c O NH20^ M J T n=2~H L° ff3c 2 to'■ J Example 157 Example 158 Example 159/x H J TZ N— ؛ /יN= HJ T o ؛~ / f3c H J T—N N 'Y / M Example 160 Example 161 Example 162 Hi T—N yO — ؛ /N—< O// X_ /f3c o __ /N NH2HJ J—N N— ؛ / f3c o __ /N NH2H J J—N— ؛ / f3cExample 163 Example 164 Example 165 H J Tj ؛؛O ؛~ / f3c 0 /^^N^NH2H J T—N N '-X'■.HH M f3c H J T—N f3cExample 166 Example 167 Example 168 H j l—NHH MHy f3c NH2 ؟ 0 ^^/ NH J J—N f3c W j T —N/ O Example 169 Example 170 Example 171 346 WO 2024/199255 PCT/CN2024/083980 hI T—N/ 0 0 /^,N NH2W J l—N N^XX....H x n^nh 2 ^؟ f y- H L / Example 172 Example 173 Example 174؛ NyNH ^؟ ^ 0 ^X. " " °/^r NxN H f y- H L / 0x/^yN y N H .H X Example 175 Example 176 Example 177NH2 HI Tf y- H L /— ؛ ץ o /__,n^/nh 2—n/ o Br 0 //N/NH2HJ l—NHI Br Example 178 Example 179 Example 180/^^N^NH2mI T—N H^ — ؛ /1^/ N f3cExample 181، NO /---./XXM w J J < > ״N NXX,b 3 N=NZ/X f3c 0 w f3cnh 2 -؟ n H> 0 #^N.d-ni y soNH2 ؟ O z^^N / ، NFvV/XX F FXV NXX F 347 WO 2024/199255 PCT/CN2024/083980 XO 0 NH2mj J ( > ״N N 'X / H / <، N O /~->/N^/NH2n^ — 0 — /JN ؛x X/ FXz Ff3c 0 NH2N— y—v 11 TU y-fl T، XN O /- .../N< ، N^J — y - Xn N^X^X rt ■° NC h'T)'__/ '—oJ NFVVBrXXN^ ، NOnX )—C| T 0 — ؛ / 'O 4 NO //^/Xx/ NH2؛ wN 0 _,N NH"W 5 VON ، NO z/N^/NH2M y-fl T، NO /^^n^nh 2N—C yy, ji j، N Ox ^^n^nh 2Xn N^'X^N N^^ ^^N N^^X 'Jr/ H ־ 2F~^y^/FXj( h y .׳■N=Xscf 3Br ، NO /^^n^nh 2nX yy ji j، NO /^^N NHN^ y<| TQ Wf 2/ N H ' JAAC' __ / ^0__ / O __/ 0 ooo c־^X/fN^F / oy-N 4 O _,N NHH Hj Ton4־> o _,n nh 2N^z —// Ji T on 7> o _,n nh nX Vx T T Q = °'^N N ''.^Q "°XN N '-^Xy ״° 348 WO 2024/199255 PCT/CN2024/083980 C 0 NH2 M Hj 1M H X)F C' Cp yO NH2< y ״N N^xx IM h p ?O — ؛ / uZ NFvv Cp 0P* VH F Mp 3^ f-? “dpp' 1Mf3c Z NO /^^N^/NHMl P T<، XN 0 /~>/N^/NH2N^ — 0MFX>Ff3c ch £C ؟' X ° p^ FOMx Hl T f x> ״xr o- p 0 NHpxx ،P^F XO 0 _,N NH2M pH 1 TZ NO //^-./N^ ip )C| I، N 0nP — "N N vX،Vj H XpPn n^X_، ' / X o(N Hnי-ס / __ 'ו 0 ؛ f3cvx FMm ، XN 0nA — f3cM0CNMPon N^ 349 WO 2024/199255 PCT/CN2024/083980 MeO2S <| NC XO 0 _,N NH2M Ma 1( > ״N N p0^ > H U0■ MeO y MeO XO 0 _,N NH2rl Ml A =Jj ״ L> f3co 330 ، N-.N o N~7 K:، o 1j^fN^7 XO 0 _,N NH2M Ml 1V) H x>^ NC X/ 0H wj T r ؛.־ •،NC hh00' ، N N^ ?'HIq'C ، N^N'OHO /^^N^/NH2ri Hl J < >״n n x^HF Cn OHO nh2rl Ml 1( > ״NO^ > H L /o — ؛ / uC NFvv00WN^׳ OHO /-/N■-/ 0K M j Mj H X> fCnV^F , p •p y —/ Ft>F /^ך o z~-_/n^,NH2a Hi TF 5 H L / o 350 WO 2024/199255 YA Y Y//N^NH2. X__ X H Y PCT/CN2024/083980 0naY"■[>—n h __/ Y، NFvv A / Y AF 5 H L /0VY F fh،7/fYf 0 _,N^NH2—XII N N^Y — ؛ ---- 1p H A /h__ / '—0 s? ay" A " f3c 8 > «8' 8 0 _ __ N NH2rY YY J JVtyntNH2QF°dXf NTNH־ ( )■"N N^XVj H x> N= x 0 = ־< ' a1F8y^u ־־ A - ، NFVV/ CTVv A Y-־ X RWr־ aYinh ؛° YYY' ° />= yYy T" X> F3C f x N d " f3c F '—N N^XY y^ NNC 8< ^־CN a>pX' KNC x Axx ״ CI^^N F3c YyaTPYyT2^°yc Qnh ־F 8 RX) CI^NNC F F N) d ״H^Q 351 WO 2024/199255 PCT/CN2024/083980 AApp*< p PX NC^^ / V o /N/>=< w j TF N h '_) '—oC^c1 QHxYh־O/ y^Y Ny NH2f pp I7Cx " NC hR) NC QHpCTWi YH2 VrrntNH2 F VN M R- NC R) » xf 3 sR)N=MNCxNC XO 0 /^n^nh 2w 1 TXO 0 _,N NH2pR y—| 1HHU N=y^ NNC A ؛ N N^x <״ )Xo^ ץ H L /ci^Rn f3cXO 0 /_,N NH2W J I Uj h-q WBr XO O NH2WJ J؛ N N^V " < )0Jj H R f3c א XO O _,N NH2pR Hl l ( ״n N^p°J) H X> f3c o 0mV־O V_^ynyNH2CN °WYTnY™2-rC F^ NCf3cf3c N 0 ,^,N NH2 ؟H mJ TF ،N h )__ / 0 Rp f3c to xx F3CA NFvvA Rf 352 WO 2024/199255 PCT/CN2024/083980 ,N=< ° f3c Bw nJJy Mhy' N J jj-—N , y X Jn XO 0 /^N NH2H HJ I ( ) "N N XuV ץ H l /N= XO O NH2xX W J J ( > ״n N^XXo^ 7 H L /CN f X'PX n^nh 2 ^؟Yun n^X/N nh 2 ؟ n ^؟ OYuN N^Y/ H /o — ؛ 7 ___ O N^/ N H2 / H /י~ס / __F 0 /^N^NH2 XII/ H // 0F^=yjF — YI )״in N XuX H W f3c 0 /^/Nx/NH2 XII>"N N X2J H U df3c XI j>u, N N XB 6־ f3c 0 /-^N^NH2 XII/ "N h^7__/ Xq Ff3cO /^^N^NH yJJ j >"N N f3c O /^^N^NH2—A YCII)uN N ■XJ H u Br O /^^N^NH2—A YCII)■׳iNJ " J>B o /^/Nx/NH2 YCII>"N N^Vx> 2 Br XII^؟, in N (■׳/ H 7__ / —o(3/f Br YCII M6״ Br 353 WO 2024/199255 PCT/CN2024/083980 ^,N NH2 Y—CII )"N N aA 2J H u ^^F 0 /^N^NH2 XII )1״N NAA 0 /^״N/NH2—A H0C 0>״N NAA 0 //N^/NH2־A Ull 0)1״N__ / ^0 0 A A XII)"N N^AAFJJ ' 0 /-^N^NH2-A Hi T AN N^XA nJ ' L°^^F I"yl FF N N H20 N.NH2 0 /-^N^NH2-a Hi Tzh 0N 0n n^H__ /___ H / ___/ AVn 1't ץ _ / HJa F o __ N NH2־a Hl TNH2 ؟ O /^^N11 —O z~-/N/NH2---- --- 1 IAn n aA ־<) H UNA0^FF3C An n^aH u df3c An n^X f3c 0 /^/Nx/NH2An nAa n h / ___/ AAn lAn l f3cyj^ F f3cW^FBr N/NH2 /~؟ 0In nAaA) H AN=C7 F 0x^AA N A N H2- 0 /^/N^/NH2 XIIH V)__ / ^0Ja Fb/ b/Bro __ N NH2APA، NyNH ^؟0N N-A, 0־ H A 0 /^/N^/NH2XIIAn nx A.H u (1F 0^Fb/ 1 354 WO 2024/199255 PCT/CN2024/083980 N N H2)—N P nh 2 ؟ n ^؟ 0 / N__ / 0(3/f I 0 /^/N^/NH2-A WJ I)—N N^Y o x AN.NH2 zpp N= o x z^N NH2 O /^^N^NH2 / H /N=< y^ F f3c > / Pd' N 0 f3c p d " f3c jpp■' f3c Ox AN.NH,ypp. f3cP PP' N=d Br Br -ppp Br BrBr Ox NH2 zpip N= 1> w d ‘ P cpr d ° Ox NH2 ؛ p^'P I 355 WO 2024/199255 PCT/CN2024/083980 356 WO 2024/199255 PCT/CN2024/083980
71. A pharmaceutical composition comprising a compound of any one of claims 1-70 or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a tautomer thereof, or a deuterated analog thereof, and a pharmaceutically acceptable excipient.
72. A method of inhibiting PRMT5 activity, comprising administering to a subject in need thereof an effective amount of a compound according to any one of claims 1-70, or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof.
73. A method of treating a disease modulated by PRMT5, comprising administering to a subject in need thereof an effective amount of a compound according to any one of claims 1-70, or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or a deuterated analog thereof.
74. A method of treating cancer, comprising administering to a subject in need thereof an effective amount of a compound according to any one of claims 1-70, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a tautomer thereof, or a deuterated analog thereof.
75. The method of claim 73, wherein the disease is cancer.
76. The method of claim 74 or 75, wherein the cancer comprises a methylthioadenosine phosphorylase (MTAP)-null solid tumor.דר. The method of any one of claims 74-76, wherein the cancer is lung cancer, bladder cancer, melanoma, pancreatic cancer, esophageal cancer, gastric adenocarcinoma, breast cancer, or glioblastoma. 357
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2023085078 | 2023-03-30 | ||
| CN2023110807 | 2023-08-02 | ||
| CN2024080582 | 2024-03-07 | ||
| PCT/CN2024/083980 WO2024199255A1 (en) | 2023-03-30 | 2024-03-27 | 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-d] PYRROLO [3, 2-b] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL323621A true IL323621A (en) | 2025-11-01 |
Family
ID=90880338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL323621A IL323621A (en) | 2023-03-30 | 2024-03-27 | 5-amino-6, 8-dihydro-1h-furo [3, 4-d] pyrrolo [3, 2-b] pyridine-2-carboxamide derivatives as mta-cooperative inhibitors of prmt5 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240368177A1 (en) |
| EP (1) | EP4688785A1 (en) |
| JP (1) | JP2026511698A (en) |
| KR (1) | KR20250166308A (en) |
| CN (3) | CN120957998A (en) |
| AR (1) | AR132251A1 (en) |
| AU (1) | AU2024254535A1 (en) |
| CL (1) | CL2025002940A1 (en) |
| CO (1) | CO2025014760A2 (en) |
| IL (1) | IL323621A (en) |
| MX (1) | MX2025011568A (en) |
| TW (1) | TW202438054A (en) |
| WO (1) | WO2024199255A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20260121A1 (en) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | PRMT5 INHIBITORS AND THEIR USES |
| CN122422327A (en) * | 2023-10-12 | 2026-07-17 | 北京双鹤润创科技有限公司 | Tricyclic-carbonyl-azacyclic derivatives and uses thereof |
| US20260130893A1 (en) * | 2024-10-21 | 2026-05-14 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026103738A1 (en) * | 2024-11-13 | 2026-05-21 | Beone Pharmaceutical (Suzhou) Co., Ltd. | Bridged cyclic 5-amino-6, 8-dihydro-1h-furo [3, 4-d] pyrrolo [3, 2-b] pyridine-2-carboxamide compounds, compositions thereof, and methods of treatment therewith |
| CN119552175B (en) * | 2025-01-26 | 2025-04-29 | 赛岚(杭州)生物医药科技有限公司 | PRMT5-MTA inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022010011A (en) * | 2020-02-12 | 2022-10-18 | Amgen Inc | Novel prmt5 inhibitors. |
| EP4251624B1 (en) * | 2020-11-24 | 2025-10-29 | Amgen Inc. | Tricyclic carboxamide derivatives as prmt5 inhibitors |
| CN117062816A (en) * | 2021-02-04 | 2023-11-14 | 美国安进公司 | Tricyclic-amide-bicyclic PRMT5 inhibitors |
| WO2024012308A1 (en) * | 2022-07-15 | 2024-01-18 | 上海和誉生物医药科技有限公司 | Prmt5 inhibitor, preparation method therefor, and pharmaceutical use thereof |
-
2024
- 2024-03-27 CN CN202480022921.XA patent/CN120957998A/en active Pending
- 2024-03-27 IL IL323621A patent/IL323621A/en unknown
- 2024-03-27 CN CN202610259696.2A patent/CN122167445A/en active Pending
- 2024-03-27 TW TW113111487A patent/TW202438054A/en unknown
- 2024-03-27 AR ARP240100758A patent/AR132251A1/en unknown
- 2024-03-27 CN CN202610260385.8A patent/CN122167446A/en active Pending
- 2024-03-27 US US18/617,913 patent/US20240368177A1/en active Pending
- 2024-03-27 EP EP24721494.3A patent/EP4688785A1/en active Pending
- 2024-03-27 KR KR1020257036222A patent/KR20250166308A/en active Pending
- 2024-03-27 AU AU2024254535A patent/AU2024254535A1/en active Pending
- 2024-03-27 WO PCT/CN2024/083980 patent/WO2024199255A1/en not_active Ceased
- 2024-03-27 JP JP2025556669A patent/JP2026511698A/en active Pending
-
2025
- 2025-09-29 CL CL2025002940A patent/CL2025002940A1/en unknown
- 2025-09-29 MX MX2025011568A patent/MX2025011568A/en unknown
- 2025-10-24 CO CONC2025/0014760A patent/CO2025014760A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN120957998A (en) | 2025-11-14 |
| KR20250166308A (en) | 2025-11-27 |
| TW202438054A (en) | 2024-10-01 |
| JP2026511698A (en) | 2026-04-14 |
| CO2025014760A2 (en) | 2025-11-07 |
| MX2025011568A (en) | 2025-11-03 |
| CN122167446A (en) | 2026-06-09 |
| AR132251A1 (en) | 2025-06-11 |
| WO2024199255A1 (en) | 2024-10-03 |
| CN122167445A (en) | 2026-06-09 |
| AU2024254535A1 (en) | 2025-11-13 |
| CL2025002940A1 (en) | 2025-12-26 |
| US20240368177A1 (en) | 2024-11-07 |
| EP4688785A1 (en) | 2026-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2933480C (en) | Inhibitors of lysine specific demethylase-1 | |
| JP6494622B2 (en) | Substituted 4,5,6,7-tetrahydropyrazolo [1,5-A] pyrazine derivatives as casein kinase 1D / E inhibitors | |
| AU2014351413B2 (en) | Pyrrolopyrrolone derivatives and their use as BET inhibitors | |
| DK2769980T3 (en) | Pyrazolquinolinderivat as pde9 inhibitors | |
| IL305087A (en) | Cdk inhibitors and methods of use thereof | |
| EP3157920B1 (en) | Indolizine derivatives as phosphoinositide 3-kinases inhibitors | |
| AU2020410470B2 (en) | Triazolopyridazine derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof | |
| JP7405468B2 (en) | Compounds with BRD4 inhibitory activity, preparation methods and uses thereof | |
| KR20160012194A (en) | Imidazopyrrolidinone derivatives and their use in the treatment of disease | |
| HUE025177T2 (en) | Condensed heteroaromatic pyrrolidinone derivatives as SYK inhibitors | |
| US20240368177A1 (en) | 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | |
| AU2025203609A1 (en) | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | |
| TW201833113A (en) | Imidazo[1,5-A]pyridinium derivatives as P13Kδ inhibitors | |
| AU2021290208B2 (en) | Tricyclic compounds | |
| CA3018602A1 (en) | Pyrimidin-4-yl imidazolidine-2-one derivatives and compositions having mutant idh inhibitory activity, preparation method and use thereof | |
| WO2025068985A1 (en) | 1-(1-oxo-1,2-dihydrophthalazin-6-yl)cycloalkyl-1-carboxamide derivatives as mta-cooperative inhibitors of prmt5 | |
| CN119707931A (en) | Intermediate and synthesis method of 1- (1-oxo-1, 2-dihydro-phthalazin-6-yl) cycloalkyl-1-carboxamide derivatives as MTA synergistic inhibitors of PRMT5 | |
| US12630554B2 (en) | Pyrimidinone compounds and uses thereof | |
| EA045220B1 (en) | Cot MODULATORS AND METHODS OF THEIR APPLICATION | |
| HK1172328B (en) | N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use | |
| HK1172328A1 (en) | N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use |